

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/061725 A1

(51) International Patent Classification⁷: C12Q 1/68, 1/02,
G01N 33/53, 33/574, A61K 45/00, 49/00, A61P 35/00

(21) International Application Number:
PCT/CA2004/002172

(22) International Filing Date:
21 December 2004 (21.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/532,601 23 December 2003 (23.12.2003) US
60/630,990 24 November 2004 (24.11.2004) US

(71) Applicants (for all designated States except US): MOUNT
SINAI HOSPITAL [CA/CA]; 600 University Avenue,
Room 970, Toronto, Ontario M5G 1X5 (CA). YORK

UNIVERSITY [CA/CA]; 4700 Keele Street, Ross
Building, Room N945, Toronto, Ontario M3J 1P3 (CA).
UNIVERSITY HEALTH NETWORK [CA/CA]; 610
University Avenue, Toronto, Ontario M5G 2M9 (CA).

(72) Inventors; and


(75) Inventors/Applicants (for US only): COLGAN, Terence
J. [CA/CA]; 46 Plymbridge Road, Toronto, Ontario M2P
1A3 (CA). SIU, K.W. Michael [CA/CA]; 27 Cobblestone
Drive, Toronto, Ontario M2J 2X6 (CA). ROMASCHIN,
Alexander D. [CA/CA]; 3 Broadfield Drive, Toronto, On-
tario M9C 1L4 (CA). YANG, Eric C.C. [CA/CA]; 23 Elyn-
hill Drive, Toronto, Ontario M2R 1C5 (CA).

(74) Agents: KURDYDYK, Linda et al.; McCarthy Tetrault,
Suite 4700, P.O. Box 48, 66 Wellington Street West,
Toronto Dominion Bank Tower (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

[Continued on next page]

(54) Title: METHODS FOR DETECTING MARKERS ASSOCIATED WITH ENDOMETRIAL DISEASE OR PHASE



(57) Abstract: Methods for detecting endometrial diseases or an en-
dometrium phase in a subject are described comprising measuring en-
dometrial markers or polynucleotides encoding the markers in a sam-
ple from the subject. The invention also provides localization or imag-
ing methods for endometrial diseases, and kits for carrying out the
methods of the invention. The invention also contemplates therapeutic
applications for endometrial diseases employing endometrial markers,
polynucleotides encoding the markers, and/or binding agents for the
markers.

WO 2005/061725 A1



CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

METHODS FOR DETECTING MARKERS ASSOCIATED WITH ENDOMETRIAL DISEASE OR PHASE

FIELD OF THE INVENTION

The invention relates to methods for identifying markers associated with endometrium, endometrial markers, methods for assessing the status of an endometrial tissue, and methods for the detection, diagnosis, prediction, and therapy of an endometrial disease.

BACKGROUND OF THE INVENTION

The endometrium, the tissue lining the uterus, is a glandular layer of variable thickness that is very sensitive to the hormones estrogen and progesterone. During the menstrual cycle the endometrium undergoes cyclic variation with a proliferation phase where the endometrium grows under the influence of estrogen, an ovulation phase where the endometrium is exposed to estrogen and progesterone, and a secretory or progesterone dominated phase where the endometrium shows signs of increased gland growth and secretion due largely to the influence of progesterone [1]. The secretory phase is followed by the shedding of the endometrium during menstruation. The histologic changes in the endometrium have been used to detect the stage or status of the endometrium, which is important for example, in determining the receptivity of patients to fertility procedures, and in determining responses to estrogen and/or progesterone therapies.

Endometrial carcinoma is a common malignancy in women, being exceeded in incidence only by that of breast, lung, and colorectal cancers [10, 11, 48, 125-131]. The lifetime probability of a Canadian woman developing endometrial carcinoma is 2.2% [10]. Although the case-fatality rate for cancer of the endometrium is lower than that of many other cancer sites, this rate does not fully reflect the health care burden posed by endometrial carcinoma. Investigation of women with perimenopausal and postmenopausal bleeding for the presence of endometrial carcinoma is one of the most common gynecologic investigations and requires invasive endometrial sampling. Yet only a small proportion of these investigations will result in a diagnosis of endometrial carcinoma [12].

At present, no methods for screening or early detection of endometrial carcinoma are available nor are there any serum tumor markers available for the monitoring of endometrial carcinoma patients [13, 14]. Consequently, patients are diagnosed following the development of symptoms, and patients with recurrent disease are detected only following the development of recurrent symptoms, or abnormalities in imaging assessments. Sensitive and specific tumor marker(s) for endometrial carcinoma are urgently needed for screening and diagnosis. There is also a need for reliable endometrial markers for determining the stage/phase, and status of the endometrium.

SUMMARY OF THE INVENTION

Applicants have developed a method for identifying markers associated with the endometrium, and in particular with proliferative endometrium, secretory endometrium, and diseased endometrial tissue. Using the method they analyzed normal endometrial tissue homogenates and endometrial tumor tissue homogenates, and identified novel endometrial markers, in particular markers of secretory and proliferative endometrium and endometrial cancer markers.

The invention relates to a method of characterizing or classifying a sample of endometrium by detecting or quantitating in the sample one or more polypeptides extracted from the sample that are characteristic of endometrium, a phase thereof or an endometrial disease, the method comprising assaying for differential

- 2 -

expression of polypeptides in the sample. Differential expression of polypeptides can be assayed using separation techniques known in the art, an antibody microarray, or mass spectroscopy of polypeptides extracted from the sample. The invention includes polypeptides identified using a method of the invention.

5 In an aspect the invention provides a method of characterizing a sample of endometrium by detecting or quantitating in the sample one or more polypeptides extracted from the sample that are characteristic of a proliferative, secretory or an endometrial disease the method comprising assaying for differential expression of proteins in the sample by mass spectroscopy of proteins extracted from the sample. In an embodiment, differential expression of the proteins is carried out using surface enhanced laser desorption/ionization (SELDI-TOF MS).

10 In an embodiment, the invention provides a method for identifying markers associated with the endometrium or a phase thereof, or associated with an endometrial disease comprising:

- (a) obtaining a sample of endometrium from a subject;
- (b) extracting proteins from the sample and producing a profile of the proteins by subjecting the proteins to mass spectrometry; and
- 15 (c) comparing the profile with a profile for normal endometrial tissue or for a known phase of endometrium to identify proteins associated with an endometrial disease or with the endometrium phase or.

In another aspect the invention is directed to bioinformatic methods for analyzing differential expression data generated from the methods of the invention to identify further markers associated with the endometrium or
20 phase thereof, or associated with endometrial disease.

The invention relates to novel markers for the endometrium, and in particular markers of an endometrial disease, and compositions comprising same.

The invention provides marker sets that distinguish the endometrium or phases thereof, or endometrial diseases, and uses therefor. A marker set may comprise a plurality of polypeptides and/or polynucleotides
25 encoding such polypeptides comprising or consisting of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the markers listed in Table 1, 4, 5, or 6. In specific aspects, the markers consist of at least 5, 6, 7, 8, 9, or 10 polypeptides listed in Table 1, 4, 5, or 6. In an aspect the protein marker sets comprise or consist of protein clusters, or proteins in pathways comprising markers listed in Table 1, 4, 5, and 6.

In embodiments of the invention, a marker is provided which is selected from the group consisting of
30 the polypeptides set forth in Table 1, which polypeptides are up-regulated biomarkers in endometrial cancer.

In embodiments of the invention, a marker is provided which is selected from the group consisting of the polypeptides set forth in Table 1, which polypeptides are down-regulated biomarkers in endometrial cancer.

The markers identified in accordance with a method of the invention, in particular the markers identified in Table 1, 4, 5, or 6, including but not limited to native-sequence polypeptides, isoforms, chimeric polypeptides,
35 all homologs, fragments, and precursors of the markers, including modified forms of the polypeptides and derivatives are referred to herein as "endometrial marker(s)". Polynucleotides encoding endometrial markers are referred to herein as "endometrial polynucleotide marker(s)", "polynucleotides encoding endometrial markers", or "polynucleotides encoding the marker(s)". The endometrial markers and endometrial polynucleotide markers are sometimes collectively referred to herein as "marker(s)". Markers of endometrial cancer are referred to herein

- 3 -

as "endometrial cancer markers", "endometrial cancer polynucleotide markers", and "polynucleotides encoding endometrial cancer markers".

Endometrial markers identified in accordance with a method of the invention, (including the endometrial cancer markers listed in Table 1, 4, 5, or 6), and polynucleotides encoding the markers, have application in the determination of the status or phase of the endometrium and in the detection of an endometrial disease such as endometrial cancer. Thus, the markers can be used for diagnosis, monitoring (i.e. monitoring progression or therapeutic treatment), prognosis, treatment, or classification of an endometrial disease (e.g. endometrial cancer), or as markers before surgery or after relapse. The invention also contemplates methods for assessing the status of an endometrial tissue, and methods for the diagnosis and therapy of an endometrial disease.

The markers characteristic of different stages or phases of endometrium identified by a method of the invention may be used to identify the physiologic stage or phase of the endometrium within the physiologic cycle. In an aspect, the endometrial markers may be used to assess and manage reproductive disorders and infertility. In particular, endometrial markers associated with the secretory phase or proliferative phase identified by a method of the invention may be used to determine if an endometrium is at the optimum stage or phase for embryo implantation. In an embodiment, the endometrial markers are characteristic of the secretory phase, and include the markers glutamate receptor subunit zeta 1 [SEQ ID NO. 26] or a tryptic fragment thereof [e.g. SEQ ID NO. 28], macrophage migration inhibitory factor [SEQ ID NO. 18], FRAT1 [SEQ ID NO. 42], myosin light chain kinase 2 [SEQ ID NO. 45], and tropomyosin 1 alpha chain [SEQ ID NO. 47], and polynucleotides encoding the polypeptides.

In accordance with methods of the invention, endometrium can be assessed or characterized, for example, by detecting the presence in the sample of (a) an endometrial marker or fragment thereof; (b) a metabolite which is produced directly or indirectly by an endometrial marker; (c) a transcribed nucleic acid or fragment thereof having at least a portion with which an endometrial polynucleotide marker is substantially identical; and/or (c) a transcribed nucleic acid or fragment thereof, wherein the nucleic acid hybridizes with an endometrial polynucleotide marker.

The levels of endometrial markers or endometrial polynucleotide markers in a sample may be determined by methods as described herein and generally known in the art. The expression levels may be determined by isolating and determining the level of nucleic acid transcribed from each endometrial polynucleotide. Alternatively or additionally, the levels of endometrial markers translated from mRNA transcribed from an endometrial polynucleotide marker may be determined.

In an aspect, the invention provides a method for characterizing or classifying an endometrial sample comprising detecting a difference in the expression of a first plurality of endometrial markers or endometrial polynucleotide markers relative to a control, the first plurality of markers consisting of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the markers corresponding to the markers listed in Table 1, 4, 5, or 6. In specific aspects, the plurality of markers consists of at least 5 of the markers listed in Table 1, 4, 5, or 6.

In an aspect, a method is provided for characterizing an endometrium by detecting endometrial markers or endometrial polynucleotide markers associated with an endometrium stage or phase, or endometrial disease in a patient comprising:

- 4 -

- (a) obtaining a sample from a subject;
- (b) detecting or identifying in the sample endometrial markers or endometrial polynucleotide markers; and
- (c) comparing the detected amount with an amount detected for a standard.

5 In an embodiment of the invention, a method is provided for detecting endometrial cancer markers or endometrial cancer polynucleotide markers associated with endometrial cancer in a patient comprising:

- (a) obtaining a sample from a patient;
- (b) detecting in the sample endometrial cancer markers or endometrial cancer polynucleotide markers; and
- 10 (c) comparing the detected amount with an amount detected for a standard.

The term "detect" or "detecting" includes assaying, imaging or otherwise establishing the presence or absence of the target endometrial markers or polynucleotides encoding the markers, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of an endometrium phase or endometrial disease
15 including cancer, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications for the endometrial markers and polynucleotides encoding the markers.

The invention also provides a method of assessing whether a patient is afflicted with or has a pre-disposition for endometrial disease, in particular endometrial cancer, the method comprising comparing:

- (a) levels of endometrial markers or polynucleotides encoding endometrial markers associated
20 with the endometrial disease in a sample from the patient; and
- (b) normal levels of endometrial markers or polynucleotides encoding endometrial markers associated with the endometrial disease in samples of the same type obtained from control patients not afflicted with the disease, wherein altered levels of the endometrial markers or the polynucleotides relative to the corresponding normal levels of endometrial markers or
25 polynucleotides is an indication that the patient is afflicted with endometrial disease.

In an aspect of a method of the invention for assessing whether a patient is afflicted with or has a pre-disposition for endometrial cancer, higher levels of endometrial cancer markers in a sample relative to the corresponding normal levels is an indication that the patient is afflicted with endometrial cancer.

In another aspect of a method of the invention for assessing whether a patient is afflicted with or has a
30 pre-disposition for endometrial cancer, lower levels of endometrial cancer markers in a sample relative to the corresponding normal levels is an indication that the patient is afflicted with endometrial cancer.

In a further aspect, a method for screening a subject for endometrial disease is provided comprising (a) obtaining a biological sample from a subject; (b) detecting the amount of endometrial markers associated with the disease in said sample; and (c) comparing said amount of endometrial markers detected to a predetermined
35 standard, where detection of a level of endometrial markers that differs significantly from the standard indicates endometrial disease.

In an embodiment, a significant difference between the levels of endometrial marker levels in a patient and normal levels is an indication that the patient is afflicted with or has a predisposition to endometrial disease.

In a particular embodiment the amount of endometrial marker(s) detected is greater than that of a standard and is indicative of endometrial disease, in particular endometrial cancer. In another particular embodiment the amount of endometrial marker(s) detected is lower than that of a standard and is indicative of endometrial disease, in particular endometrial cancer.

5 In aspects of the methods of the invention, the methods are non-invasive for detecting endometrium phase or endometrial disease which in turn allow for diagnosis of a variety of conditions or diseases associated with the endometrium.

In particular, the invention provides a non-invasive non-surgical method for detection, diagnosis or prediction of endometrial disease in a subject comprising: obtaining a sample of blood, plasma, serum, urine or saliva or a tissue sample from the subject; subjecting the sample to a procedure to detect endometrial markers or endometrial polynucleotide markers in the blood, plasma, serum, urine, saliva or tissue; detecting, diagnosing, and predicting endometrial disease by comparing the levels of endometrial markers or endometrial polynucleotide markers to the levels of marker(s) or polynucleotide(s) obtained from a control subject with no endometrial disease.

15 In an embodiment, endometrial disease is detected, diagnosed, or predicted by determination of increased levels of markers (e.g. Table 1 up-regulated markers) when compared to such levels obtained from the control.

In another embodiment, endometrial disease is detected, diagnosed, or predicted by determination of decreased levels of markers (e.g. Table 1 down-regulated markers) when compared to such levels obtained from the control.

20 The invention also provides a method for assessing the aggressiveness or indolence of an endometrial disease in particular cancer (e.g. staging), the method comprising comparing:

- (a) levels of endometrial markers or polynucleotides encoding endometrial markers associated with the endometrial disease in a patient sample; and
- 25 (b) normal levels of the endometrial markers or the polynucleotides in a control sample.

In an embodiment, a significant difference between the levels in the sample and the normal levels is an indication that the endometrial disease, in particular cancer, is aggressive or indolent. In a particular embodiment, the levels of endometrial markers are higher than normal levels. In another particular embodiment, the levels of endometrial markers are lower than normal levels.

30 In an aspect, the invention provides a method for determining whether a cancer has metastasized or is likely to metastasize in the future, the method comprising comparing:

- (a) levels of endometrial cancer markers or polynucleotides encoding endometrial cancer markers in a patient sample; and
- (b) normal levels (or non-metastatic levels) of the endometrial cancer markers or polynucleotides in a control sample.

35 In an embodiment, a significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

In another aspect, the invention provides a method for monitoring the progression of endometrial disease, in particular endometrial cancer in a patient the method comprising:

- 6 -

- 5
- (a) detecting endometrial markers or polynucleotides encoding the markers associated with the disease in a sample from the patient at a first time point;
 - (b) repeating step (a) at a subsequent point in time; and
 - (c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of the endometrial disease.

The invention contemplates a method for determining the effect of an environmental factor on the endometrium or phase thereof, or endometrial disease comprising comparing endometrial polynucleotide markers or endometrial markers in the presence and absence of the environmental factor.

10 The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting endometrial disease, and a method of selecting an agent for inhibiting endometrial disease.

The invention contemplates a method of assessing the potential of a test compound to contribute to an endometrial disease comprising:

- 15
- (a) maintaining separate aliquots of endometrial diseased cells in the presence and absence of the test compound; and
 - (b) comparing the levels of endometrial markers or polynucleotides encoding the markers associated with the disease in each of the aliquots.

20 A significant difference between the levels of endometrial markers or polynucleotides encoding the markers in an aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound potentially contributes to endometrial disease.

25 The invention further relates to a method of assessing the efficacy of a therapy for inhibiting endometrial disease in a patient. A method of the invention comprises comparing: (a) levels of endometrial markers or polynucleotides encoding the markers associated with disease in a first sample from the patient obtained from the patient prior to providing at least a portion of the therapy to the patient; and (b) levels of endometrial markers or polynucleotides encoding the markers associated with disease in a second sample obtained from the patient following therapy.

In an embodiment, a significant difference between the levels of endometrial markers or polynucleotides encoding the markers in the second sample relative to the first sample is an indication that the therapy is efficacious for inhibiting endometrial disease.

30 In a particular embodiment, the method is used to assess the efficacy of a therapy for inhibiting endometrial disease (e.g. endometrial cancer), where lower levels of endometrial markers or polynucleotides encoding same in the second sample relative to the first sample, is an indication that the therapy is efficacious for inhibiting the disease.

35 The "therapy" may be any therapy for treating endometrial disease, in particular endometrial cancer, including but not limited to therapeutics, radiation, immunotherapy, gene therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy.

Certain methods of the invention employ binding agents (e.g. antibodies) that specifically recognize endometrial markers.

- 7 -

In an embodiment, the invention provides methods for determining the presence or absence of endometrial disease, in particular endometrial cancer, in a patient, comprising the steps of (a) contacting a biological sample obtained from a patient with one or more binding agent that specifically binds to one or more endometrial markers associated with the disease; and (b) detecting in the sample an amount of marker that binds to the binding agent, relative to a predetermined standard or cut-off value, and therefrom determining the presence or absence of endometrial disease in the patient.

In another embodiment, the invention relates to a method for diagnosing and monitoring an endometrial disease, in particular endometrial cancer, in a subject by quantitating one or more endometrial markers associated with the disease in a biological sample from the subject comprising (a) reacting the biological sample with one or more binding agent specific for the endometrial markers (e.g. an antibody) that are directly or indirectly labelled with a detectable substance; and (b) detecting the detectable substance.

In another aspect the invention provides a method for using an antibody to detect expression of one or more endometrial marker in a sample, the method comprising: (a) combining antibodies specific for one or more endometrial marker with a sample under conditions which allow the formation of antibody:marker complexes; and (b) detecting complex formation, wherein complex formation indicates expression of the marker in the sample. Expression may be compared with standards and is diagnostic of an endometrial disease, in particular endometrial cancer.

Embodiments of the methods of the invention involve (a) reacting a biological sample from a subject with antibodies specific for one or more endometrial markers which are directly or indirectly labelled with an enzyme; (b) adding a substrate for the enzyme wherein the substrate is selected so that the substrate, or a reaction product of the enzyme and substrate forms fluorescent complexes; (c) quantitating one or more endometrial markers in the sample by measuring fluorescence of the fluorescent complexes; and (d) comparing the quantitated levels to levels obtained for other samples from the subject patient, or control subjects.

In another embodiment the quantitated levels are compared to levels quantitated for control subjects (e.g. normal or benign) without an endometrial disease (e.g. cancer) wherein an increase in endometrial marker levels compared with the control subjects is indicative of endometrial disease.

In a further embodiment the quantitated levels are compared to levels quantitated for control subjects (e.g. normal or benign) without an endometrial disease (e.g. cancer) wherein a decrease in endometrial marker levels compared with the control subjects is indicative of endometrial disease.

A particular embodiment of the invention comprises the following steps

- (a) incubating a biological sample with first antibodies specific for one or more endometrial cancer markers which are directly or indirectly labeled with a detectable substance, and second antibodies specific for one or more endometrial cancer markers which are immobilized;
- (b) detecting the detectable substance thereby quantitating endometrial cancer markers in the biological sample; and
- (c) comparing the quantitated endometrial cancer markers with levels for a predetermined standard.

The standard may correspond to levels quantitated for samples from control subjects without endometrial cancer (normal or benign), with a different disease stage, or from other samples of the subject. In an

- 8 -

embodiment, increased levels of endometrial cancer markers as compared to the standard may be indicative of endometrial cancer. In another embodiment, lower levels of endometrial cancer markers as compared to a standard may be indicative of endometrial cancer.

5 Endometrial marker levels can be determined by constructing an antibody microarray in which binding sites comprise immobilized, preferably monoclonal, antibodies specific to a substantial fraction of marker-derived endometrial marker proteins of interest.

Other methods of the invention employ one or more polynucleotides capable of hybridizing to one or more polynucleotides encoding endometrial markers. Thus, methods for detecting endometrial markers can be used to monitor an endometrial disease (e.g. cancer) by detecting endometrial polynucleotide markers associated
10 with the disease.

Thus, the present invention relates to a method for diagnosing and monitoring an endometrial disease (e.g. endometrial cancer) in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting endometrial marker polynucleotides associated with the disease in the sample. The presence of different levels of endometrial marker polynucleotides in the sample compared to a standard or
15 control may be indicative of endometrium phase, disease, disease stage, and/or a positive prognosis i.e. longer progression-free and overall survival.

In embodiments of the invention, endometrial cancer marker polynucleotide positive tumors (e.g. higher levels of the polynucleotides compared to a control normal or benign tissue) are a negative diagnostic indicator. Positive tumors can be indicative of endometrial cancer, advanced stage disease, lower progression-free survival,
20 and/or overall survival.

In other embodiments of the invention, endometrial cancer marker polynucleotide negative tumors (e.g. lower levels of the polynucleotides compared to a control normal or benign tissue) are a negative diagnostic indicator. Negative tumors can be indicative of endometrial cancer, advanced stage disease, lower progression-free survival, and/or overall survival.

25 The invention provides methods for determining the presence or absence of an endometrial disease in a subject comprising detecting in the sample levels of nucleic acids that hybridize to one or more polynucleotides encoding endometrial markers associated with the disease, comparing the levels with a predetermined standard or cut-off value, and therefrom determining the presence or absence of endometrial disease in the subject. In an embodiment, the invention provides methods for determining the presence or absence of endometrial cancer in a
30 subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to one or more polynucleotides encoding endometrial cancer markers; and (b) detecting in the sample a level of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of endometrial cancer in the subject.

Within certain embodiments, the amount of polynucleotides that are mRNA are detected via polymerase
35 chain reaction using, for example, oligonucleotide primers that hybridize to one or more polynucleotides encoding endometrial markers, or complements of such polynucleotides. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to one or more polynucleotides encoding endometrial markers, or complements thereof.

When using mRNA detection, the method may be carried out by combining isolated mRNA with reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of one or more endometrial polynucleotide markers in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of endometrial polynucleotide markers. The analysis step may be further accomplished by quantitatively detecting the presence of endometrial polynucleotide markers in the amplification product, and comparing the quantity of marker detected against a panel of expected values for the known presence or absence of the markers in normal and malignant tissue derived using similar primers.

Therefore, the invention provides a method wherein mRNA is detected by (a) isolating mRNA from a sample and combining the mRNA with reagents to convert it to cDNA; (b) treating the converted cDNA with amplification reaction reagents and nucleic acid primers that hybridize to one or more endometrial polynucleotide markers to produce amplification products; (d) analyzing the amplification products to detect an amount of mRNA encoding the endometrial markers; and (e) comparing the amount of mRNA to an amount detected against a panel of expected values for normal and diseased tissue (e.g. malignant tissue) derived using similar nucleic acid primers.

In particular embodiments of the invention, the methods described herein utilize the endometrial polynucleotide markers placed on a microarray so that the expression status of each of the markers is assessed simultaneously.

In a particular aspect, the invention provides an endometrial microarray comprising a defined set of genes whose expression is significantly altered by endometrium phase or endometrial disease. The invention further relates to the use of the microarray as a prognostic tool to predict endometrium phase or endometrial disease. In an embodiment, the endometrial microarray discriminates between endometrial disease resulting from different etiologies.

In an embodiment, the invention provides for oligonucleotide arrays comprising marker sets described herein. The microarrays provided by the present invention may comprise probes to markers able to distinguish endometrium phase or disease. In particular, the invention provides oligonucleotide arrays comprising probes to a subset or subsets of at least 5 or 10 gene markers up to a full set of markers which distinguish endometrium phase or endometrial disease.

The invention also contemplates a method comprising administering to cells or tissues imaging agents that carry labels for imaging and bind to endometrial markers and optionally other markers of an endometrial disease, and then imaging the cells or tissues.

In an aspect the invention provides an *in vivo* method comprising administering to a subject an agent that has been constructed to target one or more endometrial markers.

In a particular embodiment, the invention contemplates an *in vivo* method comprising administering to a mammal one or more agent that carries a label for imaging and binds to one or more endometrial marker, and then imaging the mammal.

- 10 -

According to a particular aspect of the invention, an *in vivo* method for imaging endometrial cancer is provided comprising:

- (a) injecting a patient with an agent that binds to one or more endometrial cancer marker, the agent carrying a label for imaging the endometrial cancer;
- 5 (b) allowing the agent to incubate *in vivo* and bind to one or more endometrial cancer marker associated with the endometrial cancer; and
- (c) detecting the presence of the label localized to the endometrial cancer.

In an embodiment of the invention the agent is an antibody which recognizes an endometrial cancer marker. In another embodiment of the invention the agent is a chemical entity which recognizes an endometrial cancer marker.

An agent carries a label to image an endometrial marker and optionally other markers. Examples of labels useful for imaging are radiolabels, fluorescent labels (e.g. fluorescein and rhodamine), nuclear magnetic resonance active labels, positron emitting isotopes detectable by a positron emission tomography ("PET") scanner, chemiluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short-range radiation emitters, such as isotopes detectable by short-range detector probes can also be employed.

The invention also contemplates the localization or imaging methods described herein using multiple markers for an endometrial disease (e.g. endometrial cancer).

The invention also relates to kits for carrying out the methods of the invention. In an embodiment, a kit is for assessing whether a patient is afflicted with an endometrial disease (e.g. endometrial cancer) and it comprises reagents for assessing one or more endometrial markers or polynucleotides encoding the markers.

The invention further provides kits comprising marker sets described herein. In an aspect the kit contains a microarray ready for hybridization to target endometrial oligonucleotide markers, plus software for the data analyses.

The invention also provides a diagnostic composition comprising an endometrial marker or a polynucleotide encoding the marker. A composition is also provided comprising a probe that specifically hybridizes to endometrial polynucleotide markers, or a fragment thereof, or an antibody specific for endometrial markers or a fragment thereof. In another aspect, a composition is provided comprising one or more endometrial polynucleotide marker specific primer pairs capable of amplifying the polynucleotides using polymerase chain reaction methodologies. The probes, primers or antibodies can be labeled with a detectable substance.

Still further the invention relates to therapeutic applications for endometrial diseases, in particular endometrial cancer, employing endometrial markers and polynucleotides encoding the markers, and/or binding agents for the markers.

In an aspect, the invention relates to compositions comprising markers or parts thereof associated with an endometrial disease, or antibodies specific for endometrial markers associated with an endometrial disease, and a pharmaceutically acceptable carrier, excipient, or diluent. A method for treating or preventing an endometrial disease, in particular endometrial cancer, in a patient is also provided comprising administering to a patient in need thereof, markers or parts thereof associated with an endometrial disease, antibodies specific for endometrial markers associated with an endometrial disease, or a composition of the invention. In an aspect the invention provides a method of treating a patient afflicted with or at risk of developing an endometrial disease

(e.g. endometrial cancer) comprising inhibiting expression of endometrial markers.

In an aspect, the invention provides antibodies specific for endometrial markers associated with a disease (e.g. endometrial cancer) that can be used therapeutically to destroy or inhibit the disease (e.g. the growth of endometrial cancer marker expressing cancer cells), or to block endometrial marker activity associated with a disease. In an aspect, endometrial cancer markers may be used in various immunotherapeutic methods to promote immune-mediated destruction or growth inhibition of tumors expressing endometrial cancer markers.

The invention also contemplates a method of using endometrial markers or parts thereof, or antibodies specific for endometrial markers in the preparation or manufacture of a medicament for the prevention or treatment of an endometrial disease e.g. endometrial cancer.

Another aspect of the invention is the use of endometrial markers, peptides derived therefrom, or chemically produced (synthetic) peptides, or any combination of these molecules, for use in the preparation of vaccines to prevent an endometrial disease and/or to treat an endometrial disease.

The invention contemplates vaccines for stimulating or enhancing in a subject to whom the vaccine is administered production of antibodies directed against one or more endometrial markers.

The invention also provides a method for stimulating or enhancing in a subject production of antibodies directed against one or more endometrial marker. The method comprises administering to the subject a vaccine of the invention in a dose effective for stimulating or enhancing production of the antibodies.

The invention further provides a method for treating, preventing, or delaying recurrence of an endometrial disease (e.g. endometrial cancer). The method comprises administering to the subject a vaccine of the invention in a dose effective for treating, preventing, or delaying recurrence of an endometrial disease (e.g. endometrial cancer).

The invention contemplates the methods, compositions, and kits described herein using additional markers associated with an endometrial disease (e.g. endometrial cancer). The methods described herein may be modified by including reagents to detect the additional markers, or polynucleotides for the markers.

In particular, the invention contemplates the methods described herein using multiple markers for an endometrial cancer. Therefore, the invention contemplates a method for analyzing a biological sample for the presence of endometrial cancer markers and polynucleotides encoding the markers, and other markers that are specific indicators of cancer, in particular endometrial cancer. The methods described herein may be modified by including reagents to detect the additional markers, or nucleic acids for the additional markers.

In embodiments of the invention the methods, compositions and kits use one or more of the markers listed in Table 1, 4, 5, or 6. In another embodiment, the method uses a panel of markers selected from the markers listed in Table 1, 4, 5, or 6 in particular a panel comprising two or more of the markers in Table 1, 4, 5 or 6.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

- 12 -

The invention will now be described in relation to the drawings in which:

Figure 1 shows a schematic representation of the ICAT procedure including labeling, digestion, SCX fractionation, affinity isolation, cleavage of the biotin moiety and LC-MS/MS analysis.

Figure 2 shows histologic sections of human endometrium, stained with hematoxylin and eosin. A) proliferative endometrium, sample PRO 2, and B) secretory endometrium, sample SEC2.

Figure 3 shows a NanoLC-MS TIC of SCX fraction 16, ICAT sample A.

Figure 4 shows the distribution of proteins identified from the middle ten SCX fractions of all three samples.

Figure 5 shows A) a mass spectral window of Sample A, SCX fraction 19, showing enhanced expression of glutamate receptor subunit zeta 1 precursor in the secretory endometrium. The line to the left of the isotope envelope of the heavy-labeled version of the protein denotes where the light-labeled version is expected. B) Resulting MS/MS spectra of the heavy labelled series showing sequence coverage.

Figure 6 shows A) a mass spectral window of Sample A, SCX fraction 13, showing enhanced expression of MIF in the secretory endometrium. B) Resulting MS/MS spectra of the heavy labelled series showing sequence coverage.

Figure 7 (a+b). STEP ONE Mass spectra obtained from five whole endometrial tissue homogenates on Proteinchip WCX2 using (1a) SELDI-TOF-MS, PBSIIC, and (1b) QqTOF-MS, QSTAR XL. Note, using either MS method, the three malignant cases (38, 39, 40) show a distinct protein peak, which is low in the two non-malignant cases [18, 19]. The QSTARXL MS determined the weight of this peak to be 10,843 Da. Figure 7 STEP TWO Outline of protein purification. The target protein eluted in one of the early fractions of the size exclusion HPLC, was concentrated by Proteospin and then subjected to MALDI and SDS-PAGE (see Figure 8).

Figure 8 (A to E). STEP THREE (8A). Molecular weight verification of target protein after SEC. MALDI-TOF MS of samples from Proteospin was used to locate the fraction with the 10,843 Da weight of the target protein in a malignant case (40). The corresponding fraction from normal sample was used in parallel for all the following experiments. (8B) Molecular weight verification of the target protein fraction following DTT treatment. MALDI-TOF analysis of two samples indicates that the 10,843 Da peak remained in the malignant sample even after DTT treatment. (8C) SDS-PAGE analysis of the DTT treated fractions. The gel was stained by colloidal coomassie blue (Gel-Code, Pierce). The region containing the target protein was excised according to the molecular weight marker, and the intact proteins were extracted. (8D) Tryptic peptide profiles of the SDS-PAGE protein extract. MALDI-TOF MS analysis identified six "unique" tryptic peptides in the malignant samples. Three of them with mass of 907.54, 1036.58, and 1529.82 Da matched with the tryptic peptides from chaperonin 10. The remaining three peaks, marked with *, were from Keratin. (insert) Amino acid sequence of chaperonin 10. The locations of the three peptides were underlined. (8E) Fragmentation of peptide by collision induced dissociation. The 1529.82 Da peptide was fragmented. A series of y ions confirmed that the 1529.82 Da peptide comes from chaperonin 10.

Figure 9. Western blot analysis against chaperonin 10. The malignant endometrial cases (EmCa) demonstrate a higher expression of chaperonin 10 than non-malignant cases (Normal). The level of ERK1 was used to demonstrate similar loading among all lanes.

- 13 -

Figure 10. Immunohistochemical staining for chaperonin 10. Note granular cytoplasmic positivity in several malignant endometrioid glands, while adjacent endometrial stroma and a portion of one benign endometrial gland (right) shows much reduced staining.

Figure 11 shows mass spectral windows from isotope-coded affinity tag (ICAT) experiments for three pairs of endometrial cancer / normal samples, demonstrating the over expression of calgizzarin in the cancer samples.

Figure 12: Number of peptides/ protein identified. The first (front) series corresponds to results obtained from cICAT, the second series is from the first iTRAQ run, and the third (rearmost) series is from the second iTRAQ run.

Figure 13: Cytoplasmic actin sequencing and quantification using iTRAQ. *A*: MS/MS spectrum of the doubly protonated peptide, EITALAPSTMK [SEQ ID NO. 49], at 725.4 Th. Residues in black are sequenced from the b-ion series, while those in purple from the y-ion series. Residue 'J' in the y-ion series is the iTRAQ-modified lysine residue. *B*: Expanded view of the low-m/z end of the MS/MS spectrum in 'A', showing relative abundances of the signature iTRAQ ions at 114.1, 115.1, 116.1 and 117.1 Th.

Figure 14: Relative abundances of differentially expressed proteins. The ion assignments are as follows: 114 Th, proliferative endometrium; 115 Th, secretory endometrium; 116 Th, first endometrial carcinoma; and 117 Th, second endometrial carcinoma. *A*: Tryptic peptide from chaperonin 10, showing higher abundances in the 116 and 117 Th ions relative to the 114 and 115 Th ions; *B*: tryptic peptide from alpha-1-antitrypsin precursor, showing lower abundances in the 116 and 117 Th ions relative to the 114 and 115 Th ions; *C*: tryptic peptide from creatine kinase B, showing lower abundances in the 116 and 117 Th ions relative to the 114 and 115 Th ions; *D*: tryptic peptide from transgelin, showing once more lower abundances in the 116 and 117 Th ions relative to the 114 and 115 Th ions.

Figure 15: Relative abundances of calgizzarin. cICAT analysis shows overexpression in all three cancer samples. The dotted line to the left of the heavy-label series, which originates from the cancerous sample, indicates the monoisotopic peak of the light-label series, which originates from the normal sample.

Figure 16: Distribution of proteins identified by *A*: iTRAQ and *B*: cICAT analyses.

Figure 17 shows histologic sections of human endometrium stained with hematoxylin and eosin: (a) proliferative endometrium, sample PRO2, and (b) secretory endometrium, sample SEC2.

Figure 18 is a nano LC/MS total ion chromatogram of strong cation exchange fraction 16 of sample A.

Figure 19 shows the distribution of 119 confirmed proteins. The legend shows the protein categories starting with "Structural" at 18% at the 2 o'clock position and continuing clockwise.

Figure 20 shows the appearance of selected proteins in the strong cation exchange fractions.

Figure 21 shows the (a) mass spectral window of sample A, fraction 19, showing enhanced expression of glutamate receptor subunit zeta 1 precursor in the secretory endometrium. The line to the left of the isotope envelope of the heavy-labeled version of the protein denotes where the light-labeled version is expected; (b) resulting MS/MS spectrum showing a partial sequence for the peptide LLTLALLFSCSVAR [SEQ ID NO. 28].

Figure 22 shows the mass spectral windows of the three sample pairs, fraction 15, showing enhanced expression of FRAT1.

Figure 23 shows the mass spectral windows of sample A, fraction 4, showing enhanced expression of glycodeilin in the secretory endometrium.

Figure 24 shows the mass spectral windows showing the isotopic clusters of cathepsin B. Sample A shows enhanced cathepsin B expression in the secretory endometrium; sample B shows the opposite trend.

5 Figure 25 shows SELDI MS spectral windows acquired on the QqTOF mass spectrometer (QSTAR XL): (a) typical tissue homogenate; (b) homogenate treated with 0 % hydrogen peroxide; (c) homogenate in (b) treated incubated with 3% hydrogen peroxide overnight; (d) laser fluence at 34.6 μ J; and (e) laser fluence at 76.9 μ J.

10 Figure 26 shows SELDI MS spectra of four malignant (designated by "C") and two endometrial tissue homogenates (designated by "N"): (a) full scan spectra collected on the linear QTOF mass spectrometer (PBS IIc); and (b) mass spectral windows collected on the PBS IIc, left panel, and on the QqTOF mass spectrometer (QSTAR XL), right panel.

Figure 27 shows SELDI MS spectral windows showing binding of both (a) chaperonin 10 and (b) the unknown protein at pH 6.0; and selective binding of the unknown protein at pH 7.0.

15 Figure 28 shows MS/MS spectra of three tryptic peptides from the unknown protein that identify it as calgranulin A. Peptide identities: (a) MLTELEK [SEQ ID NO. 50], (b) ALNSIIDVYHK [SEQ ID NO. 51], and (c) GADVWFK [SEQ ID NO. 52].

20 Figure 29 shows Calgranulin A immunohistochemical stain of endometrial TMA (US Biochem 1:150): (A) Endometrioid adenocarcinoma exhibits diffuse, immunostaining of numerous cells (3+) of the glandular component of the adenocarcinoma. Intense immunostaining of macrophages/granulocytes within the stroma and glandular lumina is also evident. No stromal staining is observed. (B) Endometrioid adenocarcinoma shows strong positive immunostaining of occasional malignant glands (1+). Intense individual cell staining is also apparent in macrophages/granulocytes within gland lumina and stroma.

25 Figure 30 shows Calgranulin A immunohistochemical stain of endometrial TMA (US Biochem 1:150): Note intense (3+) cytoplasmic and nuclear immunostaining in squamous areas of this endometrioid adenocarcinoma. Glandular or columnar areas of the adenocarcinoma and adjacent stroma do not demonstrate any staining in this particular case.

30 Figure 31 shows Calgranulin A immunohistochemical stain of endometrial TMA (US Biochem 1:150): The glands and stroma of this proliferative endometrium show no immunostaining. However, intense individual macrophage/granulocyte immunostaining is evident within the stroma.

DETAILED DESCRIPTION OF THE INVENTION

35 Methods are provided for characterizing the stage or phase of endometrium, detecting the presence of an endometrial disease (e.g. endometrial cancer) in a sample, the absence of a disease (e.g. endometrial cancer) in a sample, the stage of a disease, the stage or grade of the disease, and other characteristics of endometrial diseases that are relevant to prevention, diagnosis, characterization, and therapy of endometrial diseases such as cancer in a patient, for example, the benign or malignant nature of an endometrial cancer, the metastatic potential of an endometrial cancer, assessing the histological type of neoplasm associated with an endometrial cancer, the indolence or aggressiveness of an endometrial cancer, and other characteristics of endometrial diseases that are relevant to prevention, diagnosis, characterization, and therapy of endometrial diseases such as cancer in a

patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting an endometrial disease, assessing the efficacy of a therapy for an endometrial disease, monitoring the progression of an endometrial disease, selecting an agent or therapy for inhibiting an endometrial disease, treating a patient afflicted with an endometrial disease, inhibiting an endometrial disease in a patient, and assessing the disease (e.g. carcinogenic) potential of a test compound.

Glossary

"Endometrial disease" refers to any disorder, disease, condition, syndrome or combination of manifestations or symptoms recognized or diagnosed as a disorder of the endometrium, including but not limited to hyperplasia and cancer precursors, endometrial cancer or carcinoma, endometriosis, reproductive disorders, and infertility.

"Endometrial cancer" or "endometrial carcinoma" includes malignant endometrial disease including but not limited to endometrioid, mucinous, and serous adenocarcinomas, adenosquamous carcinomas, clear cell carcinomas, uterine sarcomas including stromal sarcomas, malignant mixed Mullerian tumors (carcinosarcomas), and leiomyosarcomas.

The terms "sample", "biological sample", and the like mean a material known or suspected of expressing or containing one or more endometrial polynucleotide markers or one or more endometrial markers. A test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid, lavage fluid, and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like.

In embodiments of the invention the sample is a mammalian tissue sample. In a particular embodiment, the tissue is endometrial tissue.

In another embodiment the sample is a human physiological fluid. In a particular embodiment, the sample is human serum.

The samples that may be analyzed in accordance with the invention include polynucleotides from clinically relevant sources, preferably expressed RNA or a nucleic acid derived therefrom (cDNA or amplified RNA derived from cDNA that incorporates an RNA polymerase promoter). The target polynucleotides can comprise RNA, including, without limitation total cellular RNA, poly(A)⁺ messenger RNA (mRNA) or fraction thereof, cytoplasmic mRNA, or RNA transcribed from cDNA (i.e., cRNA; see, for example, Linsley & Schelter, U.S. patent application Ser. No. 09/411,074, or U.S. Pat. Nos. 5,545,522, 5,891,636, or 5,716,785). Methods for preparing total and poly(A)⁺ RNA are well known in the art, and are described generally, for example, in Sambrook et al., (1989, Molecular Cloning – A Laboratory Manual (2nd Ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) and Ausubel et al, eds. (1994, Current Protocols in Molecular Biology, vol. 2, Current Protocols Publishing, New York). RNA may be isolated from eukaryotic cells by procedures involving lysis of the cells and denaturation of the proteins contained in the cells. Additional steps may be

utilized to remove DNA. Cell lysis may be achieved with a nonionic detergent, followed by microcentrifugation to remove the nuclei and hence the bulk of the cellular DNA. (See Chirgwin et al., 1979, *Biochemistry* 18:5294-5299). Poly(A)+RNA can be selected using oligo-dT cellulose (see Sambrook et al., 1989, *Molecular Cloning—A Laboratory Manual (2nd Ed.)*, Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). In the alternative, RNA can be separated from DNA by organic extraction, for example, with hot phenol or phenol/chloroform/isoamyl alcohol.

It may be desirable to enrich mRNA with respect to other cellular RNAs, such as transfer RNA (tRNA) and ribosomal RNA (rRNA). Most mRNAs contain a poly(A) tail at their 3' end allowing them to be enriched by affinity chromatography, for example, using oligo(dT) or poly(U) coupled to a solid support, such as cellulose or Sephadex™ (see Ausubel et al., eds., 1994, *Current Protocols in Molecular Biology*, vol. 2, Current Protocols Publishing, New York). Bound poly(A)+mRNA is eluted from the affinity column using 2 mM EDTA/0.1% SDS.

A sample of RNA can comprise a plurality of different mRNA molecules each with a different nucleotide sequence. In an aspect of the invention, the mRNA molecules in the RNA sample comprise at least 100 different nucleotide sequences.

Target polynucleotides can be detectably labeled at one or more nucleotides using methods known in the art. The label is preferably uniformly incorporated along the length of the RNA, and more preferably, is carried out at a high degree of efficiency. The detectable label can be a luminescent label, fluorescent label, bioluminescent label, chemi-luminescent label, radiolabel, and colorimetric label. In a particular embodiment, the label is a fluorescent label, such as a fluorescein, a phosphor, a rhodamine, or a polymethine dye derivative. Commercially available fluorescent labels include, for example, fluorescent phosphoramidites such as FluorePrime (Amersham Pharmacia, Piscataway, N.J.), Fluoredit (Millipore, Bedford, Mass.), FAM (ABI, Foster City, Calif.), and Cy3 or Cy5 (Amersham Pharmacia, Piscataway, N.J.).

Target polynucleotides from a patient sample can be labeled differentially from polynucleotides of a standard. The standard can comprise target polynucleotides from normal individuals (i.e., those not afflicted with or pre-disposed to endometrial disease, in particular pooled from samples from normal individuals. The target polynucleotides can be derived from the same individual, but taken at different time points, and thus indicate the efficacy of a treatment by a change in expression of the markers, or lack thereof, during and after the course of treatment.

The terms "subject", "individual" or "patient" refer to a warm-blooded animal such as a mammal. In particular, the terms refer to a human. A subject, individual or patient may be afflicted with or suspected of having or being pre-disposed to endometrial disease or a condition as described herein. The term also includes domestic animals bred for food or as pets, including horses, cows, sheep, poultry, fish, pigs, cats, dogs, and zoo animals.

Methods herein for administering an agent or composition to subjects/individuals/patients contemplate treatment as well as prophylactic use. Typical subjects for treatment include persons susceptible to, suffering from or that have suffered a condition or disease described herein. In particular, suitable subjects for treatment in accordance with the invention are persons that are susceptible to, suffering from or that have suffered endometrial cancer.

The term "endometrial marker" includes a marker associated with normal or diseased endometrial tissue identified using a method of the invention. The term includes native-sequence polypeptides isoforms, chimeric polypeptides, complexes, all homologs, fragments, precursors, and modified forms and derivatives of the markers.

5 An endometrial marker may be associated with a stage or phase of endometrial tissue such as the secretory or proliferative phase. Examples of endometrial markers associated with the secretory phase are glutamate receptor subunit zeta 1 [SEQ ID NO. 26] and parts thereof (e.g. a tryptic fragment of SEQ ID NO. 28), macrophage migration inhibitory factor [SEQ ID NO. 18], FRAT1 [SEQ ID NO. 42], myosin light chain kinase 2 [SEQ ID NO. 45], and tropomyosin 1 alpha chain [SEQ ID NO. 47].

10 An endometrial marker may be associated with an endometrial disease, in particular it may be an endometrial cancer marker. The term "endometrial cancer marker" includes a marker associated with endometrial cancer identified using a method of the invention, in particular a marker listed in Table 1.

In an aspect of the invention, an endometrial cancer marker is chaperonin 10. The term "chaperonin 10", "chaperonin 10 polypeptide" or "chaperonin protein" includes human chaperonin 10, in particular the native-
15 sequence polypeptide, isoforms, chimeric polypeptides, all homologs, fragments, precursors, complexes, and modified forms and derivatives of human chaperonin 10. The amino acid sequence for native human chaperonin 10 includes the sequences of GenBank Accession No. Q04984 and AAH23518 shown in SEQ ID NO. 1.

A "native-sequence polypeptide" comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be
20 produced by recombinant or synthetic means. The term specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g. alternatively spliced forms or splice variants), and naturally occurring allelic variants.

The term "polypeptide variant" means a polypeptide having at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity, particularly at least about
25 70-80%, more particularly at least about 85%, still more particularly at least about 90%, most particularly at least about 95% amino acid sequence identity with a native-sequence polypeptide. Particular polypeptide variants have at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in Table 1, 4, 5, or 6 (see in particular, GenBank Accession Nos. Q04984 and AAH23518, P05109, P06702, P01833 or Q81ZY7, P30086, P39687, P17066, P14174, P31949, P00938 and NP_000356, Q05586, ITHU and P01009, gi/125294 and
30 P12277, P14618, Q01995, Q14103, NP_852000, NP_444254, and P09493 and AAH07433 and SEQ ID NOs. 1, 3, 6, 9, 11, 13, 15, 18, 21, 23, 26, 30, 33, 36, 38, 40, 42, 45, and 47). Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of the polypeptide, including variants from other species, but excludes a native-sequence polypeptide. In aspects of the invention variants retain the immunogenic activity of the corresponding
35 native-sequence polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions

- 18 -

as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., *Nucleic Acids Research* 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. *J. Molec. Biol.* 215: 403-410, 1990). The BLAST X
5 program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. *J. Mol. Biol.* 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

10 An allelic variant may also be created by introducing substitutions, additions, or deletions into a polynucleotide encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is
15 one in which an amino acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the
20 native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35,
25 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a
30 polypeptide homolog, for example, a murine polypeptide.

Endometrial markers include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of an endometrial marker operably linked to a heterologous polypeptide (i.e., a polypeptide other than an endometrial marker). Within the fusion protein, the term "operably linked" is intended to indicate that an endometrial marker and the heterologous polypeptide are fused in-frame to
35 each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of an endometrial marker. A useful fusion protein is a GST fusion protein in which an endometrial marker is fused to the C-terminus of GST sequences. Another example of a fusion protein is an immunoglobulin fusion protein in which all or part of an endometrial marker is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

A modified form of a polypeptide referenced herein includes modified forms of the polypeptides and derivatives of the polypeptides, including post-translationally modified forms such as glycosylated, phosphorylated, acetylated, methylated or lipidated forms of the polypeptides. For example, an N-terminal methionine may be cleaved from a polypeptide, and a new N-terminal residue may or may not be acetylated. In particular, for chaperonin 10 the first residue, methionine, can be cleaved and the second first residue, alanine can be N-acetylated.

Endometrial markers identified in accordance with a method of the invention may be prepared by recombinant or synthetic methods, or isolated from a variety of sources, or by any combination of these and similar techniques.

“Endometrial polynucleotide marker(s)”, polynucleotides encoding the marker(s)”, and “polynucleotides encoding endometrial markers” refer to polynucleotides that encode endometrial markers including native-sequence polypeptides, polypeptide variants including a portion of a polypeptide, an isoform, precursor, complex, a chimeric polypeptide, or modified forms and derivatives of the polypeptides. An endometrial polynucleotide marker includes the polynucleotides encoding the polypeptides listed in Table 1, 4, 5, or 6. In particular, the invention includes the polynucleotides encoding glutamate receptor subunit zeta 1 [e.g. see Accession No. D13515 and SEQ ID NO. 27], a tryptic peptide thereof [SEQ ID NO. 28], macrophage migration inhibitory factor [e.g. see Accession Nos. NM_002415 and L19686 and SEQ ID NOs. 19 and 20], FRAT1 [e.g. see Accession Nos. NM_005479 and NM_181355 and SEQ ID NOs. 43 and 44], myosin light chain kinase 2 [Accession No. AF069601 and SEQ ID NO. 46], tropomyosin 1 alpha chain e.g. see Accession No. NM_000366 and BC007433 and SEQ ID NO. 48], and the endometrial markers listed in Table 1 [in particular, GenBank Accession Nos. NM_002157 and U07550, A12027, NM_002964, X06233, M21064, NM_002644, NM_002567, NM_006305, NM_002155, X51757, NM_002415, L19686, NM_005620 and D38583, NM_000365, X69723, NM_000295, K02212, NM_001823, X15334, X56494, D84342, AF026126, and SEQ ID NOs. 2, 4, 5, 7, 8, 10, 12, 14, 16, 17, 19, 20, 22, 24, 25, 31, 32, 34, 35, 37, 39, 41]. In an embodiment, a polynucleotide of the invention encodes chaperonin 10, more particularly a polynucleotide sequence of GenBank Accession No. NM_002157 and U07550 [SEQ ID NO 2], or a fragment thereof.

Endometrial polynucleotide markers include complementary nucleic acid sequences, and nucleic acids that are substantially identical to these sequences (e.g. having at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity).

Endometrial polynucleotide markers also include sequences that differ from a native sequence [e.g. see GenBank Accession Nos. NM_002157 and U07550, A12027, NM_002964, X06233, M21064, NM_002644, NM_002567, NM_006305, NM_002155, X51757, NM_002415, L19686, NM_005620 and D38583, NM_000365, X69723, D13515, NM_000295, K02212, NM_001823, X15334, X56494, D84342, AF026126, NM_005479, NM_181355, AF069601, NM_000366, and BC007433, and SEQ ID NOs. 2, 4, 5, 7, 8, 10, 12, 14, 16, 17, 19, 20, 22, 24, 25, 27, 31, 32, 34, 35, 37, 39, 41, 43, 44, 46, and 48] due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of an endometrial marker may result in silent mutations that do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a polypeptide.

Endometrial polynucleotide markers also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to an endometrial polynucleotide marker, in particular an endometrial cancer polynucleotide marker [e.g. see GenBank Accession Nos. NM_002157 and U07550, A12027, NM_002964, X06233, M21064, NM_002644, NM_002567, NM_006305, NM_002155, X51757, NM_002415, L19686, NM_005620 and D38583, NM_000365, X69723, D13515, NM_000295, K02212, NM_001823, X15334, X56494, D84342, AF026126, NM_005479, NM_181355, AF069601, NM_000366, and BC007433, and SEQ ID NOs. 2, 4, 5, 7, 8, 10, 12, 14, 16, 17, 19, 20, 22, 24, 25, 27, 31, 32, 34, 35, 37, 39, 41, 43, 44, 46, and 48]. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Endometrial polynucleotide markers also include truncated nucleic acids or nucleic acid fragments and variant forms of the nucleic acids that arise by alternative splicing of an mRNA corresponding to a DNA.

The endometrial polynucleotide markers are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method. In certain applications the term refers to antisense polynucleotides (e.g. mRNA or DNA strand in the reverse orientation to sense cancer polynucleotide markers).

“Statistically different levels”, “significantly altered levels”, or “significant difference” in levels of markers in a patient sample compared to a control or standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay. In particular embodiments, the levels may be 1.5, 2, 3, 4, 5, or 6 times higher or lower than the control or standard.

“Microarray” and “array,” refer to nucleic acid or nucleotide arrays or protein or peptide arrays that can be used to detect biomolecules associated with endometrium or phase thereof or endometrial disease, for instance to measure gene expression. A variety of arrays are made in research and manufacturing facilities worldwide, some of which are available commercially. By way of example, spotted arrays and *in situ* synthesized arrays are two kinds of nucleic acid arrays that differ in the manner in which the nucleic acid materials are placed onto the array substrate. A widely used *in situ* synthesized oligonucleotide array is GeneChip™ made by Affymetrix, Inc. Oligonucleotide probes that are 20- or 25-base long can be synthesized *in silico* on the array substrate. These arrays can achieve high densities (e.g., more than 40,000 genes per cm²). Generally spotted arrays have lower densities, but the probes, typically partial cDNA molecules, are much longer than 20- or 25-mers. Examples of spotted cDNA arrays include LifeArray made by Incyte Genomics and DermArray made by IntegriDerm (or Invitrogen). Pre-synthesized and amplified cDNA sequences are attached to the substrate of spotted arrays. Protein and peptide arrays also are known (see for example, Zhu et al., *Science* 293:2101 (2001)).

“Binding agent” refers to a substance such as a polypeptide or antibody that specifically binds to one or more endometrial markers. A substance “specifically binds” to one or more endometrial markers if it reacts at a

detectable level with one or more endometrial markers, and does not react detectably with peptides containing an unrelated or different sequence. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al., Develop. Dynamics 197: 1-13, 1993).

5 A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises one or more endometrial marker sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example, a chaperonin 10 sequence may be a peptide portion of a chaperonin 10 that is capable of modulating a function mediated by chaperonin 10.

10 An aptamer includes a DNA or RNA molecule that binds to nucleic acids and proteins. An aptamer that binds to a protein (or binding domain) of an endometrial marker or an endometrial polynucleotide marker can be produced using conventional techniques, without undue experimentation. (For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)).

15 Antibodies for use in the present invention include but are not limited to monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or (Fab)₂ fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F_v molecules (Ladner et al, U.S. Pat. No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or
20 labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant endometrial markers may be utilized to prepare antibodies. (See, for example, Kohler et al. (1975) Nature 256:495-497; Kozbor et al. (1985) J. Immunol Methods 81:31-42; Cote et al. (1983) Proc Natl Acad Sci 80:2026-2030; and Cole et al. (1984) Mol
25 Cell Biol 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) Science 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) Immunochemical Protocols, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies). Antibodies specific for an endometrial marker may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against an endometrial marker if they bind
30 with a K_a of greater than or equal to 10⁻⁷ M.

Markers

The invention provides a set of markers correlated with endometrium or phase thereof, or endometrial disease. A subset of these markers identified as useful for detection, diagnosis, prevention and therapy of endometrial disease is listed in Table 1 or 5. A subset of these markers identified as useful for detection and
35 diagnosis of endometrium phase is listed in Table 4 or 6. The invention also provides a method of using these markers to distinguish endometrium phase or to distinguish endometrial disease.

The invention provides marker sets that distinguish endometrium phase or endometrial disease and uses therefor. In an aspect, the invention provides a method for classifying an endometrium phase or endometrial disease comprising detecting a difference in the expression of a first plurality of endometrial markers or

- 22 -

endometrial polynucleotide markers relative to a control, the first plurality of endometrial markers or endometrial polynucleotide markers consisting of at least 5 of the markers listed in Table 1, 4, 5, or 6. In specific aspects, the plurality of markers consists of at least 10 of the markers listed in Table 1, 4, 5, or 6. In another specific aspect, the control comprises markers derived from a pool of samples from individual patients with no endometrial disease, or individuals with a known endometrium phase.

Any of the markers provided herein may be used alone or with other markers of endometrium phase or endometrial disease, or with markers for other phenotypes or conditions.

Identification of Endometrial Markers

The invention relates to a method for identifying markers associated with the endometrium or a phase thereof, or associated with a disease of the endometrium comprising:

- (a) obtaining a sample of endometrium from a subject;
- (b) extracting proteins from the sample and producing a profile of the proteins by subjecting the proteins to mass spectrometry; and
- (c) comparing the profile with a profile for normal endometrial tissue or for a known endometrium phase to identify proteins associated with the endometrium phase or an endometrial disease.

Proteins may be extracted from the samples in a manner known in the art. For example, proteins may be extracted by first digesting or disrupting cell membranes by standard methods such as detergents or homogenization in an isotonic sucrose solution, followed by ultra-centrifugation or other standard techniques.

The separated proteins may be digested into peptides, in particular using proteolytic enzymes such as trypsin, pepsin, subtilisin, and proteinase. For example, proteins may be treated with trypsin which cleaves at the sites of lysine and arginine, to provide doubly-charged peptides with a length of from about 5 to 50 amino acids. Such peptides may be particularly appropriate for mass spectrometry analysis, especially electrospray ionization mass spectrometry. Chemical reagents including cyanogens bromide may also be utilized to digest proteins.

Mass spectrometers that may be used to analyze the peptides or proteins include a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometer ("MALDI-TOF") (e.g. from PerSeptive Biosystems, Framingham, Mass.); an Electrospray Ionization ("ESI") ion trap spectrometer, (e.g. from Finnigan MAT, San Jose, Calif.), an ESI quadrupole mass spectrometer (e.g. from Finnigan or Perkin-Elmer Corporation, Foster City, Calif.), a quadrupole/TOF hybrid tandem mass spectrometer, QSTAR XL (Applied Biosystems/MDS Sciex), or a Surface Enhanced Laser Desorption/Ionization (SELDI-TOF) Mass Spectrometer (e.g. from Ciphergen Biosystems Inc.).

Detection Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of endometrial disease or endometrial status involving one or more endometrial markers and polynucleotides encoding the markers, and the identification of subjects with a predisposition to endometrial diseases or that are receptive to *in vitro* fertilization and embryo transfer procedures. Such methods may, for example, utilize endometrial polynucleotide markers, and fragments thereof, and binding agents (e.g. antibodies) against one or more endometrial markers, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of the presence of endometrial polynucleotide marker mutations, or the

detection of either over- or under-expression of endometrial marker mRNA relative to a non-disorder state or different endometrium phase, or the qualitative or quantitative detection of alternatively spliced forms of endometrial polynucleotide marker transcripts which may correlate with certain conditions or susceptibility toward such conditions; and (2) the detection of either an over- or an under-abundance of one or more endometrial markers relative to a non- disorder state or a different endometrium phase or the presence of a modified (e.g., less than full length) endometrial marker which correlates with a disorder state or a progression toward a disorder state, or a particular endometrium phase.

The invention contemplates a method for detecting the phase of an endometrial tissue, in particular a secretory endometrial tissue, comprising producing a profile of levels of one or more endometrial marker associated with a known endometrium phase and/or polynucleotides encoding the markers, and optionally other markers associated with the endometrium phase in cells from a patient, and comparing the profile with a reference to identify a profile for the test cells indicative of the endometrium phase. In an aspect, the endometrial markers are one or more of glutamate receptor subunit zeta 1, macrophage migration inhibitory factor, FRAT1, myosin light chain kinase 2, tropomyosin 1 alpha chain, and fragments thereof.

The invention also contemplates a method for detecting an endometrial disease, in particular an endometrial cancer, comprising producing a profile of levels of one or more endometrial marker associated with an endometrial disease and/or polynucleotides encoding the markers, and other markers associated with endometrial disease in cells from a patient, and comparing the profile with a reference to identify a profile for the test cells indicative of disease. In an aspect, the endometrial markers are one or more of chaperonin 10, calgranulin A, calgranulin B, polymeric-immunoglobulin receptor (precursor), phosphatidylethanolamine-binding protein, acidic leucine-rich nuclear phosphoprotein 32 family member A, heat shock 70 kDa protein 6, macrophage migration inhibitory factor, calgizzarin (S100C protein), triosephosphate isomerase, alpha-1-antitrypsin precursor, creatine kinase, B chain, (B-CK), pyruvate, M1 or M2 isozyme, transgelin (smooth muscle protein 22-alpha), and heterologous nuclear ribonucleoprotein D0.

The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of endometrial disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

The methods described herein can be adapted for diagnosing and monitoring endometrial tissue status or an endometrial disease by detecting one or more endometrial markers or polynucleotides encoding the markers in biological samples from a subject. These applications require that the amount of markers or polynucleotides quantitated in a sample from a subject being tested be compared to a predetermined standard or cut-off value. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a control sample. Levels for control samples from healthy subjects, different endometrial tissue phases, or subjects with an endometrial disease may be established by prospective and/or retrospective statistical studies. Healthy subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of detected endometrial

- 24 -

markers associated with disease or polynucleotides encoding same, compared to a control sample or previous levels quantitated for the same subject.

The methods described herein may also use multiple markers for an endometrial disease, in particular endometrial cancer. Therefore, the invention contemplates a method for analyzing a biological sample for the presence of one or more endometrial markers and polynucleotides encoding the markers, and other markers that are specific indicators of an endometrial disease. The methods described herein may be modified by including reagents to detect the additional markers, or polynucleotides for the markers.

Nucleic Acid Methods/Assays

As noted herein an endometrial disease or phase may be detected based on the level of endometrial polynucleotide markers in a sample. Techniques for detecting polynucleotides such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

Probes may be used in hybridization techniques to detect endometrial polynucleotide markers. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with a probe under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of an endometrial polynucleotide marker, preferably they comprise 10-200, more particularly 10-30, 10-40, 20-50, 40-80, 50-150, 80-120 nucleotides in length.

The probes may comprise DNA or DNA mimics (e.g., derivatives and analogues) corresponding to a portion of an organism's genome, or complementary RNA or RNA mimics. Mimics are polymers comprising subunits capable of specific, Watson-Crick-like hybridization with DNA, or of specific hybridization with RNA. The nucleic acids can be modified at the base moiety, at the sugar moiety, or at the phosphate backbone.

DNA can be obtained using standard methods such as polymerase chain reaction (PCR) amplification of genomic DNA or cloned sequences. (See, for example, in Innis et al., eds., 1990, PCR Protocols: A Guide to Methods and Applications, Academic Press Inc., San Diego, Calif.). Computer programs known in the art can be used to design primers with the required specificity and optimal amplification properties, such as Oligo version 5.0 (National Biosciences). Controlled robotic systems may be useful for isolating and amplifying nucleic acids.

A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P , ^3H , ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect endometrial polynucleotide markers, preferably in human cells. The nucleotide probes may also be useful in the diagnosis of

- 25 -

an endometrial disease involving one or more endometrial polynucleotide markers, in monitoring the progression of such disorder, or monitoring a therapeutic treatment.

The detection of endometrial polynucleotide markers may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

By way of example, at least two oligonucleotide primers may be employed in a PCR based assay to amplify a portion of a polynucleotide encoding one or more endometrial marker derived from a sample, wherein at least one of the oligonucleotide primers is specific for (i.e. hybridizes to) a polynucleotide encoding the endometrial marker. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75%, and more preferably at least about 90% identity to a portion of a polynucleotide encoding an endometrial marker; that is, they are at least 10 nucleotides, and preferably at least 20 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of endometrial polynucleotide marker expression. For example, RNA may be isolated from a cell type or tissue known to express an endometrial polynucleotide marker and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e. directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomczynski and Sacchi, Anal. Biochem. 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to a set of primers, at least one of which is specifically designed against an endometrial marker sequence. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with a suspected endometrial disease and an individual who is not afflicted with an endometrial disease. The reaction may be performed on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-disease sample may be considered positive for the presence of an endometrial disease.

In an embodiment, the invention provides methods for determining the presence or absence of an endometrial disease in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to endometrial polynucleotide markers; and (b) detecting in the sample a level of

- 26 -

nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of an endometrial disease in the subject. In an aspect, the endometrial disease is cancer and the endometrial markers are one or more of chaperonin 10, calgranulin A, calgranulin B, polymeric-immunoglobulin receptor (precursor), phosphatidylethanolamine-binding protein, acidic leucine-rich
 5 nuclear phosphoprotein 32 family member A, heat shock 70 kDa protein 6, macrophage migration inhibitory factor, calgizzarin (S100C protein), triosephosphate isomerase, alpha-1-antitrypsin precursor, creatine kinase, B chain, (B-CK), pyruvate, M1 or M2 isozyme, transgelin (smooth muscle protein 22-alpha), and heterologous nuclear ribonucleoprotein D0.

In another embodiment, the invention provides methods for determining uterine receptivity of a subject
 10 to *in vitro* fertilization comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to endometrial polynucleotide markers associated with an endometrial tissue phase (e.g. secretory phase); and (b) detecting in the sample a level of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, wherein the presence or absence of the endometrial marker polynucleotides as compared to non-receptive controls indicates uterine receptivity. In an aspect, the endometrial markers are one
 15 or more of glutamate receptor subunit zeta 1, macrophage migration inhibitory factor, FRAT1, myosin light chain kinase 2, tropomyosin 1 alpha chain, and fragments thereof

The invention provides a method wherein an endometrial marker mRNA is detected by (a) isolating mRNA from a sample and combining the mRNA with reagents to convert it to cDNA; (b) treating the converted cDNA with amplification reaction reagents and nucleic acid primers that hybridize to one or more endometrial
 20 marker polynucleotides, to produce amplification products; (d) analyzing the amplification products to detect amounts of mRNA encoding endometrial polynucleotide markers; and (e) comparing the amount of mRNA to an amount detected against a panel of expected values for normal and malignant tissue derived using similar nucleic acid primers.

Endometrial cancer marker-positive samples or alternatively higher levels in patients compared to a
 25 control (e.g. non-cancerous tissue) may be indicative of late stage disease, and/or that the patient is not responsive to chemotherapy. Alternatively, negative samples or lower levels compared to a control (e.g. non-cancerous tissue or negative samples) may also be indicative of progressive disease and shorter overall survival.

In another embodiment, the invention provides methods for determining the presence or absence of endometrial cancer in a subject comprising (a) contacting a sample obtained from the subject with
 30 oligonucleotides that hybridize to one or more endometrial cancer polynucleotide markers; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of endometrial cancer in the subject. In an embodiment, the endometrial cancer polynucleotide markers encode one or more polypeptides listed in Table 1. In particular, the endometrial markers are one or more of chaperonin 10, calgranulin A, calgranulin B, polymeric-immunoglobulin
 35 receptor (precursor), phosphatidylethanolamine-binding protein, acidic leucine-rich nuclear phosphoprotein 32 family member A, heat shock 70 kDa protein 6, macrophage migration inhibitory factor, calgizzarin (S100C protein), triosephosphate isomerase, alpha-1-antitrypsin precursor, creatine kinase, B chain, (B-CK), pyruvate, M1 or M2 isozyme, transgelin (smooth muscle protein 22-alpha), and heterologous nuclear ribonucleoprotein D0, and fragments thereof.

In particular, the invention provides a method wherein chaperonin 10 mRNA is detected by (a) isolating mRNA from a sample and combining the mRNA with reagents to convert it to cDNA; (b) treating the converted cDNA with amplification reaction reagents and nucleic acid primers that hybridize to a polynucleotide encoding chaperonin 10, to produce amplification products; (d) analyzing the amplification products to detect an amount of mRNA encoding chaperonin 10; and (e) comparing the amount of mRNA to an amount detected against a panel of expected values for normal and malignant tissue derived using similar nucleic acid primers.

Endometrial cancer marker-positive samples or alternatively higher levels, in particular significantly higher levels of chaperonin 10 polynucleotides in patients compared to a control (e.g. normal or benign) are indicative of endometrial cancer. Negative samples or lower levels compared to a control (e.g. normal or benign) may also be indicative of progressive disease and poor overall survival.

Oligonucleotides or longer fragments derived from an endometrial cancer polynucleotide marker may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes and to identify genetic variants, mutations, and polymorphisms. The information from the microarray may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

Thus, the invention also includes an array comprising one or more endometrial polynucleotide markers (in particular the markers listed in Table 1, 4, 5, or 6) and optionally other markers. The array can be used to assay expression of endometrial polynucleotide markers in the array. The invention allows the quantitation of expression of one or more endometrial polynucleotide markers.

Microarrays typically contain at separate sites nanomolar quantities of individual genes, cDNAs, or ESTs on a substrate (e.g. nitrocellulose or silicon plate), or photolithographically prepared glass substrate. The arrays are hybridized to cDNA probes using conventional techniques with gene-specific primer mixes. The target polynucleotides to be analyzed are isolated, amplified and labeled, typically with fluorescent labels, radiolabels or phosphorous label probes. After hybridization is completed, the array is inserted into the scanner, where patterns of hybridization are detected. Data are collected as light emitted from the labels incorporated into the target, which becomes bound to the probe array. Probes that completely match the target generally produce stronger signals than those that have mismatches. The sequence and position of each probe on the array are known, and thus by complementarity, the identity of the target nucleic acid applied to the probe array can be determined.

Microarrays are prepared by selecting polynucleotide probes and immobilizing them to a solid support or surface. The probes may comprise DNA sequences, RNA sequences, copolymer sequences of DNA and RNA, DNA and/or RNA analogues, or combinations thereof. The probe sequences may be full or partial fragments of genomic DNA, or they may be synthetic oligonucleotide sequences synthesized either enzymatically *in vivo*, enzymatically *in vitro* (e.g., by PCR), or non-enzymatically *in vitro*.

The probe or probes used in the methods of the invention can be immobilized to a solid support or surface which may be either porous or non-porous. For example, the probes can be attached to a nitrocellulose or nylon membrane or filter covalently at either the 3' or the 5' end of the polynucleotide probe. The solid support may be a glass or plastic surface. In an aspect of the invention, hybridization levels are measured to microarrays of probes consisting of a solid support on the surface of which are immobilized a population of polynucleotides, such as a population of DNA or DNA mimics, or, alternatively, a population of RNA or RNA mimics. A solid support may be a nonporous or, optionally, a porous material such as a gel.

In accordance with embodiments of the invention, a microarray is provided comprising a support or surface with an ordered array of hybridization sites or "probes" each representing one of the markers described herein. The microarrays can be addressable arrays, and in particular positionally addressable arrays. Each probe of the array is typically located at a known, predetermined position on the solid support such that the identity of each probe can be determined from its position in the array. In preferred embodiments, each probe is covalently attached to the solid support at a single site.

Microarrays used in the present invention are preferably (a) reproducible, allowing multiple copies of a given array to be produced and easily compared with each other; (b) made from materials that are stable under hybridization conditions; (c) small, (e.g., between 1 cm² and 25 cm², between 12 cm² and 13 cm², or 3 cm²; and (d) comprise a unique set of binding sites that will specifically hybridize to the product of a single gene in a cell (e.g., to a specific mRNA, or to a specific cDNA derived therefrom). However, it will be appreciated that larger arrays may be used particularly in screening arrays, and other related or similar sequences will cross hybridize to a given binding site.

In accordance with an aspect of the invention, the microarray is an array in which each position represents one of the markers described herein. Each position of the array can comprise a DNA or DNA analogue based on genomic DNA to which a particular RNA or cDNA transcribed from a genetic marker can specifically hybridize. A DNA or DNA analogue can be a synthetic oligomer or a gene fragment. In an embodiment, probes representing each of the endometrial markers and endometrial polynucleotide markers is present on the array. In a preferred embodiment, the array comprises at least 5 of the endometrial polynucleotide markers.

Probes for the microarray can be synthesized using N-phosphonate or phosphoramidite chemistries (Froehler et al., 1986, Nucleic Acid Res. 14:5399-5407; McBride et al., 1983, Tetrahedron Lett. 24:246-248). Synthetic sequences are typically between about 10 and about 500 bases, 20-100 bases, or 40-70 bases in length. Synthetic nucleic acid probes can include non-natural bases, such as, without limitation, inosine. Nucleic acid analogues such as peptide nucleic acid may be used as binding sites for hybridization. (see, e.g., Egholm et al., 1993, Nature 363:566-568; U.S. Pat. No. 5,539,083).

Probes can be selected using an algorithm that takes into account binding energies, base composition, sequence complexity, cross-hybridization binding energies, and secondary structure (see Friend et al., International Patent Publication WO 01/05935, published Jan. 25, 2001).

Positive control probes, (e.g., probes known to be complementary and hybridize to sequences in the target polynucleotides), and negative control probes, (e.g., probes known to not be complementary and hybridize to sequences in the target polynucleotides) are typically included on the array. Positive controls can be

- 29 -

synthesized along the perimeter of the array or synthesized in diagonal stripes across the array. A reverse complement for each probe can be next to the position of the probe to serve as a negative control.

The probes can be attached to a solid support or surface, which may be made from glass, plastic (e.g., polypropylene, nylon), polyacrylamide, nitrocellulose, gel, or other porous or nonporous material. The probes
5 can be printed on surfaces such as glass plates (see Schena et al., 1995, *Science* 270:467-470). This method may be particularly useful for preparing microarrays of cDNA (See also, DeRisi et al., 1996, *Nature Genetics* 14:457-460; Shalon et al., 1996, *Genome Res.* 6:639-645; and Schena et al., 1995, *Proc. Natl. Acad. Sci. U.S.A.* 93:10539-11286).

High-density oligonucleotide arrays containing thousands of oligonucleotides complementary to defined
10 sequences, at defined locations on a surface can be produced using photolithographic techniques for synthesis in situ (see, Fodor et al., 1991, *Science* 251:767-773; Pease et al., 1994, *Proc. Natl. Acad. Sci. U.S.A.* 91:5022-5026; Lockhart et al., 1996, *Nature Biotechnology* 14:1675; U.S. Pat. Nos. 5,578,832; 5,556,752; and 5,510,270) or other methods for rapid synthesis and deposition of defined oligonucleotides (Blanchard et al., *Biosensors & Bioelectronics* 11:687-690). Using these methods oligonucleotides (e.g., 60-mers) of known sequence are
15 synthesized directly on a surface such as a derivatized glass slide. The array produced may be redundant, with several oligonucleotide molecules per RNA.

Microarrays can be made by other methods including masking (Maskos and Southern, 1992, *Nuc. Acids. Res.* 20:1679-1684). In an embodiment, microarrays of the present invention are produced by synthesizing polynucleotide probes on a support wherein the nucleotide probes are attached to the support covalently at either
20 the 3' or the 5' end of the polynucleotide.

The invention provides microarrays comprising a disclosed marker set. In one embodiment, the invention provides a microarray for distinguishing endometrial disease samples comprising a positionally-addressable array of polynucleotide probes bound to a support, the polynucleotide probes comprising a plurality of polynucleotide probes of different nucleotide sequences, each of the different nucleotide sequences comprising
25 a sequence complementary and hybridizable to a plurality of genes, the plurality consisting of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the genes corresponding to the markers listed in Table 1, 4, 5, or 6. An aspect of the invention provides microarrays comprising at least 5, 10, or 15 of the polynucleotides encoding the markers listed in Table 1, 4, 5, or 6.

The invention provides gene marker sets that distinguish endometrium phase or endometrial disease and
30 uses therefor. In an aspect, the invention provides a method for classifying an endometrium phase or disease comprising detecting a difference in the expression of a first plurality of genes relative to a control, the first plurality of genes consisting of at least 5 of the genes encoding the markers listed in Table 1, 4, 5, or 6. In specific aspects, the plurality of genes consists of at least 10 or 15 of the genes encoding the markers listed in Table 1, 4, 5, or 6. In another specific aspect, the control comprises nucleic acids derived from a pool of samples
35 from individual control patients.

The invention provides a method for classifying an endometrium phase or endometrial disease by calculating the similarity between the expression of at least 5 polynucleotides encoding markers listed in Table 1, 4, 5, or 6 in a sample to the expression of the same markers in a control pool, comprising the steps of:

- 30 -

- (a) labeling nucleic acids derived from a sample, with a first fluorophore to obtain a first pool of fluorophore-labeled nucleic acids;
- (b) labeling with a second fluorophore a first pool of nucleic acids derived from two or more endometrial disease samples, and a second pool of nucleic acids derived from two or more control samples;
- (c) contacting the first fluorophore-labeled nucleic acid and the first pool of second fluorophore-labeled nucleic acid with a first microarray under conditions such that hybridization can occur, and contacting the first fluorophore-labeled nucleic acid and the second pool of second fluorophore-labeled nucleic acid with a second microarray under conditions such that hybridization can occur, detecting at each of a plurality of discrete loci on the first microarray a first fluorescent emission signal from the first fluorophore-labeled nucleic acid and a second fluorescent emission signal from the first pool of second fluorophore-labeled genetic matter that is bound to the first microarray and detecting at each of the marker loci on the second microarray the first fluorescent emission signal from the first fluorophore-labeled nucleic acid and a third fluorescent emission signal from the second pool of second fluorophore-labeled nucleic acid;
- (d) determining the similarity of the sample to patient and control pools by comparing the first fluorescence emission signals and the second fluorescence emission signals, and the first emission signals and the third fluorescence emission signals; and
- (e) classifying the sample as endometrial disease where the first fluorescence emission signals are more similar to the second fluorescence emission signals than to the third fluorescent emission signals, and classifying the sample as non-endometrial disease where the first fluorescence emission signals are more similar to the third fluorescence emission signals than to the second fluorescent emission signals, wherein the first microarray and the second microarray are similar to each other, exact replicas of each other, or are identical, and wherein the similarity is defined by a statistical method such that the cell sample and control are similar where the p value of the similarity is less than 0.01.

In aspects of the invention, the array can be used to monitor the time course of expression of one or more endometrial polynucleotide markers in the array. This can occur in various biological contexts such as tumor progression.

The array is also useful for ascertaining differential expression patterns of endometrial polynucleotide markers, and optionally other markers, in normal and abnormal cells. This may provide a battery of nucleic acids that could serve as molecular targets for diagnosis or therapeutic intervention.

Protein Methods

Binding agents may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an endometrial disease (e.g. cancer) or an endometrium phase in a subject may be determined by (a) contacting a sample from the subject with a binding agent; (b) detecting in the sample

- 31 -

a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined standard or cut-off value.

In particular embodiments of the invention, the binding agent is an antibody. Antibodies specifically reactive with one or more endometrial marker, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect one or more endometrial marker in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the level of expression of one or more endometrial marker, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of one or more endometrial marker. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on disorders (e.g. endometrial cancer) involving one or more endometrial markers, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

In an aspect, the invention provides a method for monitoring or diagnosing an endometrial disease (e.g. cancer) in a subject by quantitating one or more endometrial markers in a biological sample from the subject comprising reacting the sample with antibodies specific for one or more endometrial markers, which are directly or indirectly labeled with detectable substances and detecting the detectable substances. In a particular embodiment of the invention, endometrial markers are quantitated or measured.

In an aspect of the invention, a method for detecting an endometrial disease (e.g. cancer) is provided comprising:

- (a) obtaining a sample suspected of containing one or more endometrial markers associated with an endometrial disease;
- (b) contacting said sample with antibodies that specifically bind to the endometrial markers under conditions effective to bind the antibodies and form complexes;
- (c) measuring the amount of endometrial markers present in the sample by quantitating the amount of the complexes; and
- (d) comparing the amount of endometrial markers present in the samples with the amount of endometrial markers in a control, wherein a change or significant difference in the amount of endometrial markers in the sample compared with the amount in the control is indicative of an endometrial disease.

In an embodiment, the invention contemplates a method for monitoring the progression of an endometrial disease (e.g. cancer) in an individual, comprising:

- (a) contacting antibodies which bind to one or more endometrial markers with a sample from the individual so as to form complexes comprising the antibodies and one or more endometrial markers in the sample;
- (b) determining or detecting the presence or amount of complex formation in the sample;
- (c) repeating steps (a) and (b) at a point later in time; and
- (d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of disease, disease stage, and/or progression of the disease in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, an endometrial disease at different stages. A significant difference in complex formation may be indicative of advanced disease e.g. advanced endometrial cancer, or an unfavourable prognosis.

5 In aspects of the invention for diagnosis and monitoring of endometrial cancer, the endometrial markers are one or more of chaperonin 10, calgranulin A, calgranulin B, polymeric-immunoglobulin receptor (precursor), phosphatidylethanolamine-binding protein, acidic leucine-rich nuclear phosphoprotein 32 family member A, heat shock 70 kDa protein 6, macrophage migration inhibitory factor, calgizzarin (S100C protein), triosephosphate isomerase, alpha-1-antitrypsin precursor, creatine kinase, B chain, (B-CK), pyruvate, M1 or M2 isozyme, 10 transgelin (smooth muscle protein 22-alpha), and heterologous nuclear ribonucleoprotein D0, or fragments thereof.

In embodiments of the methods of the invention, chaperonin 10 is detected in samples and higher levels, in particular significantly higher levels compared to a control (normal or benign) is indicative of endometrial cancer.

15 In aspects of the invention for characterizing endometrium phase the endometrial markers are one or more of glutamate receptor subunit zeta 1, macrophage migration inhibitory factor, FRAT1, myosin light chain kinase 2, tropomyosin 1 alpha chain, and fragments thereof.

In another embodiment, the invention provides methods for determining uterine receptivity of a subject to *in vitro* fertilization comprising (a) contacting a sample obtained from the subject with antibodies that bind to 20 one or more endometrial marker associated with a certain endometrium phase (e.g. secretory phase); and (b) detecting in the sample a level of endometrial marker relative to a predetermined cut-off value, wherein the presence or absence of the endometrial marker as compared to non-receptive controls indicates uterine receptivity. In a particular embodiment, the marker is one or more of glutamate receptor subunit zeta 1, macrophage migration inhibitory factor, FRAT1, myosin light chain kinase 2, tropomyosin 1 alpha chain, and 25 fragments thereof, more particularly glutamate receptor subunit zeta 1 or a fragment thereof, and/or macrophage migration inhibitory factor.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of one or more endometrial marker and the antibodies. Immunoassay procedures for *in vitro* detection of antigens in fluid samples are also well known in the art. [See for example, Paterson et al., Int. J. 30 Can. 37:659 (1986) and Burchell et al., Int. J. Can. 34:763 (1984) for a general description of immunoassay procedures]. Qualitative and/or quantitative determinations of one or more endometrial marker in a sample may be accomplished by competitive or non-competitive immunoassay procedures in either a direct or indirect format. Detection of one or more endometrial marker using antibodies can be done utilizing immunoassays which are run in either the forward, reverse or simultaneous modes. Examples of immunoassays are 35 radioimmunoassays (RIA), enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, histochemical tests, and sandwich (immunometric) assays. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

According to an embodiment of the invention, an immunoassay for detecting one or more endometrial

markers in a biological sample comprises contacting binding agents that specifically bind to endometrial markers in the sample under conditions that allow the formation of first complexes comprising a binding agent and endometrial markers and determining the presence or amount of the complexes as a measure of the amount of endometrial markers contained in the sample. In a particular embodiment, the binding agents are labeled
5 differently or are capable of binding to different labels.

Antibodies may be used to detect and quantify one or more endometrial markers in a sample in order to diagnose and treat pathological states. In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect one or more endometrial markers, to localize them to particular endometrial cells and tissues (e.g. tumor cells and tissues), and to specific subcellular
10 locations, and to quantitate the level of expression.

Immunohistochemical methods for the detection of antigens in tissue samples are well known in the art. For example, immunohistochemical methods are described in Taylor, Arch. Pathol. Lab. Med. 102:112 (1978). Briefly, in the context of the present invention, a tissue sample obtained from a subject suspected of having an endometrial-related problem is contacted with antibodies, preferably monoclonal antibodies recognizing one or
15 more endometrial markers. The site at which the antibodies are bound is determined by selective staining of the sample by standard immunohistochemical procedures. The same procedure may be repeated on the same sample using other antibodies that recognize one or more endometrial markers. Alternatively, a sample may be contacted with antibodies against one or more endometrial markers simultaneously, provided that the antibodies are labeled differently or are able to bind to a different label. The tissue sample may be normal endometrial tissue, a cancer
20 tissue or a benign tissue.

An antibody microarray in which binding sites comprise immobilized, preferably monoclonal, antibodies specific to a substantial fraction of marker-derived endometrial markers of interest can be utilized in the present invention. Antibody arrays can be prepared using methods known in the art [(see for example, Zhu et al., *Science* 293:2101 (2001) and reference 20].

Antibodies specific for one or more endometrial marker may be labelled with a detectable substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g., ^3H , ^{14}C , ^{35}S , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol; enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl
30 groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or
35 colloidal gold, which are readily visualised by electron microscopy.

One of the ways an antibody can be detectably labeled is to link it directly to an enzyme. The enzyme when later exposed to its substrate will produce a product that can be detected. Examples of detectable substances that are enzymes are horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase, malate dehydrogenase, ribonuclease, urease, catalase, glucose-6-phosphate, staphylococcal

- 34 -

nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, triose phosphate isomerase, asparaginase, glucose oxidase, and acetylcholine esterase.

For increased sensitivity in an immunoassay system a fluorescence-emitting metal atom such as Eu (europium) and other lanthanides can be used. These can be attached to the desired molecule by means of metal-chelating groups such as DTPA or EDTA.

A bioluminescent compound may also be used as a detectable substance. Bioluminescence is a type of chemiluminescence found in biological systems where a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent molecule is determined by detecting the presence of luminescence. Examples of bioluminescent detectable substances are luciferin, luciferase and aequorin.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against one or more endometrial markers. By way of example, if the antibody having specificity against one or more endometrial markers is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect one or more endometrial markers. Generally, antibodies may be labeled with detectable substances and one or more endometrial markers may be localised in tissues and cells based upon the presence of the detectable substances.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies specific for one or more endometrial markers), or one or more endometrial markers may be immobilized on a carrier or support. Examples of suitable carriers or supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized antibody may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. An antibody may be indirectly immobilized using a second antibody specific for the antibody. For example, mouse antibody specific for an endometrial marker may be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where a radioactive label is used as a detectable substance, one or more endometrial marker may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

- 35 -

Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

5 In accordance with an embodiment of the invention, a method is provided wherein one or more endometrial marker antibodies are directly or indirectly labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of an enzyme and substrate, form fluorescent complexes with a lanthanide metal (e.g. europium, terbium, samarium, and dysprosium, preferably europium and terbium). A lanthanide metal is added and one or more endometrial cancer markers are quantitated in the sample by measuring fluorescence of the fluorescent complexes. Enzymes are selected based
10 on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Suitable enzymes and substrates that provide fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. Examples of suitable enzymes include alkaline phosphatase and β -galactosidase. Preferably, the enzyme is alkaline phosphatase.

Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described
15 in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

20 One or more endometrial marker antibodies may also be indirectly labelled with an enzyme. For example, the antibodies may be conjugated to one partner of a ligand binding pair, and the enzyme may be coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In an embodiment, the antibodies are biotinylated, and the enzyme is coupled to streptavidin. In another embodiment, an antibody specific for endometrial marker antibody is labeled
25 with an enzyme.

In accordance with an embodiment, the present invention provides means for determining one or more endometrial markers in a sample by measuring one or more endometrial markers by immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure one or more endometrial markers. In general, an immunoassay method may be competitive or noncompetitive. Competitive
30 methods typically employ an immobilized or immobilizable antibody to one or more endometrial marker and a labeled form of one or more endometrial marker. Sample endometrial markers and labeled endometrial markers compete for binding to antibodies to endometrial markers. After separation of the resulting labeled endometrial markers that have become bound to antibodies (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the
35 amount of endometrial markers in the test sample in any conventional manner, e.g., by comparison to a standard curve.

In an aspect, a non-competitive method is used for the determination of one or more endometrial markers, with the most common method being the "sandwich" method. In this assay, two antibodies to endometrial markers are employed. One of the antibodies to endometrial markers is directly or indirectly labeled

- 36 -

(sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or sequentially with the test sample. Sequential methods can be accomplished by incubating the capture antibody with the sample, and adding the detection antibody at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibody can be incubated with the sample first and then the capture antibody added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to complete the assay, the capture antibody is separated from the liquid test mixture, and the label is measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally it is measured in the capture antibody phase since it comprises endometrial cancer markers bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

In a typical two-site immunometric assay for endometrial markers, one or both of the capture and detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The label used in the detection antibody can be selected from any of those known conventionally in the art. The label may be an enzyme or a chemiluminescent moiety, but it can also be a radioactive isotope, a fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the ligand), and the like. In a particular aspect, the antibody is labelled with an enzyme which is detected by adding a substrate that is selected so that a reaction product of the enzyme and substrate forms fluorescent complexes. The capture antibody may be selected so that it provides a means for being separated from the remainder of the test mixture. Accordingly, the capture antibody can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables immobilization to be accomplished subsequent to introduction of the capture antibody to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, the capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

Computer Systems

Analytic methods contemplated herein can be implemented by use of computer systems and methods described below and known in the art. Thus, the invention provides computer readable media comprising one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers (e.g. markers of endometrial cancer). "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the

- 37 -

invention contemplates computer readable medium having recorded thereon markers identified for patients and controls.

5 "Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on one or more endometrial markers, and optionally other markers.

10 A variety of data processor programs and formats can be used to store information on one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and other markers on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

15 By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

20 The invention provides a medium for holding instructions for performing a method for determining uterine endometrial receptivity of a patient, or whether a patient has an endometrial disease (e.g. endometrial cancer) or a pre-disposition to an endometrial disease (e.g. cancer), comprising determining the presence or absence of one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers, and based on the presence or absence of the one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers, determining uterine endometrial receptivity, endometrial disease (e.g. cancer) or a pre-disposition to an endometrial disease (e.g. cancer), and optionally recommending a procedure or treatment.

25 The invention also provides in an electronic system and/or in a network, a method for determining uterine endometrial receptivity of a patient, whether a subject has an endometrial disease (e.g. cancer) or a pre-disposition to an endometrial disease (e.g. cancer), comprising determining the presence or absence of one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers (e.g. cancer markers), and based on the presence or absence of the one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers, determining the uterine endometrial receptivity of the patient, whether the subject has an endometrial disease (e.g. cancer) or a pre-disposition to an endometrial disease (e.g. cancer), and optionally recommending a procedure or treatment.

30 The invention further provides in a network, a method for determining whether a subject is receptive to *in vitro* fertilization, has an endometrial disease (e.g. cancer) or a pre-disposition to an endometrial disease (e.g. cancer) comprising: (a) receiving phenotypic information on the subject and information on one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers associated with samples from the subject; (b) acquiring information from the network corresponding to

- 38 -

the one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers; and (c) based on the phenotypic information and information on the one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other markers, determining whether the subject is receptive to *in vitro* fertilization, has an endometrial disease (e.g. cancer) or a pre-disposition to an endometrial disease (e.g. cancer); and (d) optionally recommending a procedure or treatment.

The invention still further provides a system for identifying selected records that identify a diseased endometrial cell or tissue (e.g. cancer cell or tissue) or an endometrium phase. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally other endometrial markers, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting endometrial cancer tissue or cells using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

- (a) creating records of one or more endometrial cancer markers, and/or polynucleotides encoding one or more endometrial cancer markers, and optionally other markers of cancer identified in a sample suspected of containing endometrial cancer cells or tissue;
- (b) providing a database comprising records of data comprising one or more endometrial cancer markers, and/or polynucleotides encoding one or more endometrial cancer markers, and optionally other markers of cancer; and
- (c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a positive indication that the markers of step (a) have been isolated from cells or tissue that are endometrial cancer cells or tissue.

The invention contemplates a business method for determining whether a subject is receptive to *in vitro* fertilization, has an endometrial disease (e.g. cancer) or a pre-disposition to endometrial cancer comprising: (a) receiving phenotypic information on the subject and information on one or more endometrial markers, and/or polynucleotides encoding the markers, and optionally other markers, associated with samples from the subject; (b) acquiring information from a network corresponding to one or more endometrial markers, and/or polynucleotides encoding the markers, and optionally other markers; and (c) based on the phenotypic information, information on one or more endometrial markers, and/or polynucleotides encoding the markers, and optionally other markers, and acquired information, determining whether the subject is receptive to *in vitro* fertilization, has an endometrial disease (e.g. cancer) or a pre-disposition to an endometrial disease (e.g. cancer); and (d) optionally recommending a procedure or treatment.

In an aspect of the invention, the computer systems, components, and methods described herein are used to monitor disease or determine the stage of disease, or determine uterine endometrial receptivity.

Imaging Methods

Binding agents, in particular antibodies, specific for one or more endometrial markers may also be used in imaging methodologies in the management of an endometrial disease or determining uterine endometrial receptivity.

5 In an aspect, the invention provides a method for imaging tumors associated with one or more endometrial cancer markers.

The invention also contemplates imaging methods described herein using multiple markers for an endometrial disease or endometrium phase. Preferably each agent is labeled so that it can be distinguished during the imaging.

10 In an embodiment the method is an *in vivo* method and a subject or patient is administered one or more agents that carry an imaging label and that are capable of targeting or binding to one or more endometrial markers. The agent is allowed to incubate *in vivo* and bind to the endometrial markers associated with endometrial cells or tissues of a particular phase or associated with diseased cells or tissues, (e.g. an endometrial tumor). The presence of the label is localized to the endometrial cells or tissues, and the localized label is
15 detected using imaging devices known to those skilled in the art.

The agent may be an antibody or chemical entity that recognizes the endometrial markers. In an aspect of the invention the agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for the endometrial markers used in the
20 methods of the invention may be obtained from scientific or commercial sources, or isolated native endometrial markers or recombinant endometrial markers may be utilized to prepare antibodies etc. as described herein.

An agent may be a peptide that mimics the epitope for an antibody specific for an endometrial marker and binds to the marker. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes either tyrosine, lysine, or
25 phenylalanine to which N_2S_2 chelate is complexed (See U.S. Patent No. 4,897,255). An anti-endocrine marker peptide conjugate is then combined with a radiolabel (e.g. sodium ^{99m}Tc pertechnetate or sodium ^{188}Re perrhenate) and it may be used to locate an endometrial marker producing cell or tissue (e.g. tumor).

The agent carries a label to image the endometrial markers. The agent may be labelled for use in radionuclide imaging. In particular, the agent may be directly or indirectly labelled with a radioisotope. Examples
30 of radioisotopes that may be used in the present invention are the following: ^{277}Ac , ^{211}At , ^{128}Ba , ^{131}Ba , ^7Be , ^{204}Bi , ^{205}Bi , ^{206}Bi , ^{76}Br , ^{77}Br , ^{82}Br , ^{109}Cd , ^{47}Ca , ^{11}C , ^{14}C , ^{36}Cl , ^{48}Cr , ^{51}Cr , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{165}Dy , ^{155}Eu , ^{18}F , ^{153}Gd , ^{66}Ga , ^{67}Ga , ^{68}Ga , ^{72}Ga , ^{198}Au , ^3H , ^{166}Ho , ^{111}In , ^{113m}In , ^{115m}In , ^{123}I , ^{125}I , ^{131}I , ^{189}Ir , ^{191m}Ir , ^{192}Ir , ^{194}Ir , ^{52}Fe , ^{55}Fe , ^{59}Fe , ^{177}Lu , ^{15}O , $^{191m-191}\text{Os}$, ^{109}Pd , ^{32}P , ^{33}P , ^{42}K , ^{226}Ra , ^{186}Re , ^{188}Re , ^{82m}Rb , ^{153}Sm , ^{46}Sc , ^{47}Sc , ^{72}Se , ^{75}Se , ^{105}Ag , ^{22}Na , ^{24}Na , ^{89}Sr , ^{35}S , ^{38}S , ^{177}Ta , ^{96}Tc , ^{99m}Tc , ^{201}Tl , ^{202}Tl , ^{113}Sn , ^{117m}Sn , ^{121}Sn , ^{166}Yb , ^{169}Yb , ^{175}Yb , ^{88}Y , ^{90}Y , ^{62}Zn and ^{65}Zn .
35 Preferably the radioisotope is ^{131}I , ^{125}I , ^{123}I , ^{111}I , ^{99m}Tc , ^{90}Y , ^{186}Re , ^{188}Re , ^{32}P , ^{153}Sm , ^{67}Ga , ^{201}Tl , ^{77}Br , or ^{18}F , and is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling, and ^{35}S labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-

126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, Nature 144:945 (1962), David et al., Biochemistry 13:1014-1021 (1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., Biochem. J. 89:114-123 (1963); Marchalonis, J., Biochem. J. 113:299-305 (1969); and Morrison, M. et al., Immunochemistry, 289-297 (1971). ^{99m}Tc-labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S. Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for ¹¹¹In-labeling biological agents are described by Hnatowich, D. J. et al., J. Immunol. Methods, 65:147-157 (1983), Hnatowich, D. et al., J. Applied Radiation, 35:554-557 (1984), and Buckley, R. G. et al., F.E.B.S. 166:202-204 (1984).

An agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo* method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

In the case of a radiolabeled agent, the agent may be administered to the patient, it is localized to the cell or tissue (e.g. tumor) having an endometrial marker with which the agent binds, and is detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using e.g., a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g., ¹¹C, ¹⁸F, ¹⁵O, and ¹³N).

Whole body imaging techniques using radioisotope labeled agents can be used for locating diseased cells and tissues (e.g. primary tumors and tumors which have metastasized). Antibodies specific for endometrial markers, or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For endometrial cancer, administration preferably is intravenous. The bio-distribution of the label can be monitored by scintigraphy, and accumulations of the label are related to the presence of endometrial cancer cells. Whole body imaging techniques are described in U.S. Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis staging and visualization of cancer, in particular endometrial cancer, so that surgical and/or radiation treatment protocols can be used more efficiently.

An imaging agent may carry a bioluminescent or chemiluminescent label. Such labels include polypeptides known to be fluorescent, bioluminescent or chemiluminescent, or, that act as enzymes on a specific substrate (reagent), or can generate a fluorescent, bioluminescent or chemiluminescent molecule. Examples of bioluminescent or chemiluminescent labels include luciferases, aequorin, obelin, mnemiopsin, berovin, a

- 41 -

phenanthridinium ester, and variations thereof and combinations thereof. A substrate for the bioluminescent or chemiluminescent polypeptide may also be utilized in a method of the invention. For example, the chemiluminescent polypeptide can be luciferase and the reagent luciferin. A substrate for a bioluminescent or chemiluminescent label can be administered before, at the same time (e.g., in the same formulation), or after administration of the agent.

An imaging agent may comprise a paramagnetic compound, such as a polypeptide chelated to a metal, e.g., a metalloporphyrin. The paramagnetic compound may also comprise a monocrystalline nanoparticle, e.g., a nanoparticle comprising a lanthanide (e.g., Gd) or iron oxide; or, a metal ion comprising a lanthanide. "Lanthanides" refers to elements of atomic numbers 58 to 70, a transition metal of atomic numbers 21 to 29, 42 or 44, a Gd(III), a Mn(II), or an element comprising a Fe element. Paramagnetic compounds can also comprise a neodymium iron oxide (NdFeO₃) or a dysprosium iron oxide (DyFeO₃). Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

An image can be generated in a method of the invention by computer assisted tomography (CAT), magnetic resonance spectroscopy (MRS) image, magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), or bioluminescence imaging (BLI) or equivalent.

Computer assisted tomography (CAT) and computerized axial tomography (CAT) systems and devices well known in the art can be utilized in the practice of the present invention. (See, for example, U.S. Patent Nos. 6,151,377; 5,946,371; 5,446,799; 5,406,479; 5,208,581; 5,109,397). The invention may also utilize animal imaging modalities, such as MicroCAT.TM. (ImTek, Inc.).

Magnetic resonance imaging (MRI) systems and devices well known in the art can be utilized in the practice of the present invention. In magnetic resonance methods and devices, a static magnetic field is applied to a tissue or a body in order to define an equilibrium axis of magnetic alignment in a region of interest. A radio frequency field is then applied to the region in a direction orthogonal to the static magnetic field direction to excite magnetic resonance in the region. The resulting radio frequency signals are then detected and processed, and the exciting radio frequency field is applied. The resulting signals are detected by radio-frequency coils that are placed adjacent to the tissue or area of the body of interest. (For a description of MRI methods and devices see, for example, U.S. Patent Nos. 6,151,377; 6,144,202; 6,128,522; 6,127,825; 6,121,775; 6,119,032; 6,115,446; 6,111,410; 6,02,891; 5,555,251; 5,455,512; 5,450,010; 5,378,987; 5,214,382; 5,031,624; 5,207,222; 4,985,678; 4,906,931; 4,558,279). MRI and supporting devices are commercially available for example, from Bruker Medical GmbH; Caprius; Esaote Biomedica; Fonar; GE Medical Systems (GEMS); Hitachi Medical Systems America; Intermagnetics General Corporation; Lunar Corp.; MagneVu; Marconi Medicals; Philips Medical Systems; Shimadzu; Siemens; Toshiba America Medical Systems; including imaging systems, by, e.g., Silicon Graphics. The invention may also utilize animal imaging modalities such as micro-MRIs.

Positron emission tomography imaging (PET) systems and devices well known in the art can be utilized in the practice of the present invention. For example, a method of the invention may use the system designated Pet VI located at Brookhaven National Laboratory. For descriptions of PET systems and devices see, for example, U.S. Pat. Nos. 6,151,377; 6,072,177; 5,900,636; 5,608,221; 5,532,489; 5,272,343; 5,103,098. Animal
5 imaging modalities such as micro-PETs (Corcorde Microsystems, Inc.) can also be used in the invention.

Single-photon emission computed tomography (SPECT) systems and devices well known in the art can be utilized in the practice of the present invention. (See, for example, U.S. Patents. Nos. 6,115,446; 6,072,177; 5,608,221; 5,600,145; 5,210,421; 5,103,098.) The methods of the invention may also utilize animal imaging modalities, such as micro-SPECTs.

10 Bioluminescence imaging includes bioluminescence, fluorescence or chemiluminescence or other photon detection systems and devices that are capable of detecting bioluminescence, fluorescence or chemiluminescence. Sensitive photon detection systems can be used to detect bioluminescent and fluorescent proteins externally; see, for example, Contag (2000) Neoplasia 2:41-52; Zhang (1994) Clin. Exp. Metastasis 12:87-92. The methods of the invention can be practiced using any such photon detection device, or variation or
15 equivalent thereof, or in conjunction with any known photon detection methodology, including visual imaging. By way of example, an intensified charge-coupled device (ICCD) camera coupled to an image processor may be used in the present invention. (See, e.g., U.S. Pat. No. 5,650,135). Photon detection devices are also commercially available from Xenogen, Hamamatsue.

Screening Methods

20 The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit an endometrial disease (e.g. cancer), potentially contribute to an endometrial disease (e.g. cancer), or inhibit or enhance an endometrium phase. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids,
25 phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)₂, and Fab expression library fragments, and epitope-binding fragments thereof)], and small organic or inorganic molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

30 The invention provides a method for assessing the potential efficacy of a test agent for inhibiting an endometrial disease (e.g. cancer) in a patient, the method comprising comparing:

- (a) levels of one or more endometrial markers, and/or polynucleotides encoding endometrial markers, and optionally other markers in a first sample obtained from a patient and exposed to the test agent; and
- 35 (b) levels of one or more endometrial markers and/or polynucleotides encoding endometrial markers, and optionally other markers, in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers, and optionally the other markers, in the first sample, relative to the

- 43 -

second sample, is an indication that the test agent is potentially efficacious for inhibiting an endometrial disease (e.g. cancer) in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

5 In an aspect, the invention provides a method of selecting an agent for inhibiting an endometrial disease (e.g. cancer) in a patient comprising:

- (a) obtaining a sample from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing one or more endometrial markers, and/or polynucleotides encoding endometrial markers, and optionally other markers, in each of the aliquots; and
- 10 (d) selecting one of the test agents which alters the levels of one or more endometrial markers, and/or polynucleotides encoding endometrial markers, and optionally other markers in the aliquot containing that test agent, relative to other test agents.

In a further aspect, the invention provides a method of selecting an agent for inhibiting or enhancing an endometrium phase in a patient comprising:

- (a) obtaining a sample of endometrium in a selected phase (e.g. secretory or proliferative phase);
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing one or more endometrial markers, and/or polynucleotides encoding endometrial markers, and optionally other markers, in each of the aliquots; and
- 20 (d) selecting one of the test agents which alters the levels of one or more endometrial markers, and/or polynucleotides encoding endometrial markers, and optionally other markers in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery business comprising:

- 25 (a) providing one or more methods or assay systems for identifying agents that inhibit an endometrial disease (e.g. endometrial cancer) or affect an endometrium phase in a patient;
- (b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and
- (c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as
- 30 having an acceptable therapeutic profile.

In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the potential of a test compound to contribute to an endometrial disease (e.g. endometrial cancer) comprising:

- 35 (a) maintaining separate aliquots of cells or tissues from a patient with an endometrial disease (e.g. cancer) in the presence and absence of the test compound; and
- (b) comparing one or more endometrial markers, and/or polynucleotides encoding endometrial markers, and optionally other markers in each of the aliquots.

- 44 -

A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses the potential to contribute to an endometrial disease (e.g. endometrial cancer).

5 Kits

The invention also contemplates kits for carrying out the methods of the invention. Kits may typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

10 The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising one or more specific endometrial marker polynucleotide or antibody described herein, which may be conveniently used, e.g., in clinical settings to screen and diagnose patients and to screen and identify those individuals exhibiting a predisposition to developing an endometrial disease.

15 In an embodiment, a container with a kit comprises a binding agent as described herein. By way of example, the kit may contain antibodies or antibody fragments which bind specifically to epitopes of one or more endometrial markers and optionally other markers, antibodies against the antibodies labelled with an enzyme; and a substrate for the enzyme. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

20 In an aspect of the invention, the kit includes antibodies or fragments of antibodies which bind specifically to an epitope of one or more protein listed in Table 1, 4, 5, or 6 and means for detecting binding of the antibodies to their epitope associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents. Containers that provide a formulation for direct use, usually do not require other reagents, as for example, where the kit contains a radiolabelled antibody preparation for *in vivo* imaging.

25 A kit may be designed to detect the level of polynucleotides encoding one or more endometrial polynucleotide markers in a sample. In an embodiment, the polynucleotides encode one or more polynucleotides encoding a polypeptide listed in Table 1, 4, 5 or 6. Such kits generally comprise at least one oligonucleotide probe or primer, as described herein, that hybridizes to a polynucleotide encoding one or more endometrial cancer markers. Such an oligonucleotide may be used, for example, within a PCR or hybridization procedure. Additional components that may be present within the kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate detection of a polynucleotide encoding one or more endometrial cancer markers.

30 The invention provides a kit containing a microarray described herein ready for hybridization to target endometrial polynucleotide markers, plus software for the data analysis of the results. The software to be included with the kit comprises data analysis methods, in particular mathematical routines for marker discovery, including the calculation of correlation coefficients between clinical categories and marker expression. The software may also include mathematical routines for calculating the correlation between sample marker expression and control marker expression, using array-generated fluorescence data, to determine the clinical classification of the sample.

- 45 -

The reagents suitable for applying the screening methods of the invention to evaluate compounds may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

5 The invention contemplates a kit for assessing the presence of endometrial cells, wherein the kit comprises antibodies specific for one or more endometrial markers, or primers or probes for polynucleotides encoding same, and optionally probes, primers or antibodies specific for other markers associated with an endometrial disease (e.g. cancer).

10 The invention relates to a kit for assessing the suitability of each of a plurality of test compounds for inhibiting an endometrial disease (e.g. endometrial cancer) in a patient. The kit comprises reagents for assessing one or more endometrial markers or polynucleotides encoding same, and optionally a plurality of test agents or compounds.

15 Additionally the invention provides a kit for assessing the potential of a test compound to contribute to an endometrial disease (e.g. cancer). The kit comprises endometrial diseased cells (e.g. cancer cells) and reagents for assessing one or more endometrial markers, polynucleotides encoding same, and optionally other markers associated with an endometrial disease.

Therapeutic Applications

One or more endometrial markers may be targets for immunotherapy. Immunotherapeutic methods include the use of antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

20 In one aspect, the invention provides one or more endometrial marker antibodies that may be used systemically to treat an endometrial disease associated with the marker. In particular, the endometrial disease is endometrial cancer and one or more endometrial marker antibodies may be used systemically to treat endometrial cancer. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue.

25 Thus, the invention provides a method of treating a patient susceptible to, or having a disease (e.g. cancer) that expresses one or more endometrial marker (in particular a marker up-regulated in endometrial cancer, for example, an up-regulated marker in Table 1), comprising administering to the patient an effective amount of an antibody that binds specifically to one or more endometrial marker.

30 In another aspect, the invention provides a method of inhibiting the growth of tumor cells expressing one or more endometrial cancer markers, comprising administering to a patient an antibody which binds specifically to one or more endometrial cancer markers in an amount effective to inhibit growth of the tumor cells.

35 One or more endometrial marker antibodies may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing one or more endometrial marker (e.g. tumor cell expressing one or more endometrial cancer marker) comprising reacting one or more endometrial marker antibody immunoconjugate or immunotoxin with the cell in an amount sufficient to inhibit the growth of, or kill the cell.

By way of example, unconjugated antibodies to endometrial cancer markers may be introduced into a patient such that the antibodies bind to endometrial cancer marker expressing cancer cells and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, altering the physiologic function of

one or more endometrial cancer markers, and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies to endometrial cancer markers, one or more endometrial cancer marker antibodies conjugated to therapeutic agents (e.g. immunoconjugates) may also be used therapeutically to deliver the agent directly to one or more endometrial cancer marker expressing tumor cells and thereby destroy the tumor. Examples of such agents include abrin, ricin A, *Pseudomonas* exotoxin, or diphtheria toxin; proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

Cancer immunotherapy using one or more endometrial cancer marker antibodies may utilize the various approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlen et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunother Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54: 6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

In the practice of a method of the invention, endometrial cancer marker antibodies capable of inhibiting the growth of cancer cells expressing endometrial cancer markers are administered in a therapeutically effective amount to cancer patients whose tumors express or overexpress one or more endometrial cancer markers. The invention may provide a specific, effective and long-needed treatment for endometrial cancer. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

Patients may be evaluated for the presence and level of expression or overexpression of one or more endometrial markers in diseased cells and tissues (e.g. tumors), in particular using immunohistochemical assessments of tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of one or more endometrial markers. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

Endometrial marker antibodies useful in treating disease (e.g. cancer) include those that are capable of initiating a potent immune response against the disease (e.g. tumor) and those that are capable of direct cytotoxicity. In this regard, endometrial marker antibodies may elicit cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins.

Endometrial marker antibodies that exert a direct biological effect on tumor growth may also be useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

The anti-tumor activity of a particular endometrial cancer marker antibody, or combination of endometrial cancer marker antibodies, may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, where human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

5 The methods of the invention contemplate the administration of single endometrial marker antibodies as well as combinations, or "cocktails", of different individual antibodies such as those recognizing different epitopes of other markers. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes of endometrial markers and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in
10 combination may exhibit synergistic therapeutic effects. In addition, the administration of one or more endometrial marker specific antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The endometrial marker specific antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

15 The endometrial marker specific antibodies used in the methods of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the function of the antibody and is non-reactive with the subject's immune systems. Examples include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally,
20 Remington's Pharmaceutical Sciences 16.sup.th Edition, A. Osal., Ed., 1980).

One or more endometrial marker specific antibody formulations may be administered via any route capable of delivering the antibodies to the a disease (e.g. tumor) site. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a
25 sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

Treatment will generally involve the repeated administration of the antibody preparation via an acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will depend upon various factors generally appreciated by those of skill in the art, including the type of disease and the
30 severity, grade, or stage of the disease, the binding affinity and half life of the antibodies used, the degree of endometrial marker expression in the patient, the extent of circulating endometrial markers, the desired steady-state antibody concentration level, frequency of treatment, and the influence of any chemotherapeutic agents used in combination with the treatment method of the invention. Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies per week may be effective and well tolerated, although even higher
35 weekly doses may be appropriate and/or well tolerated. A determining factor in defining the appropriate dose is the amount of a particular antibody necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve disease inhibition or regression. Direct administration of one or more endometrial marker antibodies is also possible and may have advantages in certain situations.

Patients may be evaluated for serum cancer markers in order to assist in the determination of the most

- 48 -

effective dosing regimen and related factors. The endometrial cancer assay methods described herein, or similar assays, may be used for quantitating circulating endometrial marker levels in patients prior to treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters such as serum levels of endometrial markers.

5 The invention further provides vaccines formulated to contain one or more endometrial marker or fragment thereof.

 In an embodiment, the invention provides a method of vaccinating an individual against one or more endometrial marker listed in Table 1 comprising the step of inoculating the individual with the marker or fragment thereof that lacks activity, wherein the inoculation elicits an immune response in the individual thereby
10 vaccinating the individual against the marker.

 The use in anti-cancer therapy of a tumor antigen in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These and similar methods can be practiced by employing one or more endometrial markers, or fragment
15 thereof, or endometrial polynucleotide markers and recombinant vectors capable of expressing and appropriately presenting endometrial marker immunogens.

 By way of example, viral gene delivery systems may be used to deliver one or more endometrial polynucleotide markers. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral
20 delivery systems may also be employed by using naked DNA encoding one or more endometrial cancer marker or fragment thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

 Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present one or more endometrial marker to a patient's immune system. For example, autologous dendritic cells which express
25 MHC class I and II, may be pulsed with one or more endometrial marker or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate the patients' immune systems (See, for example, Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380).

 Anti-idiotypic endometrial marker specific antibodies can also be used in therapy as a vaccine for inducing an immune response to cells expressing one or more endometrial marker. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic endometrial cancer marker specific antibodies that mimic an epitope on one or more endometrial cancer markers (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such an antibody can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against antigens associated with disease (e.g.
35 tumor antigens).

 Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cells expressing one or more endometrial cancer marker. One or more DNA molecules encoding endometrial markers, constructs comprising DNA encoding one or more endometrial markers/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an

individual, such that the cells of the muscle or skin take-up the construct and express the encoded endometrial markers/immunogens. The endometrial markers/immunogens may be expressed as cell surface proteins or be secreted. Expression of one or more endometrial markers results in the generation of prophylactic or therapeutic humoral and cellular immunity against the disease (e.g. cancer). Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing one or more endometrial marker. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that endometrial markers form complexes with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing one or more endometrial marker by reacting any one or a combination of the immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver polynucleotides encoding endometrial cancer markers to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct recombinant vectors that will express antisense polynucleotides for endometrial markers. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Genes encoding endometrial markers can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired endometrial marker-encoding fragment. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of a gene encoding an endometrial marker, i.e., the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, e.g. between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme

molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding an endometrial marker.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC.

- 5 Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

- 10 One or more endometrial markers and polynucleotides encoding the markers, and fragments thereof, may be used in the treatment of an endometrial disease (e.g. endometrial cancer) in a subject. In an aspect the endometrial markers and polynucleotides encoding the markers are endometrial cancer markers that are down-regulated in endometrial cancer, for example, a down-regulated marker in Table 1. The markers or polynucleotides may be formulated into compositions for administration to subjects suffering from an endometrial disease. Therefore, the present invention also relates to a composition comprising one or more
- 15 endometrial markers or polynucleotides encoding the markers, or a fragment thereof, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing an endometrial disease in a subject is also provided comprising administering to a patient in need thereof, one or more endometrial markers or polynucleotides encoding the markers, or a composition of the invention.

- The invention further provides a method of inhibiting an endometrial disease (e.g. endometrial cancer)
- 20 in a patient comprising:

- (a) obtaining a sample comprising diseased cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing levels of one or more endometrial markers, and/or polynucleotides encoding one or more endometrial markers in each aliquot;
- 25 (d) administering to the patient at least one of the test agents which alters the levels of the endometrial markers, and/or polynucleotides encoding one or more endometrial markers in the aliquot containing that test agent, relative to the other test agents.

- Endometrial markers in uterine biopsy tissue or fluid and sera may vary between known fertile and infertile women during the window of implantation, deviate in women undergoing ovarian
- 30 hyperstimulation/ovulation induction, and correlate with successful initiation of pregnancy. Therefore, endometrial markers of the invention may serve as minimally or noninvasive markers of uterine receptivity for implantation.

- The present invention further provides a method of determining uterine endometrial receptivity by first obtaining a serum, uterine fluid or endometrial biopsy sample from a patient and detecting the presence of an
- 35 endometrial marker associated with a certain endometrium phase, wherein the presence or absence of an endometrial marker as compared to controls indicates uterine receptivity. In an embodiment, the endometrium phase is the secretory phase. Where necessary for the evaluation, repetitive samples may be collected throughout the menstrual cycle. Non-receptive controls are both women who are in the non-fertile stage of the menstrual

cycle and women with known uterine dysfunction where an endometrial marker is not present or present on the endometrium throughout the menstrual cycle or certain endometrium phases.

The present invention further provides a method of monitoring the effects of ovarian hyperstimulation and/or ovulation induction protocols on uterine receptivity either for individual women receiving the treatment or for the evaluation of new protocols. In an embodiment, the method comprises: (a) obtaining a serum, uterine or fluid or endometrial biopsy sample from a patient receiving the treatments; and (b) detecting the presence of an endometrial marker of the invention present in the endometrium at the time of fertilization, early embryogenesis, and implantation; wherein presence or absence of an endometrial marker indicates receptivity. A disruption of the normal cyclic presence of an endometrial marker indicates that the treatment may adversely affect uterine receptivity. This disruption may include non-cyclic presence of an endometrial marker or an aberrant presence of an endometrial marker as compared to controls.

In an aspect the invention provides a method of determining a probability of successful implantation with an ovarian stimulation *in vitro* fertilization and embryo transfer procedure, comprising:

- (a) determining a level of an endometrial marker identified in accordance with a method of the invention in a sample obtained from a patient who has undergone an ovarian stimulation *in vitro* fertilization and embryo transfer procedure; and
- (b) determining a probability of successful implantation based on the patient's determined endometrial marker level;

wherein a significantly different endometrial marker level relative to a standard level is associated with a decreased or increased probability of successful implantation.

The present invention further provides a method of contraception by interrupting the cyclic presence of an endometrial marker. The interruption can be to reduce or eliminate a marker present during the uterine receptivity window for implantation of the menstrual cycle and to thereby alter the cyclic presence/pattern of a marker. The interruption can utilize an antagonist of a marker. The term antagonist or antagonizing is used in its broadest sense. Antagonism can include any mechanism or treatment that results in inhibition, inactivation, blocking or reduction or alteration of cyclic presence of an endometrial marker.

An active therapeutic substance described herein may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the substance. Solutions of an active compound as a free base or pharmaceutically acceptable salt can be prepared in an appropriate solvent with a suitable surfactant. Dispersions may be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, or in oils.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable

- 52 -

vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other therapeutic agents or other forms of treatment. The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The therapeutic activity of compositions and agents/compounds identified using a method of the invention and may be evaluated *in vivo* using a suitable animal model.

The following non-limiting examples are illustrative of the present invention:

Example 1

Isotope-coded affinity tag (ICAT) analysis with a cleavable tag was used to examine differentially expressed proteins in proliferative and secretory endometria. Sample complexity of the tissue homogenates was reduced by strong cation exchange (SCX) fractionation and subsequent affinity cleanup. Analysis of ten SCX fractions in triplicate by nanobore liquid chromatography – tandem mass spectrometry (nanoLC-MS/MS) resulted in the identification of approximately 400 labeled proteins and the discovery of potential biomarkers for the secretory phase of the endometrial cycle. This study demonstrated the feasibility of using this approach for identifying markers at a proteomics level for different stages of the endometrial cycle.

Tissue Samples

Endometrium tissue was retrieved from an in-house dedicated, research endometrial tissue bank. All tissues were snap frozen in liquid nitrogen within 15-20 minutes of devitalization at the time of hysterectomy, and were obtained with patient consent. In each case, the endometrium was classified as proliferative or secretory by a pathologist. The histological classification was verified by examination of a histopathologic section from the frozen research tissue. Tissue was taken for proteomic analysis from the mirror-face of the residual block. After addition of 1 ml Hanks' Balanced Salt Solution containing protease inhibitors (leupeptin, aprotinin, pepstatin at 1 µg/mL), the tissue was mechanically homogenized at 30,000 rpms using a Polytron PT 1300D handheld homogenizer (Brinkmann, Westbury, USA). The samples were stored in aliquots at -80°C and/or submitted for protein profiling. These whole tissue homogenates contain endometrial epithelium, supportive stroma and vessels, as well as any secretions. Tissue samples from six different individuals were selected for the study. Three of these tissues were classified as proliferative endometria (PRO1, PRO2 and PRO3) and the other three as secretory endometria (SEC1, SEC2, SEC3).

Chemicals

Acetonitrile, formic acid, potassium chloride, monobasic potassium phosphate, leupeptin, aprotinin, pepstatin and Hanks' Balanced Salt Solution were obtained from Sigma-Aldrich (Oakville, Canada). All reagents and buffers for the cleavable ICAT sample preparation procedure were from Applied Biosystems (Foster City, USA).

ICAT Sample Preparation Procedure

After removal of cell debris by centrifugation, the total protein content for each of the six clarified homogenates was measured using a commercially available Bradford protein assay reagent (Bio-Rad, Hercules, USA). ICAT sample preparation procedure was carried out according to the cleavable ICAT protocol (Applied Biosystems, Foster City, USA) and is illustrated in Figure 1. Following denaturing and reducing steps, 100 µg

total protein of each of the samples was labeled with either the light ICAT reagent (proliferative samples) or the heavy reagent (secretory samples). The labeled PRO1 and SEC1 samples were combined to form ICAT Sample A, PRO2 and SEC2 form ICAT Sample B, and lastly PRO3 and SEC3 form ICAT Sample C. Mixing of the labeled proliferative and secretory samples in pairs in this manner ensures that any protein or peptide losses during subsequent processing steps is the same for both samples in a pair. Since the peptides are differentially labeled, they can be traced to specific samples in the pair. Any difference detected in the levels of individual peptides can then be ascribed solely to initial differences in expression level. Chromatographic separation using a strong cation exchange (SCX) column was performed after trypsin digestion to fractionate the ICAT samples. Selected SCX fractions were purified by affinity chromatography according to the ICAT protocol, and subsequently analyzed by nanobore liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS).

Instrumentation for SCX fractionation

SCX fractionation was performed on an HP1050 LC system (Agilent, Palo Alto, USA) using a 1.5 ml injection loop and a SF-2120 Super Fraction Collector (Advantec MFS, Dublin, USA).

LC/MS/MS Instrumentation

The LC system from LC Packings (Amsterdam, The Netherlands) consisted of a Famos autosampler and Ultimate Nano LC system. It was interfaced to an API QSTAR Pulsar QqTOF mass spectrometer (Applied Biosystems/MDS Sciex, Foster City, USA) using a Protana NanoES ion source (Protana Engineering A/S, Odense, Denmark). PicoTip's SilicaTip emitters with a 10 μ m tip i.d. (New Objective, Woburn, USA) were used as spray capillaries. All data were acquired using Analyst QS SP5 with Bioanalyst Extension 1.1 and analyzed with ProICAT SP2 software (Applied Biosystems/MDS Sciex, Foster City, USA).

LC Conditions

Strong cation exchange chromatography (SCX) was performed using a PolyLC Polysulfoethyl A column (The Nest Group, Southborough, USA) equipped with a guard column of the same material with the following dimensions: 5- μ m particle size, 300-Å bead, 2.1-mm i.d., 10-mm length (guard column) and 100-mm length (analytical column). Eluent A of the mobile phase consisted of a 10 mM KH_2PO_4 solution in 25% acetonitrile and 75% deionized water (pH = 3.0). Eluent B consisted of a 10 mM KH_2PO_4 and 350 mM KCl solution in 25% acetonitrile and 75% deionized water (pH = 3.0). In each case, 1.5 ml of the total 2.4 ml sample (after acidifying with 2 ml Eluent A) was injected. Fractions were collected every 2 mins at a flow rate of 0.2 ml/min. using a binary gradient with the following profile:

<i>t</i> [min]	0.01	2	58	60
<i>c</i> (Eluent B) [%]	0	0	100	stop

All reversed-phase separations were performed using PepMap C18 nano capillary columns (LC Packings, Amsterdam, The Netherlands) with the following dimensions: 3- μ m particle size, 100-Å bead, 75- μ m i.d. and 150-mm length. Eluent A of the mobile phase consisted of 950 ml deionized water, 50 ml acetonitrile and 1 ml formic acid (pH \approx 3). Eluent B consisted of 50 ml deionized water, 950 ml acetonitrile and 1 ml formic acid. A binary gradient at a flow rate of approximately 200 nl/min with the following profile was used:

- 54 -

<i>t</i> [min]	0.01	5	125	135	157	160	163	190
<i>c</i> (Eluent B) [%]	5	5	30	60	80	80	5	Stop

Injectations of 1 µl of sample were performed in full loop mode.

MS Conditions

The source conditions were a curtain-gas setting of 20 and an ionspray voltage (in the range of 2000 - 3800 V) that was optimized daily. All data were obtained in the positive-ion detection mode. In the Q0 region, the instrument parameters were a declustering potential (DP) of 65 V and a focusing potential (FP) of 265 V. Nitrogen was used as the collision gas at a setting of CAD5 for both TOF-MS and MS/MS scans.

All LC-MS/MS data were acquired in information-dependent acquisition (IDA) mode. A TOF-MS survey scan with a mass range of $m/z = 400 - 1500$ and 1 s scan time was followed by two product ion scans with a mass range of $m/z = 70 - 2000$ and 2 s scan time. The collision energy (CE) was automatically controlled by the IDA CE Parameters script. The switching criteria were set to ions greater than $m/z = 400$ and smaller than $m/z = 1500$ with a charge state of 2 to 5 and an intensity of ≥ 10 counts/s. Former target ions were excluded for 60 s and peaks within a 4 Th window were ignored. In addition, the IDA Extensions II script was set to 2 repetitions before dynamic exclusion and to select a precursor ion nearest to a threshold of 15 count/s every 4 cycles.

RESULTS AND DISCUSSION

Figure 2 shows examples of the histologic appearance of proliferative (Figure 2A) and secretory (Figure 2B) endometrium. In both endometria the stratum basalis is characterized by a denser stroma than the physiologic responsive stratum functionalis above. Across the top of the stratum functionalis is the surface epithelium, which lines the endometrial cavity. The proliferative endometrium (PRO 2) shows small, coiled glands with lining columnar epithelium reaching to the surface. In contrast, the secretory endometrium (SEC2) is thicker, and contains more tortuous glands with intra-luminal secretions. The endometrium of both types of physiologic phases has abundant supportive stroma and vessels among the epithelial glands. In this study homogenates from the mirror faces of these tissues were used for quantitative analysis. After performing the procedure described above, SCX fractions 11 - 20 (of the 30 fractions) from each of the samples were chosen for further processing. This choice was based on the UV trace generated during fractionation. The 10 chosen fractions from each sample were affinity-purified, cleaved as per the ICAT protocol and analyzed using nanoLC-MS/MS. Figure 3 is an example of a nano LC-MS total ion chromatogram (TIC) from one of the ICAT Sample A SCX fractions. As the samples were run in IDA mode (See above), each such TIC resulted in hundreds of MS/MS spectra. A ProICAT confidence value of 75 was adopted after trial-and-error for reliable protein detection and identification for this initial investigation. This has resulted in identification of approximately 400 distinct proteins. A preliminary classification of these proteins based on function, is seen in Figure 4. As expected the majority of proteins fall under one of the metabolic, housekeeping or structural categories. The proteins classified under "other" are proteins like antibodies, which could not be included with the previously mentioned categories. There were also a significant number of proteins for which function could not be assigned or were identified from cDNA matches and are therefore classified as hypothetical. This last category often contains the most interesting cases for biologists. Adopting a less stringent confidence value resulted in apparent

identification of many more proteins; the reliability of such identifications, however, was judged much poorer after manual inspection. In addition, manual inspection of the spectra was also found necessary to confirm automated quantifications in ProICAT.

5 The results show that expression levels of the majority of proteins identified were not consistently different between the two phases of the endometrial cycle. This similarity in expression levels of proteins is not surprising since most of the abundant proteins detected tend to be housekeeping or structural in nature. In addition, similar or identical, housekeeping or structural proteins such as actin and tubulin are expressed in many tissue types. This is significant since whole tissue homogenates consist not only of epithelial cells, but also supportive stromal cells and interstitium, blood, vessels and any glandular secretions. These sources provide a major contribution to the protein profile of the overall tissue. These high abundance proteins from these adjacent cellular types may mask differential protein expression by a cellular component of the endometrium. Thirdly the differential expression of low abundance proteins in any one cellular type within proliferative and secretory endometrium may not have been detectable by the methodology used in this study.

15 Despite these limitations, some instances of differential protein expression was noted. One such example is given in Figure 5, which shows very significant enhancement of expression of a protein, identified as glutamate receptor subunit zeta 1 precursor [SEQ ID NO. 26], in all three secretory samples. The triply charged series of peaks, starting at 581.6 Th, was MS/MS-analyzed and identified as the heavy-labeled version of the tryptic peptide LLTLALLFSCSVAR [SEQ ID NO. 28], which maps to the N-terminal region of the protein. The absence of the light-labeled analogue of this protein, which would have manifested as a series of peaks starting at 20 578.6 Th, suggests a significantly lower level of the same protein in the proliferative samples. This is the first evidence of this protein being a marker for the endometrial secretory phase.

A second example is shown in Figure 6 for the protein, macrophage migration inhibitory factor (MIF). Again, the protein's expression is enhanced in the secretory endometrium (1.71 ± 0.38 times) versus the proliferative endometrium. This relative quantification is based on the three sets of samples and is calculated from the ratios of the total area of the ion peaks within the heavy-labeled series to that of the corresponding light-labeled series. Previous studies have demonstrated that MIF is expressed by the human endometrium throughout the menstrual cycle and that this expression is predominantly in the glandular epithelial cells [9]. It was found that MIF localized throughout the glandular epithelial cytoplasm in the proliferative phase, but that this distribution changed during the secretory phase, when it localized to the apical portion of the glandular epithelial cells, and was also detected in glandular secretions. Macrophages are common in female reproductive tissues. In the endometrium, they play an important role in defense. Macrophage degradation of cellular debris and foreign material may play an important role in endometrial shedding and repair. Quantification of MIF levels using ELISA assays suggested a slight increase in the mean concentration in the secretory phase (from approximately 15 to 18 ng / mg of protein based on a total of 25 samples), although the increase was not statistically significant [9]. By contrast, ICAT analysis of the six-sample set shows a significant enhancement (1.71 ± 0.38 times) of MIF expression in the secretory endometrium. The results of this study serve to illustrate the power of the ICAT method for detecting and quantifying gross as well as subtle differences in expression levels over traditional quantitative methods relied on thus far.

CONCLUSIONS

The ICAT technology employing the new, cleavable ICAT reagent is a powerful tool that can be used for discovering differentially expressed proteins, which could potentially be significant biomarkers of different histological cell states. The results demonstrate that for the human endometrium the expression levels of the majority of proteins do not vary significantly between the proliferative and the secretory phases. Two examples of differentially expressed proteins have been discussed in this study. Further investigation of the remainder of the SCX fractions from each of the three pairs of samples can be expected to yield more markers some of which might have implications for fertility/ infertility.

Example 2

The ICAT analysis as described in Example 1 was used to examine differentially expressed proteins in cancer and normal endometrial tissue. The results of the analysis are illustrated in Figure 11 which shows mass spectral windows from the ICAT experiments for three pairs of endometrial cancer/ normal samples, demonstrating the over expression of calgizzarin in the cancer samples.

Example 3

Material and Methods:

i) Tissue preparation and histologic classification

Endometrium and endometrial cancer tissues were retrieved from a dedicated, research in-house endometrial tissue bank. The consenting and tissue banking procedures for this tissue bank were approved by the relevant institutions. All tissues had been snap frozen in liquid nitrogen within 15-20 minutes of devitalization at the time of hysterectomy, and were obtained with patient consent. In each case, the endometrium was classified as non-malignant, or malignant by a pathologist. (26). Non-malignant endometrial cases included both normal physiologic states (atrophic, proliferative, secretory, menstrual) and pathologic states (benign endometrial polyp, disordered proliferative). Malignant endometrial cases included endometrioid, mucinous, and serous adenocarcinomas and malignant mixed Mullerian tumors (carcinosarcomas). This classification was performed using the routine surgical pathology sections. Study cases included only benign or malignant cases; cases of endometrial hyperplasia, some of which could be considered to represent an intermediate phenotype, were not included in this study. The histologic classification was verified by examination of a histopathologic section from the frozen research tissue. Tissue was taken for proteomic analysis from the mirror-face of the residual block.

Tissue was thawed in Hanks' balanced salt solution (HBSS, Sigma) containing protease inhibitors (leupeptine, aprotinin, pepstatin in 1 µg/mL) and followed by mechanical homogenation. The specimens were then stored in aliquots at -80°C and/or submitted for protein profiling. These whole tissue homogenates contain both endometrial epithelium or carcinoma, supportive stroma and vessels, and any secretions.

Immunohistochemical staining of selected malignant endometrial tissue was done using a polyclonal (rabbit) antibody against the putative tumor marker available from Calbiochem (San Diego, CA). Sections were cut from the paraffin embedded tissue, antibody applied in a 1:2000 dilution in Universal Strepavidin System, and immunohistochemical completed using a diaminobenzidine (DAB) chromogen.

ii) Protein profiling

Tissue lysate was fractionated to reduce the sample complexity before protein profiling. An identical quantity of proteins was used for all samples within a method; HBSS was used to compensate the initial volume to ensure equal volumes for all samples. For C18 Zip-tip (Millipore) fractionation, 2 µg of proteins from endometrial tissue homogenate in the presence of 0.3% trifluoroacetic acid (TFA) were loaded. After washing
5 with water containing 0.3% TFA, 1 µL of 60% acetonitrile with 0.3% TFA were used to elute proteins from C18 directly onto a MALDI target containing pre-dried 1 µL 10 mg/mL sinapinic acid in 60% acetonitrile. The dried protein spots were analyzed by a MALDI-TOF (Voyager DE-STR, Applied Biosystems) mass spectrometer.

For protein profiling using SELDI-TOF MS, 1 µg proteins from endometrial tissue homogenate were incubated with WCX2, SAX2, IMAC, H50 surfaces according to the manufacturer's instructions. In brief,
10 samples were diluted to 55 µL with the corresponding binding buffer, spotted onto the appropriate ProteinChip surface, and incubated in a sealed BioProcessor for one hour at room temperature. The ProteinChip surface was washed twice with the appropriate buffer for five-minutes, briefly rinsed with water and air-dried. Two times 0.5 µL of 50% saturated sinapinic acid in 50% acetonitrile was applied on the samples to form crystals. The ProteinChips were analyzed using a linear TOF analyzer, PBSIIc (Protein Biology System IIc, Ciphergen), or a
15 quadrupole/TOF hybrid tandem mass spectrometer, QSTAR XL (Applied Biosystems/MDS Sciex).

iii) Protein purification and identification

A normal and an EmCa sample were subject to chromatographic separation in parallel to yield partially purified protein for identification. 500 µg proteins from the whole tissue homogenate were fractionated using size exclusion (BioSep 2000, Phenomenex) at 1mL/min flow with phosphate buffer (pH7.9) and 0.05% (w/v)
20 sodium azide. One-millilitre fractions were collected; the eluates were then concentrated to 50 µL with a silicon carbide-based spincolumn, (ProteoSpin, MDS Sciex). Five microlitres (10%) of concentrate was desalted by C18 zip-tip and analyzed with MALDI-TOF MS to locate the fractions containing the protein marker of interest (10,843 Da) in the EmCa sample. The fractions with the enriched 10,843 Da protein were diluted to 100 µL with freshly prepared dithiothreitol (DTT) (5 mM final) in 150 mM Tris pH 8.5 buffer, and incubated at 60 C for one
25 hour. Ten microlitres (10%) of the reaction mixture was desalted by C18 zip-tip and analyzed with MALDI-TOF MS to assess the effect of DTT on the protein of interest (see Result for detail). The remaining 90 µL was precipitated by acetone (80%(v/v) final), resuspended in SDS sample buffer, and the proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein molecular weight markers (New England Biolabs) and cytochrome C (C-2506 Sigma) were included to guide the excision of gel portions
30 containing the protein of interest. Intact proteins were extracted from the gel by 50 µL extraction solution (formic acid/acetonitrile/isopropanol/water in a ratio of 50/25/15/10) at room temperature for four hours. The extracts were completely dried by SpeedVac and resuspended in 40 µL 100 mM ammonium bicarbonate. Half of the resuspended proteins was desalted by C18 zip-tip and analyzed with MALDI-TOF, the other half was digested in solution with 100 ng trypsin (Promega). The resulted tryptic peptides were analyzed by MALDI-
35 QqTOF MS. The identity of the 10,843Da protein, chaperonin 10, was determined using amino acid sequence-tag analysis (Mascot, Matrix Science).

Identification of chaperonin 10 was verified by western blot, 12 µg of proteins was resolved by 8-16% gradient SDS-PAGE and electrophoretically transferred to nitrocellulose membrane (MSI). Membranes were

incubated for two hours with 1:1000 dilution of anti-chaperonin 10 antiserum (Stressgen) or ERK1 antibodies (Santa Cruz) diluted in 5% milk with 0.2% NP-40 and one hour with secondary antibodies. Chaperonin 10 and ERK1 were detected by chemiluminescence reagent (NEN) and X-ray film according to the manufacturer's instructions.

5 **Results:**

A total of 44 malignant and non-malignant endometrial tissue samples were submitted for proteomic analysis. Twenty-three of these cases were non-malignant, and the remaining 21 cases were malignant. The exact histopathologic diagnoses are shown in Tables 2 and 3.

Protein profiling

10 Both C18 zip-tip purification and retentive separation on ProteinChip WCX2 were effective in generating protein profiles that permit differentiation between normal and tumorous epithelium samples. Distinguishing features include both appearances and disappearances of proteins. One protein at approximately $10,840 \pm 10$ Da was present in all EmCa samples and absent or greatly diminished in all normal samples tested. Figure 7 shows the mass spectra obtained on the ProteinChip WCX2 using (a) the linear TOF mass spectrometer, 15 PBSIIC, and (b) the QqTOF mass spectrometer, QSTAR XL. The superior mass accuracy and resolution of the latter afforded determination of the molecular weight of the marker protein as 10,843 Da.

Marker protein purification and identification

As detailed above and outlined in Figure 8 size-exclusion LC was employed to fractionate the tissue homogenates. The target 10,843 Da protein was found to elute in one of the early fractions from size exclusion 20 column which suggests that this protein is a part of a large protein complex (Figure 8A). After concentration on the spin column, the proteins were treated with DTT to break the tertiary structure and reduce any disulfide bonds. The molecular weight of the target protein was verified to remain as 10,843 Da after DTT treatment and before SDS-PAGE (Figure 8B). This result suggests that the 10,843 Da target protein contains no intra- or inter-polypeptide disulfide bonds. The remaining protein concentrates were further separated by SDS-PAGE, and the 25 gel was stained with colloidal Coomassie Blue (Figure 8C). There were, however, no visible bands at the region around 10-11 kDa, probably a consequence of low protein concentration and relatively low sensitivity of the Coomassie stain. The gel portions covering approximate 7,000-16,000 Da were excised as guided by the molecular weight markers (Figure 8C). After protein extraction, digestion with trypsin and MALDI analysis, six "unique" tryptic peptides were detected in the EmCa sample vs. the control (Figure 8D). All six peptides were 30 sequenced by MALDI-QqTOF MS; three were traced to keratin and three to chaperonin 10 (Figure 8D and 8E). The average molecular weight of chaperonin 10 was calculated to be 10842.5 Da after considering two putative posttranslational modifications, the removal of the N-terminal methionine and acetylation of the alanine residue. This is consistent with the measurement of the target protein and the reported molecular weight of chaperonin 10 purified from human platelet (18).

35 The differential expression of chaperonin 10 among cancerous and normal tissue was re-tested by western blot analysis. The signal of chaperonin 10 is higher in all EmCa specimens that also display a relative high 10,843 Da peak in their corresponding protein profiles (Figure 9).

Tables 2 and 3 summarizes the results in identifying chaperonin 10 by MS and western blot analyses in non-malignant and malignant endometrial tissue respectively. The results for both MS and western blotting have

been reported using a semi-quantitative system ranging from absent (0) to 5+ (for high intensity). These two independent methodologies demonstrate consistency in the detection of chaperonin 10.

Moderately strong immunohistochemical staining for chaperonin 10 was noted in the cytoplasm of an endometrioid adenocarcinoma, as compared to adjacent stroma and benign endometrial gland. (Figure 10). This result demonstrates the association of chaperonin 10 with malignant endometrial tissues, but much less with normal endometrial epithelium or supportive stroma and vessels, which were also present in the whole tissue homogenates.

Discussion:

Genomic studies of endometrial carcinoma have revealed that there are two, and possibly three, types of endometrial carcinoma that are each characterized by multistep pathogenetic pathways characterized by different molecular profiles [28]. A wide variety of genetic and enzymatic markers characterize the initiation, promotion and progression toward each type of endometrial carcinoma. Large-scale messenger RNA expression analysis of the endometrioid type of endometrial carcinoma has identified 50 genes that are capable of discriminating normal from malignant endometrial tissues [29]. Many genes that are constitutively expressed in normal endometrium show either diminished or increased expression in endometrial carcinomas. In addition, there is aberrant expression of the one hundred hormonally regulated genes that are variably expressed in normal endometrial tissues, although finally endometrial carcinoma resembles proliferative endometrium more than secretory endometrium [29].

In contrast to the genomic studies of the endometrium, no studies of the endometrial proteome are available, even though proteome analysis may offer information about protein expression, functions, and modifications which might not be fully reflected by gene expression analysis. Thus, protein expression profiling of the endometrium offers a new opportunity to identify and classify endometrial phenotypes, including carcinoma. Among the available methodologies for protein profiling, SELDI-TOF based method has the advantage of requiring only miniscule samples and high throughput capability, although the determination of any protein identity requires much more work [30].

This proteomic study of endometrium used lysates of whole tissue homogenates from both control endometrial tissues and endometrial carcinomas. Such tissues include not only the epithelial cells of interest, but also supportive stroma (including both endometrial stromal cells or fibroblasts and extracellular matrix), blood vessels (including smooth muscle cells and endothelium), any secretions, and possibly small amounts of adjacent myometrium. While the use of such whole tissue homogenates is technically straight forward, it does have inherent limitations. The heterogeneous nature of the constituent tissue will lead to a similarly heterogeneous protein profiling [17]. The resultant proteomic analysis reflects not only the cells of interest, but also the presence of contaminating cells [15, 17, 31]. Successful proteomic analysis of some types of tumors (e.g. hepatoma) may still be productive even with the limitation of whole tissue homogenization, since there is an abundance of tumor cells and minimal associated contaminating stroma [32].

In some tumor types, the inherent limitation of whole tissue homogenates must be surmounted by utilizing cell purification techniques. In the endometrium LCM may be optimal in achieving cellular purification for proteomic analysis since there is a relative abundance of stroma in endometrial carcinoma tissues [32]. Studies using laser capture microdissection (LCM) of melanoma have clearly revealed a different protein profile

for melanoma than that of the surrounding epithelium, and thus supports the use of LCM in proteomic profiling studies [21, 33-35].

Despite the limitations of using whole tissue homogenates for protein expression profiling, this preliminary study of endometrial carcinoma has shown that proteomic analysis of endometrial carcinoma can detect differences from that of normal endometrium. Furthermore, a specific protein (Chaperonin 10) was strongly associated with endometrial carcinoma cases. This potential marker might be clinically useful on tissue aspirates since its differential expression pattern can be detected without the LCM procedure.

Chaperonin 10 was not identified exclusively in malignant endometrial tissues; low levels were detected in non-malignant endometrial tissues by both mass spectrometry and western blotting techniques (Table 2). Furthermore, there is no apparent association between any particular histopathologic classification and the detection of these low levels of chaperonin 10. In contrast, high levels of chaperonin 10 were detected in 17 of 22 malignant endometrial tissues by either mass spectrometry and/or western blotting techniques (Table 3). The apparent absence of chaperonin 10 in the remaining five of the 22 malignant cases may be due to either true absence or technical factors in pre-analytic processing or proteomic analysis. In two of these five cases, re-examination of the corresponding mirror image histologic section revealed minimal tumor in one case (case 28), or abundant necrosis of tumor (case 44). Furthermore, specific protein peaks of interest may be obscured in less-than-optimal mass spectrometric analysis or by adjacent protein peaks.

Chaperonin 10 (Cpn 10) is a heat shock protein (HSP) that functions intra-cellularly as a molecular chaperone for nascent proteins [36, 37]. HSP's are ubiquitous intra-cellular proteins that ensure homeostasis of metabolism [37]. Aberrations of HSP function, including chaperonin 10, have been described in a variety of pathologic conditions, including neoplasia [37, 38]. Furthermore, HSP's are differentially expressed in a variety of neoplasms. For example, immunohistochemical studies of both primary and secondary brain tumours have shown production of other HSP's [39], and that the expression of some HSP's may depend upon proliferating potential. Furthermore, the modulation of HSP expression profile has been shown to reflect the stage of prostatic carcinoma [37].

Immunohistochemical studies have identified HSP's within the nuclei and cytoplasm of epithelium, stroma, endothelium, and lymphocytes of the endometrium, with certain types of HSP's showing preferential localization to certain cell types [40]. Whereas the expression of some HSP's occurs independent of the stage of the endometrial cycle (e.g. HSP90), the expression of other HSP's is cycle dependent. The expression of chaperonin 10 can be determined among proliferative, secretory, and menstrual endometria using proteomic, western blotting, and immunohistochemical methods. It is known that the amount of HSP27 and 60 is increased during late proliferative and early secretory phases, and subsequently reduced during mid- and late secretory and menstrual phases [40]. Studies of both decidualized endometrium (decidua) and placenta have shown that there are striking differences in the cellular localization of HSP's during normal human gestation.

There have been no studies regarding the role of HSP's or Cpn10 in endometrial carcinoma. The eutopic endometrial glands from women with endometriosis and adenomyosis shows significantly increased expression of HSP's as compared to endometria from control women – regardless of the menstrual phase [41]. The abnormal expression of HSP's may play a role in the pathophysiology of both endometriosis and adenomyosis.

Early pregnancy factor (EPF) is an extra-cellular homologue of Cpn 10 that appears within 24 hours of fertilization and persists throughout the first half of gestation [36]. It is necessary for embryonic development [42-44] and is immunosuppressive [45]. EPF is also detectable in animal models of liver regeneration and in the development of cancer [38, 46, 47]. An association between cellular growth and the appearance of extracellular EPF has been shown [38, 46, 47]. These findings suggest a role for EPF in neoplastic growth and that the detection of Cpn 10 in the serum of endometrial carcinoma has diagnostic potential.

In conclusion, this protein profiling study of non-malignant and malignant endometrial tissues has identified chaperonin 10 as a tumor marker for endometrial malignancies.

Example 4

The work described in the previous example using solid-phase extraction followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) as well as selective surface binding and surface-enhanced laser desorption/ionization (SELDI MS, Ciphergen Biosystems Inc, CA, USA) has succeeded in identifying individual markers that show significant enhanced expression in EmCa tissues. The MALDI/SELDI MS strategy relies on side-by-side comparison of spectra from proteins that have been selected via fast separation [120-124]. Using this methodology the identities of the proteins are unknown and identifying a given protein marker typically involves offline multidimensional chromatography, concentration, trypsin digestion and MS/MS. A second available strategy that highlights differentially expressed proteins involves differential tagging of proteins from samples that are being compared using isotope-coded affinity tag (ICAT) in an isotope-dilution mass spectrometry experiment [6]. This strategy has recently been applied to discover differentially expressed proteins between the proliferative and secretory phases of the human endometrium [49] using a cleavable, second-generation ICAT reagent (cICAT, Applied Biosystems Inc, CA, USA) (see above). Recently, a variation of the ICAT technology, iTRAQ (also from the Applied Biosystems Inc, CA, USA), has been introduced. Both cICAT and iTRAQ tagging permit online identification of multiple markers and relative quantification of these proteins. Although similar in their basic concepts, the two tagging reagents and methodologies differ in significant areas. The cICAT method relies on tagging cysteine residues and isolating peptides containing these tagged residues by affinity chromatography. The net result is a reduction in the complexity of peptide pools generated by digestion with proteases including trypsin [6]. In the case of the new iTRAQ method, tagging is on primary amines. This difference in labeling strategy eliminates the dependence on relatively nonabundant cysteine containing peptides intrinsic to ICAT-based methods, thus potentially allowing the tagging of most tryptic peptides. Other noteworthy features of the iTRAQ technology are that relative quantification is performed via MS/MS and that there are four possible tags, which permit multiplexing of up to four samples (tissue states) in a single experiment. Quantification is performed via the differences in abundances of four product ions, 114, 115, 116 and 117 Th that are each cleaved from one of the four possible tags. The tags have an identical mass, a result of differences in other parts of the iTRAQ tag structure, with the consequence that an identical peptide in the four samples will have an identical mass and LC retention time after tagging. This strategy simplifies analysis and will potentially increase analytical accuracy and precision. The multi-sample capability of the iTRAQ technology is ideally suited for this study, as it now provides a means to perform a proteomic analysis of both the major phases of the normal endometrium, while simultaneously comparing them against cancer samples.

This example describes a feasibility study that compares protein expression profiles between normal and cancerous endometria using iTRAQ as well as contrasts it against a similar feasibility study using the cICAT technology. Both iTRAQ and cICAT labeling afforded discovery of a number of differentially expressed proteins that are potential cancer markers (PCMs). There is little overlap in the PCMs discovered and identified, thus pointing to the complementary nature of the two technologies. It is noteworthy that application of the iTRAQ methodology permits confirmation of the overexpression of chaperonin 10 in EmCa tissues [50]; chaperonin 10 is an approximately 10 kDa heat shock protein that does not contain the cysteine residue, which is the tagging site for cICAT. Thus, in addition to an interest in the discovery of markers for endometrial carcinoma, these experiments have also helped to illustrate the relative strengths and differences of the two tagging techniques, when applied to studies of clinical samples.

Materials and Methods

Sample Preparation. Endometrial tissue was retrieved from an in-house dedicated, research endometrial tissue bank. All tissues were snap frozen in liquid nitrogen within 15-20 minutes of devitalization at the time of hysterectomy, and were obtained with patient consent. The patient consent forms and tissue-banking procedures were approved by the Research Ethics Boards of York University, Mount Sinai Hospital, University Health Network, and North York General Hospital. In each case, the endometrium was classified by a pathologist (TJC). Histological classification was verified by examination of a section from the frozen research tissue. Tissue for proteomic analysis was taken from the mirror-face of the residual block. In the case of samples used for iTRAQ analysis, 0.5 ml phosphate buffered saline (PBS) containing protease inhibitors (1mM AEBSF, 10 μ M leupeptin, 1 μ g/ml aprotinin and 1 μ M pepstatin) was added. The tissue was then mechanically homogenized at 30,000 rpm using a Polytron PT 1300D handheld homogenizer (Brinkmann, Westbury, USA). For samples used for cICAT analysis, tissues were similarly homogenized in 1 ml Hanks' Balanced Salt Solution with the same concentration of protease inhibitors as listed above. The samples were stored in aliquots at -70°C until used for further processing. These whole tissue homogenates contained not only endometrial epithelium, but supportive stroma and vessels, as well as secretions. The iTRAQ analysis involved one normal proliferative, one normal secretory, and two cancer homogenates, while the cICAT analysis combined one normal proliferative homogenate with three different cancer homogenates in pair-wise comparisons.

Chemicals. Reagent grade chemicals were purchased from Sigma Aldrich (Oakville, ON, Canada), or Fisher Scientific (Nepean, ON, Canada). All iTRAQ and cICAT reagents and buffers were obtained from Applied Biosystems (Foster City, CA, USA).

iTRAQ Sample Preparation Procedure. Cell debris from each of the homogenates was removed by centrifugation in a microfuge at 4°C for 30 min at 14,000 rpm. The clarified supernatant was then transferred to fresh microfuge tubes and the total protein content determined using a commercial Bradford assay reagent (Bio-Rad, Mississauga, ON, Canada). A standard curve for the Bradford assay was made using γ -globulin as a control. 100 μ g of each sample was then denatured and the cysteines blocked as described in the iTRAQ protocol (Applied Biosystems, Foster City, CA, USA). Each sample was then digested with 0.2 mL of a 50 μ g/mL trypsin (Promega) solution at 37 °C overnight and labeled with the iTRAQ tags as follows: normal proliferative endometrium, iTRAQ114; normal secretory endometrium, iTRAQ115; and the two EmCa samples,

iTRAQ116 and iTRAQ117. The labeled samples were then pooled and acidified by mixing with Eluent A (see later) to a total volume of 2.0 mL for strong cation exchange (SCX) chromatography. 1.5 mL of this acidified labeled sample was injected into an HP1050 LC system (Agilent, Palo Alto, CA, USA) with a 1.5 mL injection loop and a 2.1 mm internal diameter (ID) x 100 mm length PolyLC Polysulfoethyl A column packed with 5 μ m beads with 300 Å pores (The Nest Group, Southborough, MA, USA). A 2.1 mm ID x 10 mm length guard column of the same material was plumbed upstream from the analytical column. Fractionation was effected by a binary mobile-phase gradient at a total flow rate of 0.2 mL/min. Eluent A consisted of a 10 mM KH_2PO_4 solution in 25% acetonitrile and 75% deionized water acidified to a pH of 3.0 with phosphoric acid. Eluent B consisted of a 10 mM KH_2PO_4 and 350 mM KCl solution in 25% acetonitrile and 75% deionized water acidified to a pH of 3.0 with phosphoric acid. Initially, the gradient comprised 100% Eluent A. At the 2nd minute, the % Eluent B was changed linearly from 0 to 100% at the 58th min. The run was terminated at the 60th min. A total of 30 fractions were collected for the sample, one every two minutes, using an SF-2120 Super Fraction Collector (Advantec MFS, Dublin, CA, USA). Following fractionation, the samples were dried by speed vacuuming and stored at -20 °C. Prior to reverse phase nanobore liquid chromatography-tandem mass spectrometric (nanoLC MS/MS) analysis, these fractions were redissolved in an aqueous buffer containing 5% acetonitrile and 0.1% formic acid for nanoLC MS/MS.

cICAT Sample Preparation Procedure. Samples were clarified and their total protein content determined as described above. cICAT sample preparation procedure was carried out according to the cleavable ICAT protocol (Applied Biosystems, Foster City, CA, USA). Three 100 μ g aliquots of the clarified normal proliferative homogenate were paired with 100 μ g each of the three clarified cancer homogenates separately. After denaturing and reduction, the normal homogenates were labeled with the light reagent while the EmCa homogenates were labeled with the heavy reagent. A light labeled sample was then mixed with one of the heavy labeled samples to form in total three ICAT sample pairs: A, B and C. The final volume of each sample was 0.2 mL. The sample pairs were then digested by incubating each pair with 0.2 mL of a 50 μ g/mL trypsin solution at 37°C overnight. Afterwards each sample pair was mixed with 2.0 mL of Eluent A and fractionated into 30 fractions using SCX chromatography as described above. The fractions were screened by MALDI MS analysis. Those showing the signature ICAT peak pairs separated by 9 Da were further processed by affinity purification using the avidin cartridge provided with the ICAT kit. The affinity-purified sample was then dried, treated with the cleavage reagent to eliminate biotin, and dried again by speed vacuuming. The resulting solids were re-dissolved in an aqueous buffer containing 5% acetonitrile and 0.1% formic acid for nanoLC MS/MS.

Nanobore LC/MS/MS. The nanobore LC system was from LC Packings (Amsterdam, The Netherlands) and consisted of a Famos autosampler and an Ultimate Nano LC system. It was interfaced to an API QSTAR Pulsar QqTOF mass spectrometer (Applied Biosystems/MDS Sciex, Foster City, CA, USA) using a Protana NanoES ion source (Protana Engineering A/S, Odense, Denmark). The spray capillary was a PicoTip SilicaTip emitter with a 10 μ m ID tip (New Objective, Woburn, MA, USA). The nanobore LC column was a 75 μ m ID x 150 mm length reverse-phase PepMap C18 nano capillary column (LC Packings, Amsterdam, The Netherlands) packed with 3 μ m beads with 100 Å pores. One μ L of sample was injected via the full-loop mode. Separation was performed using a binary mobile-phase gradient at a total flow rate of 200 nL/min. Eluent A consisted of 94.9%

- 64 -

deionized water, 5.0% acetonitrile and 0.1% formic acid (pH \approx 3). Eluent B consisted of 5.0% deionized water, 94.9% acetonitrile and 0.1% formic acid.

The following binary gradient was used for the iTRAQ experiments:

<i>Time (min)</i>	0	5	10	125	135	155	160	162	188
<i>% Eluent B</i>	5	5	15	35	60	80	80	5	Stop

5

While the binary gradient used for cICAT experiments was:

<i>Time (min)</i>	0	5	125	135	157	160	163	190
<i>% Eluent B</i>	5	5	30	60	80	80	5	Stop

For nanospray, the source conditions were a curtain-gas setting of 20 and an ionspray voltage in the range of 1800 - 3000 V that was optimized daily. In the Q0 region, the instrument parameters were a declustering potential (DP) of 65 V and a focusing potential (FP) of 265 V. Nitrogen was used as the collision gas at a setting of CAD = 5 for both TOF-MS and MS/MS scans. All nanoLC MS/MS data were acquired in information-dependent acquisition (IDA) mode in Analyst QS SP8 with Bioanalyst Extension 1.1 (Applied Biosystems / MDS Sciex). Two sets of runs for the iTRAQ fractions were performed. For the first set, MS cycles comprised a TOF MS survey scan with an m/z range of 400 – 1500 Th for 2 s, followed by three product ion scans with an m/z range of 70 – 2000 Th for 10 s each. For the second, a 1 s TOF MS survey scan, followed by three product ion scans of 3 s each were used. For cICAT experiments, the MS cycles consisted of a TOF MS survey scan for 1 s, followed by two product ion scans of 2 s each. The ranges for the TOF MS and product ion scans were the same as those of the iTRAQ experiments. Collision energy (CE) was automatically controlled by the IDA CE Parameters script. Switching criteria were set to ions greater than m/z = 400 Th and smaller than m/z = 1500 Th with a charge state of 2 to 5 and an abundance of \geq 10 counts/s. Former target ions were excluded for 60 s and ions within a 4 Th window were ignored. In addition, for iTRAQ runs, the IDA Extensions II script was set to no repetitions before dynamic exclusion for the first run, and one repetition for the second. While for the ICAT experiments, the IDA Extensions II script was set to two repetitions before dynamic exclusion. In all three experiments, the script was set to select a precursor ion nearest to a threshold of 15 count/s every 4 cycles. These settings ensured examination of not only high abundance ions, but low abundance ones as well.

Data Analysis. Data analysis for the iTRAQ experiments was performed with ProQUANT 1.0, while that for cICAT experiments was with ProICAT 1.0 SP3. The cut off for the confidence settings for both analyses was at 75; that for the score was at 20. The tolerance set for peptide identification in ProQUANT searches were 0.15 Da for MS and 0.1 Da for MS/MS, while those for ProICAT searches were, 0.2 Da and 0.1 Da, respectively. All identifications were manually inspected for correctness. Relative quantification of proteins in the case of iTRAQ is performed on the MS/MS scans and is the ratio of the areas under the peaks at 114 Da, 115 Da, 116 Da and 117 Da which are the masses of the tags that correspond to the iTRAQ reagents. Relative quantification of

30

proteins in the case of cICAT was performed on the TOF-MS scans by calculating the relative areas between the pairs of light and heavy label series of peaks. In both cases, the results of the quantification were normalized using the overall ratio obtained for all tagged peptide pairs in the sample. On the basis of previous studies utilizing cICAT reagents to compare secretory to proliferative endometrium, which involved paired tissue analysis of samples labeled with heavy and light isotopes, it was found that many proteins were expressed within a standard deviation (SD) of < 0.3 and an expression ratio close to 1.0, when protein expression was normalized against a housekeeping protein ($n=6$) [49]. Using this SD as an approximate benchmark for variation of protein expression among proteins whose expression is not altered when utilizing this technique, it was considered that a difference of 3 SDs i.e. 1.0 plus 0.9, or about a 2 fold difference, in normalized expression levels would be outside of the variation expected by chance, with a confidence limit of $> 95\%$ using a simple Gaussian approximation. This approximation would, therefore, apply to normalized expression levels > 2.0 or in reciprocal form < 0.5 , as no assumption was made with regard to which tissue showed greater abundance. Using this approach, therefore, a two-fold expression change was chosen as an initial benchmark for potentially significant changes. In small sample sizes used for these initial studies, i.e. one sample in each group, at an alpha value of 0.05 (two-sided) and a beta value of 0.2 (80% power), the ratio of expression increase to SD must be at least 4 in order to achieve significance. This means that for minimal statistical significance to be achieved using the above alpha and beta parameters for a single paired-tissue comparison, a 2-fold mean increase in expression must be associated with an SD less than 0.5 for replicate measurements in order to satisfy the sample size equation $[n = 2 \text{ SD}^2 (Z_\alpha + Z_\beta)^2 / (\text{expression increase})^2] = 1$, when the power index $(Z_\alpha + Z_\beta)^2 = 8$ ($\alpha = 0.05$, $\beta = 0.2$). For the sample size of three paired comparisons (one normal tissue and three tumor tissues were used in the cICAT experiment), the sample-size approximation of $n = 2$ in each group was used to compensate for the fact that one normal tissue was used (i.e. $n = 1$ in the control group, and $n = 3$ in the tumor group). The ratio of expression increase to SD must be greater than 2.8 in order to satisfy the above equation for an $n = 2$ (using the same α and β error limits of 0.05 and 0.2, respectively).

Results

iTRAQ runs 1 and 2 led to sequencing and identification of 645 and 1,026 peptides, respectively. The previous studies (see above) showed that a confidence setting of 75 and a score setting of 20 were optimal. Manual inspection of hundreds MS/MS spectra concluded that while these conditions were sufficiently stringent in that most identifications were correct, they also did not exclude too many peptides that could have been identified based on spectral quality. The MS/MS spectra of all peptides that scored above the cut offs were manually inspected to verify proper identifications. The shorter MS and MS/MS cycles used for run 2 resulted in a higher number of peptides identified. A significant number of these peptides were identified more than once, thus the number of unique peptides dropped to 292 and 312 for runs 1 and 2, respectively. Many of the more abundant proteins were identified by several peptides (Figure 12); the numbers of proteins identified were 101 and 126, respectively. 63 proteins were identified in both runs. The numbers are modest, which were likely due to the small amount of starting materials.. Five proteins have abundance ratios that show more than a two-fold change (≥ 2.0 or ≤ 0.5) in both cancer samples relative to the proliferative as well as the secretory endometrium, and meet the criteria of differential expression. These are shown in Table 4.

Relative quantification is expressed as three pair-wise ratios against the proliferative endometrium (iTRAQ114) for the secretory endometrium (iTRAQ115) and the two EmCa samples (iTRAQ116 and 117). To account for small differences in protein loadings across the samples, these ratios have been normalized using the overall ratios for all proteins in the samples, as recommended by Applied Biosystems. The rationale for this choice is based on the assumption that the relative abundances for the majority of proteins are close to one. This assumption is exemplified in this study in terms of the abundance ratios in secretory versus proliferative endometrium for the following abundant proteins: cytoplasmic actin, 0.98; alpha enolase, 0.91; alpha filamin, 1.04; serum albumin precursor, 1.56; and tropomyosin alpha 4 chain, 0.99. Figure 13a shows the MS/MS spectrum for the doubly charged cytoplasmic actin peptide at 725.4 Th in one of the runs. The cluster of peaks around 115 Th is better shown in the mass spectral window 110 – 120 Th in Figure 13b, demonstrating near identical abundances in the four samples: proliferative (iTRAQ114), secretory (iTRAQ115), EmCa 1 (iTRAQ116), and EmCa 2 (iTRAQ117).

Typical MS/MS windows (110 – 120 Th) for tryptic peptides in four differentially expressed proteins, (A) chaperonin 10, (B) alpha-1-antitrypsin precursor, (C) creatine kinase B, and (D) transgelin, are shown in Figure 14. Chaperonin 10 is overexpressed in both EmCa samples, whereas alpha-1-antitrypsin precursor, creatine kinase B, and transgelin are underexpressed. The remaining differentially expressed protein, pyruvate kinase M1 or M2 isozyme, is also overexpressed in the two EmCa samples.

The cICAT experiments led to identification and quantification of 68 proteins, all were manually verified. Again, the modest number stemmed from the small sample size. Fewer proteins were identified by multiple peptides relative to iTRAQ (Figure 12), in accordance with the more selective nature of cICAT labeling on only cysteine residues. Five proteins that meet the two-fold differential expression criterion in all three EmCa versus proliferative endometrium pairs are: calgizzarin, heterogeneous nuclear ribonucleoprotein (hnRNP) D0, macrophage migration inhibitory factor (MIF), polymeric immunoglobulin receptor (PIGR) precursor, and pyruvate kinase M1 or M2 isozyme. These results are summarized in Table 5. All five proteins are overexpressed in EmCa tissues; pyruvate kinase is also shown to be overexpressed with iTRAQ. Figure 15 shows an example of overexpressed protein, calgizzarin A. Again, the relative abundance ratios are normalized to the overall ratio of all proteins in a given sample pair to account for small differences in protein loadings in the two samples. Cytoplasmic actin exhibits a heavy/light label ratio of 0.95 ± 0.24 (standard deviation of three samples).

30 Discussion

The combination of iTRAQ and cICAT labeling results in the discovery and identification of nine differentially expressed proteins that are potential cancer markers (PCMs) for EmCa. Six of the nine PCMs are overexpressed, whereas three are underexpressed in EmCa.

PCMs Overexpressed in EmCa. Chaperonin 10 is a heat shock protein that was identified as a PCM using MALDI/SELDI MS and identified by offline separation, preconcentration, trypsinization and MS/MS (see above). Overexpression of chaperonin 10 in EmCa tissues was verified independently by Western analysis; chaperonin 10 was localized to the cancerous epithelium by means of immunohistochemistry (IHC). Elevation of levels of chaperonin 10 has been associated with large bowel and cervical carcinomas [53]. The level of chaperonin 10 in serum was demonstrated to be an indicator of trophoblastic tumor [54]. The observation of

chaperonin 10 overexpression in EmCa samples in this study with iTRAQ confirms the previous finding using MALDI/SELDI MS, Western analysis and IHC. Thus, chaperonin 10 may be a serum marker protein for EmCa.

Overexpression of pyruvate kinase M1 or M2 isozyme was demonstrated by both the iTRAQ and cICAT applications. Pyruvate kinase was found to be expressed at elevated levels in both plasma and fecal samples in patients of gastrointestinal cancer [55,56]. The ability to detect pyruvate kinase in plasma samples is of particular interest as this might indicate that screening plasma for elevated pyruvate kinase levels in endometrial cancer cases may also be possible. An investigation into the activity of 12 enzymes related to the glycolytic pathway in cervical and endometrial cancers found that only two, pyruvate kinase and phosphoglucose isomerase, were significantly higher in both cancers [57].

Calgizzarin was found to be overexpressed in EmCa tissues using cICAT labeling. Calgizzarin was one of two proteins that exhibited significant upregulation in colorectal and lung carcinoma cell lines over normal colorectal mucosal cells [58]. Calgizzarin was one of three proteins that have been identified as tumor markers in mouse colon cancer [59]. The other two tumor markers were calgranulins A and B, the former of which was also identified as a protein marker in human endometrial carcinoma using SELDI MS. Identification was made possible by size-exclusion chromatography, trypsinization and online nanoLC MS/MS; confirmation of calgranulin A overexpression in EmCa was rendered by IHC in a tissue microarray format.

HnRNP D0, also known as AU-rich element RNA-binding protein 1, binds to the AU rich 3' UTR of many proto-oncogenes. One study has shown that this protein is more abundant in murine neoplastic lung epithelial cell lines and that this abundance decreases when non-tumorigenic cells reach confluence or growth arrest [60]. Conversely, it was also found that the abundance was unaffected in spontaneous transformants from this cell line. Another more recent study using transgenic mice showed that overexpression in an isoform of this protein altered mRNA levels of several oncogenes, including c-myc, c-jun, c-fos and TNF-alpha [61]. The mouse line with the highest level of this isoform developed sarcomas [61].

Macrophage Migratory Inhibitory Factor is another protein that has been well documented as being involved with cancer [62]. This ranges from hepatocellular carcinomas [63], to non small cell lung cancer [64], to brain tumors [65] and glioblastomas [66].

PIGR has previously been detected in serum from patients with lung cancer and was shown to be significantly upregulated in the secretory component by an ELISA study involving 45 lung cancer patients compared with 45 control subjects [68]. Another study has also demonstrated a possible linkage between PIGR and bladder carcinoma with protein levels in serum being significantly increased in patients with transitional cell carcinoma [69].

PCMs Underexpressed in EmCa. Alpha-1-antitrypsin precursor is one of the three proteins that are underexpressed in EmCa tissues. Recent studies have shown downregulation of alpha-1-antitrypsin to be associated with malignant lymphoma as well as liver, lung, stomach, bladder and gall bladder cancer [70,71]. There is also evidence for upregulation contributing to enhanced cell migration and metastases of human colon cells in a rat model [72]. Such a contradiction might be explained by the effect of alpha-1-antitrypsin being tissue specific which would prove useful for distinguishing between forms of cancer.

Creatine kinase B shown here as being underexpressed in EmCa has likewise been demonstrated as being downregulated in cervical, colon, and lung cancers but not in hepatocarcinoma [73,74].

Transgelin is another protein observed to be underexpressed in this study. It has also been implicated as being downregulated in breast and colon carcinomas as well as in a lung epithelial cell line [75,76]. Transgelin was isolated and identified as an antigen from renal cell carcinoma; subsequent *in-situ* hybridization experiments, however, found that the malignant cells were negative with respect to transgelin and that the transgelin source was from the mesenchymal cells of the stroma [77]. Thus, downregulation of transgelin appears to be true for renal cell carcinoma as well.

Proteins Showing Possible Differential Expression. There are four proteins that showed differential expression by cICAT, but a smaller than critical (two-fold) change by iTRAQ labeling. One such protein is cyclophilin A, which was observed as being overexpressed by approximately four-fold in the ICAT analysis; however, the iTRAQ experiments showed a smaller overexpression of 1.47 ± 0.29 across both cancer samples in both runs compared with the normal proliferative sample, which is not considered as significant according to our criterion of a two-fold change. Cyclophilin A has recently been reported as overexpressed in lung cancer [76].

Triosephosphate isomerase is another protein showing overexpression by cICAT tagging. However, the relative standard deviation for this protein at $\pm 72\%$ was also large, suggesting a variable expression level. There is a recent study that suggests triosephosphate isomerase to be upregulated by two-fold in lung cancer [78]. Triosephosphate isomerase level was found to be highly variable in renal cell carcinoma [79]. iTRAQ labeling shows an overexpression of 1.55 ± 0.28 .

Superoxide dismutase [Cu-Zn] is another protein that showed a large variation, $\pm 50\%$, in the cICAT results. This protein has been implicated in pancreatic adenocarcinoma [80]. iTRAQ results at 1.46 ± 0.08 is below the criterion of overexpression. Phosphatidylethanolamine binding protein showed a cICAT overexpression level of 3.7 ± 1.0 and an iTRAQ overexpression level of 1.39 ± 0.13 . There is evidence for upregulation in rat hepatoma cell lines [81].

The use of isotope-coded affinity tags and nanoLC/MS/MS afforded examination of a large number of proteins for differential expression. This method is a lot more efficient and powerful in terms of the number of proteins that can be examined in a given experiment than SELDI MS. However, complex data analysis and the need for manual examination of MS/MS data limit the number of samples that can be examined within a given period of time. As a consequence, iTRAQ tagging involved two normal endometrial tissues versus two EmCa tissues, whereas cICAT pairing involved only one normal endometrial versus three EmCa tissues. By contrast, PCM discovery using SELDI MS involved in excess of 40 samples [see above]. A contribution to the uncertainties of the aforementioned four proteins may simply be individual variations in protein expression, both within the normal group as well as the EmCa group. The experience with the results of chaperonin 10 and calgranulin A shows that, while there is overexpression in EmCa tissues, there are considerable variations in protein abundances, possibly reflecting variability in the cellular subpopulations of the whole tissue homogenates or in the type or nature of the EmCa. In addition, there is variation in the abundances of these proteins across individual normal endometrial samples.

Selectivity of PCMs. Literature data show that the nine differentially expressed proteins discovered and identified here are associated with cancers and are, indeed, potential cancer markers. Individually, these nine PCMs are nonspecific for endometrial carcinoma, as each has been linked with cancers other than EmCa. As the principal concern in screening, diagnosis, and monitoring of EmCa is the exclusion or omission of any malignant

endometrial disease, the fact that these PCMs have been noted in other cancers would rarely be a potential clinical drawback. In other words, for envisaged clinical use, the sensitivity is of far more concern than specificity for EmCa. It is probable that different cancers will share similar pathways in tumorigenesis, which will induce over- and underexpression of similar proteins [57]. Nevertheless, it is unlikely that the differential expression pattern involving many proteins will be identical for all or some primary tumor sites. Their collective use as a *panel* may be more effective in indicating the site of origin of a cancer [82,84], despite the association of individual markers with a variety of primary sites.

The absolute expression level of PCMs will be an important issue. Knowing protein abundances in normal and diseased states will allow establishment of threshold levels beyond which EmCa is signaled. iTRAQ permits simultaneous investigation of up to four samples, thus facilitating the inclusion of synthetic tryptic peptides of known amounts in absolute isotope-dilution experiments

iTRAQ versus cICAT. The results obtained by iTRAQ and ICAT analyses suggest that the information generated by the two methods is complementary. There are, however, a few aspects on which each of these methods has advantages over the other. Quantification by cICAT can be compromised by overlapping peaks in the MS spectrum; this complication is resolved in iTRAQ as quantification is performed on the MS/MS spectrum. iTRAQ on the other hand requires processing samples separately until after the tryptic digestion. This increases the potential for errors introduced, as a result of sample handling or different extents of tryptic digestion. Another aspect on which iTRAQ differs is complexity because of the relatively nonspecific nature of labeling. Many more proteins are identified by multiple peptides. This is not necessarily a disadvantage, as it permits quantification of multiple peptides, thereby increasing the confidence in the ratios report. After classifying identified proteins into broad categories (Figure 16), it is apparent that there is a higher proportion of signaling proteins identified by the cICAT method. Conversely, iTRAQ analysis identified a larger percentage of the more abundant ribosomal proteins and transcription factors.

Example 5

Summary

Proteomic analyses of the proliferative and secretory phases of the human endometrium were carried out to identify proteins and discover differentially expressed proteins using isotope-coded affinity tags and three stages of chromatographic separation and online MS/MS. From an initial list of 346 proteins identified by ProICAT, manual inspection of MS/MS spectra and confirmatory searches pared the list down to 119 positively identified proteins. Only five of the proteins showed consistent differential expression. The two proteins with unquestionable differential expressions in the secretory endometrium are: glutamate NMDA receptor subunit zeta 1 precursor and FRAT1. Some of the proteins that show no differential expression have previously been examined in gene-expression studies with similar conclusions.

Below are reported results of a study to identify proteins in the human endometrium, and especially proteins that are differentially expressed in the proliferative and secretory phases. Differences in protein expression levels are highlighted and determined by the use of the cleavable ICAT reagent [8]. Proteins that are identified are compared with genes that have been examined for regulatory changes.

The following materials and methods were used in the study.

Materials and Methods

Tissue samples

Endometrial tissues were retrieved from an in-house dedicated endometrial tissue bank. All tissues had been snap-frozen in liquid nitrogen within 15-20 minutes of devitalization at the time of hysterectomy. All tissue procurements were carried out after informed patient consents. The consent, procurement and banking procedures were approved by the Research Ethics Boards of York University, Mount Sinai Hospital, University Health Network, and North York General Hospital. In every case, the endometrium was classified as proliferative or secretory by a pathologist. The histological classification was verified by examination of a histopathologic section from the frozen tissue. The mirror-face of the residual block was used for proteomic analysis. After addition of 1 ml of Hanks' Balanced Salt Solution containing protease inhibitors (1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 10 μ M leupeptin, 1 μ g/ml aprotinin and 1 μ M pepstatin), the tissue sample was mechanically homogenized at 30,000 rpm using a Polytron PT 1300D handheld homogenizer (Brinkmann, Westbury, USA). The whole tissue homogenate contained not only endometrial epithelium, but supportive stroma, vessels as well as secretions. The homogenate was stored in aliquot at -80°C and/or submitted for proteomic analysis. Samples from six different individuals were selected for this study. Three of these tissues had been classified as proliferative endometria (randomly designated as PRO1, PRO2 and PRO3), and the other three as secretory endometria (randomly designated as SEC1, SEC2, SEC3).

Figure 17 shows an example of the histologic appearances of (a) a proliferative (PRO2) and (b) a secretory (SEC2) endometrium. In both endometria, the stratum basalis is characterized by a denser stroma than the physiologic responsive stratum functionalis above. Across the top of the stratum functionalis is the surface epithelium, which lines the endometrial cavity. The proliferative endometrium shows small, coiled glands with lining columnar epithelium reaching to the surface. By contrast, the secretory endometrium is thicker, and contains more tortuous glands with intra-luminal secretions. The endometria of both types of physiologic phases have abundant supportive stroma and vessels among the epithelial glands.

Chemicals

Solvents, chemicals (except otherwise noted), and Hanks' Balanced Salt Solution were obtained from Sigma-Aldrich (Oakville, ON, Canada). All reagents and buffers for the cleavable ICAT sample preparation procedure were from Applied Biosystems (Foster City, CA, USA).

Sample Preparation

After removal of cell debris by centrifugation, the total protein content for each of the six clarified homogenates was measured using a commercially available Bradford protein assay (Bio-Rad, Mississauga, ON, Canada). ICAT sample preparation procedure was carried out according to the cleavable ICAT protocol (Applied Biosystems, Foster City, CA, USA). One hundred micrograms of proteins was used per sample. The proteins were denatured with the Denaturing Buffer supplied with the ICAT reagent kit. Afterwards, disulfide bonds were cleaved by adding the reducing reagent supplied, which contained 50 mM tris-(carboxyethyl)phosphine, and boiling for 10 min. The proliferative samples were then labeled with the light ICAT reagent and the secretory samples with the heavy reagent by incubating with the respective ICAT label for 2 h at 37°C. The labeled PRO1 and SEC1 samples were combined to form ICAT sample A, PRO2 and SEC2 to form ICAT sample B, and PRO3 and SEC3 to form ICAT sample C. The final volume of each sample was 0.2 ml. Mixing of the labeled proliferative and secretory samples in pairs in this manner ensures that any protein or

- 71 -

peptide losses during subsequent processing steps is the same for both samples in a pair. The sample pairs were then digested by incubating each pair with 0.2 ml of a 50 µg/ml trypsin solution at 37°C overnight. The resulting peptides were fractionated by means of strong cation exchange chromatography using an HP1050 LC system (Agilent, Palo Alto, CA, USA) with a 1.5 ml injection loop and a 2.1 mm internal diameter (ID) x 100 mm length PolyLC Polysulfoethyl A column packed with 5 µm beads with 300 Å pores (The Nest Group, Southborough, MA, USA). A 2.1 mm ID x 10 mm length guard column of the same material was plumbed upstream from the analytical column. Fractionation was effected by a binary mobile-phase gradient at a total flow rate of 0.2 ml/min. Eluent A consisted of a 10 mM KH₂PO₄ solution in 25% acetonitrile and 75% deionized water acidified to a pH of 3.0 with phosphorus acid. Eluent B consisted of a 10 mM KH₂PO₄ and 350 mM KCl solution in 25% acetonitrile and 75% deionized water acidified to a pH of 3.0 with phosphorus acid. The trypsinized ICAT sample pair (0.4 ml) was mixed with 2.0 ml of Eluent A. 1.5 ml of the 2.4 ml sample was injected. Initially, the gradient comprised 100% Eluent A. At the 2nd minute, the % Eluent B was changed linearly from 0 to 100% at the 58th min. The run was terminated at the 60th min. A total of 30 fractions were collected, one every two minutes, using an SF-2120 Super Fraction Collector (Advantec MFS, Dublin, CA, USA). UV monitoring of the chromatographic eluent revealed abundant peptides in fractions 11-20. These 10 fractions were further purified by affinity chromatography according to the ICAT protocol recommended by Applied Biosystems. Eluted labeled peptides were treated with the Cleaving Reagent, which contains TFA in order to remove the biotin label, and resolved in a third stage of chromatographic separation using reverse-phase nanobore LC with online MS/MS.

20 Nanobore LC/MS/MS

The nanobore LC system was from LC Packings (Amsterdam, The Netherlands) and consisted of a Famos autosampler and an Ultimate Nano LC system. It was interfaced to an API QSTAR Pulsar QqTOF mass spectrometer (Applied Biosystems/MDS Sciex, Foster City, CA, USA) using a Protana NanoES ion source (Protana Engineering A/S, Odense, Denmark). The spray capillary was a PicoTip SilicaTip emitter with a 10 µm ID tip (New Objective, Woburn, MA, USA). The nanobore LC column was a 75 µm ID x 150 mm length reverse-phase PepMap C18 nano capillary column (LC Packings, Amsterdam, The Netherlands) packed with 3 µm beads with 100 Å pores. One µl of sample was injected via the full-loop mode. Separation was performed using a binary mobile-phase gradient at a total flow rate of 200 nl/min. Eluent A consisted of 94.9% deionized water, 5.0% acetonitrile and 0.1% formic acid (pH ≈ 3). Eluent B consisted of 5.0% deionized water, 94.9% acetonitrile and 0.1% formic acid. The following binary gradient was used:

<i>Time (min)</i>	0	5	125	135	157	160	163	190
<i>% Eluent B</i>	5	5	30	60	80	80	5	Stop

For nanospray, the source conditions were a curtain-gas setting of 20 and an ionspray voltage in the range of 1800 - 3800 V that was optimized daily. In the Q0 region, the instrument parameters were a declustering potential (DP) of 65 V and a focusing potential (FP) of 265 V. Nitrogen was used as the collision gas at a setting of CAD = 5 for both TOF-MS and MS/MS scans.

All LC-MS/MS data were acquired in information-dependent acquisition (IDA) mode in Analyst QS SP5 with Bioanalyst Extension 1.1 (Applied Biosystems / MDS Sciex). A TOF-MS survey scan with an m/z range of 400 - 1500 and 1 s scan time was followed by two product ion scans with an m/z range of 70 - 2000 and 2 s scan time. The collision energy (CE) was automatically controlled by the IDA CE Parameters script. The switching criteria were set to ions greater than $m/z = 400$ and smaller than $m/z = 1500$ with a charge state of 2 to 5 and an abundance of ≥ 10 counts/s. Former target ions were excluded for 60 s and ions within a 4 Th window were ignored. In addition, the IDA Extensions II script was set to 2 repetitions before dynamic exclusion and to select a precursor ion nearest to a threshold of 15 count/s every 4 cycles. These settings ensured examination of not only high abundance ions, but low abundance ones as well. Each of the three sample pairs, A, B and C, was injected twice, thus yielding a total of six sets of runs.

Data analysis was performed using ProICAT 1.0 SP3 software (Applied Biosystems / MDS Sciex). An initial setting of a confidence value of 75 and a score of 15 was used. Relative quantification of proteins between the light and heavy labels was performed on the TOF-MS scans by calculating the relative areas under the series of peaks. Differential levels of expression were based upon measured protein expression ratios in proliferative versus secretory endometrium normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression and were considered significant when they exceeded three SDs from the mean expression of housekeeping proteins (actin, tubulin α -chain and triose phosphate isomerase). All expression ratios were based on a mean of two essays. The sample size calculation for determination of minimum numbers of tissue samples for ICAT analysis (N) was based upon the difference between two means, $N = 8 (SD / \text{precision})^2$ [85]. Based on preliminary experiments, an SD value of 0.3 was observed with a target precision of 0.5, yielding a minimum sample size of 3 for each tissue group. The significance of differential protein expression between proliferative and secretory endometrium was evaluated using the Wilcoxon rank sum test.

Results

Figure 18 shows a typical nano LC/MS total ion chromatogram (TIC) from fraction 16 of sample A. As a total of 10 fractions were analyzed per sample and each sample was injected twice, there were a total of 60 TICs. The use of the IDA mode generated hundreds of MS/MS spectra per TIC.

Using the initial setting of a confidence value of 75 (ProICAT recommends a lower confidence value of 50) and a score of 15 in ProICAT 1.0 SP3 results in the identification of 346 non-redundant proteins. Manual inspection of the MS/MS spectra reveals that identification of some proteins that score between 15 and 20 may be problematic. A random selection of 50 spectra from proteins scoring between 15 and 20 shows that 15 were analyzed and sequenced correctly, 13 were probably correct, and 22 were incorrect. Manual inspection of the MS/MS spectra of the 145 proteins that score 20 or higher also reveals occasional errors in assignment, but at a rate considerably lower than that between scores 15 and 20. Unfortunately, the use of ICAT-labeling results in a reduced opportunity for corroborating identification based on a second tryptic peptide from the same protein. Although the majority of human proteins do contain more than one cysteine residue per protein, some of these residues may be located within tryptic peptides that are too small or large, others may fall into peptides that have poor ionization efficiencies. Of the 346 proteins, only 23 were identified with more than one peptide; 15 of these 23 proteins were identified with two peptides.

Table 6 lists the 119 proteins that have been identified by ProICAT and verified by manual inspection of MS/MS data. Figure 19 shows the distributions of the proteins in the form of a pie chart. Of the 119 proteins, 15 were added after manual inspection of 50 randomly selected proteins' MS/MS spectra. If the MS/MS spectra of the remaining 151 proteins was inspected, it would have been expected to confirm the identifications of an additional ~ 45 proteins. This, however, was considered impractical, especially after it was known that none of the 15 additional proteins were observed in all three runs and would contribute towards knowledge of differential expression.

The results show that expression levels of the majority of proteins identified are not consistently different between the proliferative and secretory phase of the endometrial cycle. As expected, the majority of identified proteins fall under the metabolic/housekeeping and structural categories. The proteins classified under "Others" include antibodies. A small percentage of the proteins are viral or pathogenic in origin, reflecting the possibility of infection in the biopsied endometria. A few proteins have no known functions or were identified from cDNA matches; these are, therefore, classified as hypothetical.

To normalize small variations of protein amounts, relative quantification of the protein levels is normalized to the ratio of GAPDH. Gene expression studies involving different stages in the endometrial cycle have used GAPDH expression to normalize differential mRNA expressions [88-90]. The assumption is that the constant mRNA level of GAPDH through the endometrial cycle translate to constant protein level (no variation caused by translational controls). The GAPDH ratio of 1.5 ± 0.5 (one SD) before self-normalization in the six runs is in accordance with this assumption.

The ratios of the proteins in the secretory / proliferative phase (heavy / light label) listed in Table 6 are the averages \pm SDs of the peptides in all the identified runs. In the case of more abundant proteins, e.g. serum albumin and serotransferrin, individual peptides were detected in as many as 3-4 fractions. Less abundant proteins, however, were frequently detected only in 1-2 fractions (see Figure 20). In cases of multiple fractions, multiple peptides, and/or multiple runs, the ratios listed in Table 6 are the averages and the SDs of all contributing elements. Twenty four proteins show "extreme" differential expression in that only one labeled form was observable (these are noted as "Singleton H or L"). However, only five of these 24 proteins were observed in all three samples (and an additional one in two samples). All five proteins were identified by single tryptic peptides. The expression levels of three housekeeping proteins (actin, tubulin α -chain and triose phosphate isomerase) normalized against GAPDH were pooled to establish a mean expression level of $1.07 \sim 1.1$ and an SD of 0.3. The SD of these expression levels was calculated from expression data normalized to a value of 1 for any expression ratios less than 1 to generate linear data. (This was done by taking the reciprocal of expression values less than 1 in the original data set; for example, an expression ratio of 0.7 was converted to its reciprocal 1.42.) This data was then used to calculate the SD of housekeeping protein expression. A significant differential expression value was, therefore, defined as a normalized expression ratio that was three SDs above the ratio of 1.0. On the basis of the observed data, this ratio was set as 2.0 (approximately $1.0 + 3(0.3)$). Consequently, only two-fold or larger changes in expression ratios were considered to be of significance, based on the analysis of the variation in measured expression of housekeeping proteins. An additional stringency requirement of this level of expression in all three sample pairs was imposed due to the small initial sample set.

No additional proteins in Table 6 meet the differential expression criteria of abundance ratios larger than 2.0 or smaller than 0.5 in all three sample pairs.

An example of extreme differential expression observable in all three sample pairs is shown in Figure 21, which shows very significant expression enhancement of glutamate NMDA receptor subunit zeta 1 precursor in the secretory endometrium. The absence of the light-labeled analogue, which would have manifested as a cluster of peaks beginning at 578.6 Th, demonstrates the significantly lower expression of this protein in the proliferative endometrium. The triply charged tryptic peptide at 581.6 Th was identified as LLTLALLFSCSVAR [SEQ ID NO.28], which maps to the N-terminal region of the protein. A second example is shown in Figure 22, again showing extreme differential expression in the secretory phase. This protein was identified as FRAT1. For all five proteins that met the differential expression criteria stipulated above, a minimum p value of less than 0.04 was obtained on the basis of the Wilcoxon rank sum test, suggesting that the differences observed were of statistical significance.

Discussion

The observation of similar expression levels in the majority of proteins shown in Table 6 is not surprising, as many proteins are structural and housekeeping in nature. In addition, structural and housekeeping proteins, e.g. tubulin and actin, are expressed in many tissue types. This is of significance as the biopsies that were examined comprise not only epithelial cells, but also supportive stroma cells, blood and vessels that are not expected to be affected by the endometrial cycle.

In this initial examination of three sample pairs, a conservative strategy was adopted of recognizing proteins as differentially expressed only when their expression ratios are larger than 2.0 or smaller than 0.5 in all three sample pairs. Of the 119 proteins listed in Table 6, five proteins are in this category. In fact, differential expression is in the extreme form that only single labels are apparent. There is one protein (POL polyprotein) that was seen only in the secretory endometrium, but was observed in only two sample pairs and does not meet the criteria of differential expression in this study (see later).

One of the five differentially expressed proteins is glutamate NMDA receptor subunit zeta 1 precursor, which was only observed in the secretory endometrium. This protein is a subunit of a ligand gated ion channel and is known to be involved with synaptic plasticity in neurons. A recent paper suggests that it may also play a role in glutamate-mediated toxicity to mitochondria, eventually leading to apoptosis [91]. As stated earlier, the peptide maps to the N-terminal region of the precursor, which is normally cleaved to form the mature protein.

Similarly, FRAT1 is detected only in the secretory endometrial samples under the experimental conditions. There is no direct connection between FRAT1 and the endometrium reported in the literature; however, FRAT1 is expressed in a wide range of human tissues [92]. The gene expressing FRAT1 is a known proto-oncogene that activates the WNT pathway [93,94]. This pathway is important in the endometrial cycle; FRAT1 is known to inhibit c-Jun activity, thereby inhibiting subsequent apoptosis [95]. c-Jun, in turn, has been shown to be expressed in the endometrium and this expression is at a higher level during the proliferative phase than the secretory phase [96].

Myosin light chain kinase 2 is another protein that was observed exclusively in the secretory endometrium in all three sample pairs. While there are no studies on the relative amounts of this enzyme during the endometrial cycle, previous studies showed that it is present in the human myometrium at a level that is four-

to five-fold higher than that in endometrial stromal cells [97]. It was also demonstrated that the specific activity of myosin light chain kinase, which is believed to be essential for smooth muscle contraction, was 20-fold higher in the myometrium than that in non-muscle cells, e.g. skin fibroblasts [97].

5 Isopentenyl diphosphate delta-isomerase, was present only in the secretory endometrium. This protein was identified via the peptide ITMLCTGSRTLK [SEQ ID NO. 29]. In addition to this identification with ProICAT, a subsequent search with Mascot (Matrix Science) verified this assignment. This peptide, and therefore the protein, however, is unique and found only in the bacterium *Rickettsia conorii*. BLASTing the human and the *R. conorii* isopentenyl diphosphate delta-isomerase proteins showed no region of homology. In addition, MS BLASTing the peptide ITMLCTGSRTLK against non-redundant protein databases returned no
10 other matches.

A protein that appeared in all three sample pairs was initially identified by ProICAT as a simian immunodeficient viral protein, envelope polyprotein GP160 precursor. However, searching Mascot with the same MS/MS spectra returned a different protein from clostridium, putative phosphatidylserine decarboxylase proenzyme (gi 28209853). Endometrial receptors for a clostridium toxin have been documented [98]; thus the
15 identification of a clostridium protein is not entirely surprising.

Another protein initially identified by ProICAT as POL polyprotein from Rous sarcoma virus was observed only in the secretory endometrium in two of the three sample pairs. A subsequent Mascot search, however, returned a positive hit for an unlabeled peptide from serum albumin, and strongly suggested a wrong initial identification.

20 Tropomyosin 1 alpha chain was identified in two out of three sample pairs to be selectively expressed in the secretory phase at a ratio of 2.3 ± 0.7 . An enhanced expression of this protein in the secretory endometrium is in accordance with the result of a previous gene expression study that reported an up-regulation of 3.7 times [85].

A protein that showed no difference in expression levels (1.2 ± 0.7 in three samples) is macrophage migration inhibitory factor, MIF. This observation is consistent with those in previous studies that demonstrated MIF as being expressed by the human endometrium throughout the menstrual cycle and, in particular, predominantly in the glandular epithelial cells [9]. MIF was found to localize throughout the glandular epithelial cytoplasm in the proliferative phase; however, this distribution changes in the secretory phase, when MIF localizes to the apical portion of the glandular epithelial cells and is also present in glandular secretions.
30 Macrophages are common in female reproductive tissues. In the endometrium, they play an important role in defense. In addition, macrophage degradation of cellular debris and foreign material may play an important role in endometrial shedding and repair [9].

Another protein observed in this study and for which there was precedence in the literature is glycodelin. On the basis of gene expression studies [85], glycodelin was believed to be up-regulated during the secretory phase. In this study, the precursor of this protein was identified in only one sample pair, but it was
35 identified in both runs in only the secretory endometrium (Figure 23).

Cathepsin B which, according to a previous study, does not appear to be differentially regulated during the menstrual cycle [99], was seen in two of the sample pairs with opposite trends (Figure 24). Glutathione S transferase is known to show large variability which is believed to result from individual differences, rather than

endometrial cycling [100]. The relative expression level observed in this study is 1.3 ± 0.4 . Lactate dehydrogenase is another protein not believed to have any cyclic trend [101]; the relative level measured in this study, 1.4 ± 0.3 , is in accordance with this expectation. Peptidyl-propyl cis-trans isomerase A or cyclophilin A has been observed in placental and decidual tissues, but there was no study on relative amounts between the phases of the endometrial cycle [102]. The relative expression results of 1.2 ± 0.2 show a constant level of expression. Haptoglobin is thought to be up-regulated during the secretory phase [103]. The average relative expression level of 2.2 ± 1.6 is based on two enhanced secretory expression level measurements in two sample pairs and one reduced secretory expression level measurement in another sample pair that account for the very large SD. Haptoglobin is a liver protein secreted into blood. As the amounts of blood in the biopsied tissues could not be controlled prior to homogenizing, the large SD might simply reflect that the samples contain different amounts of blood as opposed to truly representing increased or decreased haptoglobin expression.

It should perhaps be emphasized that protein identifications using ICAT-labeled peptides are reliable as the identification of one labeled peptide in a pair corroborates the identification of the other in the pair. This offsets somewhat the reduced opportunities in seeing multiple peptides because ICAT targets only cysteine-containing peptides. The chance of a missed identification increases when only one member of the labeled peptide pair is observable in the form of an extreme differential expression and there is uncertainty as to whether the observable peptide is labeled with the light or the heavy ICAT reagent. In addition, the presence of an unlabeled peptide may be mistakenly interpreted as a labeled peptide that is differentially expressed in the extreme. An unlabeled peptide will need to have a combination of "right" chemical properties and very high initial concentrations (e.g. a serum albumin peptide) to "survive" the affinity chromatography stage intended to select only labeled peptides. The above is intended to be a cautionary note in pointing out potential shortcomings in a powerful technique that readily highlights and quantifies differential protein expressions, and not as a negative opinion on the suitability and utility of ICAT in protein discovery or quantification.

Of the 46 studies published to date that centered on ICAT, the vast majority were on methods development that compared differential protein expressions in two different cell states. Most of these studies were on yeast cultured under different medium conditions and they compared protein levels of one sample pair. Only one recent study [104] targeted clinical samples, and even in this study only one sample pair was analyzed for differential protein expression. The present study is the only work in which multiple sample pairs have been examined. It is, of course, possible that a given observed deviation in protein ratio from 1, i.e. a heavy/light label ratio $\neq 1$, is due to individual differences, and that different pairing of the proliferative and secretory samples may produce a different ratio. It is because of this possibility that the criterion for differential expression was stringently set to a ratio of *larger than 2.0* and *smaller than 0.5* in *all three* sample pairs. It turns out that for the five proteins that met the above criterion of differential expression, the differences were in the extreme in that the proteins were observed in only one endometrial phase in a pair. Expression differences at this extreme level in all three sample pairs are highly unlikely to have originated from individual differences.

Conclusion

From an initial list of 346 proteins identified by ProICAT 1.0 SP3, 119 proteins were identified after manual inspection of MS/MS data and additional searches using Mascot. The expression levels of the majority of proteins do not vary significantly between the proliferative and the secretory phases. Only five proteins

- 77 -

satisfy the criteria on differential expression in having an expression ratio larger than 2.0 or smaller than 0.5 in all three sample pairs. In fact, the differential expressions observed are extreme in that the proteins are present in only one of the two endometrial phases. The two proteins with unquestionable differential expressions in the secretory endometrium are: glutamate NMDA receptor subunit zeta 1 precursor and FRAT1. Some of the proteins that show no differential expression have previously been examined in gene-expression studies with similar conclusions.

Example 6

Abstract

SELDI MS has conventionally been practiced on linear TOF which has low mass accuracy and resolution. Here in an examination of both malignant and nonmalignant endometrial tissue homogenates it is demonstrated that high mass accuracy and resolution in the MS stage are crucial. Using a commercially available QqTOF, two potential cancer markers were resolved and subsequently identified offline as chaperonin 10 and calgranulin A, that differ by 8 Da in mass. Two offline protein identification protocols were developed: the first was based on SEC, SDS PAGE, protein extraction, trypsin digestion and MALDI-MS/MS; the second on SEC and shotgun nanoLC/MS/MS. Analyses on a cohort of 44 endometrial homogenates showed 22 out of 23 nonmalignant samples had nondetectable to very low abundance of chaperonin 10 and calgranulin A; 17 of the 21 malignant samples had detectable to abundant levels of both proteins. Immunohistochemical staining of a tissue microarray of 32 samples showed that approximately half of malignant endometrial tissues exhibited positive staining for calgranulin A in the malignant epithelium, while 9 out of 10 benign tissues exhibited negative epithelial staining. In addition, macrophages/granulocytes in malignant as well as nonmalignant tissues showed positive staining. No immunostaining occurred in stroma or myometrium.

The following materials and methods were used in the study.

Materials and methods

Tissue samples and sample preparation

Endometrium and EmCa tissues were retrieved from a dedicated, research in-house endometrial tissue bank. The consenting and tissue banking procedures for this tissue bank were approved by the Research Ethics Boards of York University, Mount Sinai Hospital, University Health Network, and North York General Hospital. All tissues had been snap frozen in liquid nitrogen within 15-20 minutes of devitalization at the time of hysterectomy, and were obtained with patients' consent. In each case, the endometrium was classified as nonmalignant or malignant (EmCa) by one of the authors (TJC) [Kurman, R.J., Ed., Blaustein's Pathology of the Female Genital Tract, 5th ed. New York, Springer-Verlag, 2002]. Nonmalignant endometrium included both benign physiologic endometrial cases (atrophic, proliferative, secretory, and menstrual) and pathologic states (benign endometrial polyp and disordered proliferative). EmCa cases included adenocarcinomas and rarer malignant mixed Mullerian tumors (carcinosarcomas). This classification was performed using routine surgical pathology sections. The histologic classification of the research tissue was verified by examination of a histopathologic section from the frozen research tissue. Tissue was taken for proteomic analysis from the mirror-face of the residual block. Cases of atypical endometrial hyperplasia, which could be considered to represent an intermediate phenotype, were not available for frozen-tissue banking and MS analysis because all tissue was required for histopathologic examination, but tissue was available for tissue microarray (TMA) preparation.

- 78 -

Tissue was thawed in Hanks' balanced salt solution (HBSS, Sigma) containing protease inhibitors (1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 10 μ M leupeptide, 1 μ g/ml aprotinin and 1 μ M pepstatin) and followed by mechanical homogenation at 30,000 rpm using a Polytron PT 1300D handheld homogenizer (Brinkmann, Westbury, USA). These whole tissue homogenates contained not only endometrial epithelium, but supportive stroma, vessels, as well as secretions. The homogenate was then stored in aliquot at -80 °C until protein profiling.

Chemicals

Solvents, chemicals (except otherwise noted), and Hanks' Balanced Salt Solution were obtained from Sigma-Aldrich (Oakville, ON, Canada).

10 Protein profiling using SELD-MS

Tissue lysate was fractionated to reduce sample complexity before protein profiling. An identical quantity of proteins was used for all samples; protein amounts were measured using Bradford Assay (Bio-Rad) on a DU-65 spectrometer (Beckman) at 595 nm. HBSS or urea/thiourea 2-D lysis buffer (7 M urea, 2 M thiourea) was used to compensate the initial volume to ensure equal volumes for all samples. Two micrograms of proteins from endometrial tissue homogenate was incubated with WCX2 or CM10 ProteinChips (Ciphergen) according to the manufacturer's instructions. In brief, samples were diluted to 55 μ l with the corresponding binding buffer, spotted onto the appropriate ProteinChip, and incubated in a sealed BioProcessor (Ciphergen) for 1 h at room temperature. The ProteinChip surface was washed twice with the appropriate buffer for 5 minutes, briefly rinsed with water and air-dried. Two times 0.5 μ l of 50% saturated sinapinic acid in 50% acetonitrile was applied on the samples to form crystals. The ProteinChips were analyzed using a linear TOF analyzer, PBS IIC (Protein Biology System IIC, Ciphergen), or a hybrid QqTOF mass spectrometer, QSTAR XL (Applied Biosystems / MDS Sciex) fitted with the SELDI interface (Ciphergen). For accurate molecular-weight measurements, on-chip, internal mass calibration was performed using insulin (5,733 Da), cytochrome c (12,361 Da) and myoglobin (16,951 Da) as calibrants.

25 Protein purification and identification

Selected EmCa samples were subject to chromatographic separation to yield purified proteins for identification. Five hundred micrograms of proteins from a whole tissue homogenate was first fractionated using SEC (BioSep 2000, Phenomenex) at 1 ml/min flow with phosphate buffer (pH 7.9) containing 0.05% (w/v) sodium azide. One-millilitre fractions were collected; the eluates were then concentrated to 50 μ l with a silicon carbide-based spin column (ProteoSpin, MDS Sciex). Five microlitres of a concentrate was desalted by C18 Zip-Tip and analyzed with MALDI-MS to locate the fractions containing the protein markers of interest in the EmCa sample. Two different approaches were developed and used to identify the target proteins. Some proteins were more amenable to identification with one and others with the second approach. The first approach used SDS PAGE technique to further purify the target proteins. The fractions with the enriched proteins were diluted to 100 μ l with freshly prepared DTT (5 mM final) in 150 mM Tris pH 8.5 buffer, and incubated at 60 °C for 1 h. Ten microlitres of the reaction mixture was desalted by C18 Zip-Tip and analyzed with MALDI-MS to assess the effect of DTT on the protein of interest. The remaining 90 μ l was precipitated by acetone (80% (v/v) final), resuspended in SDS sample buffer, and the proteins were resolved by SDS PAGE. Protein molecular-weight

- 79 -

markers (New England Biolabs) and cytochrome C (C-2506 Sigma) were included to guide the excision of gel portions containing the protein of interest. Intact proteins were extracted from the gel by 50 μ l extraction solution (formic acid/acetonitrile/isopropanol/water in a ratio of 50/25/15/10) at room temperature for 4 h. The extracts were completely dried by SpeedVac and resuspended in 40 μ l 100 mM ammonium bicarbonate. Half of the resuspended proteins was desalted by C18 Zip-Tip and analyzed with MALDI-MS, the other half was digested in solution with 100 ng trypsin (Promega). The identity of the target protein was determined using MS/MS ion search (ProID, Applied Biosystems). The second approach used nanoLC/MS/MS technology. After concentration using ProteoSpin, the fractions with the enriched target proteins were further cleaned up using C18 Zip-Tips. Four C18 Zip-Tips were used for each 45 μ l of concentrated fractions. The sorbed proteins were eluted by 100 μ l of 60% acetonitrile with 0.3% TFA. The eluates were completely dried by SpeedVac and resuspended in 100 μ l of 100 mM ammonium bicarbonate. The proteins were then digested in solution with 100 ng trypsin (Promega). The resulted tryptic peptides were analyzed by MALDI-MS and online nanoLC/MS/MS. The identity of the target protein was determined using MS/MS ion search (ProID, Applied Biosystems).

NanoLC/MS/MS

The nanoLC system was from LC Packings (Amsterdam, The Netherlands) and consisted of a Famos autosampler and an Ultimate nanoLC system. It was interfaced to a second QSTAR Pulsar hybrid QqTOF mass spectrometer using a Protana NanoES ion source (Protana Engineering A/S, Odense, Denmark). The spray capillary was a PicoTip SilicaTip emitter with a 10 μ m ID tip (New Objective, Woburn, MA, USA). The nanoLC column was a 75 μ m ID x 150 mm length reverse-phase PepMap C18 nano capillary column (LC Packings, Amsterdam, The Netherlands) packed with 3 μ m beads with 100 Å pores. One microliter of desalted sample was injected via the full-loop mode. Separation was performed using a binary mobile-phase gradient at a total flow rate of 100 nl/min. Eluent A consisted of 94.9% deionized water, 5.0% acetonitrile and 0.1% formic acid (pH \approx 3). Eluent B consisted of 5.0% deionized water, 94.9% acetonitrile and 0.1% formic acid. The following binary gradient was used:

<i>Time (min)</i>	0	10	40	42	44	45	70	72
<i>% Eluent B</i>	5.0	5.0	30.0	80.0	80.0	5.0	5.0	Stop

The ion source conditions were a curtain-gas setting of 20 and an ionspray voltage in the range of 1800 - 3800 V that was optimized daily. In the Q0 region, the instrument parameters were a declustering potential (DP) of 65 V and a focusing potential (FP) of 265 V. Nitrogen was used as the collision gas at a setting of CAD = 5 for both TOF-MS and MS/MS scans.

All LC-MS/MS data were acquired in information-dependent acquisition (IDA) mode in Analyst QS SP5 with Bioanalyst Extension 1.1 (Applied Biosystems / MDS Sciex). A TOF-MS survey scan with an m/z range of 400 - 1500 and 1 s scan time was followed by two product ion scans with an m/z range of 70 - 2000 and 2 s scan time. The collision energy (CE) was automatically controlled by the IDA CE Parameters script. The switching criteria were set to ions greater than m/z = 400 and smaller than m/z = 1500 with a charge state of 2 to 5 and an abundance of \geq 10 counts/s. Former target ions were excluded for 60 s and ions within a 4 Th window

- 80 -

were ignored. In addition, the IDA Extensions II script was set to 2 repetitions before dynamic exclusion and to select a precursor ion nearest to a threshold of 15 count/s every 4 cycles. These settings ensured examination of not only high abundance ions, but low abundance ones as well.

Tissue microarray and immunohistochemical protein localization

5 A 32-core TMA was prepared to confirm the presence of an identified protein marker (10,835 Th, see later sections), and to determine its localization. Following fixation in 10% buffered formalin, benign, hyperplastic and malignant endometrial tissues were histologically processed and embedded in paraffin blocks. A single 2-mm core of tissue was removed from the paraffin block using a Manual Tissue Arrayer (Beecher Instruments). The 26 endometrial study cases included 11 benign endometrium (five secretory, four proliferative, one atrophic and one menstrual), 13 malignant endometrium (12 adenocarcinomas and one carcinosarcoma), and two cases of atypical endometrial hyperplasia. Six other control tissues were also embedded into the TMA, including four non-endometrial carcinomas and 2 benign tumors (salivary gland pleomorphic adenoma and ovarian thecoma). Following MS identification, monoclonal mouse antibodies against the potential cancer marker were procured from two sources: Research Diagnostics, Inc. (Flanders, NJ), labeled as RDI, and US Biological (Swampscott, MA), labeled as USB. Sections were cut from the TMA. The antibodies were applied in an appropriate dilution determined through a pilot study and immunohistochemically visualized using a diaminobenzidine chromogen.

Interpretations of the two immunohistochemically stained TMA sections were conducted using a standardized method; microscopic reviews were conducted blinded to the findings of the other TMA section. Positive staining (brown) for the potential marker was determined for three cellular components: macrophage/granulocyte, epithelium/carcinoma, and endometrial stroma and myometrium. Immunostaining of these three cell types was semi-quantitatively graded as: 0 (no immunostaining), 1+ (weak positivity and/or positivity in only occasional cells), 2+ (moderate positivity and/or positivity in more abundant cells), and 3+ (strong positivity and/or positivity in numerous cells).

Results and discussion

SELDI-MS details

The use of SELDI-MS profiling in discovering a protein marker, chaperonin 10, for EmCa is described above. Chaperonin 10 has a molecular weight of 10,843 Da. Performing SELDI-MS on the higher resolution QqTOF mass spectrometer (QSTAR XL) was revealing: chaperonin 10 frequently appeared as three instead of a single peak (Figure 25a). On the lower resolution PBS IIc TOF mass spectrometer, which is much more widely available and used, the peaks are unresolved. Incubating the tissue homogenate with hydrogen peroxide overnight reduced the abundance of chaperonin 10 while increased the abundance of the protein that is heavier by 16 Da (compare Figure 25b with 25c). Increasing the fluence of the MALDI laser (from 34.6 to 76.9 μJ) had the effect of increasing the abundance of the protein peak that is 18 Th lower than chaperonin 10 in m/z value. In addition, a new protein peak that is 36 Th lower in m/z value emerged (compare Figure 25d with 25e). Incubating with hydrogen peroxide enhanced oxidation of chaperonin 10, probably the lone methionine residue; as a result, the molecular weight of chaperonin 10 increased by 16 Da. Increasing the laser intensity probably promoted dehydration of chaperonin 10 within the MALDI source. The sources of the water were likely the five glutamic and eight aspartic acid residues. Laser-induced deamidation (-17 Th) could also occur, but was ruled

out after careful and repeated measurements mass-calibrated with cytochrome c. Single measurements for chaperonin 10 on the QSTAR XL with external or internal calibrants carry a typical uncertainty of ± 2 Th.

As stated earlier, the aforementioned details were unresolved on the PBS IIc TOF mass spectrometer, which displayed only one broad hump. The poor resolution in this case has no negative consequence as all peaks are different forms of chaperonin 10. However, this deficiency in resolution (and mass accuracy) may be detrimental when the sample contains a second protein of similar molecular weight. Having screened in excess of 40 endometrial homogenates (see later), it was found that a significant fraction of EmCa homogenates carry a protein that is lighter than chaperonin 10 by 8 Da. Figure 26 shows selected SELDI MS profiles, from four EmCa (designated by "C") and two normal endometria (designated by "N"), as collected on the PBS IIc TOF and the QSTAR XL QqTOF mass spectrometers. The pH of the washing buffer was 6.0. The PBS instrument exhibited better sensitivity than the QSTAR. However, the profiles generated by the former contain broad humps, while those by the latter exhibit considerable details (Figure 26B). In addition, the mass accuracy of the PBS is considerably inferior to that of the QSTAR. Sample C15 is the simplest of the four EmCa samples and contains only chaperonin 10, its oxidized (10,859 Th) and dehydrated (10,825 Th) forms (compare Figure 25). Sample C8 has a little chaperonin 10 and contains mostly this second protein (10,835 Th), its oxidized (10,851 Th) and dehydrated (10,817 Th) forms. Similarly, sample C6 has some chaperonin 10 admixed with the second protein. In sample C18, the relative abundance of chaperonin 10 and the unknown protein is approximately 1 to 1. The normal samples show traces of chaperonin 10. The possibility of having two proteins that differ by 8 Da in EmCa samples was confirmed by repeating some experiments, using pH 7.0 washing buffer. In the latter condition, the ProteinChip binds only the unknown protein (Figure 27). The abundances of chaperonin 10 and this second protein in nonmalignant and malignant endometrial tissue homogenates are summarized in Tables 7 and 8, respectively. As SELDI/MALDI analyses on the same sample exhibit considerable variation from shot to shot and from spot to spot, the scales adopted, from "0" (absence) to "5+" ($S/N \geq 10$ or higher) are intended to convey semiquantitative rather than quantitative information. For nonmalignant samples, chaperonin 10 and the second protein are absent or present in only very low abundance ("1+") in 22 out of 23 cases; the exception, however, is different for the two proteins. For the malignant samples, two out of 21 cases show absence of both chaperonin 10 and the second protein; in addition, two cases show absence of chaperonin 10 but high abundances of the second protein, while another two cases show high abundances of chaperonin 10 but absence of the second protein. The absence of the potential cancer markers in some malignant tissue homogenates may be due to nonoptimal MS conditions and/or absence of tumors in the tissue block homogenized and analyzed.

Identification of the unknown protein

The vast majority of SELDI-MS applications use spectral signatures from sera to differentiate normal and diseased states without actual protein identification [22, 25, 30, 105-108]. This strategy has come under criticisms and the clinical effectiveness of serum proteomics is currently being questioned [109-119]. The identification of chaperonin 10 in EmCa tissue homogenates as a marker for endometrial cancer is described above. The identification strategy was based on SEC, SDS PAGE isolation, protein extraction, trypsin digestion and MALDI-MS/MS identification. However, the preferred strategy is shotgun nanoLC/MS/MS after initial purification using SEC.

The unknown protein has a molecular weight of 10,835 Da. Using the TagIdent tool available at the ExPASy Website [133] with the following entries: molecular weight, $10,835 \pm 2$ Da ($\pm 0.02\%$); pI, 7 ± 5 ; and organism classification, human to search the Swiss-Prot database that contains 151,047 entries, returned only two proteins, calgranulin A (accession number, P05109) and small nuclear ribonuclear protein D homolog (accession number, Q9Y333). A sample was used that contained the 10,835 Da protein in abundance for SEC. This protein was found to have the highest concentration in SEC fraction 7. NanoLC/MS/MS of the tryptic peptides contained in this fraction identified a number of proteins (Table 9). The only protein that has the correct molecular weight is calgranulin A, 10,834 Da. The other proteins all have higher molecular weights (see later). Figure 28 shows MS/MS spectra of three tryptic peptides, (A) MLTELEK [SEQ ID NO. 50], (B) ALNSIIDVYHK [SEQ ID NO. 51] and (C) GADVWFK [SEQ ID NO. 52], that unambiguously identify calgranulin A. The first two peptides constitute residues 1–18, the third peptide residues 50–56. The three peptides constitute a sequence coverage of 25 out of a total of 93 residues or 27%.

Calgranulin

Calgranulin A is a member of the S100 family of calcium-binding proteins [134]. It is also known as S100 calcium-binding protein A8, migration inhibitory factor-related protein 8 (MRP-8), cystic fibrosis antigen (CFAG), P8, leukocyte L1 complex light chain, and calprotectin L1L subunit. It has been reported as a specific protein for several diseases [135–156], but has not been implicated in EmCa. Calgranulin A can form homodimers as well as higher-order oligomers [139]. Calgranulin A has been found to be associated with a second protein in the S100 family, calgranulin B (13,242 Da) [137,139]. This heterodimer is thought to be involved in inflammation, including the transmigration process of leukocytes and transport of arachidonic acid to target cells [134,137]. In the present study, calgranulin B was also identified along with calgranulin A, albeit by only one peptide. The possibility that calgranulin A and B coexist as members of a larger unit is in accordance with the observation that calgranulin eluted early in SEC in fraction 7 along with other proteins of much higher molecular weights (Table 9). However, calgranulin B does not appear to be retained on the ProteinChips under conditions that are favorable for calgranulin A.

Tissue microarray and immunohistochemical localization of calgranulin A

A summary of the TMA immunohistochemical studies using two different monoclonal antibodies (RDI and USB) is shown in Table 10. There is great similarity/identity between the findings from the two immunohistochemical studies. Calgranulin A was localized to the malignant epithelium of endometrial adenocarcinoma and carcinosarcoma. Approximately half of these malignant endometrial tissues showed 1+ to 3+ immunostaining for calgranulin A (Figure 29A and B). The most striking positivity was noted in the squamous areas of three endometrioid carcinomas (Figure 30). Two of four non-endometrial carcinomas also exhibited immunostaining for calgranulin A in the malignant epithelium. Immunohistochemical staining for calgranulin A was absent in 9 of 10 benign endometrial cases. A single case of menstrual endometrium exhibited focal immunostaining (1+). Macrophages/granulocytes in benign endometrium (Figure 31), malignant endometrium (Figure 29), and non-endometrial carcinomas showed discrete strong immunostaining of variable numbers of cells with immunostaining ranging from 1+ to 3+. No immunostaining for calgranulin A was noted in stroma or myometrium.

The MS results presented here show that elevated levels of calgranulin A were detectable in about two-thirds of EmCa homogenate cases, with 14 of 21 cases demonstrating 2+ or greater abundance for this protein (Table 8). By contrast, only minor levels were observed in most nonmalignant endometrium, with 22 of 23 cases demonstrating 1+ or lower abundance (Table 7).

5 The TMA findings not only confirm the presence of calgranulin A, at least as assessed by immunohistochemistry, but also indicate two cellular sources for the MS findings. In EmCa, the sources are both the malignant epithelium (carcinoma) and macrophage/granulocytes, whereas in nonmalignant endometrium, macrophages seem to be the predominant source, and only rarely benign (menstrual) endometrium (Table 10). The TMA analysis identified calgranulin A not only in a greater proportion of the epithelium in the EmCa cases, 10 but also with greater intensity, than in nonmalignant endometrial cases. Both cases of atypical hyperplasia showed 1+ immunostaining of the affected endometrial glands.

Employment of calgranulin A, in combination with other protein markers (including chaperonin 10), may provide a robust endometrial cancer diagnostic and/or screening panel. The utility of any panel will increase with the number of markers employed, and the sensitivity and specificity of individual markers. This study 15 demonstrates the complementary nature of MS and TMA in identifying and localizing sources of potential cancer markers in this search, and a possible utility of TMA in selecting cancer markers.

Conclusion

High mass accuracy and high resolution in the MS stage are crucial in SELDI MS. Using the QSTAR XL, two potential cancer markers were resolved and subsequently identified offline as chaperonin 10 and 20 calgranulin A, that differ by 8 Da in mass. These two proteins were unresolved on the PBS IIc mass spectrometer. Two offline protein identification protocols were developed: the first was based on SEC, SDS PAGE, protein extraction, trypsin digestion and MALDI-MS/MS; the second on SEC and shotgun nanoLC/MS/MS. Analyses on a cohort of 44 endometrial homogenates showed 22 out of 23 nonmalignant samples had nondetectable to very low abundance of chaperonin 10 and calgranulin A; 17 of the 21 malignant 25 samples had detectable to abundant levels of both proteins. Immunohistochemical staining of a tissue microarray of 32 samples showed that approximately half of malignant endometrial tissues exhibited positive staining for calgranulin A in the malignant epithelium, while 9 out of 10 benign tissues exhibited negative epithelial staining. In addition, macrophages/granulocytes in malignant as well as nonmalignant tissues showed positive staining. No immunostaining occurred in stroma or myometrium. Calgranulin A, in combination with chaperonin 10 and 30 other proteins, can constitute a panel of markers to permit diagnosis and screening of endometrial cancer.

- 84 -

Table 1

Differentially Expressed Proteins in Endometrial Malignancies/Cancer

5	<i>Protein</i>	<i>Gene name</i>	<i>Swiss-Prot Acc. No.</i>	<i>Expression in Em Ca</i>
10	Chaperonin 10	HSPE1	Q04984 and AAH23518 [SEQ ID 1] NM_002157 and U07550 [SEQ ID 2]	Up
15	Calgranulin A	S100A8	P05109 [SEQ ID 3] A12027 [SEQ ID 4] NM_002964 [SEQ ID 5]	Up
20	Calgranulin B	S100A9	P06702 [SEQ ID 6] X06233 [SEQ ID 7] M21064 [SEQ ID 8]	Up
25	Polymeric-immunoglobulin Receptor [precursor]	PIGR	P01833 or Q81ZY7 [SEQ ID 9] NM_002644 [SEQ ID 10]	Up
30	Phosphatidylethanolamine- binding protein (PEBP)	PBP	P30086 [SEQ ID 11] NM_002567 [SEQ ID 12]	Up
35	Acidic leucine-rich nuclear phosphoprotein 32 family member A	ANP32A	P39687 [SEQ ID 13] NM_006305 [SEQ ID 14]	Up
40	Heat shock 70 kDa protein 6	HSPA6	P17066 [SEQ ID 15] NM_002155 [SEQ ID 16] X51757 [SEQ ID 17]	Up
45	Macrophage migration Inhibitory factor (MIF)	MIF	P14174 [SEQ ID 18] NM_002415 [SEQ ID 19] L19686 [SEQ ID 20]	Up
50	Calgizzarin (S100C protein)	S100A11	P31949 [SEQ ID 21] NM_005620 and D38583 [SEQ ID 22]	Up
55	Triosephosphate isomerase	TPI1	P00938 and NP_000356 [SEQ ID 23] NM_000365 [SEQ ID 24] X69723 [SEQ ID 25]	Up
	Alpha-1-antitrypsin precursor	SERPINA1	gi/1703025 ITHU and P01009 [SEQ ID 30] NM_000295 [SEQ ID NO. 31] K02212 [SEQ ID 32]	Under
	Creatine kinase, B chain (B-CK)	CKB	gi/125294 P12277 [SEQ ID NO.33] NM_001823 [SEQ ID NO 34] X15334 [SEQ ID NO 35]	Under

- 85 -

5	Pyruvate kinase, M1 or M2 isozyme	PKM2	gi/20178296; gi/125604; KPY1_HUMAN (P14618) [SEQ ID NO.36] X56494 [SEQ ID 37]	Up
10	Transgelin (smooth muscle protein 22-alpha)	TAGLN	gi/3123283 Q01995 [SEQ ID.38] D84342 [SEQ ID 39]	Under
15	Heterologous nuclear ribonucleoprotein D	(hnRPD	ROD_HUMAN (Q14103) [SEQ ID NO.40] AF026126 [SEQ ID 41]	Up

Table 2

5 **The identification of Chaperonin 10 by mass spectrometry and Western blotting techniques in non-malignant endometrial tissue homogeneates.**

Case	Histopathologic Classification	MS results (relative intensity)	Western Blotting Results (relative intensity)
1	Proliferative	+	o
2	Proliferative	+	o
3	Secretory	+	o
4	Atrophic	+	+
5	Benign polyp	o	o
6	Atrophic	+	+
7	Secretory	o	o
8	Disordered proliferative endometrium	o	+
9	Secretory	o	+
10	Disordered proliferative	o	+
11	Secretory	o	+
12	Secretory	+	+
13	Secretory	o	+
14	Secretory	+	o
15	Atrophic	o	o
16	Secretory	+	+
17	Menstrual	+	+
18	Secretory	+	+
19	Proliferative	+	o
20	Proliferative	+	+
21	Menstrual	o	o
22	Atrophic	o	o
23	Atrophic	++	+

- 87 -

Table 3

The identification of Chaperonin 10 by mass spectrometry and Western blotting techniques in malignant endometrial tissue homogeneates.

Case	Histopathologic Classification	MS results (relative intensity)	Western Blotting Results (relative intensity)
24	Em AdCa 1/3	++	++
25	Em AdCa 1/3	O	+
26	MMMT	+++++	+++++
27	Em AdCa	++	++
28	MMMT*	+	o
29	Em AdCa 2/3	+	+++
30	Em AdCa 2/3	+	++++
31	Ser AdCa	+	+++++
32	Em AdCa 1/3	+++++	+++++
33	Em AdCa Grade n.k.	O	++++
34	Em AdCa Grade n.k.	+	+++
35	Em AdCa Grade n.k.	O	+
36	Em AdCa 1/3	+++++	++++
37	Em AdCa 1/3	++++	+++
38	Em AdCa 1/3	+++	+++
39	Muc AdCa 1/3	++	o
40	Em AdCa 1/3	+++	+++
41	Em AdCa 1/3	+++	++
42	Em AdCa – Ser AdCa	+++++	+++++
43	Em** AdCa 1/3	o	o
44	Em AdCa 2/3	++++	++++

5 *Mirror section showed minimal tumor.
 **Mirror image showed necrotic tumor only.
 Em AdCa = Endometrioid adenocarcinoma
 MMTT = Malignant Mixed Mullerian Tumor
 Muc AdCa = Mucinous adenocarcinoma
 10 n.k. = not known
 Ser AdCa = Serous adenocarcinoma

- 88 -

Table 4**Differentially expressed proteins quantified by iTRAQ.****S: P is the ratio of secretory phase relative to the proliferative phase****5 C1: P and C2: P are the ratios of cancer samples 1 and 2 relative to the proliferative phase, respectively.**

accession_id	name	S: P (\pm SD)	C1: P (\pm SD)	C2: P (\pm SD)
gi 461730	10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10)	1.06 \pm 0.12	2.71 \pm 0.52	2.23 \pm 0.29
gi 1703025	Alpha-1-antitrypsin precursor	1.25 \pm 0.39	0.34 \pm 0.07	0.44 \pm 0.16
gi 125294	Creatine kinase, B chain (B-CK)	0.96 \pm 0.04	0.38 \pm 0.16	0.52 \pm 0.06
gi 20178296 or gi 125604	Pyruvate kinase, M1 or M2 isozyme	1.03 \pm 0.11	2.75 \pm 0.03	2.02 \pm 0.08
gi 3123283	Transgelin (Smooth muscle protein 22-alpha)	1.46 \pm 0.26	0.26 \pm 0.04	0.45 \pm 0.05

- 89 -

Table 5

Differentially expressed proteins quantified using cICAT. Singleton H signifies extreme Overexpression in the cancer sample relative to the normal proliferative control. Standard deviations were calculated from all three sample pairs.

5

Accession #	Name	Avg. C: N ratio (\pm SD) Singleton H ^a
S111_HUMAN (P31949)	Calgizzarin (S100C protein) (MLN 70).	
ROD_HUMAN (Q14103)	Heterogeneous nuclear ribonucleoprotein D0	4.62 (\pm 0.39)
MIF_HUMAN (P14174)	Macrophage migration inhibitory factor (MIF)	2.74 (\pm 0.92)
PEBP_HUMAN (P30086)	Phosphatidylethanolamine-binding protein (PEBP)	3.72 (\pm 1.03)
KPY1_HUMAN (P14618)	Pyruvate kinase, M1 isozyme (EC 2.7.1.40)	4.61 (\pm 1.40)
KPY_HUMAN: PIGR_HUMAN (P01833)	Polymeric-immunoglobulin receptor precursor	9.83 (+/- 6.61)

a: Calculation of SD is not possible

- 90 -

Table 6

Proteins Identified and Secretory / Proliferative Expression Levels

Accession #	Description	Average H:L ratio	SD	Frequency
143T_HUMAN (P27348)	14-3-3 protein tau (14-3-3 protein theta)	0.81		1
RS12_ORENI (O13019)	40S ribosomal protein S12.	0.52		1
RS21_HUMAN (P35265)	40S ribosomal protein S21.	NQ		1
HPPD_MYCGR (O42764)	4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27)	Singleton L		1
RL36_VIBCH (P78001)	50S ribosomal protein L36.	0.84		1
ACTA_HUMAN (P03996) or ACTS_HUMAN (P02568)	Actin, aortic smooth muscle or Actin alpha skeletal muscle	1.86		1
ACTB_HUMAN (P02570)	Actin, cytoplasmic	0.93	0.04	3
SAH1_XENLA (P51893)	Adenosylhomocysteinase 1 (EC 3.3.1.1)	0.70		1
AFAM_HUMAN (P43652)	Afamin precursor (Alpha-albumin) (Alpha-Alb).	NQ		1
ADHL_HUMAN (P11766)	Alcohol dehydrogenase class III L chain	0.67		1
DHA1_HUMAN (P00352)	Aldehyde dehydrogenase 1A1 (EC 1.2.1.3)	0.60		1
A1AG_HUMAN (P02763)	Alpha-1-acid glycoprotein 1 precursor (AGP 1)	1.1	0.5	3
A2HS_HUMAN (P02765)	Alpha-2-HS-glycoprotein precursor (Fetuin-A)	0.82	0.54	2
ALU5_HUMAN (P39192)	Alu subfamily	1.1		1
AOP2_HUMAN (P30041)	Antioxidant protein 2 (1-Cys peroxiredoxin)	NQ		1
TRAI_AGRT5 (P33907)	Autoinducer synthesis protein traI.	0.55		1
APOH_HUMAN (P02749)	Beta-2-glycoprotein I precursor (Apolipoprotein H)	0.58		1
ARK1_HUMAN (P25098)	Beta-adrenergic receptor kinase 1 (EC 2.7.1.126)	Singleton L		1

- 91 -

Accession #	Description	Average H:L ratio	SD	Frequency
BPEA_HUMAN (O94833)	Bullous pemphigoid antigen 1, isoforms 6/9/10	0.99		1
CLP1_HUMAN (P51911)	Calponin H1, smooth muscle (Basic calponin)	1.8		1
KAP3_HUMAN (P31323)	cAMP-dependent protein kinase type II-beta	Singleton L		1
CABA_MOUSE (Q99020)	CARG-binding factor-A (CBF-A).	0.97	0.33	3
CATB_HUMAN (P07858)	Cathepsin B precursor (EC 3.4.22.1) (Cathepsin B1)	0.88	0.70	2
CB32_YEAST (P40969)	Centromere DNA-binding protein complex CBF3 subunit	NQ		1
BPHB_BURCE (P47227)	Cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase (EC	Singleton L		1
CLH_BOVIN (P49951)	Clathrin heavy chain.	0.62		1
COF1_HUMAN (P23528)	Cofilin, non-muscle isoform (18 kDa phosphoprotein)	0.95	0.15	3
CO3_HUMAN (P01024)	Complement C3 precursor	1.1	0.1	2
CFAH_HUMAN (P08603)	Complement factor H precursor (H factor 1).	NQ		1
AXO1_CHICK (P28685)	Contactin 2 precursor (Axonin-1).	0.85		1
KCRB_HUMAN (P12277)	Creatine kinase, B chain (EC 2.7.3.2) (B-CK).	6.0		1
CRBH_HUMAN (P82279)	Crumbs protein homolog 1 precursor.	NQ		1
PYRG_STAAM (Q99SD1)	CTP synthase (EC 6.3.4.2) (UTP-- ammonia ligase) (C	Singleton H		1
CYSR_HUMAN (P21291)	Cysteine-rich protein 1 (CRP1) (CRP).	4.4		1
DDX4_HUMAN (Q9NQI0)	DEAD-box protein 4 (VASA homolog).	Singleton H		1
DEST_HUMAN (P18282)	Destrin (Actin-depolymerizing factor) (ADF).	2.4		1
EF2_HUMAN (P13639)	Elongation factor 2	0.60		1
XYNA_PIRSP (Q12667)	Endo-1,4-beta-xylanase A precursor (EC 3.2.1.8) (1	0.32		1

- 92 -

Accession #	Description	Average H:L ratio	SD	Frequency
ENOA_HUMAN (P06733) or MPB1_HUMAN (P22712)	Enolase (EC 4.2.1.11) (2-phosphoglycerate dehydrat.) or c-myc promoter binding protein (MBP-1)	2.6	1.9	
ENV_SIVM1 ^a (P05885)	Envelope polyprotein GP160 precursor	Singleton L		3
LEM2_CANFA (P33730)	E-selectin precursor (Endothelial leukocyte adhesion)	Singleton H		1
FIBG_HUMAN (P02679)	Fibrinogen gamma chain precursor	1.2		1
FLNA_HUMAN (P21333)	Filamin A (Alpha-filamin) (Filamin 1)	1.6	0.8	3
ALFA_HUMAN (P04075)	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Mu)	1.2	0.2	2
G25P_HUMAN (P25763) or RAC1_HUMAN (P15154) or RHOJ_HUMAN (Q9H4E5)	G25K GTP binding protein (CDC 42 homolog) or Ras related C3 botulinum toxin substrate 1 or 2 or 3 or Rho-related GTP-binding protein Rho G or RhoJ	NQ		1
LEG1_CRIGR (P48538)	Galectin-1 (Beta-galactoside-binding lectin L-14-I)	0.67	0.52	3
GELS_HUMAN (P06396)	Gelsolin (Actin-depolymerizing factor) (ADF)	1.4		2
NMZ1_HUMAN (Q05586)	Glutamate [NMDA] receptor subunit zeta 1 precursor	Singleton H		3
GTP_HUMAN (P09211)	Glutathione S-transferase P (EC 2.5.1.18)	1.3	0.4	3
G3P2_HUMAN ^b (P04406)	Glyceraldehyde 3-phosphate dehydrogenase	1.0	0.0	3
PAEP_HUMAN (P09466)	Glycodelin precursor (GD) (Pregnancy-associated en)	Singleton H		1
HPT1_HUMAN (P00737)	Haptoglobin-1 precursor.	2.2	1.6	2
HS70_HUMAN (08107)	Heat shock cognate 71 kDa protein.	1.3	1.1	3
HS9A_HUMAN (P07900)	Heat Shock Protein HSP90-alpha	NQ		1
HBB_HUMAN (P02023)	Hemoglobin beta chain.	0.60	0.45	3
HEMO_HUMAN (P02790)	Hemopexin precursor (Beta-1B-glycoprotein).	1.1	0.3	3

- 93 -

Accession #	Description	Average H:L ratio	SD	Frequency
ROD_HUMAN (Q14103)	Heterogeneous nuclear ribonucleoprotein D0 (hnRNP D0)	1.0	0.2	3
ROK_HUMAN (Q07244)	Heterogeneous nuclear ribonucleoprotein K (hnRNP K)	0.68		1
HNT1_HUMAN (P49773)	Histidine triad nucleotide binding protein 1	1.4		1
YF48_HUMAN (Q9HCM4)	Hypothetical protein KIAA1548	0.85		1
Y885_MYCTU (Q10546)	Hypothetical protein Rv0885.	NQ		1
GC1_HUMAN (P01857)	Ig gamma-1 chain C region.	0.76	0.23	3
GC2_HUMAN (P01859) or GC4_HUMAN (P01861)	Ig gamma-2 chain C region. Or Ig gamma-4 chain C region	1.0	0.5	3
GC3_HUMAN (P01860)	Ig gamma-3 chain C region	0.85	0.22	3
KAC_HUMAN (P01834)	Ig kappa chain C region.	0.88	0.37	3
HUMAN (P01876) or (P01877)	Ig alpha - 1 chain C region or Ig alpha-2 chain C region	1.4		1
IDI2_RICCN ^c (Q92HM7)	Isopentenyl-diphosphate delta-isomerase (EC 5.3.3.	Singleton H		3
TRFL_MOUSE (P08071)	Lactotransferrin precursor (Lactoferrin).	Singleton H		1
LGUL_HUMAN (Q04760)	Lactoylglutathione lyase (EC 4.4.1.5) (Methylglyox	1.0	0.2	2
CSR3_HUMAN (P50461)	LIM domain protein, cardiac (Muscle LIM protein) (4.2		1
LDH_HUMAN (P00338) or (P07195)	L-lactate dehydrogenase (EC 1.1.1.27) (LDH).	1.4	0.3	3
MIF_HUMAN (P14174)	Macrophage migration inhibitory factor (MIF)	1.2	0.7	3
MSRE_MOUSE (P30204)	Macrophage scavenger receptor types I and II	Singleton H		1
MDHM_HUMAN (P40926)	Malate dehydrogenase, mitochondrial precursor	NQ		2
MSP1_PLAF3 (P19598)	Merozoite surface protein 1 precursor	Singleton L		1

- 94 -

Accession #	Description	Average H:L ratio	SD	Frequency
MU5A_HUMAN (P98088)	Mucin 5AC (Mucin 5 subtype AC, tracheobronchial)	NQ		1
MYH9_HUMAN (P35579) or MYHA_HUMAN (P35580)	Myosin heavy chain non muscle type A or B	0.29		1
KML2_RABIT (P07313)	Myosin light chain kinase 2	Singleton H		3
NIR_NEUCR (P38681)	Nitrite reductase [NAD(P)H] (EC 1.7.1.4).	1.3		1
NOG3_BRARE (Q9YHV3)	Noggin 3 precursor.	1.3		1
NDKA_HUMAN (P15531) or NDKB_HUMAN (P22392)	Nucleotide diphosphate kinase A or B	1.2		1
CYPH_HUMAN (P05092)	Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8)	1.2	0.2	3
PEBP_BOVIN (P13696)	Phosphatidylethanolamine-binding protein (PEBP) (B)	1.0	0.2	2
PGK_HUMAN (P00559)	Phosphoglycerate kinase (EC 2.7.2.3).	0.99		1
PMG1_HUMAN (P18669)	Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4)	0.73		1
POL_RSVP ^d (P03354)	POL polypeptide	Singleton H		2
PIGR_HUMAN (P01833)	Polymeric-immunoglobulin receptor precursor (Poly-	1.1		1
AR34_DROME (Q9VIM5)	Probable ARP2/3 complex 34 kDa subunit (P34-ARC).	3.5		1
AMPA_CAMJE (Q9PP04)	Probable cytosol aminopeptidase (EC 3.4.11.1) (Leu	0.93		1
PRO1_HUMAN (P07737)	Profilin I	1.1		1
PROP_HUMAN (P27918)	Properdin precursor (Factor P).	Singleton H		1
PRTH_PORGI (P46071)	Protease prtH (EC 3.4.22.-).	Singleton L		1
PSA5_HUMAN (P28066)	Proteasome subunit alpha type 5 (EC 3.4.25.1) (Pro	2.1		1

- 95 -

Accession #	Description	Average H:L ratio Singleton L	SD	Frequency
VN02_VACCC (P20641)	Protein N2.			1
FRT1_HUMAN (Q92837)	Proto-oncogene FRAT1	Singleton H		3
O22C_DROME (P81911)	Putative odorant receptor 22c.	0.90	0.31	3
KPY1_HUMAN (P14618)	Pyruvate kinase, M1 isozyme (EC 2.7.1.40) (Pyruvat	1.2	0.4	3
CUT1_SCHPO (P18296)	Separin (EC 3.4.22.-).	NQ		1
TRFE_HUMAN (P02787)	Serotransferrin precursor (Transferrin) (Siderophi	1.3	0.4	3
ALBU_HUMAN (P02768)	Serum albumin precursor.	1.1	0.3	3
STC_DROME (P40798)	Shuttle craft protein.	1.1		1
SLI1_HUMAN (Q13642)	Skeletal muscle LIM protein 1	2.0		1
PCP1_SCHPO (Q92351)	Spindle pole body protein pcpl.	Singleton H		1
SODC_HUMAN (P00441)	Superoxide dismutase [Cu-Zn]	0.92	0.33	3
THIO_HUMAN (P10599)	Thioredoxin.	0.87		1
TPIS_HUMAN (P00938)	Triosephosphate isomerase (EC 5.3.1.1) (TIM).	1.1	0.5	3
TPM1_HUMAN (P09493)	Tropomyosin 1 alpha chain (Alpha-tropomyosin).	2.3	0.7	2
TPM4_HUMAN (P07226) or TPM2_HUMAN (P07951)	Tropomyosin alpha 4 chain or beta 2 chain	0.75		1
TBA_HUMAN (P05209)	Tubulin alpha chain.	1.2	0.5	3
TBB_HUMAN (P07437 or P05217))	Tubulin beta chain (Fragment).	0.77	0.25	3
PTK7_HUMAN (Q13308)	Tyrosine-protein kinase like 7 precursor	0.35		1
SPK1_DUGTI (P42687)	Tyrosine-protein kinase SPK-1 (EC 2.7.1.112).	Singleton L		1
VSI1_TRYBB (P26326)	Variant surface glycoprotein ILTAT 1.21 precursor	Singleton L		1

- 96 -

Accession #	Description	Average H:L ratio	SD	Frequency
PGCV_MACNE (Q28858)	Versican core protein	4.3		1
VIME_HUMAN (P08670)	Vimentin (Fragment).	1.6	2.2	3
VINC_HUMAN (P18206)	Vinculin (Metavinculin).	3.1		2
VTDB_HUMAN (P02774)	Vitamin D-binding protein precursor (DBP) (Group-s	1.3	0.4	2
WDR1_HUMAN (O75083)	WD-repeat protein 1 (Actin interacting protein 1)	1.6	1.0	2
Z363_HUMAN (Q96PM5)	Zinc finger protein 363	Singleton L		1

Note: Frequency is the number of sample pairs in which the protein is observed

NQ = Not quantified

Singleton L = Only observed in Proliferative phase

Singleton H = Only observed in Secretory phase

^a : Subsequently identified by Mascot as *Clostridium* putative phosphatidylserine decarboxylase
proenzyme (gi: 28209853)

^b : Internal standard to which other proteins' peak areas are normalized

^c : *Rickettsia conorii* protein

^d : Subsequently identified by Mascot as unlabeled serum albumin

- 97 -

Table 7

Protein abundances in nonmalignant endometrial tissue homogenates.

Case	Histopathologic Classification	Chaperonin 10 (relative abundance) [†]	Second protein [‡] (relative abundance) [†]
1	Proliferative	1+	0
2	Proliferative	1+	0
3	Secretory	1+	0
4	Atrophic	1+	0
5	Benign polyp	0	0
6	Atrophic	1+	1+
7	Secretory	0	1+
8	Disordered proliferative	0	0
9	Secretory	0	1+
10	Disordered proliferative	0	1+
11	Secretory	0	1+
12	Secretory	1+	0
13	Secretory / menstrual	0	5+*
14	Secretory	1+	0
15	Atrophic	0	1+
16	Secretory	1+	0
17	Menstrual	1+	1+
18	Secretory	1+	0
19	Proliferative	1+	0
20	Proliferative	1+	0
21	Menstrual	0	0
22	Atrophic	0	1+
23	Atrophic	2+	1+

[†] 0 = absence, 1+ = S/N 2-3, 2+ = S/N 3-5, 3+ = S/N 5-7, 4+ = S/N 7-10, 5+ = S/N ≥ 10.

[‡] calgranulin A.

* cervical cancer present several centimeters away.

- 98 -

Table 8**Protein abundances in malignant endometrial tissue homogenates.**

Case	Histopathologic Classification	Chaperonin 10 (relative abundance) [†]	Second protein [‡] (relative abundance) [‡]
24	Em AdCa 1/3	2+	1+
25	Em AdCa 1/3	0	5+
26	MMMT	5+	1+
27	Em AdCa	2+	5+
28	MMMT	1+	4+
29	Em AdCa 2/3	1+	3+
30	Em AdCa 2/3	1+	4+
31	Ser AdCa	1+	3+
32	Em AdCa 1/3	5+	2+
33	Em AdCa Grade n.k.	0	0
34	Em AdCa Grade n.k.	1+	3+
35	Em AdCa Grade n.k.	0	0
36	Em AdCa 1/3	5+	0
37	Em AdCa 1/3	4+	2+
38	Em AdCa 1/3	3+	5+
39	Muc AdCa 1/3	2+	3+
40	Em AdCa 1/3	2+	2+
41	Em AdCa 1/3	3+	1+
42	Em AdCa – Ser AdCa	5+	0
43	Em AdCa 1/3	0	5+
44	Em AdCa 2/3	4+	4+

[†] 0 = absence, + = S/N 2-3, 2+ = S/N 3-5, 3+ = S/N 5-7, 4+ = S/N 7-10, 5+ = S/N ≥ 10.

5 [‡] calgranulin A.

Em AdCa = Endometrioid adenocarcinoma

MMMT = Malignant Mixed Mullerian Tumor

Muc AdCa = Mucinous adenocarcinoma

n.k. = not known

10 Ser AdCa = Serous adenocarcinoma

- 99 -

Table 9

Proteins in SEC fraction 7 of Endometrial Cancer Tissue Identified by nanoLC/MS/MS

	Name	Confidence ^a	Averaged mol. weight (Da)
5	Calgranulin A	99	10,834
	Calgranulin B	99	13,242
	Heat shock protein 10	99	10,800
	Hemoglobin alpha chain	90	15,126
	Hemoglobin beta chain	99	15,867
10	Putative nucleoside diphosphate kinase	75	15,529
	Nucleoside diphosphate kinase A	75	17,149
	Nucleoside diphosphate kinase B	75	17,298
	Cofilin, non-muscle isoform	90	18,502
	Cofilin, muscle isoform	90	18,736
15	Translationally controlled tumor protein	90	19,595
	Peroxiredoxin 1	99	22,110
	Peroxiredoxin 2	99	21,892
	Neutrophil gelatinase-associated lipocalin	99	22,588
	Glutathione S-transferase P	99	23,224
20	Triosephosphate isomerase	90	26,538
	Peroxiredoxin 4	90	30,540
	NADPH dehydrogenase	90	30,867
	Ig gamma-3 chain C region	75	32,331
	Ig gamma-2 chain C region	75	35,884
25	Ig gamma-4 chain C region	75	35,940
	Ig gamma-1 chain C region	75	36,106
	C-myc promoter-binding protein	99	37,087
	Hetero. nuclear ribonucleoproteins A2	99	37,429
	Cathepsin B precursor	99	37,807
30	Beta enolase	75	46,855
	Alpha enolase	99	47,037
	Gamma enolase	75	47,137
	Alpha enolase, lung specific	99	49,477
	Serum albumin precursor	99	69,366
35	Polymeric-immunoglobulin receptor precursor	75	83,313
	Cone cGMP-specific 3',5'-cyclic phosphodiesterase	75	99,102

^a "Confidence" value in ProID: the highest possible score is 99.

- 100 -

Table 10

**Immunohistochemical identification of calgranulinA in tissue microarray
using two monoclonal mouse antibodies (RDI & USB)**

Histologic Classification	Macrophage/ Granulocytic		Epithelium/ Carcinoma		Stroma/ Myometrium	
	RDI	USB	RDI	USB	RDI	USB
Benign endometrium, n = 10†	0 (1) 1+ (6) 2+ (3) 3+ (0)	0 (0) 1+ (10) 2+ (0) 3+ (0)	0 (9) 1+ (1) 2+ (0) 3+ (0)	0 (9) 1+ (1) 2+ (0) 3+ (0)	0 (10) 1+ (0) 2+ (0) 3+ (0)	0 (10) 1+ (0) 2+ (0) 3+ (0)
Atypical endometrial hyperplasia, n = 2	1+ (2)	1+ (2)	1+ (2)	1+ (2)	0 (2)	0 (2)
EmCa, n = 13‡	0 (1) 1+ (7) 2+ (3) 3+ (1)	0 (1) 1+ (8) 2+ (3) 3+ (1)	0 (6) 1+ (4) 2+ (2) 3+ (0)	0 (7) 1+ (2) 2+ (2) 3+ (2)	0 (12) 1+ (0) 2+ (0) 3+ (0)	0 (13) 1+ (0) 2+ (0) 3+ (0)
Non-endometrial carcinomas, n = 4	0 (0) 1+ (1) 2+ (3) 3+ (0)	0 (1) 1+ (1) 2+ (2) 3+ (1)	0 (2) 1+ (1) 2+ (1) 3+ (0)	0 (2) 1+ (1) 2+ (1) 3+ (0)	0 (4) 1+ (0) 2+ (0) 3+ (0)	0 (4) 1+ (0) 2+ (0) 3+ (0)
Benign non-endometrial neoplasms, n = 2	0 (0)	0 (1)	0 (0)	0 (0)	0 (0)	0 (0)

() = Number of samples

0 = No immunostaining

1+ = Positivity in occasional or few cells

2+ = Positivity in more abundant cells

3+ = Strong positivity in numerous cells

† = In TMA- RDI, one core of EmCa was not displayed

‡ = 1 of 11 benign endometrial cores (secretory) did not display in either TMA.

- 101 -

The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the antibodies, methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Below full citations are set out for references.

20

Full Citations for References

1. Buckley CH: Normal endometrium and non-proliferative conditions of the endometrium. In *Obstetrical and Gynaecological Pathology*. Fox H, Wells M. Eds. Churchill-Livingstone. 5th Ed. London, 2003, Pgs. 391 – 442.
2. Andersen JS, Mann M (2000) *FEBS Lett* 480: 25-31.
3. Yao X, Freas A, Ramirez J, Demirev PA, Fenselau C (2001) *Anal Chem* 73: 2836-2842.
4. Geng M, Ji J, Regnier F (2000) *J Chromatogr A* 870: 295-313.
5. Münchbach M, Quadroni M, Miotto G, James P (2000) *Anal Chem* 72: 4047-4057.
- 10 6. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R (1999) *Nat Biotechnol* 17: 994-999.
7. Goshe MB, Conrads TP, Panisko EA, Angell NH, Veenstra TD, Smith RD (2001) *Anal Chem* 73: 2578-2586.
8. Williamson B, Marchese J, Juhasz P, Hatten S, Patterson D, Graber A, Khainovski N, Romeo A, Martin S (2002) *Proceedings of the 50th ASMS Conference on Mass Spectrometry and Allied Topics*, Orlando.
- 15 9. Arcuri F, Ricci C, Ietta F, Cintonino M, Tripodi SA, Cetin I, Garzia E, Schatz F, Kleini P, Santopietro R, Paulesu L (2001) *Biol Reprod* 64: 1200 – 1205.
10. Canadian Cancer Statistics 2003. Canadian Cancer Society . 2003. 7-28-0003. Ref Type: Electronic Citation
11. Cancer Facts and Figures. American Cancer Society . 2003. 7-25-0003. Ref Type: Electronic Citation
- 20 12. Rose PG: Endometrial carcinoma. *N Engl J Med* 1996, 335:640-649.
13. Agboola OO, Grunfeld E, Coyle D, Perry GA: Costs and benefits of routine follow-up after curative treatment for endometrial cancer. *CMAJ* 1997, 157:879-886.
14. Duffy MJ: Clinical uses of tumor markers: a critical review. *Crit Rev Clin Lab Sci* 2001, 38:225-262.
15. Chambers G, Lawrie L, Cash P, Murray GI: Proteomics: a new approach to the study of disease. *J Pathol* 2000, 192:280-288.
- 25 16. Peng J, Gygi SP: Proteomics: the move to mixtures. *J Mass Spectrom* 2001, 36:1083-1091.
17. Wu W, Hu W, Kavanagh JJ: Proteomics in cancer research. *Int J Gynecol Cancer* 2002, 12:409-423.
18. Bryant-Greenwood PK, Petricoin 3rd EF, Abati A, Liotta L: High-Throughput Proteomic Analysis of Microdissected Cytological Specimens Yields Distinct Expression Profiles of Follicular vs Papillary Thyroid Carcinomas. *Mod Pathol* 2000, 13:30A.
- 30 19. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF, III: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. *Proteomics* 2002, 2:76-84.
20. Knezevic V, Leethanakul C, Bichsel VE, Worth JM, Prabhu VV, Gutkind JS, Liotta LA, Munson PJ, Petricoin EF, III, Krizman DB: Proteomic profiling of the cancer microenvironment by antibody arrays. *Proteomics* 2001, 1:1271-1278.
- 35 21. Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR, Cole KA, Wang Q-H, Huang J, Hu N, Yip T-T, Rich WE, Kohn EC, Linehan WM, Weber T, Taylor P, Emmert-Buck MR, Liotta LA,

- Petricoin EF, III: Rapid Protein Display Profiling of Cancer Progression Directly From Human Tissue Using a Protein Biochip. *Drug Dev Res* 2000, 49:34-42.
22. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. *Lancet* 2002, 359:572-577.
 23. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright JG, Jr.: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. *Am J Pathol* 2001, 158:1491-1502.
 24. Wright Jr GL, Cazares LH, Leung S-M, Nasim S, Adam B-L, Yip T-T, Schellhammer PF, Gong L, Vlahou A: Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. *Prostate Cancer and Prostatic Diseases* 1999, 2:264-276.
 25. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF, III: New approaches to proteomic analysis of breast cancer. *Proteomics* 2001, 1:1205-1215.
 26. Blaustein's Pathology of the Female Genital Tract. New York, Springer-Verlag, 2002.
 27. Cavanagh AC, Morton H: The purification of early-pregnancy factor to homogeneity from human platelets and identification as chaperonin 10. *Eur J Biochem* 1994, 222:551-560.
 28. Inoue M: Current molecular aspects of the carcinogenesis of the uterine endometrium. *Int J Gynecol Cancer* 2001, 11:339-348.
 29. Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ, Wilcox M: Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. *Gynecol Oncol* 2001, 83:177-185.
 30. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. *Nat Rev Cancer* 2003, 3:267-275.
 31. Walch A, Komminoth P, Hutzler P, Aubele M, Hofler H, Werner M: Microdissection of tissue sections: application to the molecular genetic characterisation of premalignant lesions. *Pathobiology* 2000, 68:9-17.
 32. Sugiyama Y, Sugiyama K, Hirai Y, Akiyama F, Hasumi K: Microdissection is essential for gene expression profiling of clinically resected cancer tissues. *Am J Clin Pathol* 2002, 117:109-116.
 33. Batorfi J, Ye B, Mok SC, Cseh I, Berkowitz RS, Fulop V: Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. *Gynecol Oncol* 2003, 88:424-428.
 34. Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A: Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. *Prostate Cancer Prostatic Dis* 1999, 2:264-276.
 35. von Eggeling F, Davies H, Lomas L, Fiedler W, Junker K, Claussen U, Ernst G: Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. *BioTechniques* 2000, 29:1066-1070.

36. Somodevilla-Torres MJ, Hillyard NC, Morton H, Alewood D, Halliday JA, Alewood PF, Vesey DA, Walsh MD, Cavanagh AC: Preparation and characterization of polyclonal antibodies against human chaperonin 10. *Cell Stress Chaperones* 2000, 5:14-20.
37. Cornford PA, Dödsen AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. *Cancer Res* 2000, 60:7099-7105.
38. Quinn KA, Morton H: Effect of monoclonal antibodies to early pregnancy factor (EPF) on the in vivo growth of transplantable murine tumours. *Cancer Immunol Immunother* 1992, 34:265-271.
39. Kato S, Kato M, Hirano A, Takikawa M, Ohama E: The immunohistochemical expression of stress-response protein (srp) 60 in human brain tumours: relationship of srp 60 to the other five srps, proliferating cell nuclear antigen and p53 protein. *Histol Histopathol* 2001, 16:809-820.
40. Tabibzadeh S, Kong QF, Satyaswaroop PG, Babaknia A: Heat shock proteins in human endometrium throughout the menstrual cycle. *Hum Reprod* 1996, 11:633-640.
41. Ota H, Igarashi S, Hatazawa J, Tanaka T: Distribution of heat shock proteins in eutopic and ectopic endometrium in endometriosis and adenomyosis. *Fertil Steril* 1997, 68:23-28.
42. Athanasas-Platsis S, Quinn KA, Wong TY, Rolfe BE, Cavanagh AC, Morton H: Passive immunization of pregnant mice against early pregnancy factor causes loss of embryonic viability. *J Reprod Fertil* 1989, 87:495-502.
43. Athanasas-Platsis S, Morton H, Dunglison GF, Kaye PL: Antibodies to early pregnancy factor retard embryonic development in mice in vivo. *J Reprod Fertil* 1991, 92:443-451.
44. Athanasas-Platsis S, Corcoran CM, Kaye PL, Cavanagh AC, Morton H: Early pregnancy factor is required at two important stages of embryonic development in the mouse. *Am J Reprod Immunol* 2000, 43:223-233.
45. Noonan FP, Halliday WJ, Morton H, Clunie GJ: Early pregnancy factor is immunosuppressive. *Nature* 1979, 278:649-651.
46. Quinn KA, Cavanagh AC, Hillyard NC, McKay DA, Morton H: Early pregnancy factor in liver regeneration after partial hepatectomy in rats: relationship with chaperonin 10. *Hepatology* 1994, 20:1294-1302.
47. Quinn KA: Active immunization with EPF suppresses the formation of immune ascites in BALB/c mice. *Immunol Cell Biol* 1991, 69 (Pt 1):1-6.
48. National Cancer Institute of Canada: Canadian Cancer Statistics 2003, Toronto, Canada, 2003 [Serial online] April 2003; Available from: URL: http://www.bc.cancer.ca/vgn/images/portal/cit_776/61/38/56158640niw_stats_en.pdf
49. DeSouza, L.; Diehl, G.; Yang, E.C.C.; Guo, J.; Rodrigues, M.J.; Romaschin, A.D.; Colgan, T.J.; Siu, K.W.M. Proteomic Analysis of the Proliferative and Secretory Phases of the Human Endometrium: Protein Identification and Differential Protein Expression. *Proteomics*. 2004, in press.

50. Yang, E.C.C.; Guo, J.; Diehl, G.; DeSouza, L.; Rodrigues, M.J.; Romaschin, A.D.; Colgan, T.J.;
Siu, K.W.M. Expression Profiling of Endometrial Malignancies Reveals a New Tumor Marker:
Chaperonin 10.J. Proteome Res. 2004 3, 636-643.
51. Guo, J.; Yang, E.C.C.; DeSouza, L.; Diehl, G.; Rodrigues, M.J.; Romaschin, A.D.; Colgan, T.J.;
5 Siu, K.W.M. A Strategy for High-Resolution and Protein Identification in Surface- Enhanced Laser
Desorption / Ionization (SELDI) Mass Spectrometry: Calgranulin A and Chaperonin 10 as Protein
Markers for Endometrial Carcinoma. Proteomics.
52. Li, J.; Steen, H.; Gygi, S.P. Protein profiling with cleavable isotope-coded affinity tag (cICAT)
reagents. Mol. Cell. Proteomics 2003, 2, 1198 – 1204.
- 10 53. Cappello, F.; Bellafiore, M.; David, S.; Anzalone, R.; Zummo, G. Ten kilodalton heat shock protein
(HSP10) is overexpressed during carcinogenesis of large bowel and uterine exocervix. Cancer Lett.
2003, 196, 35 – 81.
54. Fan, X.; Yan, L.; Jia, S.; Ma, A.; Qiao, C. A study of early pregnancy factor activity in the sera of
women with trophoblastic tumour. Am. J. Reprod. Immunol. 1999, 41, 204 – 208.
- 15 55. Kim, C.W.; Kim, J.I.; Park, S.H.; Han, J.Y.; Kim, J.K.; Chung, K.W.; Sun, H.S. Usefulness of
plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J
Gastroenterol. 2003,42, 387 –393.
56. Hardt, P.D.; Toepler, M.; Ngoumou, B.; Rupp, J.; Kloer, H.U. Fecal pyruvate kinase concentrations
(ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
20 Anticancer Res. 2003, 23, 855 – 857.
57. Marshall, M.J.; Goldberg, D.M.; Neal, F.E.; Millar, D.R. Enzymes of glucose metabolism in
carcinoma of the cervix and endometrium of the human uterus. Br J Cancer. 1978, 37, 990 – 1001.
58. Tanaka, M.; Adzuma, K.; Iwami, M.; Yoshimoto, K.; Monden, Y.; Itakura, M. Human calgizzarin;
one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern
25 blot analysis. Cancer Lett. 1995, 89, 195 – 200.
59. Chaurand, P.; DaGue, B.B.; Pearsall, R.S.; Threadgill, D.W.; Caprioli, R.M. Profiling proteins from
azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser
desorption/ionization mass spectrometry. Proteomics 2001, 1, 1320 – 1326.
60. Blaxall, B.C.; Dwyer-Nield, L.D.; Bauer, A.K.; Bohlmeier, T.J.; Malkinson, A.M.; Port, J.D.
30 Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA
binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue. Mol. Carcinog. 2000,
28, 76 – 83.
61. Gouble, A.; Grazide, S.; Meggetto, F.; Mercier, P.; Delsol, G.; Morello, D. A new player in
oncogenesis: AUF1/hnRNP overexpression leads to tumorigenesis in transgenic mice. Cancer
35 Res. 2002, 62, 1489 – 1495.
62. Nishihira, J.; Ishibashi, T.; Fukushima, T.; Sun, B.; Sato, Y.; Todo, S. Macrophage migration
inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann.
New York Acad. Sci. 2003, 995, 171 – 182.

63. Ren, Y.; Tsui, H.T.; Poon, R.T.; Ng, I.O.; Li, Z.; Chen, Y.; Jiang, G.; Lau, C.; Yu, W.C.; Bacher, M.; Fan, S.T. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. *Int. J. Cancer*. 2003, 107, 22 – 29.
64. Campa, M.J.; Wang, M.Z.; Howard, B.; Fitzgerald, M.C.; Patz, E.F. Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. *Cancer Res.* 2003, 63, 1652 – 1656.
65. Markert, J.M.; Fuller, C.M.; Gillespie, G.Y.; Bubien, J.K.; McLean, L.A.; Hong, R.L.; Lee, K.; Gullans, S.R.; Mapstone, T.B.; Benos, D.J. Differential gene expression profiling in human brain tumors. *Physiol. Genomics*. 2001, 555, 21 – 33.
66. Bacher, M.; Schrader, J.; Thompson, N.; Kuschela, K.; Gamsa, D.; Waeber, G.; Schlegel, J. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. *Am. J. Pathol.* 2003, 162, 11 – 17.
67. Mahutte, N.G.; Matalliotakis, I.M.; Goumenou, A.G.; Koumantakis, G.E.; Vassiliadis, S.; Arici, A. Elevations in peritoneal fluid macrophage migration inhibitory factor are independent of the depth of invasion or stage of endometriosis. *Fertil. Steril.* 2004, 82, 97 – 101.
68. Rossel, M.; Brambilla, E.; Billaud, M.; Vuitton, D.A.; Blanc-Jouvan, F.; Biichle, S.; Revillard, J.P. Nonspecific increased serum levels of secretory component in lung tumors: relationship to the gene expression of the transmembrane receptor form. *Am. J. Respir. Cell. Mol. Biol.* 1993, 9, 341 – 346.
69. Rossel, M.; Billerey, C.; Bittard, H.; Ksiazek, P.; Alber, D.; Revillard, J.P.; Vuitton, D.A. Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma. *Urol. Res.* 1991, 19, 361 – 366.
70. Sun, Z.; Yang, P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. *Lancet Oncol.* 2004, 5, 182 – 190.
71. Ryu, J.W.; Kim, H.J.; Lee, Y.S.; Myong, N.H.; Hwang, C.H.; Lee, G.S.; Yom, H.C. The proteomics approach to find biomarkers in gastric cancer. *J. Korean Med. Sci.* 2003, 18, 505 – 509.
72. Nejari, M.; Berthet, V.; Rigot, V.; Laforest, S.; Jacquier, M.F.; Seidah, N.G.; Remy, L.; Bruyneel, E.; Scoazec, J.Y.; Marvaldi, J.; Luis, J. Inhibition of proprotein convertases enhances cell migration and metastases development of human colon carcinoma cells in a rat model. *Am. J. Pathol.* 2004, 164, 1925 – 1933.
73. Choi, H.; Park, C.S.; Kim, B.G.; Cho, J.W.; Park, J.B.; Bae, Y.S.; Bae, D.S. Creatine kinase B is a target molecule of reactive oxygen species in cervical cancer. *Mol. Cells*. 2001, 12, 412 – 417.
74. Joseph, J.; Cardesa, A.; Carreras, J. Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas. *Br. J. Cancer*. 1997, 7776, 600 – 605.
75. Shields, J.M.; Rogers-Graham, K.; Der, C.J. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. *J. Biol. Chem.* 2002, 277, 9790 – 9799.

76. Chang, J.W.; Jeon, H.B.; Lee, J.H.; Yoo, J.S.; Chun, J.S.; Kim, J.H.; Yoo, Y.J. Augmented expression of peroxiredoxin I in lung cancer. *Biochem. Biophys. Res. Commun.* 2001, 289, 507 – 512.
77. Klade, C.S.; Voss, T.; Krystek, E.; Ahorn, H.; Zatloukal, K.; Pummer, K.; Adolf, G.R.
5 Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. *Proteomics* 2001, 1, 890 – 898.
78. Chen, G.; Gharib, T.G.; Huang, C.C.; Thomas, D.G.; Shedden, K.A.; Taylor, J.M.; Kardia, S.L.; Misek, D.E.; Giordano, T.J.; Iannettoni, M.D.; Orringer, M.B.; Hanash, S.M.; Beer, D.G. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors.
10 *Clin. Cancer Res.* 2002, 8, 2298 – 2305.
79. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. *Biochim. Biophys. Acta.* 2003, 1646, 21 – 31.
80. Crnogorac-Jurcevic, T.; Efthimiou, E.; Nielsen, T.; Loader, J.; Terris, B.; Stamp, G.; Baron, A.;
15 Scarpa, A.; Lemoine, N.R. Expression profiling of microdissected pancreatic adenocarcinomas. *Oncogene* 2002, 21, 4587 – 4594.
81. Kuramitsu, Y.; Fujimoto, M.; Tanaka, T.; Ohata, J.; Nakamura, K. Differential expression of phosphatidylethanol-amine-binding protein in rat hepatoma cell lines: analyses of tumor necrosis factor-alpha-resistant cKDH-8/11 and -sensitive KDH-8/YK cells by two-dimensional gel
20 electrophoresis. *Electrophoresis* 2000, 21, 660 – 664.
82. Srivastava, S.; Verma, M.; Henson, D.E. Biomarkers for early detection of colon cancer. *Clin. Cancer Res.* 2001, 7, 1118-1126.
83. Vlahou, A.; Schellhammer, P.F.; Mendrinos, S.; Patel, K.; Kondylis, F.I.; Gong, L.; Nasim, S.; Wright, J.G., Jr. Development of a novel proteomic approach for the detection of transitional cell
25 carcinoma of the bladder in urine. *Am. J. Pathol.* 2001, 158, 1491-1502.
84. Bundred, N.J. Prognostic and predictive factors in breast cancer. *Cancer Treat. Rev.* 2001, 27, 137-142.
85. Kao, L.C.; Tulac, S.; Lobo, S.; Imani, B.; Yang, J.P.; Germeyer, A.; Osteen, K.; Taylor, R.N.; Lessey, B.A.; Guidice, L.C., *Endocrinology* 2002, 143, 2119 – 2138.
- 30 86. Hathout, Y.; Riordan, K.; Gehrmann, M.; Fenselau, C., *J. Prot. Res.* 2002, 1, 435 – 442.
87. Rautajoki, K.; Nyman, T.A.; Lahesmaa, R., *Proteomics* 2004, 4, 84 – 92.
88. Bigonnesse, F.; Labelle, Y.; Akoum, A., *Fertility and Sterility* 2001, 75, 79 – 87.
89. Fujiwaki, R.; Iida, K.; Nakayama, K.; Kanasaki, H.; Ozaki, T.; Hata, K.; Sakai, E.; Miyazaki, K., *Virchows Arch.* 2003, 443, 672 – 677.
- 35 90. von Wolff, M.; Ursel, S.; Hahn, U.; Steldinger, R.; Strowitzki, T., *J. Clin. Endocrin. Met.* 2003, 88, 3885 – 3892.
91. Duchon, M.R., *Diabetes* 2004, 53, Suppl. 1, S96 – S102.
92. Freemantle, S.J.; Portland, H.B.; Ewings, K.; Dmitrovsky, F.; DiPetrillo, K.; Spinella, M.J.; Dmitrovsky, E., *Gene* 2002, 291, 17 – 27.

93. Jonkers, J., Korswagen, H.C., Acton, D., Breuer, M., Berns, A., *EMBO J.* 1997, 16, 441 – 450.
94. Saitoh, T., Mine, T., Katoh, M., *Int. J. Oncol.* 2002, 20, 785 – 795
95. Hongisto, V., Smeds, N., Brecht, S., Herdegen, T., Courtney, M.J., Coffey, E.T., *Mol. Cell Biol.* 2003, 23, 6027 – 6036.
- 5 96. Maldonado, V., Castilla, J.A., Martinez, L., Herruzo, A., Concha, A., Fontes, J., Mendoza, N., Garcia-Pena, M.L., Mendoza, J.L., Magan, R., Ortiz, A., Gonzalez, E., *J. Assist. Reprod. Genet.* 2003, 20, 474 – 481.
97. Richardson, M.R., Taylor, D.A., Casey, M.L., MacDonald, P.C., Stull, J.T. *In Vitro Cell Dev. Biol.* 1987, 23, 21 – 28.
- 10 98. Carson, D.D., Lagow, E., Thathiah, A., Al-Shami, R., Farach-Carson, M.C., Vernon, M., Yuan, L., Fritz, M.A., Lessey, B. *Mol. Hum. Reprod.* 2002, 8, 871 – 879.
99. Jokimaa, V., Oksjoki, S., Kujari, H., Vuorio, E., Anttila, L., *Mol. Hum. Reprod.* 2001, 7, 73 – 78.
100. Barnette, K.G., Sarkar, M.A., Glover, D.D., Li, P., Boyd, C., Lalka, D., *Gynecol. Obstet. Invest.* 1999, 47, 114 – 119.
- 15 101. Herrmann, U, Jr., Degiampietro, P., Peheim, E., Bachmann, C., *Arch. Gynecol.* 1987, 240, 233 – 240.
102. Meier, U., Beier-Hellwig, K., Klug, J., Linder, D., Beier, H.M., *Hum. Reprod.* 1995, 10, 1305 – 1310.
103. Berkova, N., Lemay, A., Dresser, D.W., Fontaine, J.-Y., Kerizit, J., Goupil, S., *Mol. Hum. Reprod.* 2001, 7, 747 – 754.
- 20 104. Li, C., Hong, Y., Tan, Y.-X., Zhou, H., Ai, J.-H., Li, S.-J., Zhang, L., Xia, Q.-C., Wu, J.-R., Wang, H.-Y., Zeng, R., *Mol. Cell Proteomics* 2004, 3, 399 – 409.
105. Issaq, H.J., Conrads, T.P., Prieto, D.A., Tirumalai, R., Veenstra, T.D., *Anal. Chem.* 2003, 75, 149A – 155A.
- 25 106. Petricoin III, E.F., Ornstein, D.K., Pawletz, C.P., Ardekani, A., Hackett, P.S., Hitt, B.A., Valassco, A., Trucco, C., Wiegand, L., Wood, K., Simone, C.V., Leving, P.J., Linchan, W.M., Emmert-Buck, M.R., Steinberg, S.M., Kohn, E.C., Liotta, L.A. *J. Natl. Cancer Inst.* 2002, 94, 1576 – 1578.
107. Kozak, K.R., Amneus, M.W., Pusey, S.M., Su, F., Luong, M.N., Luong, S.A., Reddy, S.T., Farias-Eisner, R., *Proc. Natl. Acad. Sci. USA* 2003, 100, 12343 – 12348.
- 30 108. Zhu, W., Wang, X., Ma, Y., Rao, M., Glimm, J., Kovach, J.S., *Proc. Natl. Acad. Sci. USA* 2003, 100, 14666 – 14671.
109. Diamandis, E.P., *Lancet* 2002, 360, 170.
110. Diamandis, E.P., *J. Natl. Cancer Inst.* 2003, 95, 489 – 490.
111. Diamandis, E.P., *Clin. Chem.* 2003, 49, 1271 – 1278.
- 35 112. Sorace, J.M., Zhan, B. *BMC Bioinformatics* 2003, 4, 24.
113. Cottingham, K., *Anal. Chem.* 2003, 75, 472A – 476A.
114. Marshall, J., Kupchak, P., Zhu, W., Yantha, J., Vrees, T., Furesz, S., Jacks, K., Smith, C., Kireeva, I., Zhang, R., Takahashi, M., Stanton, E., Jackowski, G., *J. Proteome Res.* 2003, 2, 361 – 372.
115. Diamandis, E.P., *Mol. Cell Proteomics* 2004, 3, 367-378.

116. Baggerly, K.A., Morris, J.S., Coombes, K.R. *Bioinformatics* 2004, 20, 777 – 785.
117. Check, E., *Nature* 2004, 429, 496 – 497.
118. Marshall, J., Jankowski, A., Furesz, S., Kireeva, I., Barker, L., Dombrovsky, M., Zhu, W., Jacks, K., Ingratta, L., Bruin, J., Kristensen, E., Zhang, R., Stanton, E., Takahashi, M., Jackowski, G. J.,
5 Proteome Res. 2004, 3, 364 – 382.
119. Wagner, L., *J. Natl. Cancer Inst.* 2004, 96, 500 – 501.
120. He, Q.Y., Chen, J., Kung, H.F., Yuen, A.P., Chiu, J.F., *Proteomics* 2004, 4, 271 – 278.
121. Zhang, Z., Bast Jr., R.C., Fung, E.T., Yu, Y., Li, J., Rosenzweig, J. *Proc. AACR Abstract No. 5739*,
2003.
- 10 122. Ye, B., Cramer, D.W., Skates, S.J., Gygi, S.P., Pratomo, V., Fu, L., Hornick, N.K., Licklider, L.J.,
Schorge, J.O., Berkowitz, R.S., Mok, S.C., *Clin. Cancer Res.* 2003, 9, 2904 – 2911.
123. Chan, D. HUPO 2nd Annual & IUBIMB XIX World Congress, Montreal, Quebec, October 8 – 11,
2003.
124. Guo, J., Yang, E.C.C., DeSouza, L., Rodrigues, M.J., Romaschin, A.D., Colgan, T.J., Siu, K.W.M.,
15 *Proc. 52nd American Society for Mass Spectrometry Conference*, Nashville, Tennessee, May 23 –
27, 2004.
125. Creasman, W.T., Endometrial Carcinoma Available from: URL:
<http://www.emedicine.com/med/topic674.htm>
126. National Cancer Institute of Canada: Canadian Cancer Statistics 2003, Toronto, Canada, 2003
20 [Serial online] April 2003; Available from: URL:
http://www.bc.cancer.ca/vgn/images/portal/cit_776/61/38/56158640niw_stats_en.pdf
127. American Cancer Society, Statistics Available from: URL:
http://www.cancer.org/docroot/STT/stt_0.asp
128. Bernstein, L., Deapen, D., Cerhan, J.R., Schwartz, S.M., *J. Natl Cancer Inst.* 1999, 91, 1654 – 1662.
- 25 129. Grady, G., Ernster V.L., Endometrial cancer In: Schottenfeld, D., Fraumeni Jr., J., Ed., *Cancer
epidemiology and prevention* 2nd ed. New York, Saunders, 1996. p. 1058 – 1089.
130. Endometrial cancer Available from: URL: [http://health.allrefer.com/health/endometrial-cancer-
info.html](http://health.allrefer.com/health/endometrial-cancer-info.html)
131. Uterine Cancer (Endometrial carcinoma) Available from: URL:
30 http://alwaysyourchoice.com/ayc/adult/womens/uterine_cancer.php
132. Kurman, R.J., Ed., *Blaustein's Pathology of the Female Genital Tract*, 5th ed. New York, Springer-
Verlag, 2002.
133. ExPASy, URL: <http://ca.expasy.org/>
134. Odink, K., Cerletti, N., Bruggen, J., Clerc, G.R., Tarcsay, L., Zwadlo, G., Gerhards, G., Schlegel,
35 R., Sorg, C., *Nature* 1987, 330, 80 – 82.
135. Stulik, J., Osterreicher, J., Koupilova, K., Knizek, J., Macela, A., Bures, J., Jandik, P., Langr, F.,
Dedic, K., Jungblut, P.R., *Electrophoresis* 1999, 20, 1047 – 1054.
136. Kerkhoff, C., Eue, I., Sorg, C., *Pathobiology* 1999, 67, 230 – 232.
137. Kerkhoff, C., Klempt, M., Sorg, C., *Biochim. Biophys. Acta.* 1998, 1448, 200 – 211.

138. Schluesene, H.J., Kremsner, P.G., Meyermann, R., *Acta Neuropathol. (Berl.)* 1998, 96, 575 – 580.
139. Hunter, M.J., Chazin, W.J., *J. Biol. Chem.* 1998, 273, 12427 – 12435.
140. Bordmann, G., Burmeister, G., Saladin, S., Urassa, H., Mwankyusye, S., Weiss, N., Tanner, M., *Clin. Diagn. Lab. Immunol.* 1997, 4, 435 – 439.
- 5 141. Luger, N., Stoll, R., Kucharzik, T., Burmeister, G., Sorg, C., Domschke, W., *Clin. Exp. Immunol.* 1995, 101, 249 – 253.
142. Fanjul, M., Renaud, W., Merten, M., Guy-Crotte, O., Hollande E., Figarella, C., *Am. J. Physiol.* 1995, 268, C1241 – C1251.
143. Schmid, K.W., Luger, N., Stoll, R., Brinkbaumer, P., Winde, G., Domschke, W., Bocker, W.,
10 Sorg, C., *Hum. Pathol.* 1995, 26, 334 – 337.
144. Uchida, T., Fukawa, A., Uchida, M., Fujita, K., Saito, K., *J. Proteome Res.* 2002, 1, 495 – 499.
145. Lundy, F.T., Chalk, R., Lamey, P.-J., Shaw, C., Linden, G.J., *J. Pathol.* 2000, 192, 540 – 544.
146. Bhardwaj, R.S., Zotz, C., Zwadlo-Karwasser, G., Roth, J., Geobeler, M., Mahnke, K., Falk, M.,
Meinardus-Hager, G., Sorg, C., *Eur. J. Immunol.* 1992, 22, 1891 – 1897.
- 15 147. Burkhardt, K., Radespiel-Troger, M., Rupprecht, H.D., Goppelt-Strube, M., Riess, R., Renders, L.,
Hauser, I.A., Kunzendorf, U., *J. Am. Soc. Nephrol.* 2001, 12, 1947 – 1957.
148. Roth, J., Teigelkamp, S., Weihe, M., Grun, L., Tummler, B., Sorg, C., *Immunobiology* 1992, 186,
304 – 314.
149. Munaron, L., Antoniotto, S., Pla, A.F., Lovisolo, D. *Curr. Med. Chem.* 2004, 11, 1533 – 1543.
- 20 150. Lin, J., Black, M., Tang, C., Zimmer, D., Rustandi, R.R., Weber, D.J., Carrier, F., *J. Biol. Chem.*
2001, 276, 35037 – 35041.
151. Lin, J., Yang, Q., Yan, Z., Markowitz, J., Wilder, P.T., Carrier, F., Weber, D.J. *J. Biol. Chem.* 2004,
279, 34071-34077.
152. Gebhardt, C., Breitenbach, U., Tuckermann, J.P., Dittrich, B.T., Richter, K.H., Angel, P. *Oncogene*
25 2002, 21, 4266 – 4276.
153. Kristinsson, J., Nygaard, K., Aadland, E., Barstad, S., Sauar, J., Hofstad, B., Stray, N., Stallemo, A.,
Haug, B., Ugstad, M., Ton, H., Fuglerud, P. *Digestion* 2001, 64, 104 – 110.
154. Tibble, J., Sigthorsson, G., Foster, R., Sherwood, R., Fagerhol, M., Bjarnason, I. *Gut* 2001, 49, 402
– 408.
- 30 155. Nacken, W., Roth, J., Sorg, C., Kerkhoff, C. *Microsc. Res. Tech.* 2003, 60, 569 – 580.
156. Donato, R. *Int. J. Biochem. Cell Biol.* 2001, 33, 637 – 668.

- 111 -

We Claim:

1. A method for detecting one or more endometrial markers or polynucleotides encoding the markers associated with an endometrial disease or an endometrium phase in a subject comprising:
 - 5 (a) obtaining a sample from a subject;
 - (b) detecting in proteins extracted from the sample one or more endometrial markers or polynucleotides encoding the markers that are associated with the disease or phase; and
 - (c) comparing the detected amount with an amount detected for a standard.
2. A method of detecting an endometrial disease in a subject, the method comprising comparing:
 - 10 (a) levels of one or more endometrial markers associated with endometrial disease that are extracted from a sample from the subject; and
 - (b) normal levels of expression of the endometrial markers in a control sample, wherein a significant difference in levels of endometrial markers, relative to the corresponding normal levels, is indicative of endometrial disease.
- 15 3. A method as claimed in claim 1 or 2 comprising:
 - (a) contacting a biological sample obtained from a subject with one or more binding agent that specifically binds to the endometrial markers or parts thereof; and
 - (b) detecting in the sample amounts of endometrial markers that bind to the binding agents, relative to a predetermined standard or cut-off value, and therefrom determining the presence or absence of the endometrial disease in the subject.
- 20 4. A method as claimed in claim 3 wherein the binding agent is an antibody.
5. A method for screening a subject for endometrial cancer comprising (a) obtaining a biological sample from a subject; (b) detecting in proteins extracted from the sample the amount of one or more endometrial cancer markers; and (c) comparing the amount of endometrial cancer markers detected to a predetermined standard, where detection of a level of endometrial cancer markers different than that of a standard is indicative of endometrial cancer.
- 25 6. A method of claim 5 wherein the level of endometrial cancer markers are significantly higher compared to the standard and are indicative of endometrial cancer.
7. A method of claim 5 wherein the level of endometrial cancer markers are significantly lower compared to the standard and are indicative of endometrial cancer.
- 30 8. A method as claimed in any preceding claim wherein the sample is obtained from tissues, extracts, cell cultures, cell lysates, lavage fluid, or physiological fluids.
9. A method as claimed in claim 8 wherein the sample is obtained from a tumor tissue.
10. A method as claimed in any preceding claim which further comprises detecting multiple cancer markers.
- 35 11. A method for determining the presence or absence of endometrial markers associated with an endometrial disease in a subject comprising detecting one or more polynucleotide encoding an endometrial marker in a sample from the subject and relating the detected amount to the presence of an endometrial disease.

- 112 -

12. A method as claimed in claim 11 wherein the polynucleotide detected is mRNA.
13. A method of claim 12 wherein the polynucleotide is detected by
- 5 (a) contacting the sample with oligonucleotides that hybridize to the polynucleotides; and
- (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined standard or cut-off value, and therefrom determining the presence or absence of an endometrial disease in the subject.
14. A method as claimed in claim 12 wherein the mRNA is detected using an amplification reaction.
15. A method as claimed in claim 14 wherein the amplification reaction is a polymerase chain reaction employing oligonucleotide primers that hybridize to the polynucleotides, or complements of such polynucleotides.
- 10 16. A method as claimed in claim 12 wherein the mRNA is detected using a hybridization technique employing oligonucleotide probes that hybridize to the polynucleotides or complements of such polynucleotides.
17. A method as claimed in claim 14 wherein the mRNA is detected by (a) isolating mRNA from the sample and combining the mRNA with reagents to convert it to cDNA; (b) treating the converted cDNA with amplification reaction reagents and primers that hybridize to the polynucleotides, to produce amplification products; (d) analyzing the amplification products to detect an amount of mRNA encoding one or more endometrial markers; and (e) comparing the amount of mRNA to an amount detected against a panel of expected values for normal tissue derived using similar primers.
- 15 18. A method for diagnosing and monitoring endometrial cancer in a subject comprising isolating nucleic acids in a sample from the subject; and detecting polynucleotides encoding endometrial cancer markers in the sample wherein the presence of higher or lower levels of polynucleotides encoding endometrial cancer markers in the sample compared to a standard or control is indicative of disease or prognosis.
- 20 19. A method for monitoring the progression of endometrial cancer in a subject, the method comprising: (a) detecting in a sample from the subject at a first time point, one or more endometrial cancer markers or polynucleotides encoding the markers; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of endometrial cancer.
- 25 20. A method for determining in a subject whether endometrial cancer has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of one or more endometrial cancer markers or polynucleotides encoding the markers, in a subject sample; and (b) normal levels or non-metastatic levels of the endometrial cancer markers or polynucleotides encoding the markers, in a control sample wherein a significant difference between the levels of expression in the subject sample and the normal levels or non-metastatic levels is an indication that the endometrial cancer has metastasized.
- 30 21. A method for assessing the aggressiveness or indolence of endometrial cancer comprising comparing: (a) levels of expression of one or more endometrial cancer markers or polynucleotides encoding the markers, in a subject sample; and (b) normal levels of expression of the endometrial cancer markers or polynucleotides encoding the markers, in a control sample, wherein a significant difference between the
- 35

- 113 -

- levels in the subject sample and normal levels is an indication that the cancer is aggressive or indolent.
22. A diagnostic composition comprising an agent that binds to an endometrial cancer marker or hybridizes to a polynucleotide encoding such marker.
23. A method for assessing the potential efficacy of a test agent for inhibiting endometrial cancer in a subject, the method comprising comparing: (a) levels of one or more endometrial cancer markers, in a first sample obtained from a subject and exposed to the test agent, wherein the endometrial cancer markers, and (b) levels of the endometrial cancer markers in a second sample obtained from the subject, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the endometrial cancer markers in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting endometrial cancer in the subject.
24. A method of assessing the efficacy of a therapy for inhibiting endometrial cancer in a subject, the method comprising comparing: (a) levels of one or more endometrial cancer markers in a first sample obtained from the subject; and (b) levels of the endometrial cancer markers in a second sample obtained from the subject following therapy, wherein a significant difference in the levels of expression of the endometrial cancer markers in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting endometrial cancer in the subject.
25. A method of selecting an agent for inhibiting endometrial cancer in a subject the method comprising (a) obtaining a sample comprising cancer cells from the subject; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of one or more endometrial cancer markers in each of the aliquots; and (d) selecting one of the test agents which alters the levels of endometrial cancer markers in the aliquot containing that test agent, relative to other test agents.
26. A method of inhibiting endometrial cancer in a subject, the method comprising (a) obtaining a sample comprising cancer cells from the subject; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of one or more endometrial cancer markers in each of the aliquots; and (d) administering to the subject at least one of the test agents which alters the levels of endometrial cancer markers in the aliquot containing that test agent, relative to other test agents.
27. A method of assessing the endometrial cancer cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of endometrial cancer cells in the presence and absence of the test compound; and (b) comparing expression of one or more endometrial cancer markers, in each of the aliquots, and wherein a significant difference in levels of endometrial cancer markers in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses endometrial cancer cell carcinogenic potential.
28. An *in vivo* method for imaging an endometrial disease comprising:
- (a) injecting a subject with one or more agent that binds to an endometrial marker, the agent carrying a label for imaging the endometrial marker;
 - (b) allowing the agent to incubate *in vivo* and bind to an endometrial marker; and
 - (c) detecting the presence of the label localized to diseased endometrial tissue.

- 114 -

29. A method as claimed in claim 28 wherein the agent is an antibody that specifically reacts with an endometrial marker.
30. Markers that distinguish an endometrium phase or endometrial disease identified by assaying for differential expression of polypeptides in endometrium samples.
- 5 31. Markers as claimed in claim 30 wherein differential expression is assayed using mass spectroscopy of polypeptides extracted from the samples.
32. Markers of claim 31 which are up-regulated in endometrial cancer.
33. Markers of claim 31 which are down-regulated in endometrial cancer.
34. A set of markers of claim 30 or 31 comprising a plurality of polypeptides comprising or consisting of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the markers listed in Table 1, 4, 5, or 6.
- 10 35. A set of markers of claim 34 wherein the polypeptides are selected from the group consisting of polypeptides with the sequence of SEQ ID NOs. 1, 3, 6, 9, 11, 13, 15, 18, 21, 23, 30, 33, 36, 38, and 40.
36. A set of markers of claim 31 wherein the polypeptides are selected from the group consisting of polypeptides with the sequence of SEQ ID NOs. 1, 3, 6, 9, 11, 13, 15, 18, 21, 23, 26, 30, 33, 36, 38, 40, 42, 45, and 47.
- 15 37. A set of markers of claim 31 wherein the polypeptides are selected from the group consisting of polypeptides with the sequence of SEQ ID NOs. 26, 42, 45, and 47.
38. A method of any preceding claim wherein the endometrial markers are one or more of the polypeptides listed in Table 1 or they have a sequence of SEQ ID NOs. 1, 3, 6, 9, 11, 13, 15, 18, 21, 23, 26, 30, 33, 36, 38, 40, 42, 45, and 47.
- 20 39. A method of any preceding claim wherein the endometrial marker is chaperonin 10.
40. A method of any preceding claim utilizing markers of claim 29, 30 or 31 or a set of markers of claim 34 or 36.
41. A method of determining uterine endometrial receptivity by first obtaining a serum, uterine fluid or endometrial biopsy sample from a subject and detecting the presence of an endometrial marker associated with a certain endometrium phase, wherein the presence or absence of an endometrial marker as compared to controls indicates uterine receptivity.
- 25 42. A method of claim 41 wherein the endometrium phase is the secretory or proliferative phase.
43. A method of monitoring the effects of ovarian hyperstimulation and/or ovulation induction protocols on uterine receptivity which comprises: (a) obtaining a serum, uterine or fluid or endometrial biopsy sample from a subject receiving the treatments; and (b) detecting the presence of an endometrial marker present in the endometrium at the time of fertilization, early embryogenesis, and implantation; wherein presence or absence of an endometrial marker indicates receptivity.
- 30 44. A method of determining a probability of successful implantation with an ovarian stimulation *in vitro* fertilization and embryo transfer procedure, comprising:
 - 35 (a) determining a level of an endometrial marker in a sample obtained from a subject who has undergone an ovarian stimulation *in vitro* fertilization and embryo transfer procedure; and
 - (b) determining a probability of successful implantation based on the subject's determined endometrial marker level;

- 115 -

wherein a significantly different endometrial marker level relative to a standard level is associated with a decreased or increased probability of successful implantation.

45. A method of any of claim 41 to 44 wherein the endometrial marker is glutamate receptor subunit zeta 1, a tryptic fragment thereof, and/or macrophage migration inhibitory factor.

5 46. A method of contraception by interrupting the cyclic presence of an endometrial marker, in particular glutamate receptor subunit zeta 1, a tryptic fragment thereof, macrophage migration inhibitory factor, myosin light chain kinase 2, and/or tropomyosin 1 alpha chain.

47. A kit for carrying out a method as claimed in any preceding claim.


48. A kit for determining the presence of an endometrial disease in a subject, comprising a known amount of one or more binding agent that specifically binds to an endometrial marker wherein the binding agent comprises a detectable substance, or it binds directly or indirectly to a detectable substance.

10 49. A kit for determining the presence of endometrial disease in a subject, comprising a known amount of an oligonucleotide that hybridizes to a polynucleotide encoding an endometrial marker wherein the oligonucleotide is directly or indirectly labeled with a detectable substance.

15

1/39


Figure 1




2/39

Figure 2

A




B



3/39

Figure 3



4/39



Figure 4

Figure 5



6/39

Figure 6




Figure 7






Figure 8A




9/39

Figure 8B




10/39

Figure 8C



11/39

Figure 8D



12/39

Figure 8E




Figure 9




14/39

Figure 10




Figure 11




16/39

Figure 12




17/39

Figure 13



18/39

Figure 14



19/39

Figure 15







Figure 16




B



A

21/39

Figure 17




(a)




(b)

22/39

Figure 18



23/39

Figure 19

24/39

Figure 20






Figure 21




26/39

Figure 22


27/39

Figure 23




28/39

Figure 24




29/39

Figure 25




30/39

Figure 26A




31/39

Figure 26B




32/39

Figure 27




33/39

Figure 28A




34/39

Figure 28B




35/39

Figure 28C




36/39

Figure 29A




37/39

Figure 29B




38/39

Figure 30



39/39

Figure 31



- 1 -

Sequence Listing**SEQ ID NO. 1**

5 Q04984 and AAH23518
Chaperonin 10

1 magqafkrfl plfdrvlver saaetvtkgg imlpeksqgk vlqatvvavg sgskgkggei
61 qpvsvkvgdk vllpeyggtk vvllddkdyfl frdgdilgky vd
10

SEQ ID NO. 2

NM_002157 and U07550
15 Human chaperonin 10 mRNA, complete cds

1 gctacactag agcagagtag gactctgagg cggagggagt aatggcagga caagcggttta
61 gaaagtttct tccactcttt gaccgagtag tgggtgaaag gactgctgct gaaactgtaa
121 ccaaaggagg cattatgctt ccagaaaaat ctcaaggaaa agtattgcaa gcaacagtag
20 181 tgcgtgttgg atcgggttct aaaggaaagg gtggagagat tcaaccagtt agcgtgaaag
241 ttggagataa agttcttctc ccagaatatg gaggcaccaa agtagttcta gatgacaagg
301 attatttcct atttagagat ggtgacattc ttggaaagta cgtagactga aataagtcac
361 tattgaaatg gcatcaacat gatgctgccc attccactga agttctgaaa tctttcgtca
421 tgtaaataat ttccatattt ctcttttata ataaactaat gataactaat gacatccagt
25 481 gtctccaaaa ttgtttcctt gtactgatat aaacacttcc aaataaaaaat atgtaaat

SEQ ID NO. 3

30 P05109
Calgranulin A

1 mltelekaln siidvyhkys likgnfhavy rddlkllet ecpqyirkkg advwfkeldi
61 ntdgavnfqe flilvikmgv aahkkshees hke
35

SEQ ID NO. 4

A12027
40 Macrophage migration inhibition factor (MRP-14) cDNA from Human
placenta (formula v)

1 cttggggttg tccaccttt tggtcttgt aaataatgct gctatgaaca tgaatgtaca
61 aacatctggt tgaatccctg cattcaattc ttttgcatat ataccagga gcagaatgat
45 121 ggatcatatg gtaattctgt gtttatattt ttgaggaaca aacttgccgt tttccataac
181 agctgcacta ttttacattc ccactaacag tgcattaggc ttccaattct ctatgccctc
241 accaacactt gttttctggg ttttaaaaga agtagtagtc atcctttagt gtgtcagggtg
301 gtatctcatt gtcgttttgc ttcatgtttt cctaaagatt agtaatttct atatgcttat
361 tgaccatttg tatatcttct tcggagaagt gtctatttga gtctttcccc aattttgatt
50 421 gggttggttg tttttgttg ttgagttgta gggattcttt tatattctgg atattaatcc
481 cttatcagat atttgtttta caaatatttt ctttgtaaca acagaaacac accacagtct
541 tcaagggttg aagccagtta atctgagtag cattttgtta gtgggtggga gaggatttgt
601 tcctcctgaa atcctgggga attggccacc tcctcttctc ctcttaggca tgaagcgcgt
661 ctggcttctc caaagaactc ttccctcca ctacctcaga gttagcttcc tctcttcagc
55 721 cagtgatcct ggggtcccag acacaataat taaccaagag aggggtgaaag gctccctgct

- 2 -

781 gtgttttatgc aatggctcag gcccttgtga agtgccgagg gaccccaagc agcctccatc
 841 tcccagggca tgggtccatcc ccagcttttca cagaacagga aagctgtgga ggagtgtggg
 901 cagcagggta ggaatggata tagcccttgg caacaacaca tttcccccaca aagcaccac
 961 ccaaaagaac aacaacgata gtttttagttt ttagtaatga gaacaatagt tctcatgact
 5 1021 aaaagccatc agccaggaca ctgttctcaa cccttttgcg gtctttggac cctttgaaac
 1081 tctgacagaa gccatggagg aatgtttctca ctgagtgcac gcaactcaaaa tgatgcattc
 1141 aacttcaatt cagtttcagg gatgtatggc ctgaccacca atgcagggga ttagcaatcg
 1201 caatagtgga gagggcatgg gagtgggaat ctggctggat caagcaagtg gatgccagca
 1261 gccagaaaa agagccccc tacctgcttt ttccttctg ggcactattg cccagcaaat
 10 1321 gcccttctct ttcgcttct cctacctccc cacccttctg tttcattctg cacagtgatt
 1381 gccacattca ctggttgaga aacagagact gtagcaactc tggcagggag aagctgtctc
 1441 tgatggcctg aagctgtggg cagctggcca agcctaaccg ctataaaaag gagctgcctc
 1501 tcagccctgc atgtctcttg tcagctgtct ttcagaagac ctggtaagtg ggactgtctg
 1561 gggtggcccc gcactttggg cttctcttgg ggagggtcag ggaagtggag cagccttctc
 15 1621 gagagaggag agagaaagct cagggaggtc tggagcaaag atactcctg aggtggggag
 1681 tgaggcaggg ataaggaagg agagtatcct ccagcacctt ccagtgggta agggcacatt
 1741 gtctcctagg ctggactttt cttgagcaga ggggtgggtg gtaaggaaag tctacggggc
 1801 cccgtgtgtg tgcacatgtc tctgtgtgaa tggacccttc cccttcccac acgtgtatcc
 1861 ctatcatccc acccttccca ccagaggcca tagccatctg ctggtttggg tatttgagag
 20 1921 tgcaggccag gacaaggcca tcgcttgggg catgaatcct ctgcgtactg ccctggccag
 1981 atgcaaatc cctgccatgg gattccccag aaggttctgt ttttcagggtg gggcaagttc
 2041 cgtgggcatc atgttgaccg agctggagaa agccttgaac tctatcatcg acgtctacca
 2101 caagtactcc ctgataaagg ggaatttcca tgccgtctac agggatgacc tgaagaaatt
 2161 gctagagacc gagtgtcctc agtatatcag ggtgaggagg ggctgggtgt ggcgggggct
 25 2221 cctcgctgg tccctggggc gccctggggc agcggctcct cctgccaccc ttcatagatg
 2281 ctatgcctcg gctctctctg agatctttaa actctggctt cttcctcctc aatcttgaca
 2341 gaaaaagggg gcagacgtct ggttcaaaga gttggatata aacactgatg gtgcagttaa
 2401 cttccaggag ttcttcattc tggtgataaa gatgggctg gcagcccaca aaaaaagcca
 2461 tgaagaaagc cacaagagat agctgagtta ctggggccag aggctggggc cctggacatg
 30 2521 tacctgcaga ataataaagt catcaatacc tcatgcctct ctcttatgct tttgtggaat
 2581 gaggttcttc ggtgtggagg gaggtttgga aaacccaaag gaagaaaaag aaatctatgt
 2641 tatcccaccc tacctctcac aagcctttcc tgctttaccc ctccacctggc ctctgccccca
 2701 cattccttca gccctcatt tcgagcattg gatttgaggc ttaaggattc aaaaagtcgt
 2761 catgaatata gctgatgatt ttatagtggg tctgaaatgg gtcggggatt tgggaacagg
 35 2821 gtggtagtat aagaacaact gatactgttc tctaagctaa atcttagctt ccagctacct
 2881 gtcttagatg tggctcttgg gaaccttaga gtgatagcta catagaagtg tgtgggtgtg
 2941 tgtgtgtgtg tctgtgtgtg tgtgtgtgag agagagacag acagaaagag agcaagagag
 3001 ggaagggggg agaggctgat tgtgtgtgtg gtgtgatgta ggtggacaat gttcagagtc
 3061 ctccattaac aggataatcc tcacacctgt ccacatacct ctagtttctc cttggggatt
 40 3121 ttgaaaattt ttctccctc tccactccca aactcccaac tcaattaaat gataaaggaa
 3181 taggcaaata ggaaaataaa ttagtaaaac ttaagtcaaa gaataggtta ttcatacgct
 3241 gcctatggga ttctatgctt tgtgatcaga aaattatcta aaaaatactt cccaagggct
 3301 ggtacaaggg aggcagaaag acgagtgggt cttctctgag gtggacatta aaaaaagaag
 3361 aaaatgaagg ggaacctttt gacaagaatg tcaccccaaa ctggattttc atgctgtggg
 45 3421 gtggggaatt ttctgttctc ctacttagg tgctggggca gtgggtgttag tgatgggtaa
 3481 aaaggtagga agctgtcaca gaatcactaa accagggttc ttaacttctc tgtctatata
 3541 tctctgaaat tgggttgaag ttgtgtgcat cattttgagt gacgcactga gaacattcct
 3601 ccacggcttc catcgagagt ctcgaaaagg cccaacacct caaaaagggt aagaacactt
 3661 gtctgtctta ctgggttttt gtaacaaatg gcagagtatt tctctctgtc tctctctctt
 50 3721 tttttttttt ttttttttag acacaggggtc ttgtctgtca cgtggactag agtacaatgg
 3781 gcatgatcat gggctcactg tagcctcgaa cacctgggct caagtaatcc tcccacctca
 3841 gcctcttttag tagctgggac tacagcatga gccactgccc ttggctaatt tttaaattat
 3901 tttttttag agatggaaac ttgctatgtt gcccaggcta gtctcaaaact cctggactca
 3961 agcgtatcct ctaccttggc ctcccaaagt gctgagatta cagtgtgatc cacaccacac
 55 4021 ctggccaaag attggagtat ttttattgct attgttgtgc tgggtgggtg ggtgggtgta

- 3 -

4081 tgctttgtgg ggacgtgtgt tgttgccaag ggctaaatca gttcctaccc tgctgcccac
 4141 agtcctccac agctttcctg ctctgtgaag ctaaggatac accccgatga taagctgtca
 4201 acata

5

SEQ ID NO. 5

NM_002964

10 Homo sapiens S100 calcium binding protein A8 (calgranulin A) S100A8,
 mRNA

1 atgtctcttg tcagctgtct ttcagaagac ctgggtggggc aagtcctggtg gcatcatggt
 61 gaccgagctg gagaaagcct tgaactctat catcgacgtc taccacaagt actccctgat
 121 aaaggggaat ttccatgccg tctacagggg tgacctgaag aaattgctag agaccgagtg
 15 181 tcctcagtat atcaggaaaa aggggtgcaga cgtctgggtc aaagagttgg atatcaacac
 241 tgatggtgca gttaacttcc aggagttcct cattctgggtg ataaagatgg gcgtggcagc
 301 ccacaaaaaa agccatgaag aaagccacaa agagtagctg agttactggg cccagaggct
 361 gggcccttgg acatgtacct gcagaataat aaagtcacat atacctcaaa aaaaaaaaaa
 421 aaaaaaaaaa

20

SEQ ID NO. 6

P06702

25 Calgranulin B/MRP-14

1 mtckmsqler nietiintfh qysvklghpd tlnqgefkel vrkdlnflk kenknekvie
 61 himedldtna dkqlsfefi mlmarltwas hekmhegdeg pghhhkpglg egtp

30

SEQ ID NO. 7

X06233

35 Human mRNA for calcium-binding protein in macrophages (MRP-14)
 macrophage migration inhibitory factor (MIF)-related protein

aaaacactct gtgtggctcc tcggctttga cagagtgcac gacgatgact tgcaaaatgt
 cgcagctgga acgcaacata gagaccatca tcaacacctt ccaccaatac tctgtgaage
 tggggcaccg agacaccctg aaccaggggg aattcaaaga gctgggtgca aaagatctgc
 40 aaaattttct caagaaggag aataagaatg aaaagggtcat agaacacatc atggaggacc
 tggacacaaa tgcagacaag cagctgagct tcgaggagtt catcatgctg atggcgagggc
 taacctgggc ctcccacgag aagatgcacg aggggtgacga gggccctggc caccaccata
 agccaggcct cggggagggc accccctaag accacagtgg ccaagatcac agtggccacg
 gccacggcca cagtcatggt ggccacggcc acagccaccc at

45

SEQ ID NO. 8

M21064

50 Human migration inhibitory factor-related protein 14 (MRP14) gene,
 complete cds

1 atcactgttg agtaggggaa gggcactcct ggggtggcaa ggtgggaggt gggccctgtg
 61 ttcccacagt gggcagggag gtagtgaaag ggaagctggc cggacaggaa gggccattcc
 55 121 aagagggctt tgtgcgcagg gctaagccaa gctttctcca taggcaatgg ggagcaactg

- 4 -

	181	gaggttcgta	gcaggagaag	gacacatcaa	gcccaccagg	aggctaagta	aaaacagttg
	241	tctcccaagt	tataagttcc	tgaaccctt	gctgggagca	ggatttagaa	aaatgatgct
	301	gagagatgct	agaaacatat	tgcacctgag	gctctctcac	tcagactgca	agaggaaggt
	361	atcatcagaa	ttgcccttaa	ccaggaacca	gaatagctgg	gtcccttcc	tgccaagtca
5	421	gcaaccagct	atgtgacctt	gctcaggtec	atctccgggt	gtcagtttct	tcatctacaa
	481	tgcaagaggg	ttgcccacct	ctgagaaccc	ttctaaccct	aaatctcacc	ctatgaatct
	541	aagaacacaa	cccctcgcca	tctaagtat	cacagagcca	ggcaagcatg	ggtgagagct
	601	cagaccatcc	ttgttggact	aaaaggaagg	ggcagactgc	catggggggc	agccgagagg
	661	gtcaggcccc	cataggtcct	cagcctgctt	caacctcaaa	ggggatgggg	ggctgagtgg
10	721	tgccagagga	gcagcaggct	cgctcgggga	gagtagggcc	ttagggataga	agggaaatga
	781	actaaacaac	cagcttctcg	caaaccagtt	tcaggccagg	gctgggaatt	tcacaaaaaa
	841	gcagaaggcg	ctctgtgaac	atttctctgc	ccgccccagc	cccttctctg	gcagcattag
	901	cacactgctc	acctgtgaag	caatcttccg	gagacagggc	caaagggcaa	gtgccccagt
	961	caggagctgc	ctataaatgc	cgagcctgca	cagctctggc	aaacactctg	tgtggctcct
15	1021	cggttttgg	aagtgaagctg	ccagcttccc	caggcagaag	cctgcctgcc	gattccttct
	1081	ttccttccct	gacccaactt	ccttccaaat	cctcctccta	gaagccctcc	ttgggttggcc
	1141	ctgccctactt	taaagcttct	ttcacatttt	cttaggtcat	gttccctctg	ggcctcctgc
	1201	cctcaaatgc	tttgcttttt	ggcactctgt	agatattcta	aaaaatcatt	ttgtacatgt
	1261	gtgtgacagg	ccatctccca	gttaagttgc	agcctgtgct	ttctttttat	tttgcaattc
20	1321	ccccactatt	tctgtgagtg	cttagtagga	agtgtcaaag	aagcttgaca	gcattttctt
	1381	ctaagtgtcc	caactcttgg	ttttccatta	cacagacaga	gtgcaagacg	atgacttgca
	1441	aatgttcgca	gctggaacgc	aacatagaga	ccatcatcaa	caccttccac	caatactctg
	1501	tgaagctggg	gcacccagac	accctgaacc	agggggaatt	caaagagctg	gtgcgaaaag
	1561	atctgcaaaa	ttttctcaag	gtagggctgg	actctggcag	gtctgaccca	gcctcacccg
25	1621	agtttgggtt	gacaaggag	gatgggagta	tgggctacag	caatcaaggg	gaagatttga
	1681	gctcctggag	cccagcccca	agacgcagcg	agtgtcctgt	tatacagggc	aggtgtcac
	1741	agttacacag	gacgacagg	tcaagaaatt	gctcaattga	acacctgcta	tttgtcgggc
	1801	cctgttcttg	gcagagggat	gtagtggtaa	atgggagccc	actattccat	gaggagacac
	1861	acagtaaagt	tgttgcccaa	taaagagcac	agataaagcc	aatgccaat	aagtgcctgg
30	1921	aagaaaatga	gatagagtgc	gctgtgggca	atggggctgg	gtggggtgga	ggtgaccagt
	1981	taggggtacat	gagaagggcc	tcttttagga	ggtaacattt	gagctgagcc	ccgaatgttg
	2041	gggaggggaag	cccctgagga	tgacacttgg	cacaaagctg	aggagaccct	aagcctcagg
	2101	gcgaacttgg	ggtggaagac	ttgggggctt	ttctaactct	aagggtctgc	ggtggaaaat
	2161	gaatgcataa	agagcacatg	gagagcacct	gcacagcact	cagggaaactg	ggaggttttt
35	2221	cccccgctcc	aaaaatgatt	aggcagttct	aagaaaaagg	ctgagcactt	ccaacagcct
	2281	ttttgttttc	ttttcaaat	tggggaaagt	cgggaaaacag	aggcctgcat	taagaagggt
	2341	ggaacacatg	ggtctcagtc	tcagttccag	tcccggagcc	agacatcctg	gggtaggtcc
	2401	ccagccctcc	cagtgcctcc	ccctccgct	tggtaagggtg	gagaattgca	gccttcagag
	2461	ttaggggccc	tgacagctct	ccataggtgg	aggcctcagg	caggcaggat	gctgggtggg
40	2521	gtaggcaaga	aagggccccag	cagagaggcc	gcacgggaaa	actatcctcc	atgtgacccc
	2581	ctatgcccgc	ttcaccccc	acctgacatc	ccccaccaga	agcaaagcga	tgctgtggga
	2641	aaggaagcag	agcctcatgg	atgggctgca	caggagagtg	ctcgcatgg	ctgggtaccc
	2701	cacagggttct	gggaggggac	ttagcgaggt	gactcagtg	ctcgccctcc	caaagtctcg
	2761	ggattacaag	catgagccac	cctgtccgac	catctccct	tttatacttt	atcacaccct
45	2821	tgagggtcagc	ggagcacata	ctctgctctc	tgacctoca	tctccctg	ccacacctag
	2881	gtttttctag	tgtttccccg	ttgtattggt	tgaaataagt	ttcactaatt	ggtaacctcc
	2941	agagggaagg	gaagggaagg	cagggaagg	agtgaagtgc	agagggttag	cagagtggaa
	3001	ctggcctcta	agtcagatct	gaatttgc	gacctcaata	gtcaagcctg	tgaaaactaa
	3061	tgacctctc	taggacctgt	ttcaagtctt	cctccaggaa	gataccattc	ctagctgtta
50	3121	aagttgttat	aaggaccaa	tgaggtgaca	tttccaggct	tactcatg	atgaccagg
	3181	caagaccctg	gaactcagct	tcctcttcta	taaatagaga	atcagcacc	aagtcacagg
	3241	gtcatggagg	gaataaactg	gagagcgctt	ggtatgtgct	cagtgctctg	tccattgtgc
	3301	gcactcagcc	tatggtcatt	tttaattttt	aaatccagcc	ccagggtcga	ggcttccctg
	3361	tacatttgcc	agctgggtcat	ttactgtgct	cccagtcctc	acctctggcc	acacccagct
55	3421	ctcacagcct	tctctcccca	cccgacagaag	gagaataaga	atgaaaagg	catagaacac

- 5 -

```

3481 atcatggagg acctggacac aaatgcagac aagcagctga gcttcgagga gttcatcatg
3541 ctgatggcga ggctaacctg ggctccccc gagagatgc acgagggtga cgagggccct
3601 ggccaccacc ataagccagg cctcggggag ggcacccct aagaccacag tggccaagat
3661 cacagtggcc acggccacgg ccacagtcag ggtggccacg gccacaggcc actaatcagg
5 3721 agggcaggcc accctgcctc tacccaacca gggccccggg gctgttatgt caaactgtct
3781 tggctgtggg gctaggggct ggggcaaata agtctcttcc tccaagtacg tgctctgtgt
3841 gcttcttcca cctcttctcc aacctgcct tcccagggt ctggcattta gacagccctg
3901 tccttatctg tgactcagcc ccctcattca gtattaacaa aatgagaagc agcaaaacat
3961 gggctctgtg tgggccctt ggctcacctc cctgaccatg tcctcacctc tgacttcagg
10 4021 cccactgtt cagatcccag gctccctgcc ccactcaga caccctgtcc agcctgtcca
4081 gctgacaaa tggcccttgt cactgtacac tgtagaaagc aaaaaggcat atctctaccc
4141 cttgatatgc ctgctacctc accaaccagc cccaagcctg tcttcaccca tctgtgcta
4201 cacagccctc tctctctct aacagaattc tattctctct aaagtcttca gaaactggac
4261 ctagatagtg ccatgtctgg ggaggaatat ggcaccaggc agtggaaca aggacagatc
15 4321 ggtgtgttat ctacatttg atcagagagc atgatctctc ttaacagacc tgccacccta
4381 atcaacggga gtgtcacac aagtgggagt ctgagagctt agccctatgc ccacctgg

```

SEQ ID NO. 9

20

P01833 and Q81ZY7

Polymeric-immunoglobulin receptor (precursor)

```

1 mllfvltcll avfpaistks pifgpeevns vegnsvsitc yypptsvnrh trkywcrqga
25 61 rggcitoliss egyvsskyag ranltnfpen gtfvvnial sqddsgrykc glginsrgls
121 fdvslevsqq pglindtkvy tvdlgrtvti ncpfktenaq krkslykqig lypvlvidss
181 gyvnpnytgr irlidiqgtg llfsvvinql rlsdagqylc qagddsnsnk knadlqvlkp
241 epelvyedlr gsvtfhcalg pevanvakfl crqssgencd vvvntlgkra pafegrilln
301 pqdkdgsfsv vitglrkeda grylcgahsd gqlqegspiq awqlfvnees tiprsptvvk
30 361 gvagssvavl cpynrkesks ikywclwega qngrcp11vd segwvkaqye grlsilleepg
421 ngftftvilnq ltsrdagfyw cltngdtlwr ttveikiieg epnlkvpgnv tavlgctlkv
481 pchfpckfss yekywckwnn tgcqalpsqd egpskafvnc densrlvslt lnlvtrades
541 wywcvkvqgh fygetaavyv aveerkaags rdvslakada apdekylvds freienkaiq
601 dprlfaeka vadtrdqadg srasvdsqss eeqgssral vstlvplglv lavgavavgv
35 661 ararhrknvd rvsirsyrtd ismsdfensr efgandnmga ssitqetslg gkeefvatte
721 sttetkepkk akrsskeae maykdfllqs stvaaeaadg pqea

```

SEQ ID NO. 10

40

NM_002644

Homo sapiens polymeric immunoglobulin receptor (PIGR), mRNA

```

1 agagtttcag ttttggcagc agcgtccagt gccctgccag tagctcctag agaggcaggg
45 61 gttaccaact ggccagcagg ctgtgtccct gaagtcagat caacgggaga gaaggaagtg
121 gctaaaacat tgcacaggag aagtcggcct gagtgggtgcg gcgctcggga cccaccagca
181 atgctgctct tcgtgctcac ctgctgctg cggtcttcc cagccatctc cacgaagagt
241 cccatatttg gtcccagga ggtgaatagt gtggaaggta actcagtgtc catcacgtgc
301 tactaccac ccacctctgt caaccggcac acccggaagt actggtgccg gcaggagct
50 361 agagggtggc gcataacct catctcctcg gagggctacg tctccagcaa atatgcaggc
421 aggggctaacc tcaccaact cccggagaac ggcacatttg tgggtaacat tgcccagctg
481 agccaggatg actccggcg ctacaagtgt ggctgggca tcaatagccg aggcctgtcc
541 tttgatgtca gcctggaggt cagccagggt cctgggctcc taaatgacac taaagtctac
601 acagtggacc tgggcagaac ggtgaccatc aactgccctt tcaagactga gaatgtctaa
55 661 aagaggaagt cctgtacaa gcagataggg ctgtaccctg tgctgggtcat cgactccagt

```

- 6 -

	721	ggttatgtaa	atcccaacta	tacaggaaga	atacgcccttg	atattcaggg	tactggccag
	781	ttactgttca	gcgttgatcat	caaccaactc	aggctcagcg	atgctgggca	gtatctctgc
	841	caggctgggg	atgattccaa	tagtaataag	aagaatgctg	acctccaagt	gctaaagccc
	901	gagcccgagc	tggtttatga	agacctgagg	ggctcagtga	ccttccactg	tgcctggggc
5	961	cctgaggtgg	caaacgtggc	caaatttctg	tgccgacaga	gcagtgggga	aaactgtgac
	1021	gtggctcgtca	acaccctggg	gaagagggcc	ccagcccttg	agggcaggat	cctgctcaac
	1081	ccccaggaca	aggatggctc	atcagtggtg	gtgatcacag	gcctgaggaa	ggaggatgca
	1141	gggcgctacc	tgtgtggagc	ccattcggat	ggtcagctgc	aggaaggctc	gcctatccag
	1201	gcctggcaac	tcttcgtcaa	tgaggagtcc	acgattcccc	gcagccccac	tgtggtgaag
10	1261	ggggtggcag	gaggctctgt	ggccgtgctc	tgccctaca	accgtaagga	aagcaaaagc
	1321	atcaagtact	gggtgtctctg	ggaaggggccc	cagaatggcc	gctgccccct	gctggtggac
	1381	agcgaggggt	gggttaaggc	ccagtaacag	ggccgctct	ccctgctgga	ggagccaggc
	1441	aacggcacct	tactgtcat	cctcaaccag	ctcaccagcc	gggacgcggg	cttctactgg
	1501	tgtctgacca	acggcgatac	tctctggagg	accaccgtgg	agatcaagat	tatcgaagga
15	1561	gaaccaaacc	tcaaggatcc	aggggaatgtc	acggctgtgc	tgggagagac	tctcaaggctc
	1621	ccctgtcact	ttccatgcaa	attctcctcg	tacgagaaat	actggtgcaa	gtggaataac
	1681	acgggtgccc	aggccctgcc	cagccaagac	gaaggcccca	gcaaggcctt	cgtgaactgt
	1741	gacgagaaca	gccggcttgt	ctccctgacc	ctgaacctgg	tgaccagggt	tgatgagggc
	1801	tggtaactggt	gtggagtga	gcagggccac	ttctatggag	agactgcagc	cgtctatgtg
20	1861	gcagttgaag	agaggaaggc	agcggggtcc	cgcgatgtca	gcctagcgaa	ggcagacgct
	1921	gctcctgatg	agaagggtct	agactctggt	tttcgggaga	ttgagaacaa	agccattcag
	1981	gatcccaggc	tttttgacaga	ggaaaaggcg	gtggcagata	caagagatca	agccgatggg
	2041	agcagagcat	ctgtggattc	cggcagctct	gaggaacaag	gtggaagctc	cagagcgctg
	2101	gtctccaccc	tgggtgcccc	gggctggtg	ctggcagtgg	gagccgtggc	tgtgggggtg
25	2161	gccagagccc	ggcacaggaa	gaactccag	cgagtttcaa	tcagaagcta	caggacagac
	2221	attagcatgt	cagacttcga	gaactccagg	gaatttgagg	ccaatgacaa	catgggagcc
	2281	tcttcgatca	ctcaggagac	atccctcgga	ggaaaagaag	agtttgttgc	caccactgag
	2341	agcaccacag	agaccaaaga	acccaagaag	gcaaaaagg	catccaagga	ggaagccgag
	2401	atggccctaca	aagacttcct	gctccagtcc	agcaccgtgg	ccgcccaggc	ccaggacggc
30	2461	ccccaggaag	cctagacggt	gtgcgcgcct	gctccctgca	cccatgacaa	tcaccttcag
	2521	aatcatgtcg	atcctggggc	cctcagctcc	tggggacccc	actccctgct	ctaacacctg
	2581	cctaggtttt	tctactgtc	ctcagaggcg	tgctggtccc	ctcctcagt	acatcaaagc
	2641	ctggccctaat	tgttccctatt	ggggatgagg	gtggcatgag	gaggtcccac	ttgcaacttc
	2701	ttctgtttga	gagaacctca	ggtacggaga	agaatagagg	tccctatggg	tccttgaag
35	2761	gaagagggac	caggggtggga	gagctgattg	cagaaaggag	agacgtgcag	cgccccctctg
	2821	cacccttatc	atgggatgtc	aacagaattt	ttccctccac	tccatccctc	cctcccgctc
	2881	ttccccctctt	cttctttctc	tccatcaaaa	gatgtatttg	aattcatact	agaattcagg
	2941	tgctttgcta	gatgctgtga	caggtatgcc	accaacactg	ctcacagcct	ttctgaggac
	3001	accagtga	gaagccacag	ctcttctctg	cgtatttata	ctcactgagt	cttaactttt
40	3061	caccaggggt	gctcacctct	gccccatttg	ggagagggtca	taaaatgtct	cgagtcctaa
	3121	ggccttaggg	gtcatgtatg	atgagcatat	acacaggtaa	ttataaaccc	acattcttac
	3181	catttcacac	ataagaaaaat	tgaggtttgg	aagagtgaag	cgtttttctt	tttctttttt
	3241	tttttttgaga	cggagtctct	cactgtcgcc	caggctggag	tgcatggg	caatctcgcc
	3301	tcaactgcaac	ctccgcctcc	caggttgaca	ccattctcct	gcctcaccct	cccaagtagc
45	3361	tgggactaca	ggcgccctgc	agcacgcctg	gctaattttt	tgtattttta	gtagagacag
	3421	ggtttcaccg	tgtagccag	gatggtctcg	atctcctgac	ctcgtgatcc	gcctgcctct
	3481	gcctcccaaa	gtgctgggat	tacaggcggtg	agccaccg	tccggcctct	ttttttcttt
	3541	tctttttttt	gagacaaaagt	ctcactgtgt	caccagact	ggaatgcagt	gacacaatct
	3601	cggtcactg	aaacctctgc	cttccagggt	caagctattc	tcagcctca	gcctctcaag
50	3661	tagctgggac	tacagatgtg	ggccaccatg	tctggcta	tttttttttt	tttttttttt
	3721	ttttagagaga	caggggttctg	ccatgttgac	gagactggtc	tcgaactcct	ggcctcaagt
	3781	gatctgccgc	ctcagcttct	caaagtactg	ggattatata	ggcatgagcc	actgagcctg
	3841	gcccgaagc	gtttttctca	aaggccctca	gtgagataaa	ttagatttgg	catctcctgt
	3901	cctggggccag	ggatctctct	acaagagccc	ctgcccctct	gttggaggca	cagtttttaga
55	3961	ataaggagga	ggaggggagaa	gagaaaatgt	aaaggaggga	gatctttccc	aggccgcacc

- 7 -

4021 atttctgtca ctcacatgga cccaagataa aagaatggcc aaaccctcac aaccctgat
 4081 gtttgaagag ttccaagttg aagggaaaca aagaagtgtt tgatggtgcc agagaggggc
 4141 tgctctccag aaagctaaaa tttaatttct ttttctctct gagttctgta cttcaaccag
 4201 cctacaagct ggcacttgct aacaaatcag aaatatgaca attaattgatt aaagactgtg
 5 4261 attgcc

SEQ ID NO. 11

10 P30086 - Homo sapiens
 Phosphatidylethanolamine binding protein (PEBP)

1 mpvdlskwsg plslqevdeq pqhplhvtya gaavdelgkv ltptqvknrp tsiswdglds
 61 gklytlvltd pdapsrkdpk yrewhhflvv nmkgndissg tvlsdyvgsq ppkggtglhry
 15 121 vwlvyeqdrp lkcdpilsn rsgdhrqgfk vasfrkkyel rapvagtcyq aewddyvpkl
 181 yeqlsgk

SEQ ID NO. 12

20 NM_002567
 Homo sapiens prostatic binding protein (PBP), mRNA

1 tggggcggcg ctgaggcgcg tgctctcgcg tggctcgctgg gtctgcgtct tcccgagcca
 25 61 gtgtgctgag ctctccgct cgcctctgtc gcccggcctt ggcctaccgc ggcactcccg
 121 gctgcacgct ctgcttggcc tcgccatgcc ggtggacctc agcaagtggc cggggccctt
 181 gagcctgcaa gaagtggacg agcagccgca gcaccgctg catgtcacct acgcccgggc
 241 ggcgggtggac gagctgggca aagtgtctgac gccaccacag gttaagaata gaccaccag
 301 catttcgtgg gatggtcttg attcagggaa gctctacacc ttggtcctga cagaccgga
 361 tgctcccagc aggaaggatc ccaaatacag agaattggcat catttcctgg tggtaacat
 421 gaagggcaat gacatcagca gtggcacagt cctctccgat tatgtgggct cggggcctcc
 481 caagggcaca ggctccacc gctatgtctg gctgggttac gagcaggaca ggccgctaaa
 541 gtgtgacgag cccatcctca gcaaccgatc tggagaccac cgtggcaaat tcaaggtggc
 601 gtccctccgt aaaaagtatg agctcagggc cccggtggct ggcaagtgtt accaggccga
 661 gtgggatgac tatgtgcccc aactgtacga gcagctgtct ggggaagtagg ggggttagctt
 721 ggggacctga actgtcctgg agggcccaag ccattgtccc cagttcagtg ttgcatgtat
 781 aatagatttc tcctcttcct gcccccttg gcatgggtga gacctgacca gtcagatggt
 841 agttgagggt gacttttctt gctgcoctggc ctttataatt ttactcactc actctgattt
 901 atgttttgat caaatttgaa cttcattttg ggggggtattt tgggtactgtg atggggcat
 961 caaattatta atctgaaaat agcaaccacg aatgtaaaaa agaaaaaact ggggggaaaa
 1021 agaccaggctc tacagtgata gagcaaagca tcaaagaatc ttttaaggag gtttaaaaaa
 1081 aaaaaaaaaa aaaaagattg gttgcctctg cctttgtgat cctgagtcga gaattgata
 1141 caatgtgatt ttatggtgat gtcaactcac tagacaacca gaggctggca ttgaggctaa
 1201 cctccaacac agtgcatctc agatgcctca gtaggcatca gtatgtcact ctggctccct
 1261 taaagagcaa tcctggaaga agcaggaggg aggggtggctt tgctgtgtgtt gggacatggc
 1321 aatctagacc ggtagcagcg ctgcctgaca gcttgggagg aaacctgaga tctgtgtttt
 1381 ttaaattgat cgttcttcat gggggtaaga aaagctggctc tggagttgct gaattgtgca
 1441 ttaattgtgc tgtttgcttg tagttgaata aaaatagaaa cctgaatgaa gaaaaaaaaa
 1501 aaaaaaa

SEQ ID NO. 13

P39687 - Homo sapiens
 55 Acidic leucine-rich nuclear phosphoprotein 32 family member A

- 8 -

1 memgrrihle lrnrtpsdkv elvldnsrsn egklegltde feeleflsti nvgltsianl
 61 pklnklkkle lsdnrvsggl evlaekcpnl thlnlsgnki kdlstieplk klenlksidl
 121 fncevtnlnd yrenvfkllp qltyldgydr ddkeapdsda egyvegldde eededeeeyd
 5 181 edaqvvedee dedeeeeegee edvsgeeeed eegyndgevd deedeelge eergqkrkre
 241 pedegeddd

SEQ ID NO. 14

10

NM_006305

Homo sapiens acidic (leucine-rich) nuclear phosphoprotein 32
 family, member A (ANP32A), mRNA

15 1 cgggtgctgg gggctcgaga accgagcgga gctggttgag ccttcaaagt cctaaaacgc
 61 ggggccgtgg gttcgggggt tattgattga attccgccgg cgcgggagcc tctgcagaga
 121 gagagcgcca gagatggaga tgggcagacg gattcattta gagctgcgga acaggacgcc
 181 ctctgatgtg aaagaacttg tcttggacaa cagtcggtcg aatgaaggca aactcgaagg
 241 cctcacagat gaatttgaag aactggaatt cttaagtaca atcaacgtag gcctcacctc
 20 301 aatcgcaaac ttaccaaagt taaacaaact taagaagcct gaactaagcg ataacagagt
 361 ctgagggggc ctggaagtat tggcagaaaa gtgtccgaac ctacgcgcatc taaatttaag
 421 tggcaacaaa attaaagacc tcagcacaaat agagccactg aaaaagttag aaaacctcaa
 481 gagcttagac cttttcaatt gcgaggtaac caacctgaac gactaccgag aaaatgtgtt
 541 caagctcctc ccgcaactca catatctcga cggctatgac cgggacgaca aggaggcccc
 25 601 tgactcggat gctgagggtc acgtggaggg cctggatgat gaggaggagg atgaggatga
 661 ggaggagtat gatgaagatg ctcaggtagt ggaagacgag gaggacgagg atgaggagga
 721 ggaaggtgaa gaggaggacg tgagtggaga ggaggaggag gatgaagaag gttataacga
 781 tggagaggta gatgacgagg aagatgaaga agagcttggt gaagaagaaa ggggtcagaa
 841 gcgaaaacga gaacctgaag atgaggggaga agatgatgac taagtggaaat aacctatatt
 30 901 gaaaaattcc tattgtgatt tgactgtttt taccatatac ccctctcccc cccccctcca
 961 atcctgcccc ctgaaactta tttttttctg attgtaacgt tgctgtggga acgagagggg
 1021 aagagtgtac tgggggttgc ggggggaggg atggcggggtg ggggtggaat aaaatactat
 1081 ttttactgcc actctttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa

35

SEQ ID NO. 15

P17066 - Homo sapiens
 Heat shock 70kDa protein

40

1 mqaprelavg idlgttyscv gvfgqgrvei landqgnrtt psyvaftdte rlvгдаaksq
 61 aalnphntvf dakrligrkf adttvqsdmk hwpfrvvseg gkpkvrvcyr gedktfypee
 121 issmvlskmm etaeaylgqp vkhavitvpa yfndsqrqat kdagaiagln vlriinepta
 181 aaiayglldrr gagernvlif dlgggtfdvs vlsideagvfe vkatagdthl ggedfdnrlv
 45 241 nhfmeefrrk hgkdlsnkr alrrlrtae rakrtlssst qatleidslf egvdfytsit
 301 rarfeelcsd lfrstlepve kalrdakldk aqihdvvlvg gstripkvqk llqdffngke
 361 lnksinpdea vaygaavqaa vlmgdkcekv qdlllldvap lslgletagg vmttliqrna
 421 tiptkqtqtf ttysdnqpgv fiqvyegera mtkdnllgr felsgippap rgvpqievtf
 481 didangilsv tatdrstgka nkititndkg rlskeeverm vheaeykae deaqrdrvaa
 50 541 knsleahvfh vkgsllgeesl rdkipeedrr kmqdkcrevl awlehnqlae keeyehqkre
 601 leqicrpifs rlyggpgvpg gsscgtqarq gdpstgpiie evd

SEQ ID NO. 16

55

- 9 -

NM_002155

Homo sapiens heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA.

```

      1 agagccagcc cggaggagct agaaccttcc cgcatttct ttcagcagcc tgagttagag
5      61 gcgggctggc ctggcgtagc cgcagcagct cgcggctcat gcccgatct gcccgaacct
      121 tctcccgggg ttagcgccgc gcgcgcccac cgcgctgagt cagcccgggc gggcgagagg
      181 ctctcaactg ggcggaagg tgcggaagg tgcggaagg ttcgcgaaag ttcgcggcgg
      241 cgggggtcgg gtgaggcgca aaaggataaa aagcccgtag aagcggagct gagcagatcc
      301 gagccgggct ggctgcagag aaaccgcagg gagagcctca ctgctgagcg cccctcgacg
10      361 gcggagcggc agcagcctcc gtggcctcca gcatccgaca agaagcttca gccatgcagg
      421 cccacagggg gctcgcggtg ggcacgacc tgggcaccac ctactcgtgc gtggcgctgt
      481 ttcagcaggg cgcgctggag atcctggcca acgaccaggg caaccgcacc acgcccagct
      541 acgtggcctt caccgacacc gagcggctgg tcggggacgc ggccaagagc caggcggccc
      601 tgaacccccca caacaccgtg ttcgatgcca agcggctgat cgggcgcaag ttcgcggaca
15      661 ccacggtgca gtccgacatg aagcactggc ccttcggggt ggtgagcgag ggcggcaagc
      721 ccaaggtgcg cgtatgctac cgcggggagg acaagacgtt ctaccccgag gagatctcgt
      781 ccatggtgct gagcaagatg aaggagacgg ccgaggcgta cctgggccag cccgtgaagc
      841 acgcagtgat caccgtgccc gccattttca atgactcgca gcgccaggcc accaaggacg
      901 cggggggccat cgcggggctc aacgtgttgc ggatcatcaa tgagcccacg gcagctgcca
20      961 tcgcctatgg gctggaccgg cggggcgagg gagagcgcaa cgtgctcatt tttgacctgg
      1021 gtggggggcac cttcgatgtg tcggttctct ccattgacgc tgggtgtctt gaggtgaaag
      1081 ccaactgctgg agataccacc ctgggaggag aggacttcga caaccggctc gtgaaccact
      1141 tcatggaaga attccggcgg aagcatggga aggacctgag cgggaacaag cgtgccctgc
      1201 gcaggtgctg cacagcctgt gagcgcgcca agcgcaccct gtccctccagc acccaggcca
25      1261 cccctggagat agactccctg ttcgagggcg tggacttcta cactgcatc actcgtgccc
      1321 gctttgagga actgtgtcta gacctcttcc gcagcaccct ggagcgggtg gagaaggccc
      1381 tgcgggatgc caagctggac aaggcccaga ttcattgacgt cgtcctggtg gggggctcca
      1441 ctgcgcatcc caaggtgcag aagttgtctg aggacttctt caacggcaag gagctgaaca
      1501 agagcatcaa ccctgatgag gctgtggcct atggggctgc tgtgcaggcg gccgtgttga
30      1561 tggggggacaa atgtgagaaa gtgcaggatc tcctgctgct ggatgtggct cccctgtctc
      1621 tgggggctgga gacagcaggt ggggtgatga ccacgctgat ccagagggaac gccactatcc
      1681 ccaccaagca gaccagact ttcaccacct actcgacaaa ccagcctggg gtcttcatcc
      1741 aggtgtatga gggtagaggg gccatgacca aggacaacaa cctgctgggg cgttttgaac
      1801 tcagtggcat cctcctgccc ccacgtggag tccccagat agaggtgacc tttgacattg
35      1861 atgctaattg catcctgagc gtgacagcca ctgacaggag cacaggtaag gctaacaaga
      1921 tcaccatcac caatgacaag ggccggctga gcaaggagga ggtggagagg atggttcatg
      1981 aagccgagca gtacaaggct gaggatgagg ccagaggga cagagtggct gccaaaaact
      2041 cgctggaggc ccatgtcttc catgtgaaag gttcttttga agaggaaagc cttagggaac
      2101 agattcccga agaggacagg cgcaaaatgc aagacaagtg tcgggaagtc cttgcctggc
40      2161 tggagcacaa ccagctggca gagaaggagg agtatgagca tcagaagagg gagctggagc
      2221 aaatctgtcg ccccatcttc tcaggtctct atggggggcc tgggtgtcct gggggcagca
      2281 gttgtggcac tcaagccgc cagggggacc ccagcaccgg ccccatcatt gaggaggttg
      2341 attgaatggc ccttcgtgat aagtcagctg tgactgtcag ggctatgcta tgggccttct
      2401 agactgtctt ctatgatcct gcccttcaga gatgaacttt ccctccaaag ctagaacttt
45      2461 cttcccagga taactgaagt cttttgactt tttgggggga gggcggttca tcctcttctg
      2521 cttcaaataa aaagtcatta atttattaaa acttgtgtgg cactttaaca ttgctttcac
      2581 ctatatattt tgtactttgt tacttgcatg tatgaatttt gttatgtaaa atatagttat
      2641 agacctaaat aaaaaaaaaa aaaa

```

50

SEQ ID NO. 17

X51757

Human heat-shock protein HSP70B gene

55

- 10 -

1 cccgggcccggg cgagaggctc tcaactggggc gggaagggtgc gggaagggtgc ggaaagggttc
 61 gcgaaagtgc gcggcggcgg ggttcgggtg aggcgcacaaa ggataaaaaag cccgtggaag
 121 cggagctgag cagatccgag ccgggctggc tgcagagaca ccgcaggagg agcctcactg
 181 ctgagcggcc ctgcagggcg gacgggcagc agcctccgtg gcctccagca tccgacaaga
 5 241 agcttcagcc atgcaggccc cacgggagct cgcgggtggc atcgacctgg gcaccacctta
 301 ctctgtcgtg ggcgtgtttc agcaggggccg cgtggagatc ctggccaacg accaggggcaa
 361 ccgcaccacg ccagctacg tggccttcac cgacaccgag cggctggctg gggacgcggc
 421 caagagccag gcggccctga acccccacaa caccgtgttc gatgccaaag ggctgatcgg
 481 gcgcaagtgc gcggacacca cgtgacgtc ggacatgaag cactggccct tccgggtggt
 10 541 gagcgagggc ggcaagccca aggtgccggg atcgtaaccg cgggaggaac agacgttcta
 601 ccccgaggag atctcgtcca tgggtcgtgag caagatgaag gagacggccg aggcgtacct
 661 gggccagccc gtgaagcacg cagtgatcac cgtgcccgcg tttttcaatg actcgcagcg
 721 ccaggccacc aaggacgcgg gggccatcgc ggggctcaac gtgttcgga tcatcaatga
 781 gccacggca gctgccatcg cctatgggct ggaccggcgg gcgcgggag agcgcaacgt
 15 841 gctcatTTTT gacctgggtg ggggcacctt cgatgtgtcg gttctctcca ttgacgtgg
 901 tgtctttgag gtgaaagcca ctgctggaga taccacctg ggaggagagg acttcgacaa
 961 ccggctcgtg aaccacttca tggaaagaatt ccggcggaaag catgggaagg acctgagcgg
 1021 gaacaagcgt gccctcggca ggtgcgcac agcctgtgag cgcgccaagc gcaccctgtc
 1081 ctccagcacc caggccaccc tggagataga ctccctgttc gagggcgtgg acttctacac
 20 1141 gtccatcact cgtgcccgtc ttgaggaaact gtgctcagac ctcttccgca gcaccctgga
 1201 gccggtggag aaggccctgc gggatgccaa gctggacaag gccagattc atgacgtcgt
 1261 cctgggtggg ggctccactc gcatcccca ggtgcagaag ttgctgcagg acttcttcaa
 1321 cggcaaggag ctgaacaaga gcatcaaccc tgatgaggct gtggcctatg gggctgctgt
 1381 gcaggcggcc gtgttgatgg gggacaaatg tgagaaagtg caggatctcc tgctgctgga
 25 1441 tgtggctccc ctgtctctgg ggtcggagac agcagggtgg gtgatgacca cgtgatcca
 1501 gaggaacgccc actatcccca ccaagcagac ccagactttc accacctaact cggacaacca
 1561 gcctggggtc ttcattccagg tgtatgaggg tgagaggggc atgaccaagg acaacaacct
 1621 gctggggcgt tttgaactca gtggcatccc tcctgcccc cgtggagtcc cccagataga
 1681 ggtgaccttt gacattgatg ctaatggcat cctgagcgtg acagccactg acaggagcac
 30 1741 aggtaaggct aacaagatca ccatcaccaa tgacaagggc cggctgagca aggaggagg
 1801 ggagaggatg gttcatgaag ccgagcagta caaggctgag gatgaggccc agagggacag
 1861 agtggctgcc aaaaactcgc tggaggccca tgtcttccat gtgaaagggt ctttgcaaga
 1921 ggaagcctt agggacaaga ttcccgaaga ggacaggcgc aaaatgcaag acaagtgtcg
 1981 ggaagtccct gcctggctgg agcacacaoca gctggcagag aaggaggagt atgacatca
 35 2041 gaagaggggag ctggagcaaa tctgtcgccc catcttctcc aggtctctatg gggggcctgg
 2101 tgtccctggg ggcagcagtt gtggcactca agcccgcag ggggacccca gcaccggccc
 2161 catcattgag gaggttgatt gaatggccct tcgtgataag tcagctgtga ctgtcagggc
 2221 tatgctatgg gccttctaga ctgtcttcta tgatcctgcc cttcagagat gaactttccc
 2281 tccaaagcta gaactttctt cccaggataa ctgaagtctt ttgacttttt gcggggaggg
 40 2341 cggttcatcc tcttctgctt caaataaaaa gtcattaatt tattaanaact tgtgtggcac
 2401 tttaacattg ctttcacctt tattttgtgt actttgttac ttgcatgtat gaattttgtt
 2461 atgtaaaata tagttataga cctaaataag ct

45 SEQ ID NO. 18

P14174

macrophage migration inhibitory factor - Homo Sapiens

50 1 mpmfivntnv praspvpgfl seltqqlaqa tgkppqyia hvvpdqlmaf ggssepccalc
 61 slhsigkigg aqnrsyskll cgllaerlri spdrvyinyy dmnaanvgwn nstfa

SEQ ID NO. 19

55

- 11 -

NM_002415 - Homo Sapiens

Homo sapiens macrophage migration inhibitory factor
(glycosylation-inhibiting factor) (MIF), mRNA

```

5      1 accacagtgg tgtccgagaa gtcaggcacg tagctcagcg gcggccgcgg cgcgtgcgtc
      61 tgtgcctctg cgcgggtctc ctggtccttc tgccatcatg ccgatgttca tcgtaaacac
     121 caacgtgccc cgcgcctccg tgcggacgg gtccctctcc gagctcacc accagctggc
     181 gcaggccacc ggcaagcccc ccagtacat cgcggtgcac gtggctcccg accagctcat
     241 ggcttccggc ggctccagcg agcgtgccc gctctgcagc ctgcacagca tcggcaagat
10     301 cggcggcgcg cagaaccgct cctacagcaa gctgctgtgc ggctgctgg ccgagcgcct
     361 gcgcacagc cgggacaggg tctacatcaa ctattacgac atgaacgcgg ccaatgtggg
     421 ctggaacaac tccaccttcg cctaagagcc gcagggaacc acgctgtctg cgtgtgctcc
     481 acccggaac ccgcccacg ctgtgttcta ggcccgcaca cccaacctt ctggtgggga
     541 gaaataaacg gtttagagac t
15

```

SEQ ID NO. 20

L19686

20 Homo sapiens macrophage migration inhibitory factor (MIF) gene,
complete cds

```

      1 ctgcaggaac caatacccat aggctatttg tataaatggg ccatggggcc tcccagctgg
      61 aggctggctg gtgccacgag ggtcccacag gcatgggtgt ccttcctata tcacatggcc
25     121 ttcactgaga ctggtatatg gattgcacct atcagagacc aaggacagga cctccctgga
     181 aatctctgag gacctggcct gtgatccagt tgctgccttg tctcttccct gctatgtcat
     241 ggcttatctt ctttcaccca ttcatctatt cattcattca ttcagcagta ttagtcaatg
     301 tctcttgata tgcctggcac ctgctagatg gtccccgagt ttaccattag tggaaaagac
     361 atttaagaaa ttcaccaagg gctctatgag aggccataca cgggtggacct gactaggggtg
30     421 tggcttccct gaggagctga agttgcccag agggccagag aaggggagct gagcacgttt
     481 gaaccactga acctgctctg gacctgcctt ccttccttcg gtgcctccca gcatcctatc
     541 ctctttaaag agcagggggt cagggaagtt ccttggatgg tgattcgcag gggcagctcc
     601 cctctcacct gccgcatgac taccgcgccc catctcaaac acacaagctc acgcatgcgg
     661 gactggagcc cttgaggaca tgtggcccaa agacaggagg tacaggggct cagtgcgtgc
35     721 agtggaatga actgggcttc atctctggaa gggtaagggg ccatcttccg gggtcaaccg
     781 cgcaccccca ccccggcac agcgcctcct ggcgactaac atcgggtgact tagtgaaagg
     841 actaagaaaag acccgaggcg aggcgggaac aggccgattt ctagccgcca agtggagaac
     901 aggttgaggc ggtgcgccc gcttagcggc ggttgctgga ggaacgggag ggtcgcgcca
     961 gggctcctgc ctgcgggggt cgagccgagg caggcgggtga cttccccact cggggcggag
40    1021 ccgcagcctc gcgggggagg ggccctggcg cggcgggtgg gtcaaaaaag gcgggaccac
     1081 agtgggtgtc gagaagttag gcacgtagct cagcggcggc cgcggcgctg gcgtctgtgc
     1141 ctctgcgcgg gtctcctggt ccttctgcca tcatgccgat gttcatcgta aacaccaacg
     1201 tgccccgcgc ctccgtgccg gacgggttcc tctccgagct caccagcag ctggcgagg
     1261 ccaccggcaa gccccccag gtttgccggg aggggacagg aagagggggg tgcccaccgg
45    1321 acgagggggt ccgcgctggg agctggggag gcgactcctg aacggagctg gggggcgggg
     1381 cggggggagg acggtggctc gggcccgaag tggacgttcg gggcccgaag aggtcgctgg
     1441 ggcgggctga ccgcgcctt tctcgcagt acatcgcggt gcacgtggtc ccggaccagc
     1501 tcatggcctt cggcggtcc agcgagcgt gcgcgctctg cagcctgcac agcatcggca
     1561 agatcggcgg cgcgcagaac cgctcctaca gcaagctgct gtgcgccctg ctggccgagc
50    1621 gcctgcgcac cagcccggac aggtacgcgg agtcgcggag gggcggggga gggcgggcgg
     1681 cgcgcggcca ggcccgggac tgagccaccc gctgagtcgg gctcctccc cccgcagggt
     1741 ctacatcaac tattacgaca tgaacgcggc caatgtgggc tggaaacaact ccaccttcgc
     1801 ctaagagccg cagggaacca cgtgtgtctg gctggctcca ccgggaacc cgcgcacgc
     1861 tgtgttctag gccgcgccc cccaaccttc tgggtggggag aaataaacgg ttttagagact
55    1921 aggagtgcct cggggttcc tggcttgcgg gaggaattgg tgcagagccg ggacattggg

```

- 12 -

1981 gagcgaggtc gggaaacggt gttgggggcg ggggtcaggg ccgggttgct ctccctgaac
 2041 ctgctgttcg ggagcccttt tgtccagcct gtccctccta cgctcctaac agaggagccc
 2101 cagtgtcttt ccattctatg gcgtacgaag ggatgaggag aagttggcac tctgccctgg
 2161 gctgcag

5

SEQ ID NO. 21

P31949

10 Calgizzarin - Homo sapiens

1 makissptet ercieszliav fqkyagkdgy nytlsktefl sfmntelaaf tknqkdpqvl
 61 drmmkkldtn sdgqldfsef lnligglama chdsflkavp sqkrt

15

SEQ ID NO. 22

NM_005620 and D38583 - Homo sapiens

Homo sapiens S100 calcium binding protein A11 (calgizzarin) (S100A11),
 mRNA

20

1 gggcaaggct gggccgggaa gggcgtgggt tgaggagagg ctccagaccc gcacgccgcg
 61 cgcacagagc tctcagcgcc gctcccagcc acagcctccc gcgcctcgct cagctccaac
 121 atggcaaaaa tctccagccc tacagagact gagcgggtgca tcgagtcctt gattgctgtc
 25 181 ttccagaagt atgctggaaa ggatgggttat aactacactc tctccaagac agagttccta
 241 agcttcatga atacagaact agctgccttc acaaagaacc agaaggaccc tgggtgtcctt
 301 gaccgcatga tgaagaaact ggacaccaac agtgatggtc agctagattt ctcagaattt
 361 cttaaatctga ttggtggcct agctatggct tgccatgact ccttctccta ggctgtccct
 421 tcccagaagc ggacctgagg accccttggc cctggccttc aaaccaccc cctttccttc
 30 481 cagcctttct gtcattcatc ccacagccca cccatccctt gagcacacta accacctcat
 541 gcaggcccca cctgccaata gtaataaagc aatgtcactt ttttaaaaca tgaaa

SEQ ID NO. 23

35

P00938 and NP_000356 - Homo sapiens
 Triosephosphate isomerase

1 mapsrkffvg gnwkmngrkq slgeligtln aakvpadtev vcapptayid farqkldpki
 40 61 avaaqncykv tngaftgeis pgmikdcgat wvvlghserr hvfgesdeli gqkvahalae
 121 glgviacige kldereagit ekvvfeqtkv iadnvkdwsd vvlapepwa igtgktatpq
 181 qaqevneklr gwlsnvsda vaqstriiyg gsvtgatcke lasqpddvdf lvvgaslkpe
 241 fvdiinakq

45

SEQ ID NO. 24

NM_000365

Homo sapiens triosephosphate isomerase 1 (TPI1), mRNA

50

1 ccttcagcgc ctgggtccca gcgccatggc gccctccagg aagttcttcg ttgggggaaa
 61 ctggaagatg aacgggaggga agcagagtct gggggagctc atcggcactc tgaacgcggc
 121 caaggtgccg gccgacaccg aggtgggttg tgctccctct actgcctata tcgacttcgc
 181 ccggcagaag ctagatccca agattgctgt ggctgcgcag aactgctaca aagtgactaa
 55 241 tgggggtttt actggggaga tcagccctgg catgatcaaa gactgaggag ccacgtgggt

- 13 -

301 ggtcctgagg cactcagaga gaaggcatgt ctttggggag tcagatgagc tgattgggca
 361 gaaagtggcc catgctctgg cagaggggact cggagtaatc gcctgcattg gggagaagct
 421 agatgaaagg gaagctggca tcaactgagaa ggttggtttc gagcagacaa aggtcatcgc
 481 agataacgtg aaggactgga gcaaggctcgt cctggcctat gagcctgtgt gggccattgg
 5 541 tactggcaag actgcaacac cccaacaggc ccaggaagta cacgagaagc tccgaggatg
 601 gctgaagtcc aacgtctctg atgcgggtggc tcagagcacc cgtatcattt atggaggctc
 661 tgtgactggg gcaacctgca aggagctggc cagccagcct gatgtggatg gcttccttgt
 721 ggggtggtgct tccctcaagc ccgaattcgt ggacatcatc aatgccaaac aatgagcccc
 781 atccatcttc cctacccttc ctgccaagcc agggactaag cagcccagaa gccagtaac
 10 841 tgccctttcc ctgcatatgc ttctgatggg gtcatctgct ccttcctgtg gcctcatcca
 901 aactgtatct tcctttactg tttatatctt caccctgtaa tgggtgggac caggccaatc
 961 ccttctccac ttactataat ggttggaaact aaacgtcacc aagggtggctt ctcttggct
 1021 gagagatgga aggcgtgggt ggatttgctc ctgggttccc tagggcctag tgagggcaga
 1081 agagaaacca tcctctccct tcttacaccg tgaggccaag atccctcag aaggcaggag
 15 1141 tgctgccctc tcccatgggt ccgctgcctc tgtgtgtgt atgtgaacca ccatgtgag
 1201 ggaataaacc tggcactagg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa

SEQ ID NO. 25

20

X69723

H.sapiens TPI1 gene for triosephosphate isomerase.

1 ctgcagttcc tgccaggcct tgccagccgg ggcgaggggt gggatgatcc tggcggccta
 25 61 tgccctgtgt ggctgcccct cccgctgtga accctgcatt tgtcccga gttttcactc
 121 aggtagaact cctgggtaca aggggtgcct ctacagcagtc gggcatgagc tgctccgatg
 181 ggcgaaggag gttgtctatt ccacagttgg agagggggccc tctctgcccc agtgggcatg
 241 ctgggctacg gccaaagtgc caccagctag ttccgcttga aaaccacttc tggccccgtg
 301 ggggactcaa gtgcccaagc gaggggtccc ctgagcgcgc gagctcacag gtctcgcctt
 361 gtcccgaaag ccccgcaatc gagggcgagg cgaccgagcc cccgactctc ctagaacgtt
 421 gccacaagaa gggggaaagt cggaaacagt catcatcggg cggcgggccgg ggcggcgcca
 481 ggagggcggg cggggggcag ggctccgggg gactgggagg gccatggcgg aggacggcga
 541 ggagggcgag ttccacttcg cggcgctcta tataagtggg cagtggcgcg gactgcgcgc
 601 agacactgac cttcagcgcc tcggctccag cgccatggcg cctccagga agttcttcgt
 35 661 tgggggaaac tggaaagtga acggggcgaa gcagagtctg ggggagctca tcggcactct
 721 gaacgcggcc aagggtgcgg ccgacaccgg taagccctcg ccgaggagg gtctggccgg
 781 gccggggccg ggccggggca ggagtggcag cgcctctccc gagggccgag gtccggggccg
 841 gtatccgcgc ggacctgatg cagggctgtg ggacgagggc cgtggggtc cgggcagggg
 901 cctcgcagcc gcagccccgt cgggtgcgtc agggggcagg gcggagcaca tgatgccctt
 40 961 tggactacgg ggcaggtaag gacgttttgg gtctcctgga ggaaggcgg cccggggcgc
 1021 gcaactggctg tgcccggcag gcgacggggg taggagccga gcccgaggct ctgcgggaga
 1081 ccgggggagg ctgggcccgc tgggcttccg ctccctgcc tggcctccgc gtgcgcgcgc
 1141 ccgcacgtag ccccgactc ctccccctcc tcgcccggct cgtcccgcgc cgagctgctg
 1201 ctgccctgag ccccagatc tgaacccctt ccttcggca acctgagcga ctccgcctt
 45 1261 ccacggaagg gaccgagccc gtgccaaaca ggctgagcga tttgggagtg aggagccatc
 1321 ctaccgcttt cccaacctg gaaacagcaa agcgcaaggc ctctgagtca gttaggtctc
 1381 tgccacccac gggcaaagga tgctctcctc catcctcctt cctccctcca ccgaaatcgg
 1441 agagccgcgg gcctgatcca aagaggcatc cccttctcgt tcattcccca gaggcctcaa
 1501 tacaaacccc aggagtggc cctctcctt ttgctacaaa tccttgccct gcaaagggga
 50 1561 ggtgaggatg ggctatttta gaagggaagc aggggttgct cctggagaat cctgagctctg
 1621 tgagggtgct atgccgagaa tagctcgagg aaattggagc ccagctgtt aaaagagcag
 1681 agggcagggt gagggccgtg gctctcagg gtatctggaa ggctctcga gttgagtga
 1741 gacccagcct tgggctggaa aatggacaaa ggtcatcttg ctggggtgaa aagggggaga
 1801 gcagaaccaa gaagaagagg gtgagggctg gggggctcca gggcactggg taggaattgt
 55 1861 ggggaatgaa ggctttcttt agtctcatcc ccctgtggta ccatcttgct ctacagggtg

- 14 -

1921 gtttgtgctc cccctactgc ctatatcgac ttcgcccgcc agaagctaga tcccaagatt
 1981 gctgtggctg cgcagaactg ctacaaagtg actaatgggg cttttactgg ggagatcagg
 2041 tgagatcgag gtggagaggg gtgtgtggga cccttccctc actttcctcg ttgaggggaa
 2101 agccacaggg tgggctccct gctgaacctt ggcttcatct cttcctttag ccctggcatg
 5 2161 atcaaagact gcggagccac gtgggtggct ctggggcact cagagagaag gcatgtcttt
 2221 ggggagtcag atgaggtttag tagccaagag agaagataag ggatgtcttt tccaagaag
 2281 gatgtctcac caagtctgtt tctcaacagc tgattgggca gaaagtggcc catgctctgg
 2341 cagagggact cggagtaatc gcctgcattg gggagaagct agatgaaagg gaagctggca
 2401 tcaactgagaa ggttgttttc gagcagacaa aggtcatcgc aggtatctct ggagaaaggg
 10 2461 acctttgagc ctatccaggg ccacagagac tcagagggta gggtcaggcc ctggagcctg
 2521 tcttgggtccc catgctgac cagaaaaggga aaaaggggag ggggagtgac aatctttgct
 2581 tggggcctat gacttctcca gcccacaggt agatgccacc tggaaatccc ccaatgtcca
 2641 ctaggggggca gtagggccacc gttcttctga ctccggagaa cctggctgga gagctctttc
 2701 ttgttcaccc ttccctccat ctgtatctct gccctgcaga taacgtgaag gactggagca
 15 2761 aggtcgtcct ggcctatgag cctgtgtggg ccattgggtac tggcaagact gcaacacccc
 2821 aacaggtaac cgggcccagg agccctgccc tcatcccagc ctgcctcaat aggtttggac
 2881 agacacagcc cacatggagc aacccttat ttcaaagaca cagagacctt gaaccagag
 2941 acagtgactt gtccaagggc atccagttca gggcctggct tggatcagag cctgggtact
 3001 ctgactcagt cagaaaccac actaagtgtc cactgggtgcc agtgattttt cctcttagag
 20 3061 aggcagaaaa ggtcttactt agggcagctt cttgttctag gccaggaag tacacgagaa
 3121 gctccgagga tggctgaagt ccaacgtctc tgatgcggtg gctcagagca ccggtatcat
 3181 ttatggaggt gagtggcttt ggttcccgcc tgaggtggag tgggctgagg actagactga
 3241 gccctcggac atggaggtgg ggatggggca gactcatccc attcttgacc aagcccttgt
 3301 tctgctccct tcccaggtc tgtgactggg gcaacctgca aggagctggc cagccagcct
 25 3361 gatgtggatg gcttccctgt ggggtgggtg tccctcaagc ccgaattcgt ggacatcatc
 3421 aatgccaaac aatgagcccc atccatcttc cctacccttc ctgccaaagc agggactaag
 3481 cagcccagaa gccagtaac tgccctttcc ctgcataatg ttctgatggt gtcatctgct
 3541 ccttcctgtg gcctcatcca aactgtatct tcttttactg ttatatctt caccctgtaa
 3601 tggttgggac caggccaatc ccttctccac ttactataat ggttggaaact aaacgtcacc
 30 3661 aaggtggctt ctccctggct gagagatgga aggcgtgggt ggatttgctc ctgggtccc
 3721 taggcccctag tgagggcgaga agagaaacca tctctccct tcttacaccg tgaggccaag
 3781 atcccctcag aaggcaggag tgctgcctc tcccatgggt cccgtgcctc tgtgtgtgt
 3841 atgtgaacca cccatgtgag ggaataaacc tggcactagg tcttgtgggt tctctgcctt
 3901 cactggactt gccagataa tcttctttt tgaggcagct atataaatga tcatttgtgc
 35 3961 aagaaaaaaa aaaaaaacaag aacaggtttc tataacaaca tctcttacta tttttacttg
 4021 aaaaaatgtt ttgcgtagca gactgtcata gccttgaacg ccggctccct ttcttccctc
 4081 ctccaagtgg ctctggggct gttgattttc gcagagcttg ggttggggta gggctcagcc
 4141 tcaccagctt tcagcagctg gtctaggcca gcagtgcctc cccacctccc caagggaggg
 4201 tgggtggcaag acctcagcac agtctgtggt atcacaggct cactggtaga gcagtagcgc
 40 4261 ttcatgcagg gggcaagggc agggcagaca cctggccgag cggatatccc aggttgtggc
 4321 gcacacacag gcggctcagg tgcagaaggg agtgtggctc cgctgggaga gagaaggagg
 4381 ggaatgtaag tatgggtgca gccaccagcc agatgtcctc aaactacggg gtccatcatc
 4441 gatgcctttc tgctttcctg cttcgagtgt gccacactgg ctgaaagggg aatttgagat
 4501 acccggaagt tctgcctccc agataagatt tcacacatcc ctagtacagag ctgggggtga
 45 4561 agagctggct aaggccctct aaacaacagg ccaaggtggc tctgacagtg gtggagctgg
 4621 cccaggcttt gactccagag gcttggggagc tggggctgag gtgaggaggg atggccctcc
 4681 actctacagc ccaacacaac tgcagagagc agctccaagc cctggacca gtcatctcct
 4741 ggggaggctc ctccctgct gcccaccctc aaggcctgcc tctccactg ctctcctcct
 4801 ccttgggtgcc cagggcccca gtgtctccat cctgaggtgt ggtgaggaa ggaagtaggt
 50 4861 atgtggcaca gagacaggtt agagcccagg gaatccggta tacagctgg gtacctcgtc
 4921 tgcccatcct tcttttggac ctgtacatca aaccagtag ctaaccgttt gcacctcttg
 4981 cctaggggtg attactcctg aattc

55 SEQ ID NO. 26

- 15 -

Q05586 - Homo sapiens
Glutamate [NMDA] receptor subunit zeta 1 precursor

```

5  MSTMRLTLA LLFSCSVARA ACDPKIVNIG AVLSTRKHEQ MFREAVNQAN KRHGSKWIKQL
   NATSVTHKPN AIQMALSVCE DLISSQVYAI LVSHPTTPND HFTPTPVSYT AGFYRIPLVLG
   L'TTRMSIYSD KSIHLSFLRT VPPYSHQSSV WFEMMRVYSW NHIILLVSDD HEGRAAQKRL
   ETLLEERESK AEKVLQFDPG TKNVTALLME AKELEARVII LSASEDDAAT VYRAAAMLNM
10  TGSQYVWLVG EREISGNALR YAPDGILGLQ LINGKNESAH ISDAVGVAQ AVHELLEKEN
   LVQVGITYNGT HVIPNDRKII WPGGETEKPR GYQMSTRLKI VTIHQEPFVY VKPTLSDGTC
   KEEFTVNGDP VKKVICTGPN DTSPGSPRHT VPQCCYGFCI DLLIKLARTM NPTYEVHLVA
   DGKFGTQERV NNSNKKEWNG MMGELLSGQA DMIVAPLTIN NERAQYIEFS KPFKYQGLTI
   LVKKEIPRST LDSFMQPFQS TLWLLVGLSV HVVAVMLYLL DRFSFGRFK VNSEEEBEDA
15  LTLSSAMWFS WGVLLNSGIG EGAPRSFSAR ILGMVWAGFA MIIVASYTAN LA AFLVLD RP
   EERITGINDP RL RNPSDKFI YATVKQSSVD IYFRROVELS TMYRHMKEHN YESAAEAIQA
   VRDNKLHAFI WDSAVLEFEA SQKCDLVTTG ELFFRSGFGI GMRKDSWPWK NVSLSILKSH
   ENGFMEDLDK TWVRYQECDS RSNAPATLTF ENMAGVFMLV AGGIVAGIFL IFIBIAYKRH
   KDARRKQMQQL AFAAVNVWRK NLQDRKSGRA EPDPKKKATF RAITSTLASS FKRRRSSKDT
20  STGGGRGALQ NQKDTVLPFR AIEREEGQLQ LCSRHRHS

```

SEQ ID NO. 27

25 D13515
Homo sapiens mRNA for key subunit of N-methyl-D-aspartate receptor,
complete cds

```

1  gcttcagcgc cccttccctc ggccgacgtc ccgggaccgc cgctccgggg gagacgtggc
30  61  gtccgcagcc cgcggggccg ggcgagcgca ggacggcccg gaagccccgc gggggatgcg
   121  ccgagggccc cgcgttcgcg ccgcgcagag ccaggcccgcc ggcccagacc catgagcacc
   181  atgcgcctgc tgacgctcgc cctgctgttc tctgctcgc tcgcccgctgc cgcgtgcgac
   241  cccaagatcg tcaacattgg cgcggtgctg agcacgcgga agcacgagca gatgttccgc
   301  gaggccgtga accaggccaa caagcggcac ggctcctgga agattcagct caatgccacc
35  361  tccgtcacgc acaagcccaa cgccatccag atggctctgt cgggtgtgca ggacctcatc
   421  tccagccagg tctacgccat cctagttagc catccacctt cccccaacga ccacttcact
   481  cccacccctg tctcctacac agccggttc taccgcatac ccgtgctggg gctgaccacc
   541  cgcattgtcca tctactcgga caagagcatc cacctgagct tctgcgccac cgtgccgccc
   601  tactcccacc agtccagcgt gtggtttgag atgatgcgtg tctacagctg gaaccacatc
40  661  atcctgctgg tcagcgacga ccacgagggc cgggcggctc agaaacgcct ggagacgctg
   721  ctggaggagc gtgagtcaa ggcagagaag gtgctgcagt ttgaccagg gaccaagaac
   781  gtgacggccc tgctgatgga ggcgaaagag ctggaggccc gggctcatcat cctttctgcc
   841  agcgaggacg atgctgccac tgtataccgc gcagccgcga tgctgaacat gacgggctcc
   901  ggggtacgtg ggctggtcgg cgagcgcgag atctcgggga acgcctgctg ctacgccccca
45  961  gacggcatcc tcgggctgca gctcatcaac ggcaagaacg agtcggccca catcagcgac
   1021  gccgtggggc tgggtggcca ggcggtgcac gagctcctcg agaaggagaa catcaccgac
   1081  ccgcccgggg gctgcgtggg caacaccaac atctggaaga ccgggcccgt cttcaagaga
   1141  gtgctgatgt cttccaagta tgcggatggg gtgactggtc gcgtggagtt caatgaggat
   1201  ggggaccgga agttcgccaa ctacagcatc atgaacctgc agaaccgcaa gctgggtgcaa
50  1261  gtgggcatct acaatggcac ccacgtcatc cctaatagaca ggaagatcat ctggccaggc
   1321  ggagagacag agaagcctcg aggggtaccag atgtccacca gactgaagat tgtgacgac
   1381  caccaggagc ccttcgtgta cgtcaagccc acgctgagtg atgggacatg caaggaggag
   1441  ttacacagtca acggcgaccc agtcaagaag gtgatctgca ccgggcccga cgacacgtcg
   1501  ccgggcagcc ccgcccacac ggtgectcag tgttgctacg gcttttgcat cgacctgctc
55  1561  atcaagctgg caccgaccat gaacttcacc tacgaggtgc acctgggtggc agatggcaag

```

SUBSTITUTE SHEET (RULE 26)

- 16 -

```

1621 ttccggcacac aggagcgggt gaacaacagc aacaagaagg agtgggaatgg gatgatgggc
1681 gagctgctca gcgggcaggc agacatgac gtggcgccgc taaccataaa caacgagcgc
1741 ggcgagtaca tcgagttttc caagcccttc aagtaccagg gcctgactat tctggccaag
1801 aaggagattc cccggagcac gctggactcg ttcattgcagc cgttccagag cacactgtgg
5 1861 ctgctgggtgg ggctgtcggg gcacgtgggtg gccgtgatgc tgtacctgct ggaccgcttc
1921 agcccccctcg gccggttcaa ggtgaacagc gaggaggagg aggaggagcg actgaccctg
1981 tcctcggcca tgtggttctc ctggggcgctc ctgctcaact ccggcatcgg ggaaggcgcc
2041 cccagaagct tctcagcgcg catcctgggc atggtgtggg ccggcttttg catgatcatc
2101 gtggcctcct acaccgcca cctggcgccc ttcctggtgc tggaccggcc ggaggagcgc
10 2161 atcacgggca tcaacgacc tcggctgagg aaccctcgg acaagtttat ctacgccacg
2221 gtgaagcaga gctccgtgga tatctacttc cggcgccagg tggagctgag caccatgtac
2281 cggcatatgg agaagcaca ctacgagagt gcggcgagg ccattccaggc cgtgagagac
2341 aacaagctgc atgccttcat ctgggaactcg gcggtgctgg agttcgaggc ctgcgagaag
2401 tgcgacctgg tgacgactgg agagctgttt ttcgctcgg gcttcggcat aggcattgcgc
15 2461 aaagacagcc cctggaagca gaacgtctcc ctgtccatcc tcaagtccca cgagaatggc
2521 ttcatggaag acctggacaa gacgtgggtt cgggtatcagg aatgtgactc gcgcagcaac
2581 gccccctgcga ccttacttt tgagaacatg gccggggtct tcatgctggt agctgggggc
2641 atcgtggcgg ggaatcttct gattttcctc gagattgcct acaagcggca caaggatgct
2701 cgccggaagc agatgcagct ggccctttgccc gccgttaacg tgtggcgga gaacctgcag
20 2761 gatagaaaga gtggtagagc agagcctgac cctaaaaaga aagccacatt tagggctatc
2821 acctccaccc tggcttccag cttcaagagg cgtaggtcct ccaaagacac gaggaccggg
2881 ggtggacgcg gcgctttgca aaacaaaaaa gacacagtgc tgccgcgacg cgctattgag
2941 agggaggagg gccagctgca gctgtgttcc cgtcataggg agagctgaga ctccccgcc
3001 gccctcctct gcccctccc ccgcagacag acagacagac ggacgggaca gcgcccgccg
25 3061 ccacgcagag ccccgagca ccacgggggc gggggaggag cacccccag

```

SEQ ID NO. 28

30 LLTLLALLFSCSVAR

SEQ ID NO. 29

35 ITMLCTGSRTLK

SEQ ID NO. 30

40 ITHU and P01009 - Homo sapiens
 α -1-antitrypsin precursor

```

mpssvswgil llaglcclvp vslaedpagg aaktdtshh dqdhptfnki tpnlaefafs
lyrqlahqsn stniffspvs iatafamls1 gtkadthdei leglnfnlte ipeaqihiegf
45 qellrtlnqp dsqqlttn gn glflsegklk vdkfledvkk lyhseaftvn fgdteeakkq
indyvekgtq gkivdlvkel drdtvfalvn yiffkgkwer pfevkdteee dfhvdqvttv
kvpmmkrlgm fniqhckkls swllmkylg nataiffllpd egklqhlene lthdiitkfl
enedrrsas1 hlpklsitgt ydlksvlgql gitkvfsnga dlsgvteeap lklskavhka
vltidekgte aagamfleai pmsippevkf nkpfvflmie qntksplfmg kvvnptqk
50

```

SEQ ID NO. 31

NM_000295

- 17 -

Homo sapiens serine (or cysteine) proteinase inhibitor, clade A(alpha-1 antiproteinase, antitrypsin), member 1 (SERPINA1), transcript variant 1, mRNA

```

5      1 aatgactcct ttcggttaagt gcagtgggaag ctgtacactg cccaggcaaa gcgtccggggc
      61 agcgtaggcg ggcgactcag atcccagcca gtggacttag cccctgtttg ctccctccgat
     121 aactggggtg accttggtta atattcacca gcagcctccc ccgttgcccc tctggatcca
     181 ctgcttaaat acggacgagg acagggccct gtctcctcag cttcaggcac caccactgac
     241 ctgggacagt gaatcgacaa tgccgtcttc tgtctcgtgg ggcatcctcc tgcctggcagg
10     301 cctgtgctgc ctgggtccctg tctccctggc tgaggatccc cagggagatg ctgcccagaa
     361 gacagataca tcccaccatg atcaggatca cccaaccttc aacaagatca cccccaacct
     421 ggctgagttc gccttcagcc tatacggcca gctggcacac cagtccaaca gcaccaatat
     481 cttcttctcc ccagttagca tgcctacagc ctttgcaatg ctctccctgg ggaccaaggc
     541 tgacactcac gatgaaatcc tggagggcct gaatttcaac ctcacggaga ttccggaggc
15     601 tcagatccat gaaggcttcc aggaactcct ccgtaccctc aaccagccag acagccagct
     661 ccagctgacc accggcaatg gcctgttctc cagcgagggc ctgaagctag tggataagtt
     721 tttggaggat gttaaaaagt tgtaccactc agaagccttc actgtcaact tcggggacac
     781 cgaagaggcc aagaaacaga tcaacgatta cgtggagaag ggtactcaag ggaaaattgt
     841 ggatttggtc aaggagcttg acagagacac agtttttgct ctggtgaatt acatcttctt
20     901 taaaggcaaa tgggagagac cctttgaagt caaggacacc gaggaagagg acttccacgt
     961 ggaccaggtg accaccgtga aggtgcctat gatgaagcgt ttaggcattg ttaacatcca
    1021 gcactgtaag aagctgtcca gctgggtgct gctgatgaaa tacctgggca atgccaccgc
    1081 catcttcttc ctgcctgatg aggggaaact acagcacctg gaaaatgaac tccccacga
    1141 tatcatcacc aagttcctgg aaaatgaaga cagaaggtct gccagcttac atttacccaa
25    1201 actgtccatt actggaacct atgatctgaa gagcgtcctg ggtcaactgg gcatcactaa
     1261 ggtcttcagc aatggggctg acctctccgg ggtcacagag gaggcacccc tgaagctctc
    1321 caaggccgtg cataaggctg tgctgacctc cgacgagaaa gggactgaag ctgctggggc
    1381 catgttttta gaggccatac ccatgtctat ccccccgag gtcaagttca acaaacctct
    1441 tgtcttctta atgattgaac aaaataccaa gtctccctc ttcatgggaa aagtggtgaa
30    1501 tccccccaa aaataactgc ctctcgctcc tcaaccctc ccctccatcc ctggccccct
     1561 ccctggatga cattaagaa gggttgagct ggtccctgcc tgcaaaa

```

SEQ ID NO. 32

35

K02212

Human alpha-1-antitrypsin gene (S variant), complete cds

```

      1 gaattccagg ttggagggggc ggcaacctcc tgccagcctt caggccactc tcctgtgcct
40     61 gccagaagag acagagcttg aggagagctt gaggagagca ggaaagggtg aacattgctg
     121 ctgctgctca ctcagttcca caggtgggag gaacagcagg gcttagagtg ggggtcattg
     181 tgcagatggg aaaacaaagg ccagagaggg ggaagaaatg cctaggagct accgagggca
     241 ggcgacctca accacagccc agtgctggag ctgtgagtggt atgtagagca gcggaatatc
     301 cattcagcca gctcagggga aggacagggg cctgaagcc aggggatgga gctgcaggga
45     361 agggagctca gagagaaggg gaggggagtc tgagctcagt ttcccgtgc ctgaaaggag
     421 ggtggtacct actcccttca cagggttaact gaatgagaga ctgcctggag gaaagctctt
     481 caagtgtggc ccaccccacc ccagtgcacac cagccctga caggggggag ggagggcagc
     541 atcaggaggg gctttctggg cacacccagt acccgtctct gagctttcct tgaactgttg
     601 cattttaatc ctcacagcag ctcaacaagg tacataccgt caccatcccc attttacaga
50     661 tagggaaatt gaggtcggga gcggttaaac aactcacctg aggcctcaca gccagttaagt
     721 gggttccctg gtctgaatgt gtgtgctgga ggatcctgtg ggtcactcgc ctggtagagc
     781 ccaagggtgg aggcataaat gggactgggt aatgacagaa ggggcaaaaa tgcactcatc
     841 cattcactct gcaagtatct acggcacgta cgccagctcc caagcaggtt tgcgggttgc
     901 acagcggagc gatgcaatct gatttaggct tttaaaggat tgcaatcaag tgggaccacac
55     961 tagcctcaac cctgtacctc cctccctc caccocagc agtctccaaa ggcctccaac

```

- 18 -

	1021	aacccccagag	tggggggccat	gtatccaaag	aaactccaag	ctgtatacgg	atcacactgg
	1081	ttttccagga	gcaaaaaacag	aaacagcctg	aggctgggtca	aaattgaacc	tctctctgct
	1141	ctgagcagcc	tagggggcag	actaagcaga	gggctgtgca	gacccacata	aagagcctac
	1201	tgtgtgccag	gcacttcacc	cgaggcactt	cacaagcatg	cttggggaatg	aaacttccaa
5	1261	ctctttggga	tgcaggtgaa	acagttcctg	gttcagagag	gtgaagcggc	ctgcctgagg
	1321	cagcacagct	cttctttaca	gatgtgcttc	cccacctcta	ccctgtctca	cggcccccca
	1381	tgccagcctg	acggttgtgt	ctgcctcagt	catgctccat	ttttccatcg	ggaccatcaa
	1441	gaggggtgtt	gtgtctaaag	ctgactgggt	aaactttggat	gagcgggtctc	tccgctccga
	1501	gcctgtttcc	tcactctgtca	aacgggctct	aaaccactct	gatctcccag	ggcggcagta
10	1561	agtcttcagc	atcaggcatt	ttgggggtgc	tcagtaaatg	gtagatcttg	ctaccagtg
	1621	aacagccact	aaggattctg	cagtgcagagc	agagggccag	ctaagtggta	ctctcccaga
	1681	gactgtctga	ctcacgccac	cccctccacc	ttggacacag	gacgtgtggg	tttctgagcc
	1741	aggtacaatg	actcctttcg	gtaagtgcag	tgggaagctgt	acactgcccc	ggcaaagcgt
	1801	ccgggcagcg	taggcgggcg	actcagatcc	cagccagtg	acttagcccc	tgtttgctcc
15	1861	tccgataact	gggggtgacct	tggttaatat	tcaccagcag	cctcccccg	tgcctctctg
	1921	gatccactgc	ttaaatacgg	acgaggacag	ggccctgtct	cctcagcttc	aggcaccacc
	1981	actgacctgg	gacagtgaat	cgtaagtatg	cctttcactg	cgaggggttc	tgggagaggct
	2041	tccgagctcc	ccatggccca	ggcaggcagc	aggctctggg	caggaggggg	gttgtggagt
	2101	gggtatccgc	ctgctgaggt	gcagggcaga	tggagaggct	gcagctgagc	tctctatttc
20	2161	ataataacag	cagccatgag	ggttgtgtcc	tgtttcccag	tctgtcccgg	ttccccctcg
	2221	gtacctcctg	gtggatacac	tggttcctgt	aagcagaagt	ggatgagggg	gtctaggtct
	2281	gcagtcctgg	caccccagga	tgggggacac	cagccaagat	acagcaacag	caacaaagcg
	2341	cagccatttc	tttctgtttg	cacagctcct	ctgtctgtcg	ggggctcctg	tctgttgtct
	2401	cctataagcc	tcaccacctc	tctactgtct	tgggcatgca	tctttctccc	cttctataga
25	2461	tgaggagggt	aaggttcaga	gaggggtggg	gaggaacgcc	ggctcacatt	ctccatcccc
	2521	tccagatatg	accaggaaca	gacctgtgcc	agcctcagcc	ttacatcaaa	atgggctctc
	2581	ccatgcaccg	tggacctctg	ggccctcctg	tcaccagtga	ggacaggaag	ctgtgagggg
	2641	cactgtcacc	cagggctcaa	gctggcattc	ctgaataatc	gctctgcacc	aggccacggc
	2701	taagctcagt	gcgtgattaa	gcctcataac	cctccaaggc	agttactagt	gtgattccca
30	2761	ttttacagat	gaggaagatg	gggacagaga	ggtgaataac	tggcccccac	tcacacacca
	2821	tccataaatc	gggctcaggc	acctggctcc	agtcocccaa	ctcttgaacc	tggccctagt
	2881	gtcactgttt	ctcttgggtc	tcaggcgctg	gatggggaa	aggaaaacctg	ggctgaactt
	2941	gagggctctc	tgatgtctgg	tgacttctga	cagttgtctc	acctctctgt	tctcttggg
	3001	aaaacatgat	aacctttgac	ttctgtcccc	tccctcacc	ccacctgacc	ttgatctctg
35	3061	aagtgttggg	aggatttaac	ttttcctgca	ctgagttttg	gagacaggtc	aaaaagatga
	3121	ccaaggccaa	ggtggccagt	ttcctataga	acgcctctaa	aagacctgca	gcaatagcag
	3181	caagaactgg	tattctcgag	aaacttgcgt	gcagcaggca	cttcttggca	ttttatgtgt
	3241	atttaatttc	acaatagctc	tatgacaaag	tcacaccttc	tcactctccg	gaaactgagg
	3301	ttcagagagg	ttaagtaact	tgtccaaggt	cacacagcta	atagcaagtt	gacgtggagc
40	3361	aatctggcct	cagagccttt	aattttagcc	acagactgat	gctccccctc	tcatttagcc
	3421	aggctgcctc	tgaagttttc	tgattcaaga	cttctggctt	cagctttgta	cacagagatg
	3481	attcaatgtc	aggttttgga	gcgaaatctg	tttaatccca	gacaaaacat	ttaggattac
	3541	atctcagttt	tgtaagcaag	tagctctgtg	attttttagtg	agttatttaa	tgctctttgg
	3601	ggctcaattt	ttctatctat	aaaatagggc	taataatttg	caccttatag	ggtaagcttt
45	3661	gaggacagat	tagatgatac	gggtgcctgt	aaacaccagg	tgtttagtaa	tgtggcaatg
	3721	atgggtgacg	tgaggctgtg	tttgcttagc	atagggttag	gcagctggca	ggcagtaaac
	3781	agttggataa	tttaatggaa	aatttgccaa	actcagatgc	tgttcactgc	tgagcaggag
	3841	ccccttctct	ctgaaatggg	cctggggagt	gcagcaggct	ctccgggaag	aaatctacca
	3901	tctctcgggc	aggagctcaa	cctgtgtgca	ggtacaggga	gggcttctct	acctgggtgc
50	3961	cactcatgca	ttacgtcagt	tattcctcat	ccctgtccaa	aggattctct	tctccattgt
	4021	acagctatga	agctagtgtc	caaagaagtg	aagtcattta	ccccaggccc	cctgccagta
	4081	agtgacaggg	cctggtcaca	cttgggttta	tttattgccc	agttcaacag	gttgtttgac
	4141	cataggcgag	attctcttcc	ctgcacctg	ccgggttgct	cttggctcct	tattttatgc
	4201	tcttgggtag	aaatggtg	agattaggca	gggagtgagc	gcttccctgt	ccctggcccc
55	4261	gcaaagagtg	ctcccacctg	ccccgatccc	agaaatgtca	ccatgaagcc	ttcattcttt

- 19 -

	4321	tggttttaaag	cttggcctca	gtgtccgtac	accatgggggt	ccttggccag	atggcgactt
	4381	tctcctctcc	agtccgcctc	ccaggcacta	gcttttagga	gtgcaggggtg	ctgcctctga
	4441	tagaagggcc	aggagagagc	aggtttttga	gacctgatgt	tataaggaac	agcttgggag
	4501	gcataatgaa	cccaacatga	tgtttgagac	caatgtcaca	gccaatttct	gacattcatc
5	4561	atctgagatc	tgaggacaca	gctgtctcag	ttcatgatct	gagtgtctggg	aaagccaaga
	4621	cttgttccag	ctttgtcact	gaattgtctgt	atagcctcaa	caaggccctg	accctctctg
	4681	ggcttcaaac	tcttcactgt	gaaaggagga	aaccagagta	ggtgatgtga	caccaggaaa
	4741	gatggatggg	tgtgggggaa	tgtgtctctc	ccagctgtca	ccccctcgcc	accctccctg
	4801	caccagcctc	tccacctcct	ttgagcccag	aattcccttg	tctaggaggg	cacctgtctc
10	4861	gtgcctagcc	atgggaattc	tccatctgtt	ttgctacatt	gaaccagat	gccattctaa
	4921	ccaagaatcc	tggctgggtg	caggggctct	cgctgtaac	cccagcactt	tgggaggcca
	4981	aggcaggcgg	atcaagaggt	caggagtcca	agacctgcct	ggccaacacg	gtgaaacctc
	5041	agctctacta	aaaatacaaaa	aattagccag	gcgtggtggc	acacgcctgt	aatcccagct
	5101	atlttgggaag	ctgagacaga	agaatttctt	gaaccgggga	ggtggagggtt	tcagttagcc
15	5161	gagatcacgc	cactgcactc	cacctgtggc	gataaagcga	gactctgtct	caaaaaaac
	5221	cacaaaaacct	atgttagtgt	acagagggcc	ccagtgaagt	cttctccag	ccccactttg
	5281	cacaactggg	gagagtggag	ccccaggacc	agaggattct	tgctaaaggc	caagtggata
	5341	gtgatggccc	tgccaggcta	gaagccacaa	cctctggccc	tgaggccact	cagcatattt
	5401	agtgtcccca	ccctgcagag	gcccactccc	ctctgacca	ctgagccctg	taatgatggg
20	5461	ggaatttcca	taagccatga	aggactgcac	aaagttcagt	tgggagtga	agagaaatta
	5521	aaggggagatg	gaaatataca	gcactaattt	tagcaccgtc	ttcagttcta	acaacactag
	5581	ctagctgaag	aaaatacaaaa	catgtattat	gtaatgtgtg	gtctgttcca	tttggattac
	5641	ttagaggcac	gagggccaag	gagaaagggtg	gtggagagaa	accagctttg	cacttcattt
	5701	gttgctttat	tggaaaggaaa	ctttttaaag	tccaaggggg	ttgaagaatc	tcaatatttg
25	5761	tattttccag	cttttttctt	ccagtttttc	atltccccaa	ttcaaggaca	cctttttctt
	5821	tgtattttgt	taagatgatg	gtttttgggtt	tgtgactagt	agttaacaat	gtggctgccg
	5881	ggcatattct	cctcagctag	gacctcagtt	ttcccatctg	tgaagacggc	aggttctacc
	5941	tagggggctg	caggcagggtg	gtccgaagcc	tgggcatatc	tggagttaga	ggatcactgt
	6001	ggggcagggc	aggttctgtg	ttgtctgtga	tgacgttgac	tttgaccatt	gctcggcaga
30	6061	gcctgtctct	gctgggtcag	ccacaggccc	caccactccc	tattgtctca	gccccgggta
	6121	tgaaacatgt	attcctcact	ggcctatcac	ctgaagcctt	tgaatttgca	acacctgcc
	6181	acccctccct	caaaaaggtt	gcccctctca	gatccttttg	atgtaagggt	tggtgttgag
	6241	acttatttca	ctaaattctc	atacataaac	atcactttat	gtatgaggca	aaatgaggac
	6301	caggggagatg	aatgacttgt	cctggctcat	acacctggaa	agtgaacag	tcagattaga
35	6361	tcttaggtct	atctgaagtt	aaaagagggtg	tcttttctct	ttccacctcc	tccatctact
	6421	ttaaagcagc	acaaaccctt	gcttttcaag	agagatgagc	gtctctaaag	cccctgacag
	6481	caagagccca	gaactgggac	accattagtg	acccagacgg	caggtaagct	gactgcagga
	6541	gcatacagcct	attcttgtgt	ctgggaccac	agagcattgt	ggggacagcc	ccgtctcttg
	6601	ggaaaaaaac	cctaagggtc	gaggatcctt	gtgagtgttg	ggtgggaaca	gctcccagga
40	6661	ggtttaatca	cagcccctcc	atgctctcta	gctgttgcca	ttgtgcaaga	tgcatttccc
	6721	ttctgtgcag	cagtttccct	ggccactaaa	tagtgggatt	agatagaagc	cctccaaggg
	6781	ctccagcttg	acatgattct	tgattctgat	ctgaccgat	tctgataatc	gtgggcaggc
	6841	ccattctctct	tcttgtgcct	cattttctct	ttttgtaaaa	caatggctgt	accatttgca
	6901	tcttagggtc	attgcagatg	aaagtgttgc	tgtccagagc	ctgggtgcag	gacctagatg
45	6961	taggattctg	gttctgtctac	ttctcagtg	acattgaata	gctgacctaa	tctctctggc
	7021	tttgggtttct	tcactctgtaa	aagaaggata	ttagcattag	cacctcacgg	gattgttaca
	7081	agaaagcaat	gaattaacac	atgtgagcac	ggagaacagt	gcttggcata	tggtaagcac
	7141	tacgtacatt	ttgctattct	tctgattctt	tcagtgttac	tgatgtcgcc	aagtacttgg
	7201	cacaggctgg	tttaataatc	cctaggcact	ttcacgttgt	gtcaatccct	gatcactggg
50	7261	agtcataatg	tgccttgact	cgggcctggc	cccccatct	ctgtcttgca	ggacaatgoc
	7321	gtcttctgtc	tcttggggca	tcctcctgct	ggcaggcctg	tgtgtcctgg	tcctgtctc
	7381	cctggctgag	gatccccagg	gagatgctgc	ccagaagaca	gatacatccc	accatgatca
	7441	ggatcaccca	accttcaaca	agatcacccc	caacctggct	gagttcgct	tcagcctata
	7501	ccgccagctg	gcacaccagt	ccaacagcac	caatatcttc	ttctccccag	tgagcatcgc
55	7561	tacagccttt	gcaatgctct	ccctggggac	caaggctgac	actcacgatg	aaatcctgga

- 20 -

	7621	gggocctgaat	ttcaacctca	cggagattcc	ggaggctcag	atccatgaag	gcttccagga
	7681	actcctccgt	accctcaacc	agccagacag	ccagctccag	ctgaccaccg	gcaatggcct
	7741	gttcctcagc	gagggcctga	agctagtggg	taagtttttg	gaggatgtta	aaaagttgta
	7801	ccactcagaa	gccttcactg	tcaacttcgg	ggacaccgaa	gaggccaaga	aacagatcaa
5	7861	cgattacgtg	gagaagggta	ctcaagggaa	aattgtggat	ttgggtcaagg	agcttgacag
	7921	agacacagtt	tttgctctgg	tgaattacat	cttctttaaa	ggtaagggtg	ctcaaccagc
	7981	ctgagctggt	tcccatagaa	acaagcaaaa	atattttctca	aaccatcagt	tcttgaactc
	8041	tccttggcaa	tgcatatggg	gccatagcaa	tgcttttcag	cgtggattct	tcagttttct
	8101	acacacaaac	actaaaatgt	ttccatcat	tgagtaattt	gaggaaataa	tagattaaac
10	8161	tgtaaaaact	actgacgctc	tgcaagaactt	ttcagagcct	ttaatgtcct	tgtgtatact
	8221	gtatatgtag	aatatataat	gcttagaact	atagaacaaa	ttgtaataca	ctgcataaag
	8281	ggatagtttc	atggaacata	ctttacacga	ctctagtgtc	ccagaatcag	tatcagtttt
	8341	gcaatctgaa	agacctgggt	tcaaactcctg	cctctaacac	aattagcttt	tgacaaaaac
	8401	aatgcattct	acctctttga	ggtgctaatt	tctcatctta	gcatggacaa	aataccattc
15	8461	ttgctgtcag	gttttttttag	gattaaacaa	atgacaaaaga	ctgtggggat	ggtgtgtggc
	8521	atacagcagg	tgatggactc	ttctgtatct	caggctgcct	tcctgcccct	gaggggttaa
	8581	aatgccaggg	tcctgggggc	cccagggcat	tctaagccag	ctcccactgc	cccaggaaaa
	8641	cagcataggg	gaggggaggt	gggaggcaag	gccaggggct	gcttcctcca	ctctgaggct
	8701	cccttgctct	tgaggcaaaag	gagggcagtg	gaggcaagcc	aggetgcagt	cagcacagct
20	8761	aaagtccctg	ctctgctgtg	gccttagtgg	gggccaggt	ccctctccag	cccagctctc
	8821	ctccttctgt	ccaatgagaa	agctgggatc	aggggtccct	gaggcccctg	tccactctgc
	8881	atgcctcgat	ggtgaagctc	tgttgggtatg	gcagagggga	ggctgctcag	gcactctgat
	8941	ttcccctgcc	aactctagagg	atgaggaag	ctctcaggaa	tagtaagcag	aatgtttgcc
	9001	ctggatgaat	aactgagctg	ccaatttaaca	aggggcaggg	agccttagac	agaaggtacc
25	9061	aaatatgcct	gatgctccaa	cattttattt	gtaatatcca	agacaccctc	aaataaacat
	9121	atgattccaa	taaaaatgca	cagccacgat	ggcatctctt	agcctgacat	cgccacgatg
	9181	tagaaattct	gcactcttct	ctagttttga	attatcccca	cacaatcttt	ttcggcagct
	9241	tggatgggtca	gtttcagcac	cttttacaga	tgatgaagct	gagcctcgag	ggatgtgtgt
	9301	cgtcaagggg	gctcagggct	tctcagggag	gggactcatg	gtttcttatt	ctgctacact
30	9361	cttccaaaacc	ttcactcacc	cctgggtgatg	cccaccttcc	cctctctcca	ggcaaatggg
	9421	agagaccctt	tgaagtcaag	gacaccgagg	aagaggactt	ccacgtggac	caggtgacca
	9481	cogtgaaggt	gcctatgatg	aagcgtttag	gcatgtttta	catccagcac	tgtaagaagc
	9541	tgtccagctg	ggtgctgctg	atgaaatacc	tgggcaatgc	caccgccttc	ttcttctctg
	9601	ctgatgaggg	gaaactacag	cacctggtaa	atgaactcac	ccacgatata	atcaccaagt
35	9661	tcctggaaaa	tgaagacaga	aggtgattcc	ccaacctgag	ggtgaccaag	aagctgcccc
	9721	caoctcttag	ccatgttggg	actgaggccc	atcaggactg	gccagagggc	tgaggagggg
	9781	gaaccccaca	tccttgggtc	actgctactc	tgtataaaact	tggtctccag	aatgaggcca
	9841	ccactgagtt	caggcagcgc	cgtccatgct	ccatgaggag	aacagtaacc	agggtgagga
	9901	ggtaaagggtc	tcgtccctgg	gaacttccca	ctccagtgtg	gacactgtcc	cttcccaata
40	9961	tcagtgccc	aaggcagggg	cagcagcacc	accacacgtt	ctggcagaac	caaaaaggaa
	10021	cagatgggct	tcctggcaaa	ggcagcagtg	gagtgtggag	ttcaagggta	gaatgtccct
	10081	ggggggacgg	gggaagagcc	tgtgtggcaa	ggcccagaaa	agcaagggtc	ggaattggaa
	10141	cagccagggc	atgttcgcag	aaggccttgcg	tttctctgtc	actttatcgg	tgctgttaga
	10201	ttgggtgtcc	tgtagtaagt	gatacttaaa	catgagccac	acattagtgt	atgtgtgtgc
45	10261	attcgtgatt	atgcccatgc	cctgtctgatc	tagttcgttt	tgtacactgt	aaaaccaaga
	10321	tgaaaataca	aaagggtgtcg	gggttcataat	aggaatcgag	gctggaattt	ctctgttcca
	10381	tgccagcacc	tcctgaggtc	tctgtctccag	gggttgagaa	agaacaaaaga	ggctgagagg
	10441	gtaacggatc	agagagccca	gagccagctg	ccgctcacac	cagaccctgc	tcaggggtggc
	10501	attgtctccc	catggaaaaac	cagagaggag	cactcagcct	ggtgtgggtca	ctcttctctt
50	10561	atccactaaa	cggttgtcac	tgggcactgc	caccagcccc	gtgtttctct	gggtgtaggg
	10621	ccctggggat	gttacaggct	ggggggccagg	tgacccaaca	ctacagggca	agatgagaca
	10681	ggcttccagg	acacctagaa	tatcagagga	ggtggcattt	caagcttttg	tgattcattc
	10741	gatgttaaca	ttctttgact	caatgtagaa	gagctaaaaag	tagaacaac	caaagccgag
	10801	ttcccatctt	agtgtgggtg	gaggacacag	gagtaagtgg	cagaaataat	cagaaaagaa
55	10861	aacacttgca	ctgtggtggg	tcccagaaga	acaagaggaa	tgtgtgtcca	tgccttgaat

- 21 -

```

10921 ttcttttctg caccacaggt ctgccagctt acattttaccc aaactgtcca ttactggaac
10981 ctatgatctg aagagcgtcc tgggtcaact gggcatcact aaggtcttca gcaatggggc
11041 tgacctctcc ggggtcacag aggaggcacc cctgaagctc tccaagggtga gatcaccttg
11101 acgaccttgt tgcaccatgg tatctgtagg gaagaatgtg tgggggctgc agcactgtcc
5 11161 tgaggctgag gaaggggccc agggaaacaa atgaagaccc aggtctgagct cctgaagatg
11221 cccgtgattc actgacacgg gacgggtgggc aaacagcaaa gccaggcagg ggctgctgtg
11281 cagctggcac tttcggggcc tcccttgagg ttgtgtcact gacctgaat ttcaactttg
11341 cccaagacct tctagacatt gggccttgat ttatccatac tgacacagaa aggtttgggc
11401 taagttgttt caaaggaatt tctgactcct tcgatctgtg agatttggtg tctgaattaa
10 11461 tgaatgattt cagctaaaagt gacacttatt ttggaaaact aaaggcgacc aatgaacaac
11521 ctgcagttcc atgaatggct gcattatctt ggggtctggg cactgtgaag gtcactgcca
11581 gggctccgtgt cctcaaggag cttcaagccg tgtactagaa aggagagagc cctggaggca
11641 gacgtggagt gacgatgtc ttcctgttcc tgagttgtgg gtgcacctga gcagggggag
11701 aggcgcttgt caggaagatg gacagagggg agccagcccc atcagccaaa gccttgagga
15 11761 ggagcaaggc ctatgtgaca gggagggaga ggatgtgcag ggccaggggc gtccaggggg
11821 agtgagcgct tccctggagg tgtccacgtg agccttgctc gaggcctggg atcagcctta
11881 caacgtgtct ctgcttctct cccctccagg ccgtgcataa ggctgtgctg accatcgacg
11941 agaaagggac tgaagctgct ggggccatgt ttttagaggc cataccatg tcatccccc
12001 ccgaggtcaa gttcaacaaa ccctttgtct tcttaatgat tgaacaaaat accaagtctc
20 12061 ccctcttcat gggaaaagtg gtgaatccca cccaaaaata actgcctctc gctcctcaac
12121 ccctcccctc catccctggc cccctccctg gatgacatta aagaagggtt gagctggctc
12181 ctgcctgcat gtgatctgta aatccctggg atgttttctc tg

```

25 SEQ ID NO. 33

gi/125294, P12277 - Homo sapiens
Creatine kinase, B chain (B-CK)

```

30 mpfsnshnal klrfpaedef pdlsahnnhm akvltpeyla elrakstpsg ftlddviqtg
vdpnpgpyim tvgcvagdee syevfkdlfd pilledrhggy kpsdehktdl npdnlqggdd
ldpnyvlssr vrtgrsirgf clpphcsrge rraieklave alssldgdla gryyalksmt
eaeqqqlidd hflfdkpvsp lllasgmard wpdargiwhn dnktflvwvn eedhlrvism
qkggnmkevf trfctgltqi etlfkskdye fmwnphlgyi ltcpnlgtg lragvhihklp
35 nlgkhekfse vlkrlrlqkr gtggvdtaav ggvfdvsnad rlgfsevelv qmvvdgvkll
iemeqrlegg qaiddlmpaq k

```

SEQ ID NO. 34

40

NM_001823 Homo sapiens creatine kinase, brain (CKB), mRNA
Creatine kinase, B chain (B-CK)

```

1 getgttcgcc tgcgtcgctc cgggagctgc cgacggacgg agcgcccccg cccccgcccg
45 61 gccgccccgc cgccgcccgc atgcccttct ccaacagcca caacgcactg aagctgcgct
121 tcccggccga ggacgagttc cccgacctga gcgccacaaa caaccacatg gccaaagggtg
181 tgacccccga gctgtacggc gagctgcgcg ccaagagcac gccgagcggc ttcacgctgg
241 acgacgtcat ccagacaggc gtggacaacc cgggccaccc gtacatcatg accgtgggct
301 gcgtggcggg cgacgaggag tctactgaag tgttcaagga tctcttcgac ccatcatcg
50 361 aggaccggca cggcggtac aagccagcg atgagcacia gaccgacctc aacccccgaca
421 acctgcaggc cggcgacgac ctggacccca actacgtgct gagctcgcgg gtgcgcacgg
481 gccgcagcat ccgtggcttc tgccctcccc cgactgcag ccgcggggag cgccgcgcca
541 tcgagaagct cgcggtggaa gccctgtcca gcctggacgg cgacctggcg ggccgatact
601 acgcgctcaa gagcatgacg gagggcgagc agcagcagct catcgacgac cacttctct
55 661 tcgacaagcc cgtgtcgccc ctgctgctgg cctcgggcat ggcccgcgac tggcccgacg

```

- 22 -

```

721 cccgcggtat ctggcacaat gacaataaga ccttcctggt gtgggtcaac gaggaggacc
781 acctgcgggt catctccatg cagaaggggg gcaacatgaa ggaggtgttc acccgcttct
841 gcaccggcct caccagatt gaaactctct tcaagtctaa ggactatgag ttcatgtgga
901 accctcacct gggctacatc ctcactgcc catccaacct gggcaccggg ctgcgggcag
5 961 gtgtgcatat caagctgccc aacctgggca agcatgagaa gttctcggag gtgcttaagc
1021 ggctgcgact tcagaagcga ggcacaggcg gtgtggacac ggctgcggtg ggcggggctct
1081 tcgacgtctc caacgctgac cgcctgggct tctcagaggt ggagctggtg cagatggtgg
1141 tggacggagt gaagctgctc atcgagatgg agcagcggct ggagcagggc caggccatcg
1201 acgacctcat gcctgcccag aaatgaagcc cggcccacac ccgacaccag ccctgctgct
10 1261 tcctaactta ttgcctgggc agtgcgccac atgcaccct gatgttcgcc gtctggcgag
1321 cccttagcct tgctgtagag acttcctgca cccttggtag agtttatttt ttgatggct
1381 aagatactgc tgatgctgaa ataaactagg gttttggcct gcctgcgtct g

```

15 SEQ ID NO. 35

X15334

Human gene for creatine kinase B (EC 2.7.3.2).

```

20 1 gatcagtttt tttttttaat cgcacttatg cttattgttt attagcgttt cctcccatct
61 ttgcctgaag tctccgggga ctgcctttgg gggtcgggta aacttgtccc ctgcgaagag
121 ggcccagggt tggggctctgg aaactccgag gctgcacttg ccagcggcct chtaaggcca
181 cagcgtcccc gtggtttctg gctcgcagcc ccccgagacc caggacttgt ccaaggtcag
241 ggcaccgcgg gtgcccccgg gctgggcccgc agcagactgc gcttcccgcg cgccttcgct
25 301 ttgcaccagg atcgcccagg aaatgcctgc gggcaccttg aggaaggctg gcggctccgg
361 gccagctcgc actggccggg gtggggcggg ggcggtacct gctgcggaag ccccgaaagc
421 ttgcgccgg ccctcgcgg cgcgcgggg ggtgggtgg actaggcggg caggctcgag
481 gatgcggatg aacccaagcg tctcagatg cccggaggct ctccgcctca gtttcccgcc
541 cagaggcaag ggcgtgcgag gggatccaga tatccaagga cctgaggttt cggcctcgag
30 601 gtcttgggcg ggggactggg caggctgcgc ggggtcccag cgaggggaca gctcgggtgg
661 gcgccaggg tggtgggggc tggggggcgc ggacaaagcg gcggcaccac cccgcggcgc
721 gggccaatgg aatgaatggg ctataaatag ccgccaatgg gcgggccgcg ttgtgcccct
781 taagagccgc gggagcgcgc agcgccgcgt gtctgcctgc gtgcctccgg gagctgccga
841 cggacggagc gccccgcgcc ccgcccggcc gcccggtgag tggggccggg ggcgggggc
35 901 gtcgcgccc gggctagggg cgtcgcagc aaagggggcg cgtcgcctgg agcgcgcgc
961 ggaccggccg ggggtccccg gcgatgatgg cgtcccgcgc gcgcgctgcg gaccccgctg
1021 accttggccg cgtcccgggg ggcgcgggg ggcggcgcg cgggggctg agtggtacgc
1081 gggagcccgg gaaccccggc gtgcgggtcc cctctgaccc cgcgtctccc cgcagccgc
1141 cgcgcgccatg cccttctcca acagccacaa cgcactgaag ctgcgttcc cggccgagga
40 1201 cgagttcccc gacctgagcg ccacacaaca ccacatggcc aaggtgctga ccccgagct
1261 gtacgcggag ctgcgcgcca agagcacgcc gagcggcttc acgctggacg acgtcatcca
1321 gacaggcgtg gacaacccgc gtacgcgacc cctcggggcc ggggtcccgg cccccctcc
1381 ccccgcgag ccgcagggtc ctcagcagcg cgtcggggcc cggcagtgac gtactgtcc
1441 cgtcccgcg cccctcccc caggccaccc gtacatcatg accgtgggct gcgtggcggg
45 1501 cgacgaggag tcctacgaag tggtcaagga tctcttcgac cccatcatcg aggaccggca
1561 cggcgggtac aagcccagcg atgagcacia gaccgacctc aaccccgaca acctgcagg
1621 gcggggctgc gggcgggcgg ggcggggcg gccgggtct tcgggcgctc actccgctct
1681 cgcctcccag ggcggcgag acctggaccc caactacgtg ctgagctcgc ggggtgcgcac
1741 gggcgcgagc atcgtgggt tctgcttccc ccgcactgc agcggcgggg agcgccgagc
50 1801 cctcgagaag ctgcgggtgg aaggtagggg cggggcgggc cgagggcgcg cggcgccgc
1861 gtccccctcc cggcgcggtc ccgcgcgcgt tttgtttaag tcgcccggga gcggcagccg
1921 cgtcgcgct cttatctgcg cgcgcgggg ttcatgttcc cggacccacc gagggacgga
1981 ggcgcagccc ccgcgcgcc agcggcctgg ggcgcaggga gggcgggctc tggcgcgggg
2041 tcacgcgctg ggacgtcgc ccgggcgctg aggactggac gccgcagat ccgggcgggt
55 2101 gggggccctc gacgtcccc gaggtggggc acggggcgcg gcggtccgc gctgcgggt

```

- 23 -

2161 ggagggggcgg gcgcggggagc ccagcgtcct gagcgcaccc ctgcagccc tgtccagcct
 2221 ggacggcgac ctggcgggcc gatactacgc gctcaagagc atgacggagg cggagcagca
 2281 gcagctcatc gacgaccact tcctcttcga caagcccgtg tcgcccctgc tgetggcctc
 2341 gggcatggcc cgcgactggc ccgacgcccg cggatatctgg tcgctgtccc tctgcgccct
 5 2401 ctgcggcgt cctccctccc cgctacctcc gctttccctc tcgccccct cgggggggtg
 2461 gggccccctc cggcgaggag gagggaggag aggaggagg ggcggcgcc gctccgggtc
 2521 tgggttcctg gccgcgcctc ctctgcgcc ggtgaccttg gccgagcagg tgcgttaagg
 2581 gactggggcc cggcccgtgg gggctcagga ctcagcaaca cctccccacc ccgagacgtg
 2641 aggtgggggc ggggctctct ggcgcctctc cccgacggcc ctgggagctg gagctctttg
 10 2701 ttttcttttc tcaactcctcc gccgctggga ttctaccagg ggctggtagc gccaaagctt
 2761 ctccaggggc agggctccta ccccaactgt gggggcgggg tcgggctgtc tggcggtcc
 2821 ctggccccgc cccacctcgg gccacagcgc atgatggcag ctggggttct cctgctgtga
 2881 ggcgtcccgc ttccccgcc cgcctcgtgt tggcggggtg agtcttgga gcagcctcca
 2941 ctctggggca tggcagggag cagcacctca gggacttggg aagttccttt ggtctggggg
 15 3001 cggcctgggg cttttttctg ggtatgccct gagaccagcc ctcccgcagg cacaatgaca
 3061 ataagacctt cctggtgtgg gtcaacgagg aggaccacct gcgggtcatc tccatgcaga
 3121 agggggggcaa catgaaggag gtgttcaccc gcttctgcac cggcctcacc caggtgccag
 3181 ggacggggga ggcccagacc ccagggcccc agcagggatg tgggtgcccc agcatcagtc
 3241 cccccggggg atttccggca ctggggagtc tcagggcctg taggggtttc aggcaggcct
 20 3301 tctccctcat accctcttct ccgtctgcag attgaaactc tcttcaagtc taaggactat
 3361 gagttcatgt ggaacctca cctgggctac atcctcacct gcccatccaa cctgggcacc
 3421 gggctgcggg caggtgtgca tatcaagctg cccaacctgg gcaagcatga gaagttctcg
 3481 gaggtgctta agcggctgcg acttcagaag cgaggcacag gtgagcaggg caggtgctgc
 3541 ggcttcccgt ggcttttggg cagccctgtt tcctccgccc tgacttgctg tctcccagg
 25 3601 cgggtgtggc acggctgcgg tgggcggggt cttcgacgtc tccaacgtg accgcctggg
 3661 cttctcagag gtggagctgg tgcagatggt ggtggacgga gtgaagctgc tcatcgagat
 3721 ggaacagcgg ctggagcagg gccaggccat cgacgacctc atgcctgccc agaaatgaag
 3781 cccggccccac acccgacacc agccctgctg cttcctaact tattgcctgg gcagtgccca
 3841 ccatgcaccc ctgatgttcg ccgtctggcg agcccttagc cttgctgtag agacttccgt
 30 3901 cacccttggg agagtttatt tttttgatgg ctaagatact gctgatgctg aaataaacta
 3961 gggtttttggc ctgcctgcgt ctgagtggtg cctctccttt cccagggggg agggggaagg
 4021 gcagcagcca ggccccagga gtcttgagtc ctgggctgct tgtgggcctc gccttctgtg
 4081 agatgggaca agagccagga ggtggccact ctgttctgcc tgccctacct agtccatggg
 4141 ccccttccct cgtgtctatc gggctgtgca ggcaggaaca tgggagagag cgaggaggga
 35

SEQ ID NO. 36

P14618 - Homo sapiens

40 Pyruvate kinase M1 or M2 isozyme

mskphseagt afiqtqqlha amadtflehm crldidsppi tarntgiict igpasrsvet
 lkemiksgmn varlnfshgt heyhaetikn vrtatesfas dpilyrpvav aldtkgpeir
 tgliksgta evelkkgatl kitldnayme kcdenilwld yknickvvev gskiyvddgl
 45 islqvkkqga dflvteveng gslgskkgvn lpgaavdlpa vsekdiqdlk fgveqdvdmv
 fasfirkasd vhevrvklge kgknikiisk ienhegvrrf deileasdgi mvargdlgie
 ipaekvflaq kmmigrnra gkpvicatqm lesmikkprp traegsdvan avldgadcim
 lsgetakgdy pleavrmqhl iareaeaaay hlqlfeelrr lapitsdpte atavgaveas
 fkccsgaiiv ltksgrasah varyrprapi iavtrnpqta rqahlyrgif pvlckdpvqe
 50 awaedvdlrv nfamnvkar gffkkgdvvi vltgwrpgsg ftntmrvvvp p

SEQ ID NO. 37

55 X56494

- 24 -

H.sapiens M gene for M1-type and M2-type pyruvate kinase

	1	ggctcttcaca	ttttgaatgc	gcaacattgt	atctgtgaat	gaaggcaaga	gttaacagct
	61	gttttaattga	taactgctcg	catcattagt	tgctgggctaa	caactgggaa	atcagaaaat
5	121	gtctttaga	aaaatgtaag	aaaagtcca	acaatactga	cttaaacacg	agcaaagggtg
	181	aaaacagaaa	tgtctgactcc	tgcatagggt	atcgggcccta	atgttctgac	ttgatatttc
	241	cagatgcccc	gctctgcgct	aatatcaaca	ccgtctatct	actttctact	ctgaggcatt
	301	cgctctgcag	gattccagac	cctactaaat	tattcacatg	gccccaacccg	gtccctccct
	361	gttccgcggg	cccaacacaa	tgaatgggtc	taagaggaaa	acggcctcgg	ctcccgctcc
10	421	aggcccactt	cgcagtcctt	agttctccct	actgcccgtc	cagtgcacga	gccccctcga
	481	aggcgccag	gacctccaac	cacgcacaag	tctgcagctc	tccccaaactt	tccgttcagc
	541	tcagtctccg	aggggtgcgc	agagcagaca	cccgaggagag	tggggagtgg	cagggcgggg
	601	ccgggagaat	gctgccccgg	aaccataaaa	ttcgggccctg	cccaggtagg	ccgggacagc
	661	tggggtgcc	tggggccgaga	gccaagaaaa	gagaccccat	ctggacgccc	aacttggcgg
15	721	caacaggtgg	ccggcgcccg	gggtctggg	aggaaagtgc	ctccggcgcg	gccccgttgc
	781	cccgcgcgt	ccccattggg	catcagggtt	cttaaaatgt	gactctgaat	ctgtgtcctt
	841	ccgcgcgaga	atctagtccc	accgaaaagg	caacctgccc	gcgcgtcccg	cccccctcgc
	901	cgcgttccct	cctgaagggt	actcgagccc	ggggggacgc	agggggcggg	gccccgggtc
	961	cccgagccg	ggattgggca	gaggcgggg	cgggcgaggg	attgcggcgg	cccgacgcg
20	1021	gataaccttg	aggctgaggc	agtggctcct	tgcacagcag	ctgcacgcgc	cgtggctccg
	1081	gatctcttcg	tctttgcagc	gtagcccgag	tccgtcagca	gcccggaggtg	agcgggtgcag
	1141	gcagtaacgc	atcagtcctc	accaagggcc	agtcgcccgg	ctagtgccga	atcccggcgc
	1201	gcccgcggc	cccgggcacg	caggcagggc	ggcgccaggat	ccctgtgcta	aatgggtatat
	1261	taaccaacttc	tcagtccttac	cactctcttt	caatttgcct	cgaccacgga	cctcagcagc
25	1321	catgtcgaag	ccccatagtg	aagccgggac	tgccttcatt	cagacccagc	agctgcacgc
	1381	agccatggct	gacacattcc	tggagcacat	gtgcgccttg	gacattgatt	caccacccat
	1441	cacagcccg	aacactggca	tcatctgtac	catttggtgag	tgggtgtccc	ccttccccca
	1501	aaaagggctt	catgggcagt	gacctttctc	tctgaaaag	agctccatgc	actttttaaa
	1561	gacttttgag	ctatttgagg	gaggaaaaat	tttcagggaa	aaaaattctt	taaacttaaa
30	1621	gcaaaactta	atgtttttcc	ttggttgaat	aattaatact	tgtggcttta	aaacttttcc
	1681	taataggccc	agcttcccga	tcagtggaga	cggtgaagga	gatgattaag	tctggaatga
	1741	atgtggctcg	tctgaacttc	tctcatggaa	ctcatgaggt	gagctgtggc	tggaccctat
	1801	cctggcaggg	gaattggagc	tggattctag	tgtgggagca	cgcttgcat	cttcttctt
	1861	ttccccagct	accatgcgga	gaccatcaag	aatgtgcgca	cagccacgga	aagctttgct
35	1921	tctgacccca	tctctacccg	gcccgttgct	gtggctctag	acactaaagg	acctgagatc
	1981	cgaactgggc	tcatcaaggg	cgtgagtatt	ctgcggagag	cgaggggaag	gctcagtagg
	2041	caatatgccc	cagagacatg	attccttccg	aggtgatgct	gtactgggtg	tctccagttt
	2101	ggactcttcc	ttactctctt	gtccctagag	cggcactgca	gaggtggagc	tgaagaaggg
	2161	agccaacttc	aaaatcacgc	tggataacgc	ctacatggaa	aagtgtgacg	agaacatcct
40	2221	gtggctggac	tacaagaaca	tctgcaaggt	ggtggaagtg	ggcagcaaga	tctacgtgga
	2281	tgatgggctt	atctctctcc	aggtgaagca	gaaaggtagc	tatgggagct	ggagtccagt
	2341	tgtctaaaaa	agtcttttgt	ctctaaaact	ctcgtctctg	cctccccaac	ttaccctttt
	2401	ttatacaggt	gccgacttcc	tgggtgacgga	gggtggaaaat	gggtggctcct	tgggcagcaa
	2461	gaaggggtgtg	aaccttccctg	gggctgctgt	ggacttgccct	gctgtgtcgg	agaaggacat
45	2521	ccaggatctg	aagtttgggg	tgcagcagga	tgttgatatg	gtgtttgcgt	cattcatccg
	2581	caaggcatct	gatgtccatg	aagttaggaa	ggctcctggga	gagaagggaa	agaacatcaa
	2641	gattatcagc	aaaatcgaga	atcatgaggg	gggtcggagg	caagtccccg	ttgtccctgg
	2701	tctactgcca	tacttgtagc	ctctgttcta	tataacctct	ctccccccca	ctttgtccat
	2761	caggtttgat	gaaatcctgg	aggccagtg	tgggatcatg	gtggctcgtg	gtgatctagg
50	2821	cattgagatt	cctgcagaga	aggtcttccct	tgtcagaag	atgatgattg	gacgggtgcaa
	2881	ccgagctggg	aagcctgtca	tctgtgtctac	tccaggtcgt	gcccacccctt	ccccacattc
	2941	tcatgtgcac	actcgcatgt	ttgtatggga	aagctctgga	ggctgtctga	tctcttccca
	3001	tggaaattgtc	gcaacgtaac	acacagataa	tccccctccc	ccatgtacct	acacaaagcc
	3061	atactctgtg	tacctactca	ctatccagag	gatcagcttg	ctgtcatttg	tctctgaaga
55	3121	cagctcaagc	tacatctcac	taatgctctg	tccccctcca	gatgctggag	agcatgatca

- 25 -

	3181	agaagccccc	gcccactcgg	gctgaaggca	gtgatgtggc	caatgcagtc	ctggatggag
	3241	ccgactgcat	catgctgtct	ggagaaacag	ccaaagggga	ctatcctctg	gaggctgtgc
	3301	gcatgcagca	cctgggtgagt	tctgggctcg	ccccatcccc	cagggcttcg	gactgggcct
	3361	gggatggatg	caagctcttg	tgcagagctt	tttaggtttc	tccatcctct	tatgcacagc
5	3421	ctttcattat	cctccaagtt	acagcagcaa	gaggggtggg	gtggaagtgg	aggtggcctt
	3481	ttttttttct	cctgttcctg	cattcctgcc	cacaccccca	cccctctcat	ttccttctgc
	3541	tctggaggca	cctccttcat	tggacaccac	acagtttatt	tcacttctga	cttcaagggt
	3601	gtgaattctt	cccattggctt	aagtcctggg	atacttctgc	agtgaaggga	ggtcttgtac
	3661	ctcttcctca	gagtcagaag	ttctgagtag	ctttgcctta	ttctgaaaag	ggctaggggc
10	3721	tcctgctccc	agctgccctc	ttcctttggc	ttccaattca	gttccctctg	ccccgcatcc
	3781	tgcagacagg	cgctcccgca	gggggcccct	gtggacctgc	actggagtct	gttgccctca
	3841	ctgagctgcc	tgtgctggcc	ttgcatgggt	cctgtagggg	gatttgcctt	gctgtgccat
	3901	tgggttacag	ctgctgctct	tactctagac	caaaaagtgc	ggttgagtga	ctgggtggcag
	3961	ggccaagata	gagacagcgg	ggaggggtgg	tgaccctggc	ggccctggac	tgagcgtctg
15	4021	gaggagtctg	ggaggctctt	tccttctctt	ctcctctgag	agctcgctct	tcaggctctt
	4081	ccagcttgtc	atgtcgagtg	cctggccact	gctcaggggt	ggaggctcag	tccttttgcc
	4141	ctgtctgttc	cagctctgga	gctaactcag	ggatccctga	tcagggttac	gtaggtttgg
	4201	taaaatgagt	gctggaaatt	aactttctcc	cagtagtctt	aggtctagct	cagtgaactt
	4261	aaactttatc	cagatatggg	ttttccttca	gcctttctat	tccttttcta	gccagtgaac
20	4321	gacccgctgc	cctttgacct	cagccccctc	caagccccc	agtttaaaac	gccacccctt
	4381	gccaccagaa	aaaacagaaa	aaaaaaaaaa	aaaaaaaaact	aaaacaccca	tctggctctg
	4441	gcatcttctc	tcctttttca	ctatgtatcc	tgttactggg	cttaaacagc	tttcagagaa
	4501	gagatgtcat	ttctattaaa	tgctctttca	gtagcgaact	gagttcacac	ttgactaagg
	4561	atattttccg	gactgtctgt	catcagcatc	cttagtgggt	ttcccatat	ttaaattggg
25	4621	agagggccag	gatgggtggc	cacacctgta	atctcagtag	tttgggaggg	caaggtaggt
	4681	ggattgcttg	agctcagaag	accagcctgg	gcaacctggg	gaaaacctgt	ctctactaaa
	4741	aattcaagtt	agctagctgg	gcatgggtgat	gcacttctgt	agtccagct	acttggagag
	4801	ggggtgggtg	tggggcagca	ggatcgctta	aaccaggag	gttaagggtg	cagtcagcca
	4861	agatgggtacc	agcctaggtg	acaaagtgc	accctgtctc	aaaaaagaaa	ccaaacaaac
30	4921	ataaaaaaaaa	aaacaaaaaa	atcggtagag	agtgatttct	ctccagggcc	cacttaatgt
	4981	agactgggcc	tggctgacac	ctcaccattc	gtgtgatgtg	attgctgttc	tgatgcttag
	5041	atactcttgg	cgcagctctc	caattggc	catggtagga	aggtgtccag	gagacgggtg
	5101	accctgaacc	agtcaccact	aaagtggctg	cctttctggg	tctctccaca	catccctctc
	5161	ctctaatttc	cctacttaat	cgtgtgactt	catgggtctca	aaggagggaac	agagctgat
35	5221	cttgacttag	atatactgaa	ccatgaaatc	actgcataga	atgtggggac	ttgaatgtgt
	5281	ctttgggcaa	gtcatttaac	ctcttaagac	ctcatctgta	aaatggatta	gatattgtta
	5341	attatagcct	tagcattaaa	tattcattgc	tgttattatt	aagtgtctga	taagtctctg
	5401	tgtacatgga	tgtaatcttc	ctaaactcca	ttacctccat	ttatagatga	gggttatatg
	5461	gccaataaag	cctgggtttg	aatctaggtc	tactgcctcc	aaagccagtc	ttctctcctg
40	5521	caacatcatg	ctctgtctag	caggagatga	gaacaggtct	ccatttggag	cctgtcagtg
	5581	gggtcagaga	ctaagattca	ggctcagggg	ctaaattccg	tatcctttct	tcataccct
	5641	ggtgtttcct	atgaacagat	agatacttta	gggctgcaag	gtttggattg	catggcactg
	5701	ctcagaagat	aagttacagg	tctgggctag	gctgtagctg	cccctccagg	tggctagacc
	5761	tttccctttct	gtgtcaccag	ttaacactgg	ccaacagttc	cttccattaa	ctgttccactg
45	5821	ctttctcctg	tgtctaactg	atgcagttta	tgaccataaa	ctaagagcag	taccaggtat
	5881	ggctctgttt	cctgttcattg	tcccctgtcc	tctgggctgc	atgcattccg	ttcttacaga
	5941	aagaatacct	ttaacctagt	acatcctgcc	acacatctgc	ttctactgtg	aaattgatga
	6001	gggggtatta	ccgattcttc	cctctcccat	catttactga	gatgctgggtg	attgcattat
	6061	aatcctctta	agcttacatt	gtctttctga	ttcttgggtc	tatctgagca	agtgtcttat
50	6121	aaataactca	gtggctttct	catgactgtt	tttaattatta	gatttttaac	aggtgtctta
	6181	ttaaatataat	ctgcatgctt	ccacaggcat	ctgtctcttc	acatggctgt	tcagtgtgcc
	6241	tctcacaact	tagcccaaac	tcagttgagc	tgcttgcctt	tggctttgac	ccagctttcc
	6301	agcgtctgct	aatctgttgc	catggcaggc	cattggaaag	gctcagttca	tcccctgtgc
	6361	tgaagccaag	tgagcgtctc	ctccatgcat	gcatggaggc	tgggcaggag	cctgcctaatt
55	6421	caaccagcca	tgtgaggagg	gagggcctgt	tccttctctg	aagctatgtc	atgaggcagc

- 26 -

	6481	gtgggtcaagt	cctctgccag	ggagtggcct	ggcccagcct	gggcatgttt	tcatgccagg
	6541	gtgctagagc	ctactgccag	attgtctccc	tccaccccca	atgaaaaaat	ccttccagaa
	6601	gggaagagcc	aatttccccc	gtattggagg	ggaagtggca	gcacctcctg	aagcagttgg
	6661	actttcatca	ccctacctct	gcctctgcct	gaaggacaga	tttagccaat	taacctaaag
5	6721	ttaccttcct	ctctgataaa	ttccccattc	tgtcttccca	tgtgttgtgt	ctcgtttttt
	6781	tcctcctcct	tccctcttcc	ttgccccctc	ttcccctaaa	ccttacagat	agctcgtgag
	6841	gctgaggcag	ccatgttcca	ccgcaagctg	tttgaagaac	ttgtgcgagc	ctcaagtcac
	6901	tccacagacc	tcatggaagc	catggccatg	ggcagcgtgg	aggcttctta	taagtgttta
	6961	gcagcagctt	tgatagttct	gacggagtct	ggcaggtagg	gccctaaggg	caggtaacac
10	7021	tgttaggata	accagcctct	tgctgcacct	gccccaggag	aagagagaag	gccccacctg
	7081	gcctctggga	acagagcctc	ttctcgtctg	taggaacacc	gccagggaag	tcatggcagg
	7141	gcagaccaaa	gggtcctgtg	gctcagtagg	cacagtagat	gtcacaggca	cttgggtgaag
	7201	gactgggttc	tgtggagtct	tgatcttggc	tcagctcaga	atctccagtg	attgggctcc
	7261	tcttggcctt	tgttcccagg	aactgttccc	tcaccagctg	tccggtgact	cttccccctc
15	7321	ctctcctttt	gtgacaaaag	ctctgtcccc	ctctcgtccc	tctggacgga	
	7381	tgttgctccc	ctagattgcc	cgtgaggcag	aggctgccat	ctaccacttg	caattatttg
	7441	aggaaactcc	cgcctggcgc	cccattacca	gcgacccccc	agaagccacc	gcggtgggtg
	7501	cgttggaggc	ctccttcaag	tgctgcagtg	gggccataat	cgtcctcacc	aagtctggca
	7561	ggtaggaggc	ggcagcggct	ccttggaaatg	ccctgctcag	tggtacctca	ccttgggggt
20	7621	cctgggagca	gtccattgaa	caatgctcag	gtggcactga	gccaaaggtaa	gacccctctg
	7681	cctgccacct	tgggcctgca	gggaaggatt	gagcagagcc	ccttcccagg	gccccaaagg
	7741	ctctaggtag	cactcataag	gaatgtcaga	acatttggtg	caaaagcaaa	tttatgctgg
	7801	agattttatta	cataacagtg	cacaggctga	ctacaaatgg	ttatttgata	ttgaaaattt
	7861	agtcctctaa	aattgtaaaa	gataccaact	ttgcttattc	cagttactat	gtgctcttta
25	7921	aaaatttcag	ttgggaaatg	aatttattta	aatgctgttt	actgtgcctc	catttggcac
	7981	actagtccct	gctgtttttg	agccctaaag	acaaattggg	ttccagctca	ggagagggtg
	8041	ctgtgctatc	ttggctgaca	ttctgtgggc	ctggcagcca	ggctgaggac	tgtgtggcct
	8101	atgctgggoc	tccaacttgg	gatcccttcc	ttggcccagg	acattgagtt	aatgtccttc
	8161	actctcctag	ttaggggagta	tgctccttgt	ccctgtccac	aggggagcaa	gggtttcctg
30	8221	gaagagggga	gcaaacaggc	agtgcacctg	cactgaggag	cagcagatgg	gcgtgggcag
	8281	cccagagaa	caggacacaa	gctctgtgca	gatccctcag	cagagggctc	cagcctccca
	8341	ctcttggttg	aacagctcca	acccgtaggg	ttgaccttcc	ttaaaagggt	cagttcttgc
	8401	tgtttggcta	ttttaagctc	tagtcttctg	gggtttcact	cagctggctc	tggcttcagc
	8461	aattgcttcc	ctctgaaggc	cttgctataga	ggccaagcgt	gaagtgcagg	gactctctg
35	8521	ctgtgatgtg	gcttaagttt	ccctgacacc	tggtgagtg	cctcataact	tcccttctgg
	8581	tgcccctccc	cagctcctga	gaccagctgc	agctacaagt	gtgcagtgtc	agtgttcaag
	8641	aaagtgcctg	gcagaggggc	tttagaaggg	tcccctgcct	tccaaaggag	ctttggcagg
	8701	cagacgtgct	cctgcagcaa	cactcccat	tccgttctct	gcctgctgag	tagcacctag
	8761	atttctaagc	ctcatctaga	tactcagatt	tgattctggg	cctttatagc	ccagttgctg
40	8821	ggactgtttc	aggagctagg	ggccatgtgg	ggcaggggaga	gggcacaaaa	gtagagaagc
	8881	ctgatgttga	ttcccagggg	gctggctcagc	tctgctactg	ctccttgcag	atgtcaagag
	8941	tcaggtgcta	gtcacgtgct	gcttggcttg	tcactgtcat	tggcagcgag	aggaatgggt
	9001	gctgggtgaca	ttggggccagg	gctgcctctc	tgtgtcagag	ttcagggtgt	aggaggggtt
	9061	ctgccaaacca	tgggctgtgt	ggggtaagtg	gggtgaggct	gatctttctg	gggtcaagggt
45	9121	atcctgagcc	cttgccctgtg	gaatgggggt	agagggcaat	ggtaacctag	ctagcatgct
	9181	gtgggggata	taggatgagg	ggctgcccga	ccctcgggag	gggtcctagg	gagcagatgt
	9241	tgaagaggcc	agagccctca	gtgagctgga	tgaggggggtg	agccgtttga	actccctgag
	9301	ggtaacttct	ggggcctcgt	gtaatggctc	cttctgtatg	tcccccatcc	catctcaggt
	9361	ctgctcacca	ggtggccaga	taccgcccac	gtgcccccat	cattgtctgtg	accgggaatc
50	9421	cccagacagc	tcgtcaggcc	cacctgtacc	gtggcatctt	cctgtctctg	tgcaaggacc
	9481	cagtccaggga	ggcctgggct	gaggacgtgg	acctccgggt	gaacttttgc	atgaatgttg
	9541	gtacgtggct	ggagcagggg	ctagagccta	gaggagcttg	gggatgcttg	agcattggcc
	9601	accaacctcc	cttctcttcc	tccaggcaag	gcccagggct	tcttcaagaa	gggagatgtg
	9661	gtcattgtgc	tgaccggatg	gcgccttggt	tccggcttca	ccaacacccat	gcgtgttgtt
55	9721	cctgtgcctg	gatggacccc	agagcccctc	ctccagcccc	tgtcccaccc	ccttccccca

- 27 -

9781 gccatccat taggccagca acgctttag aactcactct gggctgtaac gtggcactgg
 9841 taggttggga caccagggaa gaagatcaac gcctcactga aacatggctg tgtttgcagc
 9901 ctgctctagt gggacagccc agagcctggc tgcccatca tgtggccca cccaatcaag
 9961 ggaagaagga ggaatgctgg actggaggcc cctggagcca gatggcaaga ggggtgacagc
 5 10021 ttcctttcct gtgtgtactc tgtccagtcc ctttagaaaa aatggatgcc cagaggactc
 10081 ccaaccctgg cttgggggtca agaaacagcc agcaagagtt aggggtcctt agggcactgg
 10141 gctgttgttc cattgaagcc gactctggcc ctggccctta ctgtctctc tagctctcta
 10201 ggcctctcca gtttgcacct gtccccaccc tccactcagc tgtcctgcag caaacactcc
 10261 accctccacc ttccatttcc ccactactg cagcacctcc aggcctgttg ctatagagcc
 10 10321 tacctgtatg taataaacia cagctgaagc acctgtttcc tctctttt

SEQ ID NO. 38

15 Q01995 - Homo sapiens
 Transgelin

20 mankgpsygm srevqskiek kydeeleerl vewiivqcgp dvgrpdrgl gfvwlkngr
 ilsklvnsly pdgskpvkvp enppsmvfkg meqvaqflka aedygviktd mfgtvdlfeg
 kdmaavqrtl malgslavtk ndghyrgdnp wfmkkagehk refteqlqe gkhviglqmg
 snrgasqagm tgygrprqii s

SEQ ID NO. 39

25

D84342

Homo sapiens DNA for SM22 alpha, complete cds

1 cggggtgaaa gcagagtgc cctgaccct ctgcccctcc ctccctccacc ctggcctgct
 30 61 ttagctttcc ccagacatgg ccaacaaggg tccttcctat ggcattgagcc gcgaagtcca
 121 gtccaaaatc gagaagaagt atgacgagga gctggaggag cggctgggtgg agtggatcat
 181 agtgacagtgt ggcctgatg tgggcccggc agaccgtggg cgcttgggct tccaggctg
 241 gctgaagaat ggcgtggtga gtggcaccct gggctagggc gctggggggc tggggtgtga
 301 cccctgtga gtccctgggc aatccctgag gactgctaag ctgcgtccta tgccctatgc
 35 361 ctggttagatt ctgagcaagc tgggtgaacag cctgtaccct gatggctcca agccggtgaa
 421 ggtgcccag aaccacccct ccattggtct caagcagatg gagcagggtg ctcagttcct
 481 gaaggcggct gaggactatg gggtcaccaa gactgacatg ttccagactg ttgacctct
 541 tgaaggtaga gaggagaatg ctgggggagg aggtgggcag gaggacaggg tgctgggaca
 601 gggagagggg atgacaaaat atgccacaac taggggtgtg ctgcccgcga cacagcaggg
 40 661 atgggatatg ccgagaataa cagccacgc tcacaggggc cactgagagg cctcccttga
 721 attggggaca actcttggcc ctggtttggc catttttttg tgagagacgg gggcaggccc
 781 tggcttggag tcttgtttat acgttcttga tgttcatctc ctctctctg tcttctcaca
 841 ggcaagaca tggcagcagt gcagaggacc ctgatggctt tgggcagctt ggcatgacc
 901 aagaatgatg ggcactaccg tggagatccc aactgggtta tgaagtatgt ggccccagg
 45 961 gagcttgagt ctccgcatgg ggtgggagg ggttgttct aaggagcttg cgggaaggat
 1021 taggggaagc agatagccaa gaaaggataa agtgagggtc tgggatgggg aataatgggt
 1081 ccttaatact ccttgacccc tccctttcca cctcctgcg ctcatctcc ctagcctatg
 1141 aggcaagcta gattagggaa aaaaagtga acaggaaggc aatgggattg ggctaggacg
 1201 taacagaggg atcagaaaac ggggtgaaaa cacaagttc tacciaagtct ttatcctgct
 50 1261 tctcctctct ctaggaaagc gcaggagcat aagagggaa tccagagag ccagctgcag
 1321 gagggaaagc atgtcattgg ccttcagatg ggcagcaaca gaggggcctc ccaggccggc
 1381 atgacaggct acggacgacc tcggcagatc atcagttaga gcggagaggg ctagccctga
 1441 gccgggccct ccccccagctc cttggctgca gccatcccgc ttagcctgcc tcacccacac
 1501 ccgtgtggtg ccttcagccc tggccaagct ttgaggctct gtcactgagc aatggtaact
 55 1561 gcacctgggc agctcctccc tgtgccccca gcctcagccc aacttcttac ccgaaagcat

- 28 -

1621 cactgccttg gccctccct cccggctgcc cccatcacct ctactgtctc ctccctgggc
 1681 taagcagggg agaagcgggc tgggggtagc ctggatgtgg gccaaagtcca ctgtcctcct
 1741 tggcggcaaa agcccattga agaagaacca gccagcctg cccctatct tgtcctggaa
 1801 tatttttggg gttggaactc tc

5

SEQ ID NO. 40

Q14103 - human

10 Heterogeneous nuclear ribonucleoprotein

mseeqfggdg aaaaataavg gsageqegam vaatqgaaaa agsgagtggg tasggteggg
 aesegakida skneede ghs nssprhseaa taqreewkmf igglswdttk kdlkdyfskf
 gevvdctlk1 dpitgrsrgf gfvlfkeses vdkvmdqkeh klngkvidpk rakamktkep
 15 vkkifvvggl pdtpeekire yfggfgeves ielpmdnkt nrrrgfcfitf keeepvkkim
 ekkyhvnvlg kceikvamsk eqyqqqqwg srggfagrar grggggsqnw nqgysnywnq
 gygnygynsq gygygygydy tgynnygyg dysnqqsgyg kvsrrrghqn sykpy

20 SEQ ID NO. 41

AF026126

Homo sapiens heterogeneous nuclear ribonucleoprotein D (HNRPD)
 gene, complete cds

25

1 tcgcagaggt gcagccacac cccggcctaa cgtgttggtc ccccgatcac tggagtgggtg
 61 gggaggggtga gtggactcca ggaatcctcg gaagggcgagg ggcggaggca gggggcccct
 121 ctacgcgcta cttcgaaaca gcattccttg ttctcgatgg tcccgcgcg actgtcttag
 181 ctacgcacac ttccggttcc ttttaaaggc ccccaaggct gtgcaacgcg gagcgtgaga
 30 241 ggaaggtata aagggtagcg agagggcgagg accgaggagg aaagggaaaa aaaaaaaact
 301 agggggatag ggggtggggg acgcgcggaag ggcgcgctct cgcgtcacgt gaccgggacg
 361 cgcggttctt cgcgcgcca ttttaggtgg tccgcggcgg cgcattaaa gcgaggagga
 421 ggcgagagcg gccgcgctg gtgcttattc ttttttagtg cagcgggaga gagcgggagt
 481 gtgcgcgcg cgagagtggg aggcgaagg ggcaggccag ggcaggcgcg agagccttt
 35 541 gcagccacgc gcgcgccttc cctgtcttgt gtgcttcgag aggtagagcg ggcgcgcggc
 601 agcgcgggga ttactttgct gctagtttcg gttcgcggca ggcgggtgta gtctcggcgg
 661 cagcggcgga gacactagca ctatgtcgga ggagcagttc ggcggggacg ggcggcgggc
 721 agcggcaacg gcggcggtag gcggctcggc ggcgagcag gaggagacca tgggtggcggc
 781 gacacagggg gcagcggcgg cggcggggaag cggagccggg accgggggag gaaccgcgtc
 40 841 tggaggcacc gaagggggca gcgcgagtc ggagggggcg aagattgacg ccagtaagaa
 901 cgaggaggat gaaggggtgag taaggggcat cccaggatag tcaggcccaa ctagtcccc
 961 tccccctctt tattccccg ccattagcgc tggttccgc tctcagccg ttctcgggc
 1021 cccatgcagc ctcttgcac tgggtctccct ttttctatgt tgggttcccc ggaccttcat
 1081 ttcttctctt ctttgcctgc ttatcgcccc cctcccccat cacacagtt tccaccttta
 45 1141 gccgtcacca tgctgtcct cggcccgccc tcttttctc cctcgccatg ggtctcctcc
 1201 caccgactta gccgcagat tttttccgc ctgtcgtgg gtacctttt tctttccatg
 1261 ctgtccctc tttttccct tttctacagt cttgggcata aaaacacaga cacaacacgc
 1321 ttctctgttt gtattactaa ggtttatttg gtgcttctcc accatcctga aacgatgcga
 1381 ttgtttataa gcacatgttt tggggaaacgc gtaggctgtc cacctctgcc tctccttctg
 50 1441 cggccttacg ccgactgttt tcttgggatt ttgaataagt ttgcctaag gatttactca
 1501 ttttctccac catacgtat cgcacaatgg catactcata caggccctac attttgacat
 1561 gcagacaaa ttgggtctgg tgaatgtct cgagtttctt gttggtacat tggttttgct
 1621 ccgcgggctc tgggttaagt cttagtcgat cgggcctgca cttgactgga gctgttctca
 1681 tctccggcct agcatctacc cttccccac cccactgagt tattctaacc gcgcacctt
 55 1741 ttcgcgcct cagctattgg gttccccac tgtagtaga gattgtacct tactttttat

- 29 -

1801 gtgcaacctt atttttttaca acccccagcc ccccttttttt cccgggtgccc aggatccctat
 1861 tttgggtgtct tgatatctgt ttcccgcaca ctaagggagg cctgtagtcc tcttaagaga
 1921 aacaaatcac tgtattgtgc tatgggatac tttttttttc tttttgggtc aaattttotta
 1981 gtatttaactt gcttcctcca attgaaataa cagttgtata tactacctaa atctgcattt
 5 2041 agtgtatttaa aatgcagcat ttgggattgg gaacataata cgggagttag caggagggac
 2101 taaatcagggt ttcttgggtg agttttctta gctccgatta ctgaccgatg atcgtgggtt
 2161 cagccttcca ttccctttttg taatggggag ggggtgtgtg gtgtctgaat ttttttttaa
 2221 ctgtaaagag aaagggtgtg gtggatataa caagatgtcg ctttaattcta gtattagaaa
 2281 acacgattttc ttttactgag aaagagccca ggatttggag ggaaagtggg gaggggagaa
 10 2341 gcacttttggg atatatgggtt tattaagccc agcttaggca gattctgtgc aggcgttttg
 2401 atgatagtgc tgggttttggg ggagtgggtg tgggaaggga agcaaacttt taaaaattaa
 2461 acagaaccac ctcgaattgt atatagctta tttgagaaag gaagatgtta gatatttggg
 2521 aacttaaaac ctttaacatt ttgggttttgc tttgctgaat tctgttcttt ggacagaggc
 2581 accaaaatga ttaattgtat aacttctctg ttggggcagg ctttctgtta gccctgataa
 15 2641 ttcaaatcgc aaagcagctg actttatagt tacctactgt tgaagtgtaa atgaattaaa
 2701 gttttttaacc ctaacagtgt caaaaactaa aactagaatt ttgattgggt gctgtaccgg
 2761 ttgttaattc cctagccatt caaactctc cccacgacac tctgaagcag cgacggcaca
 2821 gcgggaagaa tggtaaatct tttaaatttt atttctgtat tataaagggt tcagtagtca
 2881 taatatgtag aggcgtgtga ttgggttagtt gccattgat cccaggaaa ttctagacca
 20 2941 tagtacatac agtaggtttg tacctgggat atataccttt tataggcatc atgtgtaatc
 3001 tttgggcaaa attgatgccg ttacatggta tttgggtctg ggtaatgcat gtagttgcag
 3061 tttggcaatt taagctaaac aattagtaac gatattttta tatcgagcaa gaaaaaatat
 3121 taccgtaatc ttcacatttg atttatttta agatgaaaaa tatttttgtt ggaatttaag
 3181 tttaatggct aaatatgaag actccttgat ataaaaatatt gtgtttaaaa tgtcatgcat
 25 3241 gttatactga aatattctgg agatgtctga agcagttctt taagcagcac tgtgtattat
 3301 ggaaaaatgt ttgtctttta cctagcatat ttgtaaatag accttaata aatgtgtgt
 3361 gtgtgtgtgt gtgtgtgtgt gtgtatatat atataccatt aaaagggtggg ctaatgtggc
 3421 tttccactac agctcttacc agattttttta ttttcagtgt gatttggctg gaatattaat
 3481 aacagttgggt tgacatgtat tcacaattgc atgacttctc tttggaagct ggtaggttga
 30 3541 gtattgtttct ttttatccat cctttccctc cccctaaatg tcagtcttct tgcttttagg
 3601 attatatttg aattttcagg ggtttataca ccaccactgg agagtagaag gccactaact
 3661 tgcaggcagt taacttatat ctttacaagc tacattctat ttttaagagcc tatttaggggt
 3721 aacattttaa gatttgcctt tcaactgtatt ctcatccact gaaatcagtc cagctttacc
 3781 ttggagaaaa agcagatggg aaacaggcaa ggggaaaaagc aaaaaagagg aaaaaaaaag
 35 3841 actgggggtca cagtttcgat gaatgttatt ccctgtattt ggtgagtggt gggcactagc
 3901 agctcaattt cactgctagc taatagtggc aaattaagat taaactataa actattttgac
 3961 attactccat tatgtatttt gagtctcatg taattgtttc cagtgtattg aaatgaccat
 4021 aaacttaaat ttgaagggtca gtgtttttgac tcttcgaagt aattacactt gacctgtac
 4081 ctaaaacgat gtaataattac aacttttttg aataatctca ggaaaaatgg agaaatgttt
 40 4141 atattcatag ttaataaaca ttctagatag taaccaactg tcatttactg aaaataaaaat
 4201 tttaccaggt tttattttat ttttgagacg gagtttagct tttgttgccc aggcgtggagt
 4261 gcagtggtgt gatcttggct cagcgcaacc tccacctccc aggttcaagc aattctctctg
 4321 cctcagcctc caaagtagtt gggattacag gcatattcca ccatgcctgg ctaattttgt
 4381 attttttagta gagacaggggt ttcttcatgt tgggtcaggct ggtctcgaac tcccgacctc
 45 4441 aggtgatccg cctgcctcgg cctccccaag tgctgtaatc acaggcgtga gccactgcgc
 4501 ccggcctagc caggttgatt ttaaaattac acttaaaaaat aatgttctca tttttaagggt
 4561 ctctaataat tgacttttct taactttcca attatgcagc cctatcctgt tccagacggt
 4621 aaggcctttct ttttgaatga aaaaactttca gacttttttc tctctcttt tttttttttt
 4681 tgggtgtctgc actccccacc gtatctgtcc cttctcttt cttccatttt gagggatatt
 50 4741 ataagggcaa cagttttata gtctcaatat tgagggttaag actgggttaat agatagagta
 4801 tccaaattga atttattaaa cacagttctg tgtgcatttc cttctgcaaa tctgagaata
 4861 aagtgtttac agtttcatcc taaaataact taaaaatcag ttgggttttag aaatagggtt
 4921 ttttcccttt gcattgtaaga atggacagct attttttagga aggcagtcac ctgttatccc
 4981 agctactcag gaggttgagg caggagaatt gcttgaaccc gggaggtgga ggttgcagtg
 55 5041 agcctagatc atgocattgc actccagccc gggcgacaga gtgagactct gtttaaaaag

- 30 -

	5101	aaaaaaataa	gtattttgtaa	atgtatatat	atatatatat	acacacacac	acacacatat
	5161	atatataaaa	tcattatgcc	atcagtttga	gggagagcat	gtatgccaac	attgtaaaga
	5221	ctaagtgtccc	atztatccat	aattaagata	agcagacttt	tccccattgt	actataaagt
	5281	tagagtttgg	ggctgggtat	ggtaacttccg	cctgtaatcc	cagcagtttg	ggaggctgga
5	5341	gcgggcggat	cacttgaggc	caggagtcca	agaccagcct	ggccaacgag	gggaaacccc
	5401	gtctctacta	aaaatgcaaa	aatcaagtca	ggcgtgggtg	tgcagcctgt	aatccctccc
	5461	acggagggtg	aggaatgaga	atcactttga	acctgggagg	cagaggttgc	agtgagctga
	5521	gattgtgcca	ctgcgctcca	gcttgggcga	cagagtgaga	ctgtctcaaa	aactaagcaa
	5581	ccagaaacag	aaaaagatgg	aatggaatta	atatgttcca	tttagtaaag	atggaataga
10	5641	attgggtccag	tttgtgttca	ttgtagcata	ttcacctatt	tggtctgcaa	ccattttttt
	5701	tttttttaaag	cctaagcata	ccctgagaac	aacaaccttt	tttgattaga	acagaagaaa
	5761	aagccagaat	gttcttgggc	tgccaaaata	ttaatacgtt	tgtctcaaa	acgaaccact
	5821	taggtgcttg	cttagagact	tctactttac	acagaatttg	aaaagtttga	cagctggcta
	5881	cttactctgc	aaaacggaag	ggagactttt	tagaacagca	actggtgatc	tggcaaaaat
15	5941	gaaaagtaga	acttgtgaag	aaatgagatg	gacttgggtg	attaatagct	aatttttagaa
	6001	gaccctgtgg	atatttctaaa	tcagcataat	agtgatgtct	gagccatagt	gttaaattat
	6061	gattactgta	tttgaagtat	aagaaggcag	aaaagtgtga	tgtgttaga	aaaaaatctc
	6121	atttcaaatg	attgaagggt	aaaaacaatt	ggggaaagat	tagagagggc	aggcggtgct
	6181	ttaagggagg	tggaataata	cttggctcct	tattctccaa	aagtgtctga	tagctgaagt
20	6241	ttttaaatatt	ctggataaatt	gatatattgat	tatttagttta	ggagggatag	catcttcagt
	6301	gaacccttgt	agctctaagg	taggcatatt	aaacaactac	catactaaag	gtggggagta
	6361	cgtttgagga	gcactttgct	gggccagctg	atgatatgct	taggtgatat	ttaagaaaat
	6421	ctgcttcttg	tctgaaaaac	atttggggct	tcagaataat	accacatacc	tcattcttgg
	6481	tgttttaatt	tatttctttg	taattgtttt	ctgtttctta	ataattttta	attaagggtta
25	6541	ttttcccaat	ataaacattg	ctttttgggt	aaataaaatc	aaaactagtt	ctgtctccat
	6601	atctgaatag	accagacaga	gaattttctt	gcctttcaac	agcttaaaaa	atgtttttgt
	6661	tagaactgtt	gtgttcaggc	tgaaataact	tcaaagtttg	ttagttatta	ttgagaaatt
	6721	tctgtaataa	tcattgaaag	ggtaatttaa	tagttaaatc	tcaacttaat	tgaagttatt
	6781	tctgttggtg	aacttatggt	catcttagca	agaggctcatt	gctttatagt	cagttctctt
30	6841	tctcattaaa	aatatagtg	actcaccttt	acagggtgaa	tggttggttaa	taacttctgt
	6901	ctgtgaagga	agtattctgg	acctgtaagt	taaaaaataag	gtgttttatag	caaattatgt
	6961	aaataaagat	tgtatattag	aagggtacaca	ctattcaaat	ttaaagaaaa	tgtatattga
	7021	gaaaataaact	caaattcttc	catgaaattg	gcaagaagta	aacatttcaa	atcacacaaa
	7081	cattatgggt	atttttgttc	atttgattat	aaaatgccaa	agttgtttta	taaatgtctac
35	7141	ttcaagcctg	gaaactttga	ggaagtcttg	aacattaagc	atataaatgg	cccagctcta
	7201	gaatacatgt	aagttgaaaa	gctaacctga	agtgggaagc	gcagtatata	cctaagactt
	7261	actctgcact	gaaagtttgc	tttgtcacta	gaagtaaaac	aagactgtgg	taggatagta
	7321	agatcagtaa	cacctcagtt	aatcagggtat	cttggaggaa	gtgaagaaag	accctaattc
	7381	aagggacagt	taattggcct	tttattccaa	gaatgggcct	tagtggcagt	atcttaaaag
40	7441	cccacaagat	ggagatgttt	cctaatagaa	ggcctttaat	ttcttttatag	agctgagtta
	7501	gtgtcacatc	ccagtcccca	cccatgacc	ttccccagtt	aaaaagaaga	gaaaatgttg
	7561	agcaagtctg	atltgattcc	catgggtgaca	tttttagcca	ttatgtaaca	aattctgaca
	7621	gtttaccctt	aaaattaaaa	acctccagtc	ctgtcttttt	aaagggtaga	aagaaggtta
	7681	ggtataggat	agctttttat	ttattttatt	atlttttttt	gtacaaaggg	agcctatgta
45	7741	aagctgccag	atctgaactt	tctgggtgtt	tgctgtaatg	ttagtaagat	ttcgcttaa
	7801	aatattttat	tttgagtata	tacgtttggt	cttagagtgt	cttgggtggat	ttccgcttac
	7861	cacctcatca	tttctgcatt	ttaaaggctt	aaatacttta	ttgctgggtta	actgaggttc
	7921	tactgtaaac	gaatcatcta	agttaattag	tggaattgtac	ttcaatggat	aatttttact
	7981	aaattgtttt	tattgcacat	tacttttgtc	ttaaggactc	ttagcacatc	aaaaaaattg
50	8041	gctcacaact	taattgtgag	actgtagaatt	ttccatttta	tgtagctaaga	gttttggttaa
	8101	tgagagaaact	gttaaaatag	aaaaggagct	tcagcataga	caccaatgct	gggtgtctgag
	8161	atcagtgggg	aactgcatag	catttttaaca	agtttaaatga	acatttgga	gagaaatttg
	8221	aagctaagat	tctgggtttt	ttgctgttaa	cttttttaatt	ttttaatcta	aggaaaactt
	8281	ttatgtacag	tatttttact	ttgggtatat	gtttatcttt	tagcaagttg	aaagacttaa
55	8341	tttgcctgct	gctcactatt	ttgtaattat	ttgggagcag	cagtaataag	ccagcttttt

- 31 -

	8401	ggaataggat	gttcctgatg	tgtgggttatg	taggaagaat	gatgttttaa	tatactgccc
	8461	agtaaaactgg	tgcagtttgg	aaaagggtg	ttattgatgt	ggataaatatt	taaggcaatt
	8521	ttttttaagc	attttaatac	tgctttttgt	ctttacagga	aaatgtttat	aggaggcctt
	8581	agctgggaca	ctacaaagaa	agatcctaag	gaaaactttt	atgtacagta	tttttacttt
5	8641	gggtatatgt	ttatctttta	gcaagttgaa	agacttaatt	tgctgcttgc	tcactatttt
	8701	gtaattattt	gggagcagca	gtaataagcc	agcttttttg	aataggatgt	tcctgatgtg
	8761	tggttatgta	ggaagaatga	tgttttaata	tactgcccag	taaactgggtg	cagtttggaa
	8821	aaggtgtgtt	attgatgtgg	ataatattta	aggcaatttt	ttttaagcat	tttaatactg
	8881	ctttttgtct	ttacaggaaa	atgtttatag	gaggccttag	ctgggacact	acaaagaaag
10	8941	atctgaagga	ctacttttcc	aaatttgggtg	aagtgtgaga	ctgcactctg	aagttagatc
	9001	ctatcacagg	gcatcaagg	ggttttggct	ttgtgctatt	taaagaatcg	gagagtgtag
	9061	ataaggtagt	gtgttacgtg	ttctgatcag	tttaataatat	aaaatatata	catatggata
	9121	gtttgataca	atgagtttgc	ctatttgtgg	ttccccattt	tgatagtata	ggaaggaaga
	9181	atagttcttg	ccccaatag	ttttatgaag	atagaggtag	gttcaggaat	tatttcttga
15	9241	ataatttgtg	ttccaggctc	tgctaaattt	tgaaattaac	tttaaagata	ctatagactt
	9301	aaagatgcct	agttaaaagg	atgtgtttta	gcaattcaca	gaagtccata	ttttgaaatt
	9361	ttgttaggca	agcaactttt	aactgaatca	ttattttgat	cctgggctaa	agggaagtag
	9421	cagttatgtt	tgtatatagt	gctaaaggga	agtagcagtc	atgtttgtat	atattgaagg
	9481	taatggttat	ctagtaattg	gttaaatttg	tgtatgtcct	accattctta	ccttttagatt
20	9541	taaacagtat	atgttagttg	atgttacatc	accaccatga	cttgacagtt	taatcttgag
	9601	caagtcaaca	tatgcttggc	attatctgta	tttatagtta	tttttaagta	agttaatagt
	9661	ctctgaactt	cagttaagat	atataattttt	taaatgaaaa	cttcaatttc	cttaggtcat
	9721	ggatcaaaaa	gaacataaat	tgaatgggaa	gggtgattgat	cctaaaaggg	ccaaagccat
	9781	gaaaacaaaa	gagccgggta	aaaaaatttt	tgttgggtggc	ctttctccag	atacacctga
25	9841	agagaaaaata	agggagtact	ttgggtgggtt	tgggtgaggtg	tgttataaat	ggtttgacct
	9901	agttttatgtc	aaaattagtg	tgaatgtgat	tgtcccatga	tggactcaga	gtcacttggc
	9961	ttttcaaagc	tgttagggta	gattatgtga	tctgttttgg	aataaggata	ttgtaaatat
	10021	ttcatttagca	ggtctttgaa	ggttggataa	tgtgtttttc	tcatttagca	cctactctat
	10081	gcagagtatt	gctggggtag	agtataccaa	agatgaaata	gacaaacatt	cttaaatata
30	10141	gacaattaag	aggaagaaat	ctagattaga	aggagacttt	tgttgaaaat	aggaaaggaa
	10201	ttaagaatag	ggtgtagtgc	cttatcagtt	gaaatgcatg	tgttaagtga	aatttaatga
	10261	gactaatcat	tatagactca	ttagttaggc	tggacgcgat	ggctcatgct	gtagtaatcc
	10321	cagcacttgg	gaggccgaag	tgggtggatt	actggagacc	aggagatgaa	gaccatcctg
	10381	gacaacatag	tggaccggtc	tcaattaaaa	gtaaaacaaa	cttagactca	ttagtgaaat
35	10441	aggtagataa	tagaggtttc	ttttatgaat	taatgaatta	atgaaagttg	agaaatttgt
	10501	ggccttgggc	tccagatacg	tcccacagac	atttatgtgt	tgttgaaac	aataagtgtc
	10561	tttttagtgt	tgaggatttg	agatattgcc	cacaaaactc	agtatctagc	tttttaaaaa
	10621	atatttgcaa	gagcacgcaa	catgggaact	gacgtgccc	tcctgtacgg	cagcatctct
	10681	caaactgagt	agtagcttcc	atcttgggtt	gggcataatg	tcctcagttt	ttagtagtcc
40	10741	tcaccaccct	acttctgtgt	ttctctcaaa	tacatttttt	ttctgttttt	cttagatttg
	10801	actgttttct	tcttgttctt	tgtgggcatt	tgaatttgtg	acccttgagt	taggtagtaa
	10861	atgtcagtg	gtggtaaaag	ttatttttgt	aaatagtgtg	gaagacctta	gatggaatgg
	10921	gtgttcta	ttgaagaatt	ccttaaaagg	attagaataa	atagggagaa	acaggagact
	10981	agaacttcag	tgccaaatac	atgttttctt	tgtgtgtttt	ccccctcta	aacttgtgtt
45	11041	tcttttaagg	tcaataaaat	gcatgttagc	atattaaaa	ttgtttttta	ataccaggtg
	11101	gaatccatag	agctcccat	ggacaacaag	accaataaga	ggcgtgggtt	ctgctttatt
	11161	acctttaagg	aagaagaacc	agtgaagaag	ataatggaaa	agaaatacca	caatgttgg
	11221	cttagtaaa	taagttaagc	atocatttac	ttgtagagaa	aactagctgt	tgtaaagagc
	11281	ttaaaccattt	atctttctct	gtaaaggctt	aagttctttg	catgctttta	aaacttctca
50	11341	ttggttactt	accattgacc	aactttttgt	ggggagcagg	atggacacat	ttgttagtgt
	11401	ttttgtctag	gctttcacaa	aaatagtttt	tagaacttga	caagtaaaat	gaagtaacat
	11461	cactagcaag	tactcataag	tgattactct	taagtactaa	atattgggtt	aattaataaa
	11521	ctgactgagg	aaagtttcaa	attagcctac	tctattttaa	catgttggct	attctgggta
	11581	ttagaaactt	atttagcaac	ttttattttc	ttgagtcagt	tttaataatg	aatttttctc
55	11641	tttttagtgtg	aaataaaaag	agccatgtcg	aaggacaat	atcagcaaca	gcaacagtgg

- 32 -

	11701	ggatctagag	gaggatttgc	aggaagagct	cgtggaagag	gtggtggttaa	gctagagcct
	11761	aagtttactc	tatcttaagc	ttttctgctt	tttaattatc	ctgaagttaa	gatctttgct
	11821	gatcttctga	cttttagtgaa	cctattaatg	tgcctgcaggc	cccagtcaaa	actggaacca
	11881	gggatatagt	aactattgga	atcaaggcta	tggcaactat	ggatataaca	gccaagggtta
5	11941	cggtggttat	ggaggatatg	actacactgg	ttacaacaac	tactatggat	atggtgatta
	12001	tagcagtaag	tactatactt	tttatattaa	ctgctatttg	acattttatt	tgtacaaatt
	12061	tggataggca	gaaaggttag	tgtagccttg	ccaagtgcaa	atgtcttcag	gtttcgaatt
	12121	cctggaaact	tgaaactgca	gccattttat	tgcttggttc	ctcccagcct	atatcacaca
	12181	cacattataa	gggtagggtg	tatgtgtggt	tcctatatatg	tttgctgggc	atttgtttta
10	12241	cttggattta	aaaattttta	gctcagttca	gatcttttaa	gctcaaggta	ttctaaatgt
	12301	cacttcttgg	accaaccaat	aatcttggca	tgatgtgtct	taatcctata	aaactgaata
	12361	ataccacatg	ttgccagtta	aaactaatag	tatcctcgct	ttaggattat	taatgtagaa
	12421	actcttaaaa	cagatgttga	gcttgataga	acaaaaaac	tgactttta	gacatggaaa
	12481	gccctgactt	cattgtgcaa	ctaaggtagt	tgcctccac	ctgatttgta	gcaactgttg
15	12541	agtcgtcagg	taaagggttc	tactagaagc	aatcttacat	ttttttggag	gagagtgggt
	12601	gcattgggtg	cattgtttta	agtggttttt	cttttccttc	cttgggttaga	ccagttcttg
	12661	gagttatata	ctttcttagg	tgactaggcc	tgcctgcacaa	taataggtta	attaaagtca
	12721	gaagaaggtc	agcaaagatg	gattgggtga	gattggggcc	cttttcttag	aagggcagag
	12781	atactaagca	ctgattgtgg	ttgacaattt	gttctaaatt	ttaagatatt	ttttgctggt
20	12841	ggttgtgaaa	gggtcagctg	tcctatcctt	gaaacttaaa	acttttaaac	tgtaagggtg
	12901	aggggattgt	ctcccatttt	atacaataag	tcaagtaatc	agctcattct	gaatgcctgc
	12961	cattgtatgc	attcactaca	tattttggtaa	attatttgat	aaatgattgc	tcagggtgaa
	13021	tttttcacac	ttgggaatta	agctaccctt	aattttttga	gattgtttta	aattaggtac
	13081	tgttctgatt	attagtatgt	aaccactacc	gttctgggtc	taacacttgt	tttatttttag
25	13141	accagcagag	tggttatggg	aaggatccca	ggcgaagggtg	tcatacaaat	agctacaaac
	13201	catactaaat	tattccattt	gcaacttata	cccaacaggt	atgttctaaa	aatagttttt
	13261	ttttgtcatt	tacaatagta	gtttttataa	tctatatgtt	tcataaaaaca	atgcttaatt
	13321	taagagtttc	acagcaccca	gaagtgcctt	ccatattata	acatagtgc	tttcaaaaga
	13381	tatgtaacac	aggtgctctt	aagcttttgc	ctttttgtcc	tattattaac	aagtcagtaa
30	13441	agttaacagg	taaagtactg	ctaattgggt	caaattaagg	aattgcagca	aaaaagtatt
	13501	gctactaac	tctgacatta	taccttggtt	gtaccgccag	cgggaacttc	attgcaggcc
	13561	ctgtgtcgcg	ctgacttcag	attctcacag	gcccgtcaa	tgccgacagg	gtaaccgagat
	13621	gctccacgct	ctcgaatgct	gccgtttggt	atggctctct	ccaacatcct	gtatcagcat
	13681	tataaaataa	aatggatact	tcaagctttg	ccttcaactta	tttctttgct	ttttaaaaaac
35	13741	tattttgtaat	gtaattttta	tgcatttttt	acaggcccag	taatgggtta	atacgtcagc
	13801	ttactgaata	atttttaacta	tttattcttc	taaggataca	gcttgtctct	ggattttcca
	13861	gtcttaattt	tatattttat	taatctattt	taatgcttgc	ttttcccatt	tatagacgtt
	13921	gtagcagtaa	ttgcaagaag	ttcttgagct	gaattcctgt	tgtgacaact	tcctataatt
	13981	acagtagata	actttttctt	ttagtcgtat	ataacttttc	tataacttgt	gatggacaag
40	14041	agatatgctt	atccaataaa	ataagcttaa	atatttagatg	ctcttgggtc	aaaatgtcct
	14101	tttaccaaat	tgaccttttt	atgagttctt	tgggtaaata	ctttaaagct	ttttatatatt
	14161	taaagaatac	ttgtaaaagc	atatcacatc	ttaaaaccagt	ggtgcacatg	tggattttaca
	14221	gctcatggac	tctactgttc	agctttaatt	tataaaacat	atcacacatt	taatgttata
	14281	cagtattttac	atatagtggg	acatagggat	aactcagttt	tatgtaaaatt	tttggttaagt
45	14341	gttgtagcct	gcccagagtg	acttctattt	tttcttcttt	gtctccaggt	ggtgaagcag
	14401	tattttccaa	tttgaagatt	cattttgaagg	tggctcctgc	cacctgctaa	tagcagttca
	14461	aactaaattt	tttgtatcaa	gtccctgaat	ggaagtatga	cgttgggtcc	ctctgaagtt
	14521	taattctgag	ttctcattaa	aagaaatttg	ctttcattgt	tttatttctt	aattgctatg
	14581	cttcagaatc	aattttgtgtt	ttatgccctt	tccccagta	ttgtagaigca	agtcttgtgt
50	14641	taaaagccca	gtgtgacagt	gtcatgatgt	agtagtgtct	tactggtttt	tttaataaatc
	14701	cttttgtata	aaaatgtatt	ggctctttta	tcacacagaat	aggaaaaaat	tgtcatggat
	14761	tcaagttatt	aaaagcataa	gtttggaaga	caggcttgcc	gaaattgagg	acatgattaa
	14821	aattgcagtg	aagttttgaa	tgttttttagc	aaaatctaatt	ttttgccata	atgtgtcctc
	14881	cctgtccaaa	ttgggaatga	cttaatgtca	atttgtttgt	tggttgtttt	aataataactt
55	14941	ccttatgtag	ccattaagat	ttatatgaat	attttcccca	atg	

- 33 -

SEQ ID NO. 42

5 NP_852000
GSK-3 Binding Protein - FRAT1

mpcrreeeee ageaaegee eedsflllqq svalgssgev drlvaqiget lqldaaqhsp
aspcgppgap lrapgplaaa vpadkarspa vp1llppala etvgpappgv lrcalgdrgr
10 vrgraapycv aelatgpsal splppqadld gppgagkqgi pqp1sgpcrr gw1rgaaasr
rlqrrrgsqp etrtgdddp rllqqlv1sg nlikeavrr1 hsr1qlrak lpqrpl1gpl
sapvheppsp rspraacsdg gasgraqlrt gdgvlvpgs

15 SEQ ID NO. 43

NM_005479
Homo sapiens frequently rearranged in advanced T-cell lymphomas
FRAT1), transcript variant 1, mRNA

20 1 ggattccggc tcccgcggct gcaggcgcgc ggctagagt cctggcgggc tccggcttcc
61 gcgtccgccc cggccccggc ccagacttag tcttcagctc cgcgcccgct ccgcgcgggc
121 ccaccgcgcc cgcgcgcagc cgagccccca ggcagcggcg cacagctccg ggtgcccaga
181 caggggggcca tgccgtgccg gagggaggag gaagaggaa cggcgagga ggcggagggg
25 241 gaggaagagg aggaggacag cttcctccta ctgcagcagt cagtggcgct gggcagctcg
301 ggcgaggtgg accggctggg ggcagagatc ggcgagacgc tgcagctgga cgcggcgagc
361 cacagcccg cctcgccgtg cgggcccccg gggcgccgcg tgcgggcccc ggggccccctg
421 gctgcggcgg tgccggcgga caaggccagg tccccggcgg tgccgctgct gctgccgccc
481 gcgttggcgg agactgtggg cccggcgccc cctgggggtc tgcgctgccc cctgggggac
30 541 cgcggcccg tgcggggccc cgctgcgcgc tactgctgg cgcagctcgc cacaggcccc
601 agcgcgctgt cccactgcc cctcaggcc gaccttgatg ggcctccggg agctggcaag
661 cagggeatcc cgcagccgct gtccgggtccg tgccggcgag gatggctccg gggcgccgcc
721 gcctcccgcc gcctgcagca gcgacgcggg tcccaaccag aaaccgcac aggcagcagc
781 gacccgcacc ggcttctgca gcagctagt ctctctggaa acctcatcaa ggaggccgtg
35 841 cgaaggcttc attcgcgacg gctgcagtta cgtgcaaagc ttccccacg cccgctcctg
901 ggacctctgt cggccccggg gcatgaacc ccttcgcctc gcagccctcg cgcggcctgc
961 agtgaccctg gcgcctccg gagggcgag ctcagaactg gcgacggcgt tcttgctcct
1021 ggcagctaac acgcccggg tggccacagc gccagcctca gactggaggg caagggttcc
1081 ccttgagggc tgcagttcta ctcaggctgg tggagaactc tggcttttgg aagcgagagt
40 1141 aaaaagctaa tgacgaggaa ccgaaaaatc gcgagtgttt cgcgggtaac tggggttgag
1201 gggcaaaata tttggaatga aggacttggc cctatttaag gcagatttta cagagcgac
1261 ctcaaacgta caagtcagta ggactcctta tttggcgtga cccgacctg cgcggagcc
1321 tgcatttct cgcagcctct cagtgccttc cagccccgcg accatgtggc cacaatccac
1381 gcttctccg atcgcggtgc ggcggaacca cggaggatga tgccagttac ttgctttacc
45 1441 ttttcagggc tggctcctga tccactttgg gggaggagaa catgagtaga taatttcagg
1501 gtgcagccca atctgccaga cttaaaaaaa ccatcttggt tctttggagg tgctgcttaa
1561 taccaaacat gcggtgccat gaagggaccc tttgggggtt gaataggagt taaccctgc
1621 gctctcttt caactgtctc tcttctcaga gtggtggggg aaggctgtac gacacgggtg
1681 gggaaaggag gtggggcgcg ggagttatga atggtggtgg aagggttagag aggcgcggag
50 1741 tgaacccac gccctgtcta aagtgtatct tcagagccgg cccgctctc ctcggtcaa
1801 ggtcactgt tccctgggac gcactgggtt gcgggacaga gttagccagg tctgcccgtg
1861 ctcggaag agcgcagtg tttgcaagt ctggagtctc ctgaggacac gcgcgtcgcc
1921 gccaccgcgg gtgtgggaaa gcgcggacgt gctgggcggc tgtgcttcgg taggcgacca
1981 ccgcccctgg ccgcgtccg ggctttcacg gaaactccc agaccgggac ctgggttct
55 2041 cctctctac tcggtctctg agtcctactc aagcgggtgg ctctgggata ctgggggcct

- 34 -

```

2101 gggttggggg ctagggagac gccatgtgat ggacactcca gggacacaca gcctagcaca
2161 gcagcttata atgggctctc cggggccatt tgcaataaca gctgcaattc cctggataga
2221 cgagttgatt tcctccctct gcccctcccc cagccatgcc agctggcctt tghtaagtga
2281 ggaaaccgag tagaaaatgt gaccctccaa atggagaagc tgcaggcttt gccatttgtga
5 2341 accatggtga agtgcttgga acatactgtt cactcactct aaaggcgctg agactgtgct
2401 gttgttctcg tttttatagt caatggcttg ttcacatccc agatgtggct actgacatat
2461 ctacacttcg caccggagtg tctggaattg tggtatccct gattatagga ttttaactta
2521 actgaaatgc ctgctttgaa taaatgtgtt gggttttttg tttggtttta ttttatactt
2581 gccatcagtg aaaaagatgt acagaacaca tttctctgat ctccataaac atgaaaacac
10 2641 ttgaaatctc aaa

```

SEQ ID NO. 44

15 NM_181355
Homo sapiens frequently rearranged in advanced T-cell lymphomas
FRAT1), transcript variant 2, mRNA

```

1 ggattccggc tcccgcggt gccggcgcg ggctagagt cctggcgggc tccggcttcc
20 61 gcgtccgccc cggccccggt ccagacttag tcttcagctc cgcgcccgt ccgcgcgggc
121 ccaccgcgcc cgcgggcagc cgagcccca gcgacgcccg cacagctccg ggtgcccaga
181 cagggggcca tgccgtgccg gagggaggag gaagagggaag ccggcgagga ggcggagggg
241 gaggaagagg aggaggacag cttctccta ctgcagcagt cagtggcgct gggcagctcg
301 ggcgaggtgg accggctggt ggcccagatc ggcgagacgc tgcagctgga cgcggcgagc
25 361 cacagcccgg cctcgccgtg cgggccccgc ggggcccgcg tgccggcccc ggggccccctg
421 gctgcggcgg tgccggcgga caaggccagg tcccggcgcg tgccgctgct gctgcgcgcc
481 gcgttggegg agactgtggg cccggcgccc cctgggggtcc tgccgtgcgc cctgggggac
541 cgcggccgcg tgccggggcc cgctgcgccc tactgcgtgg ccgagctcgc cacaggcccc
601 agcgcgctgt cccactgcc cctcagggcc gaccttgatg ggctccggg agctggcaag
30 661 cagggcatcc cgcagccgct gtcgggtccg tgccggcgag gatggctccg gggcgccgcc
721 gcctcccgcc gcctgcagca gcgacgcggg tcccaccag aaaccgcac aggcgacgac
781 gaccgcacc ggcttctgca gcagctagt ctctctggaa acctcatcaa ggaggccgtg
841 cgaaggcttc attcgcgac gctgcagtt cgtgcaaagc tcccccaac cccgctcctg
901 ggacctctgt cggccccggt gcattgaacc ccttcgcctc gcaacctcg cgcgcctgc
35 961 agtgacctg gcgcctccgg gagggcgcag ctcagaactg gcgacggcgt tcttgtgct
1021 ggcagctaac acgcccgggg tggccacagc gccagcctca gactggagg caaggggttc
1081 ccttgagggc tgcagttcta ctcaggctgg tggagaactc tggcttttg aagcgagagt
1141 aaaaagctaa tgacgaggaa ccgaaaaatc gcgagtgtt cgcgggtaac tggggttgag
1201 ggccaaaata tttggaatga aggacttggc cctattttaag gcagatttta cagagcgcac
40 1261 ctcaaacgta caagtcagta ggactcctta tttggcgtga cccgacctgg ccgcggagcc
1321 tgcatttcct cgcagcctct cagtgcctc cagccccgcg acctgtggc cacaatccac
1381 gcttctccgg atcgcggtgc gccggaacca cggaggatga tgccagttac ttgctttacc
1441 ttttcagggc tggctcctga tccacttttg gggaggagaa catgagtaga taatttcagg
1501 gtgcagccca atctgccaga cttaaaaaaa ccactctgtg tctttggagg tgcgtcttaa
45 1561 taccaaacat gcggtgccat gaagggaccc tttgggggtt gaataggagt taaccctgc
1621 gctctctttg caactgtctc tcttctcaga gtggtggggg aaggctgtac gacacgggtg
1681 gggaaaggag gtgggggcgg ggagtattga atggtggtgg aagggtagag aggcgcggag
1741 tgaacccccc gccctgtcta aagtgtattt tcagagccgg cccgcctctc ctcggttcaa
1801 ggtcactgtt tcctgggcac gactgggtt gcgggacaga gtagccagg tctgccggtg
50 1861 ctcggagaag agcgcagtg tttgcaagt cttgagctc ctggagtcac cgcgctgcc
1921 gccaccgcgg gtgtgggaaa gcgcggacgt gctgggcggc tgtgcttcgt caatggcttg
1981 ttcacatccc agatgtggct actgacatat ctacacttcg caccggagtg tctggaattg
2041 tggctatccct gattatagga ttttaactta actgaaatgc ctgctttgaa taaatgtgtt
2101 gggttttttg tttggtttta ttttatactt gccatcagtg aaaaagatgt acagaacaca
55 2161 tttctctgat ctccataaac atgaaaacac ttgaaatctc aaa

```

- 35 -

SEQ ID NO. 45

NP_444254

5 myosin light chain isoform kinase 2

```

mgdvklvass hisktslsvd psrvdsmpit eapafilppr nlcikegata kfegrvrgyp
epqvtwhrng qpitsggrfl ldcgirtgfs lvihavheed rgkytceatn gsgarqvtve
ltvegsfakq lgqpvvsktl gdrfsasave trpsiwgecp pkfatklgrv vvkeggmgrf
10 sckitgrpqp qvtwlkgnvp lqpsarvsvs ekngmqvlei hgvnqddvgv ytcivvngsg
kasmsaelsi qglasansrf vretkatnsd vrkevtntvis keskldslea aakskncssp
qrggsppwaa nsqpqppres klesckdspr tapqtpvlqk tsssitlqaa rvqpeprapg
lgvlspsgge rkrpapprrpa tfptrqpglg sqdvvskaan rripmegqrd safpkfeskp
qsqevkenqt vkfrceglav mevapsfssv lkdcaviegg dfvlqcsvrg tpvpriwll
15 ngqpiqyars tceagvaelh iqdalpedhg tytclaenal gqvscsawvt vhekksrks
eyllpvapsk ptapiflqgl sdlkvmdgsq vtmtvqvsgn pppeviwlhn gneiagesedf
hfeqrgtqhs lciqevfped tgytceawn sagevrtqav ltvqepdgt qpwfiskprs
vtaslgqsvl iscaiaagdpf ptvhwlrldgk alckdtghfe vlqnedvftl vlkkvqpwha
gqyeillknr vgecsqcvsl mlqnssaral prgrepasce dlcgggvgad gggdsdrygsi
20 rpgwpargqg wleedgedv rgvlkrrvet rghteeairq geveqlldfrd llgkkvstkt
lseddlkeip aeqmdfrnl qrqvkpktvs eeerkvhspq qvdfrsvlak kgtsktpvpe
kvpppkpatp dfrsvlggk klpaengsss aetlnakave sskplsnaqp sgplkpvgna
kpaetlkpmg nakpaetlkp mgnakpdenl ksaskeelkk dvkndvncr ghagttndek
rsesqgtapa fkqklqdvhv aegkklillq qvssdppati iwtlngktlk ttkfiillsq
25 gslcsvsiek alpedrglyk cvakndagga ecscqvtvdd apasentkap emksrrpkss
lppvlgted atvkkkpkap tppkaampq iiqfpedqkv ragesvelfg kvttgtqpitc
twmkfrkqiq esehmkvens engsktila arqehcgcyt llvenklgsr qaqvnlttvvd
kpdppagtpc asdirsslt lswygssydg gsavqsysie iwdsanktwk elatcrstsf
nvqdlldpde ykfrvrainv ygtsepsges elttvgekpe epkdevevsd ddekepevdy
30 rtvtinteqk vsdfydieer lgsgkfgqvrl rlvkktrkv wagkffkays akekenirqe
isimncihhp klvqcvdaf ekanivmle ivsggelfer iidedfelte recikymrqi
segveyihkq givhldlkpe nimcvnktgt riklidfgla rrlenagslk vlfgtpefva
pevinypig yatdmwsigv icyilvsgls pfmgdndnet lanvtsatwd fddeafdeis
ddakdfisnl lkkdmknrld ctqclqhpwl mkdtknmeak klskdrmkky marrkwqktg
35 navraigrs smamisglsg rksstgspts plnaeklese edvsqaflea vaeekphvkv
yfsktirdle vvegsaarfd ckiegydppe vvwfkddqsi resrhfqidy dedgncllii
sdvcgdddak ytckavnsig eatctaeliv etmeegegeg eeeee

```

40 SEQ ID NO. 46

AF069601

Homo sapiens myosin light chain kinase isoform 2 (MLCK) mRNA,
complete cds

```

45 ccggctgcct ctgctgcagt tcagagcaac ttcaggagct tcccagccga gagcttcagg
acgcctttcc tgtcccactg gccagttgc cacaacaaac aacagagaag acggtgacca
tgggggatgt gaagctggtt gcctcgtcac acattttcaa aacctccctc agtgtggatc
cctcaagagt tgactccatg cccctgacag agggccctgc ttcatatttg cccctccgga
acctctgcat caaagaagga gccaccgcca agttcgaagg gcgggtccgg ggttaccag
50 agccccaggt gacatggcac agaaacgggc aaccatcac cagcgggggg cgcttcctgc
tggtattgagg catccggggg actttcagcc ttgtgattca tgctgtccat gaggaggaca
ggggaaagta tacctgtgaa gccaccaatg gcagtggtgc tcgccagggt acagtggagt
tgacagtaga aggaagtttt gcgaagcagc ttggtcagcc tgttggtttcc aaaaccttag
gggatagatt ttcagcttca gcagtggaga cccgtccctag catctggggg gagggtcccac

```

- 36 -

	caaagtttgc	taccaagctg	ggccgagttg	tggtcaaaga	aggacagatg	ggacgattct
	cctgcaagat	cactggccgg	cccccaaccg	aggtcacctg	gctcaaggga	aatgttccac
	tgcagccgag	tgcccgtgtg	tctgtgtctg	agaagaacgg	catgcagggt	ctggaaatcc
	atggagtcaa	ccaagatgac	gtgggagttg	acacgtgcct	gggtggtgaac	gggtcgggga
5	aggcctcgat	gtcagctgaa	ctttccatcc	aaggtttgga	cagtgccaat	aggtcatttg
	tgagagaaac	aaaagccacc	aattcagatg	tcaggaaaga	ggtgaccaat	gtaatctcaa
	aggagtcgaa	gctggacagt	ctggaggctg	cagccaaaag	caagaactgc	tccagccccc
	agagagggtg	ctccccaccc	tgggctgcaa	acagccagcc	tcagccccc	agggagtcca
	agctggagtc	atgcaaggac	tcgccagaa	cggccccgca	gaccccggtc	cttcagaaga
10	cttcacagctc	catcaccttg	caggccgcaa	gagttcagcc	ggaaccaaga	gcaccaggcc
	tgggggtcct	atcaccttct	ggagaagaga	ggaagaggcc	agctcctccc	cgtccagcca
	ccttccccac	caggcagcct	ggcctgggga	gccaaagtgt	tgtgagcaag	gctgctaaca
	ggagaatccc	catggagggg	cagagggatt	cagcattccc	caaatttgag	agcaagcccc
	aaagccagga	ggtcaaggaa	aatcaaactg	tcaagttcag	atgtgaagg	cttgccgtga
15	tggaggtggc	cccctccttc	tccagtgtcc	tgaaggactg	cgctgttatt	gagggccagg
	atcttgtgtc	gcagtgtctc	gtacggggga	ccccagtgcc	ccggatcact	tggctgctga
	atgggcagcc	catccagtac	gctcgctcca	ctgcgaggcc	cggcgtggct	gagctccaca
	tccaggatgc	cctgcgggag	gaccatggca	cctacacctg	cctagctgag	aatgccttgg
	ggcaggtgtc	ctgcagcgcc	tgggtcaccg	tccatgaaaa	gaagagtagc	aggaagagtg
20	agtaccttct	gcctgtggct	cccagcaagc	ccactgcacc	catcttctct	cagggcctct
	ctgatctcaa	agtcattggat	ggaagccagg	tcaactatgac	tgtccaagtg	tcagggaatc
	caccccttga	agtcattctg	ctgcacaatg	ggaatgagat	ccaagagtca	gaggacttcc
	actttgaaca	gagaggaact	cagcacagcc	tttggatcca	ggaagtgttc	ccggaggaca
	cgggcacgta	cacctgcgag	gcctggaaca	gcgctggaga	ggtccgcacc	cagggcgtgc
25	tcacggtaca	agagcctcac	gatggcaccc	agccctgggt	catcagtaag	cctcgctcag
	tgacagcctc	cctggggccag	agtgtcctca	tctcctgcgc	catagctggt	gaccccttcc
	ctaccgtgca	ctggctcaga	gatggcaaa	ccctctgcaa	agacactggc	cacttcgagg
	tgcttcagaa	tgaggacgtg	ttcaccttgg	ttctaaagaa	ggtgcagccc	tggcatgccg
	gccagtatga	gatcctgctc	aagaaccggg	ttggcgaatg	cagttgccag	gtgtcactga
30	tgtacagaaa	cagctctgcc	agagcccttc	cacgggggag	ggagcctgcc	agctgcgagg
	acctctgtgg	tggaggagtt	ggtgctgatg	gtggtggtag	tgaccgctat	gggtccctga
	ggcctggctg	gccagcaaga	gggcagggtt	ggctagagga	ggaagacggc	gaggacgtgc
	gaggggtgct	gaagaggcgc	gtggagacga	ggcagcacac	tgaggaggcg	atccgcagc
	aggaggtgga	gcagctggac	ttccgagacc	tcctggggaa	gaagggtgag	acaaagaccc
35	tatcggaaga	cgacctgaag	gagatcccgg	ccgagcagat	ggatttccgt	gccaacctgc
	agcggcaagt	gaagccaaag	actgtgtctg	aggaagagag	gaagggtgcac	agccccagc
	aggtcgatbt	tcgctctgtc	ctggccaaga	aggggacttc	caagaccccc	gtgcctgaga
	aggtgccacc	gccccaaact	gccaccccg	attttctgctc	agtgtgggt	ggcaagaaga
	aattaccagc	agagaatggc	agcagcagtg	ccgagaccct	gaatgccaa	gcagtggaga
40	gttccaagcc	cctgagcaat	gcacagcctt	cagggccctt	gaaacccgtg	ggcaacgcca
	agcctgctga	gacctgaag	ccaatgggca	acgccaagcc	tgccgagacc	ctgaagccca
	tgggcaatgc	caagcctgat	gagaacctga	aatccgctag	caaagaagaa	ctcaagaag
	acgttaagaa	tgatgtgaac	tgcaagagag	gccatgcagg	gaccacagat	aatgaaaaga
	gatcagagag	ccaggggaca	gccccagcct	tcaagcagaa	gctgcaagat	gttcattgtg
45	cagagggcaa	gaagctgctg	ctccagtgcc	aggtgtcttc	tgacccccca	gccaccatca
	tctggacgct	gaatggaaa	accctcaaga	ccaccaagtt	catcatcctc	tcccaggaag
	gctcactctg	ctcgtctctc	atcgagaagg	cactgcctga	ggacagaggc	ttatacaagt
	gtgtagccaa	gaatgacgct	ggccaggcgg	agtgtcctct	ccaagtccac	gtggatgatg
	ctccagccag	tgagaacacc	aaggccccag	agatgaaatc	ccggaggccc	aagagctctc
50	ttcctcccg	gctaggaact	gagagtgtat	cgactgtgaa	aaagaaacct	gcccccaaga
	cacctccgaa	ggcagcaatg	ccccctcaga	tcatccagtt	ccctgaggac	cagaagggtac
	gocgaggaga	gtcagtggag	ctgtttggca	aagtgcagag	cactcagccc	atcacctgta
	cctggatgaa	gttccgaaa	cagatccagg	aaagcgagca	catgaagggt	gagaacagcg
	agaatggcag	caagctcacc	atcctggccg	cgcgccagga	gcaactgcgg	tgctacacac
55	tgctgggtgga	gaacaagctg	ggcagcaggc	aggcccaggt	caacctcact	gtcgtggata

- 37 -

```

5  agccagaccc cccagctggc acaccttgtg cctctgacat tccgagctcc tcaactgaccc
   tgtcctggta tggctcctca tatgatgggg gcagtgtgtg acagtcctac agcatcgaga
   tctgggactc agccaacaag acgtggaagg aactagccac atgccgcagc acctctttca
   acgtccagga cctgctgcct gaccacgaat ataagttccg tgtacgtgca atcaacgtgt
10 atggaaccag tgagccaagc caggagtctg aactcacaac ggtaggagag aaacctgaag
   agccgaagga tgaagtggag gtgtcagatg atgatgagaa ggagcccgag gttgattacc
   ggacagtgc aatcaatact gaacaaaaag tatctgactt ctacgacatt gaggagagat
   taggatctgg gaaatttgga caggtctttc gacttgtaga aaagaaaact cgaaaagtct
   gggcagggaa gttcttcaag gcatattcag caaaagagaa agagaatatc cggcaggaga
15 ttagcatcat gaactgcctc caccacccta agctgggtcca gtgtgtggat gcctttgaag
   aaaaggccaa catcgtcatg gtcttgagaa tctgttcagg aggggagctg tttgagcgca
   tcattgacga ggactttgag ctgacggagc gtgagtgcac caagtacatg cggcagatct
   cggagggagt ggagtacatc cacaagcagg gcatcgtgca cctggacctc aagccggaga
   acatcatgtg tgtcaacaag acgggcacca ggatcaagct catcgacttt ggtctggcca
20 ggaggctgga gaatgcgggg tctctgaagg tctcttttgg caccocagaa tttgtggctc
   ctgaagtgat caactatgag cccatcggct acgccacaga catgtggagc atcgggggtca
   tctgctacat cctagtcagt ggcctttccc ccttcattgg agacaacgat aacgaaacct
   tggccaacgt tacctcagcc acctgggact tgcagcacga ggcattcgat gagatctccg
   acgatgccaa ggatttcatc agcaatctgc tgaagaaaga tatgaaaaac cgcctggact
25 gcacgcagtg ccttcagcat ccatggctaa tgaaagatac caagaacatg gaggccaaga
   aactctccaa ggaccggatg aagaagtaca tggcaagaag gaaatggcag aaaacgggca
   atgctgtgag agccattgga agactgtcct ctatggcaat gatctcaggg ctcagtggca
   ggaaatcctc aacagggtca ccaaccagcc cgctcaatgc agaaaaacta gaatctgaag
   aagatgtgtc ccaagctttc cttgaggctg ttgctgagga aaagcctcat gtaaaacctt
30 atttctctaa gaccattcgc gatttagaag ttgtggaggg aagtgtctgt agatttgact
   gcaagattga aggataccca gaccccgagg ttgtctgggt caaagatgac cagtcaatca
   gggagtcccc ccacttcag atagactacg atgaggacgg gaactgctct ttaattatta
   gtgatgtttg cggggatgac gatgccaaat acacctgcaa ggctgtcaac agtcttggag
   aagccacctg cacagcagag ctcatgtgtg aaacgatgga ggaagggtgaa ggggaagggg
35 aagaggaaga agagtgaac aaagccagag aaaagcagtt tctaagtcac attaaaagga
   ctatttctct caaaatcca

```

SEQ ID NO. 47

35 AAH07433 and P09493
tropomyosin 1 alpha chain.

```

1 mdaikkkmqm lkldkenald raeqaeadkk aaedrskqle delvslqkkl kgtedeldky
61 sealkdaqek lelaekkatd aeadvaslnr riqlveeeld ragerlatal qkleaaekaa
40 121 desergmkvi esraqkdeek meiqeiqlke akhiaedadr kyeevarklv iiesdlrae
   181 eraelsegqv rgleeqlrim dqtikalmaa edkysqkedr yeeeikvlsl klkeaetrae
   241 faersvtkle ksiddledel yaqklkykai seeldhalnd mtism

```

45 SEQ ID NO. 48

NM_000366 and BC007433
Homo sapiens tropomyosin 1 (alpha), mRNA (cDNA clone), complete cds

```

50 1 gaggaatgcg gtcgccccct tgggaaagta catatctggg agaagcaggc ggctccgcgc
   61 tcgcactccc gctcctccgc ccgaccgcgc gctcgccccg ccgctcctgc tgcagcccca
   121 gggccccctc ccgcgcgcac catggacgcc atcaagaaga agatgcagat gctgaagctc
   181 gacaaggaga acgccttgga tcgagctgag caggcggagg ccgacaagaa ggcggcgga
   241 gacaggagca agcagctgga agatgagctg gtgtcactgc aaaagaaact caagggcacc
55 301 gaagatgaac tggacaaata ttctgaggct ctcaaagatg cccaggagaa gctggagctg

```

- 38 -

```

361 gcagagaaaa aggcacaccga tgctgaagcc gacgtagctt ctctgaacag acgcatccag
421 ctgggttgagg aagagttgga tcgtgccag gagcgtctgg caacagcttt gcagaagctg
481 gaggaagctg agaaggcagc agatgagagt gagagaggca tgaaagtcac tgagagtcga
541 gcccaaaaag atgaagaaaa aatggaaatt caggagatcc aactgaaaga ggcaaagcac
5 601 attgctgaag atgccgaccg caaatatgaa gaggtggccc gtaagctggt catcattgag
661 agcgacctgg aacgtgcaga ggagcgggct gagctctcag aaggccaagt ccgacagctg
721 gaagaacaat taagaataat ggatcagacc ttgaaagcat taatggctgc agaggataag
781 tactcgcaga aggaagacag atatgaggaa gagatcaagg tcctttccga caagctgaag
841 gaggctgaga ctgggctga gtttgcgag aggtcagtaa ctaaattgga gaaaagcatt
10 901 gatgacttag aagacgagct gtacgctcag aaactgaagt acaaagccat cagcgaggag
961 ctggaccacg ctctcaacga tatgacttcc atgtaaacgt tcatccactc tgcttgctta
1021 caccctgccc tcatgctaataa ataagtttct ttgcttcact tctcccaaga ctccctcgtc
1081 gagctggatg tccacacctc ctgagctctg catttgctta ttctccagct gaccctgggt
1141 ctctctctta gcatcctgcc ttagagccag gcacacactg tgctttctat tgtacagaag
15 1201 ctcttcgttt cagtgtcaaa taaacactgt gtaagctaaa aaaaaaaaaa aaaaaa

```

SEQ ID NO. 49

20 EITALAPSTMK

SEQ ID NO. 50

25 MLTELEK

SEQ ID NO. 51

30 ALNSIIDVYHK

SEQ ID NO. 52

35 GADVWFK

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/002172

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C12Q-1/68; C12Q-1/02; G01N-33/53, 33/574; A61K-45/00, 49/00; A61P-35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(7): C12Q-1/68; C12Q- 1/02; G01N-33/53, 33/574; A61K-45/00, 49/00; A61P-35/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

DELPHION, CPD, BIOSIS, CAPLUS, EMBASE, MEDLINE, STN REGISTRY; Keywords: endometrial (markers, cancer), polypeptide, nucleic, in vivo, imaging, PET, MRI, chaperonin 10, groES

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No(s).
X	WO98/10291 A1 (CENTER FOR CLINICAL & BASIC RESEARCH (DK)) 12 March 1998 - the entire document	1, 2, 5, 6, 8-10, 38 (partial), 47 (partial), 48, 49
Y		3, 4
A		7, 11-22, 28, 29, 39
X	WO99/63115 A2 (REPROGEN INC (US)) 9 December 1999 - the entire document	1, 2, 5, 6, 8-17, 22, 47 (partial), 48, 49
Y		3, 4
A		7, 18-21, 38 (partial), 39

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 April 2005 (11-04-2005)

Date of mailing of the international search report

11 May 2005 (11-05-2005)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 001(819)953-2476

Authorized officer
Michael W. De Vouge (819) 997-2952

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/002172

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant	Relevant to claim No(s).
X	WO99/63116 A2 (REPROGEN INC (US)) 9 December 1999 - the entire document	1, 2, 5, 6, 8-17, 22, 47 (partial), 48, 49
Y		3, 4
A		7, 18-21, 38 (partial), 39
X	WO01/62959 A2 (PROCREA BIOSCIENCES INC (CA)) 30 August 2001 - the entire document	1, 2, 5, 6, 8-17, 22, 47 (partial), 48, 49
Y		3, 4
A		7, 18-21, 38 (partial), 39
X	WO01/92338 A1 (THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US); THE OHIO STATE UNIVERSITY (US)) 6 December 2001 - the entire document	1-5, 7-9, 11, 18, 47 (partial), 48, 49
Y		28, 29
A		6, 10, 12-17, 19-21, 38 (partial), 39
X	SHAARAWY, M. and EL-SHARKAWY, S.A. Biomarkers of intrinsic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncologica, 2001, Vol. 40, No. 4, pages 513-518, ISSN 0284-186X.	1-6, 8, 9, 19, 21, 22
Y		28, 29
A		7, 10-18, 38 (partial), 39, 47 (partial), 48, 49
X	KLEIN, A.K. et al. Detection of circulating tumor cells by cytokeratin 20 in the blood of patients with endometrial carcinoma. Gynecologic Oncology, September 2000, Vol. 78, No. 3 (pt.1), pages 352-355, ISSN 0090-8258.	1-6, 8, 9, 11-18, 20, 22
Y		28, 29
A		7, 10, 38 (partial), 39, 47 (partial), 48, 49
Y	WO00/16805 A1 (DIADEXUS LLC (US)) 30 March 2000 - the entire document	28, 29
A		1-22, 38 (partial), 39, 47 (partial), 48, 49

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/002172

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. ☐ Claim Nos. :
because they relate to subject matter not required to be searched by this Authority, namely :
2. ☒ Claim Nos. : 40 (partial)
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

that portion of claim 40 that is part of Invention No. I is so grouped on the basis of its dependency on markers of claim 29. However, claim 29 is directed to an imaging method that does not define specific markers.
3. ☐ Claim Nos. :
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :
indicated on extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :
1-22, 28, 29, 38 (partial), 39, 40 (partial), 47(partial), 48, 49
Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/002172

continuation of Box No. III:

The International Search Authority found multiple groups of inventions in this international application, as follows:

I. Claims 1-22, 28, 29, 38 (partial), 39, 40 (partial), 47(partial), 48, 49:

Methods, kits and diagnostic compositions for detecting and *in vivo* imaging endometrial markers associated with an endometrial disease, particularly endometrial cancer.

II. Claims 23-25, 38 (partial), 39, 40 (partial), 47(partial):

Methods and kits for assessing efficacy of a test agent for inhibiting endometrial cancer.

III. Claims 26, 38 (partial), 39, 40 (partial), 47(partial):

Methods and kits for inhibiting endometrial cancer in a subject.

IV. Claims 27, 38 (partial), 39, 40 (partial), 47(partial):

Methods and kits for assessing the endometrial cancer cell carcinogenic potential of a test compound.

V. Claims 30-37, 47(partial):

Markers identified by differential expression in endometrial samples that distinguish an endometrial phase or disease; kits thereof. The claimed markers are considered to be a distinct invention in that the markers are unlinked to any of the other inventions by dependency thereto. Consequently, it is held that the claims are directed to compounds not limited to a specific use.

VI. Claims 41-45:

Methods and kits for determining uterine endometrial receptivity and probability of successful implantation, monitoring effects of ovarian stimulation on uterine endometrial receptivity.

VII. Claim 46, 47 (partial):

Method of contraception by interrupting presence of endometrial marker; kit therefor.

INTERNATIONAL SEARCH REPORT

information on patent family members

International application No.
PCT/CA2004/002172

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO9810291 A1	12-03-1998	AU4127597 A	26-03-1998
		CA2265470 A1	12-03-1998
		EP0931262 A1	28-07-1999
		GB9618600D D0	16-10-1996
		GB9707132D D0	28-05-1997
		JP2001501300T T	30-01-2001
		US2003044795 A1	06-03-2003
WO9963115 A2	09-12-1999	AU765750 B2	25-09-2003
		AU4230499 A	20-12-1999
		CA2334117 A1	09-12-1999
		EP1076723 A2	21-02-2001
		JP2002517208T T	18-06-2002
		NZ508690 A	30-05-2003
		US6387629 B1	14-05-2002
		US2002187499 A1	12-12-2002
WO9963116 A2	09-12-1999	AU760613 B2	22-05-2003
		AU4230599 A	20-12-1999
		CA2299436 A1	09-12-1999
		EP1002136 A2	24-05-2000
		JP2002517209T T	18-06-2002
		US6753138 B1	22-06-2004
		US2004096884 A1	20-05-2004
WO0162959 A2	30-08-2001	AU3717801 A	03-09-2001
		BR0108685 A	30-12-2003
		CA2399259 A1	30-08-2001
		EP1290218 A2	12-03-2003
		JP2003531580T T	28-10-2003
		US6777182 B2	17-08-2004
WO0192338 A1	06-12-2001	US6649359 B2	18-11-2003
WO0016805 A1	30-03-2000	CA2343918 A1	30-03-2000
		EP1115426 A1	18-07-2001
		JP2002526055T T	20-08-2002